

## Publications of EUTox Members 1995 to 2014 (March)



Please also see [www.EUTox.info](http://www.EUTox.info)

1. Aalten P, Verhey FR, Boziki M, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K, Frisoni G, Girtler N, Holmes C, Hurt C, Marriott A, Mecocci P, Nobili F, Ousset PJ, Reynish E, Salmon E, Tsolaki M, Vellas B, Robert PH: Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. *Dement Geriatr Cogn Disord* 24:457-463, 2007
2. Aalten P, Verhey FR, Boziki M, Brugnolo A, Bullock R, Byrne EJ, Camus V, Caputo M, Collins D, De Deyn PP, Elina K, Frisoni G, Holmes C, Hurt C, Marriott A, Mecocci P, Nobili F, Ousset PJ, Reynish E, Salmon E, Tsolaki M, Vellas B, Robert PH: Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. *Dement Geriatr Cogn Disord* 25:1-8, 2008
3. Aarsland D, Bronnick K, Ehrst U, De Deyn PP, Tekin S, Emre M, Cummings JL: Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. *J Neurol Neurosurg Psychiatry* 78:36-42, 2007
4. Abdulmalik A, Cohen G: The use of echocardiographic contrast-enhanced rapid diagnosis of ruptured aortic dissection with transthoracic echocardiography. *J Am Soc Echocardiogr* 20:1317, 2007
5. Abordo EA, Westwood ME, Thornalley PJ: Synthesis and secretion of macrophage colony stimulating factor by mature human monocytes and human monocytic THP-1 cells induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. *Immunol Lett* 53:7-13, 1996
6. Abordo EA, Thornalley PJ: Synthesis and secretion of tumour necrosis factor- $\alpha$  by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. *Immunol Lett* 58:139-147, 1997
7. Abordo EA, Minhas HS, Thornalley PJ: Accumulation of alpha-oxoaldehydes during oxidative stress: a role in cytotoxicity. *Biochem Pharmacol* 58:641-648, 1999
8. Abraham D, Podar K, Pacher M, Kubicek M, Welzel N, Hemmings BA, Dilworth SM, Mischak H, Kolch W, Baccarini M: Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. *J Biol Chem* 275:22300-22304, 2000
9. Abreo K, Sella M, Gautreaux S, De SR, Vogeleere P, Ringoir S, Vanholder R: P-Cresol, a uremic compound, enhances the uptake of aluminum in hepatocytes. *J Am Soc Nephrol* 8:935-942, 1997
10. Adamczak M, Wiecek A, Kokot F: [Role of restricting dietary sodium in treatment and prevention of essential hypertension--state of knowledge in 1996]. *Pol Arch Med Wewn* 97:260-267, 1997
11. Adamczak M, Kokot F, Wiecek AW: Relationship between plasma renin profile and leptinaemia in patients with essential hypertension. *J Hum Hypertens* 14:503-509, 2000
12. Adamczak M, Kokot F, Chudek J, Wiecek A: Effect of renin-angiotensin system activation by dietary sodium restriction and upright position on plasma leptin concentration in patients with essential hypertension. *Med Sci Monit* 8:CR473-CR477, 2002
13. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y: Decreased plasma adiponectin concentration in patients with essential hypertension. *Am J Hypertens* 16:72-75, 2003
14. Adamczak M, Kokot F, Witkowicz J, Wiecek A: Plasma neuropeptide Y concentration in kidney transplant patients during the early posttransplant period. *Ann Transplant* 9:37-39, 2004
15. Adamczak M, Rzepka E, Chudek J, Wiecek A: Ageing and plasma adiponectin concentration in apparently healthy males and females. *Clin Endocrinol (Oxf)* 62:114-118, 2005
16. Adamczak M, Chudek J, Wiecek A: Which target blood pressure is optimal for renoprotection? *Nat Clin Pract Nephrol* 2:58-59, 2006
17. Adamczak M, Szotowska M, Chudek J, Karkoszka H, Cierpka L, Wiecek A: Plasma adiponectin concentration in patients after successful kidney transplantation--a single-center, observational study. *Clin Nephrol* 67:381-390, 2007
18. Adamczak M, Czerwienska B, Chudek J, Wiecek A: Renal extraction of circulating adiponectin in patients with renovascular hypertension. *Acta Physiol Hung* 94:143-148, 2007
19. Adesida A, Edwards LG, Thornalley PJ: Inhibition of human leukaemia 60 cell growth by mercapturic acid metabolites of phenylethyl isothiocyanate. *Food Chem Toxicol* 34:385-392, 1996
20. Agalou S, Ahmed N, Dawney A, Thornalley PJ: Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis. *Biochem Soc Trans* 31:1394-1396, 2003
21. Agalou S, Ahmed N, Thornalley PJ, Dawney A: Advanced glycation end product free adducts are cleared by dialysis. *Ann N Y Acad Sci* 1043:734-739, 2005
22. Agalou S, Ahmed N, Babaei-Jadidi R, Dawney A, Thornalley PJ: Profound mishandling of protein glycation degradation products in uremia and dialysis. *J Am Soc Nephrol* 16:1471-1485, 2005
23. Ahlm C, Juto P, Stegmayr B, Settergren B, Wadell G, Tarnvik A, Elgh F: Prevalence of serum antibodies to hantaviruses in northern Sweden as measured by recombinant nucleocapsid proteins. *Scand J Infect Dis* 29:349-354, 1997
24. Ahmed E, Trifunovic J, Stegmayr B, Hallmans G, Lefvert AK: Autoantibodies against oxidatively modified LDL do not constitute a risk factor for stroke: a nested case-control study. *Stroke* 30:2541-2546, 1999
25. Ahmed E, Stegmayr B, Trifunovic J, Weinehall L, Hallmans G, Lefvert AK: Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Vasterbotten cohort project. *Stroke* 31:1289-1293, 2000
26. Ahmed N, Thornalley PJ: Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. *Biochem J* 364:15-24, 2002
27. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ: Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine-and Nepsilon-(1-carboxyethyl)lysine-modified albumin. *Biochem J* 364:1-14, 2002
28. Ahmed N, Battah S, Karachalias N, Babaei-Jadidi R, Horanyi M, Baroti K, Hollan S, Thornalley PJ: Increased formation of methylglyoxal and protein glycation, oxidation and nitrosation in triosephosphate isomerase deficiency. *Biochim Biophys Acta* 1639:121-132, 2003
29. Ahmed N, Thornalley PJ, Dawczynski J, Franke S, Strobel J, Stein G, Haik GM: Methylglyoxal-derived hydroimidazolone advanced glycation end-products of human lens proteins. *Invest Ophthalmol Vis Sci* 44:5287-5292, 2003
30. Ahmed N, Thornalley PJ: Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. *Biochem Soc Trans* 31:1417-1422, 2003  
Ahmed N, Thornalley PJ, Luthen R, Haussinger D, Sebekova K, Schinzel R, Voelker W, Heidland A: Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. *J Hepatol* 41:913-919, 2004

31. Ahmed N, Mirshekar-Syahkal B, Kennish L, Karachalias N, Babaei-Jadidi R, Thornalley PJ: Assay of advanced glycation endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. *Mol Nutr Food Res* 49:691-699, 2005
32. Ahmed N, Thornalley PJ: Peptide mapping of human serum albumin modified minimally by methylglyoxal in vitro and in vivo. *Ann N Y Acad Sci* 1043:260-266, 2005
33. Ahmed N, Babaei-Jadidi R, Howell SK, Beisswenger PJ, Thornalley PJ: Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. *Diabetologia* 48:1590-1603, 2005
34. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Munch G: Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. *J Neurochem* 92:255-263, 2005
35. Ahmed N, Babaei-Jadidi R, Howell SK, Thornalley PJ, Beisswenger PJ: Glycated and oxidized protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. *Diabetes Care* 28:2465-2471, 2005
36. Ahmed N, Luthen R, Haussinger D, Sebekova K, Schinzel R, Voelker W, Heidland A, Thornalley PJ: Increased protein glycation in cirrhosis and therapeutic strategies to prevent it. *Ann N Y Acad Sci* 1043:718-724, 2005
37. Ahmed N, Dobler D, Dean M, Thornalley PJ: Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. *J Biol Chem* 280:5724-5732, 2005
38. Ahmed N, Thornalley PJ: Advanced glycation endproducts: what is their relevance to diabetic complications? *Diabetes Obes Metab* 9:233-245, 2007
39. Akel A, Wiecek A, Nowicki M, Kokot F: [The effect of treatment with enalapril versus losartan on levels of insulin resistance in patients with essential hypertension]. *Pol Arch Med Wewn* 103:123-131, 2000
40. Al BM, Marescau B, D'Hooge R, Van ME, Van DA, Levillain O, De Deyn PP: Biochemical and histopathological changes in nephrectomized mice. *Metabolism* 47:355-361, 1998
41. Al BM, D'Hooge R, Marescau B, De Deyn PP: Behavioural deficits during the acute phase of mild renal failure in mice. *Metab Brain Dis* 14:173-187, 1999
42. Al BM, Marescau B, D'Hooge R, Engelborghs S, De Deyn PP: Consequences of renal mass reduction on amino acid and biogenic amine levels in nephrectomized mice. *Amino Acids* 18:265-277, 2000
43. Al BM, Marescau B, Possemiers I, D'Hooge R, Levillain O, De Deyn PP: NG, NG-dimethylarginine and NG, NG-dimethylarginine in renal insufficiency. *Pflugers Arch* 439:524-531, 2000
44. Al BM, Marescau B, D'Hooge R, De Deyn PP: The effect of high protein diet on urea and guanidino compound levels in renal insufficient mice. *Amino Acids* 21:401-415, 2001
45. Al BM, Marescau B, D'Hooge R, Van ME, De Deyn PP: Biochemical, histological and behavioral consequences of nephrectomy in young and aged mice. *Nephron* 89:90-100, 2001
46. Al BM, Marescau B, Van ME, D'Hooge R, De Deyn PP: Long-term effect of partial nephrectomy on biological parameters, kidney histology, and guanidino compound levels in mice. *Metabolism* 50:1418-1425, 2001
47. Alenius GM, Stegmayr BG, Dahlqvist SR: Renal abnormalities in a population of patients with psoriatic arthritis. *Scand J Rheumatol* 30:271-274, 2001
48. Aljama P, Bommer J, Canaud B, Carrera F, Eckardt KU, Horl WH, Krediet RT, Locatelli F, Macdougall IC, Wikstrom B: Practical guidelines for the use of NESP in treating renal anaemia. *Nephrol Dial Transplant* 16 Suppl 3:22-28, 2001
49. Alpa M, Ferrero B, Cavallo R, Perna A, Naretto C, Gennaro M, Di SD, Bellizia L, Mansouri M, Rossi D, Modena V, Giachino O, Sena LM, Roccatello D: Anti-GM1 and anti-sulfatide antibodies in patients with systemic lupus erythematosus, Sjogren's syndrome, mixed cryoglobulinemia and idiopathic systemic vasculitis. *Clin Exp Rheumatol* 25:556-562, 2007
50. Ameloot P, Fiers W, De BP, Ware CF, Vandenabeele P, Brouckaert P: Identification of tumor necrosis factor (TNF) amino acids crucial for binding to the murine p75 TNF receptor and construction of receptor-selective mutants. *J Biol Chem* 276:37426-37430, 2001
51. Ameloot P, Declercq W, Fiers W, Vandenabeele P, Brouckaert P: Heterotrimers formed by tumor necrosis factors of different species or muteins. *J Biol Chem* 276:27098-27103, 2001
52. Ameloot P, Takahashi N, Everaerd B, Hostens J, Eugster HP, Fiers W, Brouckaert P: Bioavailability of recombinant tumor necrosis factor determines its lethality in mice. *Eur J Immunol* 32:2759-2765, 2002
53. Ameloot P, Fiers W, Buurman WA, De BP, Brouckaert P: Characterization of the interaction between murine tumour necrosis factor and monoclonal antibodies. *Cytokine* 18:158-163, 2002
54. Ameloot P, Brouckaert P: Production and characterization of receptor-specific TNF muteins. *Methods Mol Med* 98:33-46, 2004
55. Ammarguella F, Gogusev J, Drueke TB: Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. *Nephrol Dial Transplant* 11:687-692, 1996
56. Andersson C, Wikberg A, Stegmayr B, Lithner F: Renal symptomatology in patients with acute intermittent porphyria. A population-based study. *J Intern Med* 248:319-325, 2000
57. Andrejak M, Gras V, Massy ZA, Caron J: [Adverse effects of statins]. *Therapie* 58:77-83, 2003
58. Anzenbacherova E, Anzenbacher P, Zidek Z, Buchar E, Kmonickova E, Potmesil P, Nekvindova J, Veinlichova A, Holy A: In vivo study of the effect of antiviral acyclic nucleotide phosphonate (R) -9-[2-(phosphonomethoxy)propyl]adenine (PMPA, tenofovir) and its prodrug tenofovir disoproxil fumarate on rat microsomal cytochrome P450. *Physiol Res* 2007
59. Apsner R, Winkler S, Schneeweiss B, Horl WH: The shampoo clue: two cases of infection of a ventriculoatrial shunt. *Clin Infect Dis* 31:1518-1519, 2000
60. Apsner R, Buchmayer H, Lang T, Unver B, Speiser W, Sunder-Plassmann G, Horl WH: Simplified citrate anticoagulation for high-flux hemodialysis. *Am J Kidney Dis* 38:979-987, 2001
61. Apsner R, Horl WH, Sunder-Plassmann G: Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. *Blood* 97:2914-2915, 2001
62. Apsner R, Muhm M, Unver B, Horl WH, Sunder-Plassmann G: Expanding our interventional skills: placement of totally implantable injection ports by internists/intensivists. *Acta Med Austriaca* 28:23-26, 2001
63. Apsner R, Gruber D, Horl WH, Sunder-Plassmann G: Parathyroid hormone secretion during citrate anticoagulated hemodialysis in acutely ill maintenance hemodialysis patients. *Anesth Analg* 99:1199-1204, table, 2004
64. Argiles A, Garcia-Garcia M, Derancourt J, Mourad G, Demaille JG: Beta 2 microglobulin isoforms in healthy individuals and in amyloid

- deposits. *Kidney Int* 48:1397-1405, 1995
- Argiles A, Mion CM: Calcium balance and intact PTH variations during haemodiafiltration. *Nephrol Dial Transplant* 10:2083-2089, 1995
65. Argiles A, Mourad G, Mion C: Oral vitamin D or calcium carbonate in the prevention of renal bone disease? *Curr Opin Nephrol Hypertens* 5:329-336, 1996
  66. Argiles A, Mion CM: Low-calcium dialysate worsens secondary hyperparathyroidism. *J Am Soc Nephrol* 7:635-636, 1996
  67. Argiles A, Gouin-Charnet A, Wu YC, Mourad G, Friedlander MA: Elevated pentosidine content in amyloid deposits and in insoluble amyloid fibrils from patients with beta 2-microglobulin amyloidosis. *Nephrol Dial Transplant* 11:2371-2372, 1996
  68. Argiles A, Fichoux A, Thomas M, Bosc JY, Kerr PG, Lorho R, Flavier JL, Stec F, Adele C, Leblanc M, Garred LJ, Canaud B, Mion H, Mion CM: Precise quantification of dialysis using continuous sampling of spent dialysate and total dialysate volume measurement. *Kidney Int* 52:530-537, 1997
  69. Argiles A, Mourad G, Mion C: Seasonal changes in blood pressure in patients with end-stage renal disease treated with hemodialysis. *N Engl J Med* 339:1364-1370, 1998
  70. Argiles A, Mourad G: How do we have to use the calcium in the dialysate to optimize the management of secondary hyperparathyroidism? *Nephrol Dial Transplant* 13 Suppl 3:62-64, 1998
  71. Argiles A, Lorho R, Mourad G: The irritable patient. *Nephrol Dial Transplant* 13:2481-2483, 1998
  72. Argiles A, Mourad G, Gouin-Charnet A, Schmitt-Bernard CF: Antiproteases and cells in the pathogenesis of beta(2)-microglobulin amyloidosis: role of alpha(2)-macroglobulin and macrophages. *Nephron* 86:1-11, 2000
  73. Argiles A, Mourad G: Histologic characteristics of sternoclavicular beta2-microglobulin amyloidosis. *Kidney Int* 57:345-347, 2000
  74. Argiles A, Garcia GM, Mourad G: Phagocytosis of dialysis-related amyloid deposits by macrophages. *Nephrol Dial Transplant* 17:1136-1138, 2002
  75. Argiles A, Lorho R, Serval MF, Couret I, Chong G, Mourad G: Blood pressure is correlated with vitamin d(3) serum levels in dialysis patients. *Blood Purif* 20:370-375, 2002
  76. Argiles A, Frapier JM, Lorho R, Serval MF, Garrigue V, Canet S, Chong G, Albat B, Mourad G: Life-threatening vascular complications of severe hyperphosphataemia. *Nephrol Dial Transplant* 18:201-205, 2003
  77. Argiles A, Lorho R, Serval MF, Chong G, Kerr PG, Mourad G: Seasonal modifications in blood pressure are mainly related to interdialytic body weight gain in dialysis patients. *Kidney Int* 65:1795-1801, 2004
  78. Argiles JM, Busquets S, Lopez-Soriano FJ: Anti-inflammatory therapies in cancer cachexia. *Eur J Pharmacol* 668 Suppl 1: S81-6. , 2011
  79. Argiles JM, Lopez-Soriano FJ, Toledo M, Betancourt A, Serpe R, Busquets S: The cachexia score (casco): A new tool for staging cachectic cancer patients. *J Cachexia Sarcopenia Muscle* 2:87-93, 2011
  80. Arlestig L, Wallberg JS, Stegmayr B, Rantapaa-Dahlqvist S: Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis. *Clin Exp Rheumatol* 25:866-871, 2007
  81. Armstrong VL, Brunet PM, He C, Nishimura M, Poole HL, Spector FJ: What is so critical?: a commentary on the reexamination of critical periods. *Dev Psychobiol* 48:326-331, 2006
  82. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Druke TB: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. *J Clin Invest* 95:2047-2053, 1995
  83. Asberg KH, Johansson L, Staaf A, Stegmayr B, Wester PO: [Life after stroke--a new national study. Renewed follow-up of stroke patients shows increased dependency on the support from the next-of-kin]. *Lakartidningen* 102:2938-2941, 2005
  84. Asplund K, Nasic S, Janlert U, Stegmayr B: Smokeless tobacco as a possible risk factor for stroke in men: a nested case-control study. *Stroke* 34:1754-1759, 2003
  85. Asplund K, Hulter AK, Norrving B, Stegmayr B, Terent A, Wester PO: Riks-stroke -a Swedish national quality register for stroke care. *Cerebrovasc Dis* 15 Suppl 1:5-7, 2003
  86. Asplund K, Eliasson M, Janlert U, Stegmayr B: [What the MONICA project has taught us about cardiovascular diseases--society, public health and health care]. *Lakartidningen* 103:3006-3011, 2006
  87. Atanasiu D, Whitbeck JC, Cairns TM, Reilly B, Cohen GH, Eisenberg RJ: Bimolecular complementation reveals that glycoproteins gB and gH/gL of herpes simplex virus interact with each other during cell fusion. *Proc Natl Acad SciUS A* 104:18718-18723, 2007
  88. Atman AP, Brunet P, Geng J, Reydellet G, Claudin P, Behringer RP, Clement E: From the stress response function (back) to the sand pile "dip". *Eur Phys J E Soft Matter* 17:93-100, 2005
  89. Auchere D, Tardivel S, Gounelle JC, Druke T, Lacour B: Role of transcellular pathway in ileal Ca2+ absorption: stimulation by low-Ca2+ diet. *Am J Physiol* 275:G951-G956, 1998
  90. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C: Galantamine treatment of vascular dementia: a randomized trial. *Neurology* 69:448-458, 2007
  91. Avesani CM, Carrero JJ, Axelsson J, Qureshi AR, Lindholm B, Stenvinkel P: Inflammation and wasting in chronic kidney disease: Partners in crime. *Kidney Int Suppl* S8-S13, 2006
  92. Avignon A, Standaert ML, Yamada K, Mischak H, Spencer B, Farese RV: Insulin increases mRNA levels of protein kinase C-alpha and -beta in rat adipocytes and protein kinase C-alpha, -beta and -theta in rat skeletal muscle. *Biochem J* 308 ( Pt 1):181-187, 1995
  93. Axelsson J, Rashid QA, Suliman ME, Honda H, Pecoits-Filho R, Heimbürger O, Lindholm B, Cederholm T, Stenvinkel P: Truncal fat mass as a contributor to inflammation in end-stage renal disease. *Am J Clin Nutr* 80:1222-1229, 2004
  94. Axelsson J, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P, Barany P: Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. *Am J Kidney Dis* 46:628-634, 2005
  95. Axelsson J, Heimbürger O, Lindholm B, Stenvinkel P: Adipose tissue and its relation to inflammation: the role of adipokines. *J Ren Nutr* 15:131-136, 2005
  96. Axelsson J, Bergsten A, Qureshi AR, Heimbürger O, Barany P, Lonnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P: Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. *Kidney Int* 69:596-604, 2006
  97. Axelsson J, Heimbürger O, Stenvinkel P: Adipose tissue and inflammation in chronic kidney disease. *Contrib Nephrol* 151:165-174, 2006
  98. Axelsson J, Moller HJ, Witasz A, Qureshi AR, Carrero JJ, Heimbürger O, Barany P, Alvestrand A, Lindholm B, Moestrup SK, Stenvinkel P: Changes in fat mass correlate with changes in soluble sCD163, a

- marker of mature macrophages, in patients with CKD. *Am J Kidney Dis* 48:916-925, 2006
99. Axelsson J, Qureshi AR, vino-Filho JC, Barany P, Heimbürger O, Lindholm B, Stenvinkel P: Are insulin-like growth factor and its binding proteins 1 and 3 clinically useful as markers of malnutrition, sarcopenia and inflammation in end-stage renal disease? *Eur J Clin Nutr* 60:718-726, 2006
100. Axelsson J, Carrero JJ, Avesani CM, Heimbürger O, Lindholm B, Stenvinkel P: Adipokine signaling in the peritoneal dialysis patient. *Contrib Nephrol* 150:166-173, 2006
101. Axelsson J, Devuyst O, Nordfors L, Heimbürger O, Stenvinkel P, Lindholm B: Place of genotyping and phenotyping in understanding and potentially modifying outcomes in peritoneal dialysis patients. *Kidney Int Suppl* 138-S145, 2006
102. Axelsson J, Witasz A, Carrero JJ, Qureshi AR, Suliman ME, Heimbürger O, Barany P, Lindholm B, Alvestrand A, Schalling M, Nordfors L, Stenvinkel P: Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. *Am J Kidney Dis* 49:237-244, 2007
103. Axelsson J, O'Byrne SM, Blaner WS, Carrero JJ, Bruchfeld A, Heimbürger O, Barany P, Lindholm B, Stenvinkel P: Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5. *Am J Nephrol* 29:447-453, 2009
104. az-Buxo JA, Passlick-Deetjen J, Gotloib L: Potential hazards of polyglucose. *ASAIO J* 47:602-607, 2001
105. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ: Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. *Diabetes* 52:2110-2120, 2003
106. Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley PJ: High-dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. *Diabetologia* 47:2235-2246, 2004
107. Babinska M, Chudek J, Owczarek AJ, Prochaczek F, Wiecek A: [Acute coronary syndrome in patients with chronic kidney disease--risk stratification]. *Pol Arch Med Wewn* 114:1226-1235, 2005
108. Babinska M, Chudek J, Owczarek AJ, Prochaczek F, Wiecek A: [Treatment of coronary artery disease in patients with chronic kidney diseases]. *Kardiol Pol* 65:703-708, 2007
109. Bahlmann FH, deGroot K, Duckert T, Niemczyk E, Bahlmann E, Boehm SM, Haller H, Fliser D: Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. *Kidney Int* 64:1648-1652, 2003
110. Bahlmann FH, de GK, Haller H, Fliser D: Erythropoietin: is it more than correcting anaemia? *Nephrol Dial Transplant* 19:20-22, 2004
111. Bahlmann FH, de GK, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D: Erythropoietin regulates endothelial progenitor cells. *Blood* 103:921-926, 2004
112. Bahlmann FH, Song R, Boehm SM, Mengel M, von WR, Lindschau C, Kirsch T, de GK, Laudeley R, Niemczyk E, Guler F, Menne J, Haller H, Fliser D: Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. *Circulation* 110:1006-1012, 2004
113. Bahlmann FH, de GK, Mueller O, Hertel B, Haller H, Fliser D: Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. *Hypertension* 45:526-529, 2005
114. Bahlmann FH, Kielstein JT, Haller H, Fliser D: Erythropoietin and progression of CKD. *Kidney Int Suppl* S21-S25, 2007
115. Bahlmann FH, Speer T, Fliser D: Endothelial progenitor cells in chronic kidney disease. *Nephrol Dial Transplant* 25:341-346., 2009
116. Baier C, Baader SL, Jankowski J, Gieselmann V, Schilling K, Rauch U, Kappler J: Hyaluronan is organized into fiber-like structures along migratory pathways in the developing mouse cerebellum. *Matrix Biol* 2007
117. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R: The effects of lowering ldl cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): A randomised placebo-controlled trial. *Lancet* 377:2181-2192, 2011
118. Baillieux H, De Smet HJ, Lesage G, Paquier P, De Deyn PP, Marien P: Neurobehavioral alterations in an adolescent following posterior fossa tumor resection. *Cerebellum* 5:289-295, 2006
119. Baillieux H, Weyns F, Paquier P, De Deyn PP, Marien P: Posterior fossa syndrome after a vermian stroke: a new case and review of the literature. *Pediatr Neurosurg* 43:386-395, 2007
120. Baldi A, De C, V, Giordano DR, Lamberti R, Perna A, Picone C, Lucariello A, Feroce F, Grattacaso S, De LA: Cystic nephroma: report of a case and review of the literature. *In Vivo* 21:895-896, 2007
121. Balke N, Holtkamp U, Horl WH, Tschesche H: Inhibition of degranulation of human polymorphonuclear leukocytes by complement factor D. *FEBS Lett* 371:300-302, 1995
122. Ballaux D, Verhelst J, Pickut B, De Deyn PP, Mahler C: Ectopic macroprolactinoma mimicking a chordoma: a case report. *Endocr Relat Cancer* 6:117-122, 1999
123. Banyai-Falger S, Gottsauner-Wolf M, Stepan E, Strobl W, Jansen M, Heinz G, Horl WH, Derfler K: Lipoprotein pattern in end-stage renal disease and following successful renal transplantation. *Clin Transplant* 11:545-551, 1997
124. Banyai-Falger S, Maier U, Susani M, Wiener H, Watschinger B, Horl WH, Banyai M: High incidence of nephrogenic adenoma of the bladder after renal transplantation. *Transplantation* 65:511-514, 1998
125. Banyai S, Falger J, Haag-Weber M, Horl WH: Minimal-change glomerulonephritis associated with infantile autosomal recessive polycystic kidney disease. *Nephrol Dial Transplant* 12:2726-2727, 1997
126. Banyai S, Streicher J, Strobl W, Gabriel H, Gottsauner-Wolf M, Rohac M, Weidinger F, Horl WH, Derfler K: Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoadsorption. *Metabolism* 47:1058-1064, 1998
127. Barany P, Stenvinkel P, Ottosson-Seeberger A, Alvestrand A, Morrow J, Roberts JJ, Salahudeen AK: Effect of 6 weeks of vitamin E administration on renal haemodynamic alterations following a single dose of neoral in healthy volunteers. *Nephrol Dial Transplant* 16:580-584, 2001
128. Bardin N, Moal V, Anfosso F, Daniel L, Brunet P, Sampol J, Dignat GF: Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. *Thromb Haemost* 90:915-920, 2003
129. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cendoroglo M, Draibe SA, Moyses RM, Neves KR, Jorgetti V, Blair A, Guiberteau R, Fernandes Canziani ME: Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. *Kidney Int* 67:1576-1582, 2005

130. Barreto DV, Lenglet A, Liabeuf S, Kretschmer A, Barreto FC, Nollet A, Slama M, Choukroun G, Brazier M, Massy Z: Prognostic implication of plasma osteopontin levels in patients with chronic kidney disease. *Nephron Clin Pract* 117:c363-372, 2011
131. Bartel G, Wahrmann M, Exner M, Regele H, Schillinger M, Horl WH, Bohmig GA: Determinants of the Complement-Fixing Ability of Recipient Presensitization Against HLA Antigens. *Transplantation* 83:727-733, 2007
132. Bartel G, Wahrmann M, Exner M, Regele H, Huttary N, Schillinger M, Kormoczi GF, Horl WH, Bohmig GA: In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. *Am J Transplant* 8:41-49, 2008
133. Barth C, Boer W, Garzoni D, Kuenzi T, Ries W, Schaefer R, Schneditz D, Tsobanelis T, van der SF, Wojke R, Schilling H, Passlick-Deetjen J: Characteristics of hypotension-prone haemodialysis patients: is there a critical relative blood volume? *Nephrol Dial Transplant* 18:1353-1360, 2003
134. Basile C, Druete T, Lacour B: Has parathyroid hormone any influence on lipid metabolism in chronic renal failure? *Nephrol Dial Transplant* 10:1942-1943, 1995
135. Bataille P, Coevoet B, Cuvelier D, Descoedres C, Druete T, Moynot A, Poignet JL, Ryckelynck JP, Stroumza P: [Factors determining the choice of a modality of treatment by dialysis: a study of nine dialysis centers]. *Nephrologie* 21:57-63, 2000
136. Baumann M, Mischak H, Dammeier S, Kolch W, Gires O, Pich D, Zeidler R, Delecluse HJ, Hammerschmidt W: Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation. *J Virol* 72:8105-8114, 1998
137. Baumann M, Gires O, Kolch W, Mischak H, Zeidler R, Pich D, Hammerschmidt W: The PKC targeting protein RACK1 interacts with the Epstein-Barr virus activator protein BZLF1. *Eur J Biochem* 267:3891-3901, 2000
138. Baumann M, Witzke O, Dietrich R, Haug U, Deppisch R, Lutz J, Philipp T, Heemann U: Prolonged catheter survival in intermittent hemodialysis using a less thrombogenic micropatterned polymer modification. *ASAIO J* 49:708-712, 2003
139. Baumert M, Wiecek A, Kokot F, Osuch-Jaczevska R: [Para/endocrine function of the vascular endothelium of healthy pregnant women and pregnant women with preeclampsia and their neonates]. *Pol Arch Med Wewn* 105:271-278, 2001
140. Baumert M, Wiecek A, Kokot F, Sikora J, Osuch-Jaczevska R: [Do preterm infants differ from healthy newborns by endothelin para/endocrine function?]. *Pol Merkuri Lekarski* 12:57-60, 2002
141. Becherer A, Deicher R, Jilma B, Haas M, Staudenherz A, Horl WH, Dudczak R, Kletter K: Leukocyte scintigraphy with 99mTc-exametazine-labeled leukocytes is not useful for follow-up of systemic vasculitis. *Wien Klin Wochenschr* 114:28-32, 2002
142. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E, Fliser D: Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. *J Am Soc Nephrol* 16:1091-1098, 2005
143. Beige J, Lokies J, Schaberg T, Finckh U, Fischer M, Mauch H, Lode H, Kohler B, Rolfs A: Clinical evaluation of a Mycobacterium tuberculosis PCR assay. *J Clin Microbiol* 33:90-95, 1995
144. Beige J, Weber A, Engeli S, Offermann G, Distler A, Sharma AM: Angiotensinogen-M235T genotype and post-transplant hypertension. *Nephrol Dial Transplant* 11:1538-1541, 1996
145. Beige J, Scherer S, Weber A, Engeli S, Offermann G, Opelz G, Distler A, Sharma AM: Angiotensin-converting enzyme genotype and renal allograft survival. *J Am Soc Nephrol* 8:1319-1323, 1997
146. Beige J, Zilch O, Hohenbleicher H, Ringel J, Kunz R, Distler A, Sharma AM: Genetic variants of the renin-angiotensin system and ambulatory blood pressure in essential hypertension. *J Hypertens* 15:503-508, 1997
147. Beige J, Ringel J, Hohenbleicher H, Rubattu S, Kreutz R, Sharma AM: HpaII-polymorphism of the atrial-natriuretic-peptide gene and essential hypertension in whites. *Am J Hypertens* 10:1316-1318, 1997
148. Beige J, Offermann G, Distler A, Sharma AM: Angiotensin-converting-enzyme insertion/deletion genotype and long-term renal allograft survival. *Nephrol Dial Transplant* 13:735-738, 1998
149. Beige J, Engeli S, Ringel J, Offermann G, Distler A, Sharma AM: Donor G protein beta3 subunit 825TT genotype is associated with reduced kidney allograft survival. *J Am Soc Nephrol* 10:1717-1721, 1999
150. Beige J, Sharma AM, Distler A, Offermann G, Preuschhof L: Monitoring dialysis efficacy by comparing delivered and predicted Kt/V. *Nephrol Dial Transplant* 14:683-687, 1999
151. Beige J, Hohenbleicher H, Distler A, Sharma AM: G-Protein beta3 subunit C825T variant and ambulatory blood pressure in essential hypertension. *Hypertension* 33:1049-1051, 1999
152. Beige J, Sone J, Sharma AM, Rudwaleit M, Offermann G, Distler A, Preuschhof L: Computational analysis of blood volume curves and risk of intradialytic morbid events in hemodialysis. *Kidney Int* 58:1805-1809, 2000
153. Beige J, Ringel J, Distler A, Sharma AM: G-protein beta(3)-subunit C825T genotype and nephropathy in diabetes mellitus. *Nephrol Dial Transplant* 15:1384-1387, 2000
154. Beige J, Kreutz R, Tscherkaschina I, Scherer S, Sharma AM, Zidek W, Offermann G: Matrix analysis for the dissection of interactions of G-protein beta3 subunit C825T genotype, allograft function, and posttransplant hypertension in kidney transplantation. *Am J Kidney Dis* 40:1319-1324, 2002
155. Beige J, Perez-Canto A, Moosmayer I, Offermann G, Zidek W, Klingel R: Immunoabsorption with tryptophan adsorbers for successful treatment of late steroid-refractory recurrent focal glomerulosclerosis. *Am J Transplant* 3:1459,
156. Beige J, Bellmann A, Sharma AM, Gessner R: Ethnic origin determines the impact of genetic variants in dopamine receptor gene (DRD1) concerning essential hypertension. *Am J Hypertens* 17:1184-1187, 2004
157. Beige J, Kreutz R, Rothermund L: [Acute renal failure: pathophysiology and clinical management]. *Dtsch Med Wochenschr* 132:2569-2578, 2007
158. Beige J, Heipmann K, Stumvoll M, Korner A, Kratzsch J: Paradoxical role for adiponectin in chronic renal diseases? An example of reverse epidemiology. *Expert Opin Ther Targets* 13:163-173, 2009
159. Beige J, Lutter S, Martus P: On-site production of a dialysis bath from dry salts. Results of solute concentration control by routine clinical chemistry. *Clin Kidney J* 5:207-211, 2012
160. Belhocine T, Weiner SM, Brink I, De Deyn PP, Roland J, Van der BT, Flamen P: A plea for the elective inclusion of the brain in routine whole-body FDG PET. *Eur J Nucl Med Mol Imaging* 32:251-256, 2005
161. Bender FC, Samanta M, Heldwein EE, de Leon MP, Bilman E, Lou H, Whitbeck JC, Eisenberg RJ, Cohen GH: Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions. *J Virol* 81:3827-3841, 2007

162. Bender TO, Riesenhuber A, Endemann M, Herkner K, Witowski J, Jorres A, Aufricht C: Correlation between HSP-72 expression and IL-8 secretion in human mesothelial cells. *Int J Artif Organs* 30:199-203, 2007
163. Bengrine A, Da Silveira C, Massy ZA, Boullier A, Bugnicourt JM, Chillon JM: Cerebral arterioles preparation and pecam-1 expression in c57bl/6j and apoe<sup>-/-</sup> mice. *Front Biosci* 17:2367-2371, 2011
164. Benyahia M, Shahapuni I, Ghazali A, Massy Z, Fournier A: Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. *Nephrol Dial Transplant* 19:2153-2154, 2004
165. Berland Y, Brunet P, Dussol B: Ultrafiltration and depurative parameters. *Contrib Nephrol* 113:45-59, 1995
166. Berland Y, Brunet P, Ragon A, Reynier JP: Dialysis fluid and water: their roles in biocompatibility. *Nephrol Dial Transplant* 10 Suppl 10:45-47, 1995
167. Berland Y, Brunet P: Morbidity and mortality in hemodialysis: the role of schedules. *Artif Organs* 19:827-831, 1995
168. Berlanga J, Cibrian D, Guillen I, Freyre F, Alba JS, Lopez-Saura P, Merino N, Aldama A, Quintela AM, Triana ME, Montequin JF, Ajamieh H, Urquiza D, Ahmed N, Thornalley PJ: Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. *Clin Sci (Lond)* 109:83-95, 2005
169. Bertuzzi A, Mingrone G, Gandolfi A, Greco AV, Ringoir S, Vanholder R: Binding of indole-3-acetic acid to human serum albumin and competition with L-tryptophan. *Clin Chim Acta* 265:183-192, 1997
170. Bervoets AR, Spasovski GB, Behets GJ, Dams G, Polenakovic MH, Zafirovska K, Van H, V, De Broe ME, D'Haese PC: Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. *Am J Kidney Dis* 41:997-1007, 2003
171. Best L, Thornalley PJ: Trioses and related substances: tools for the study of pancreatic beta-cell function. *Biochem Pharmacol* 57:583-588, 1999
172. Billheden J, Boman J, Stegmayr B, Wieslander J, Settergren B: Glomerular basement membrane antibodies in hantavirus disease (hemorrhagic fever with renal syndrome). *Clin Nephrol* 48:137-140, 1997
173. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, bu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Druke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. *N Engl J Med* 350:1516-1525, 2004
174. Boes E, Fliser D, Ritz E, Konig P, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Riegler P, Kronenberg F: Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. *J Am Soc Nephrol* 17:528-536, 2006
175. Bogaerts V, Engelborghs S, Kumar-Singh S, Goossens D, Pickut B, van der ZJ, Slegers K, Peeters K, Martin JJ, Del-Favero J, Gasser T, Dickson DW, Wszolek ZK, De Deyn PP, Theuns J, Van BC: A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. *Brain* 130:2277-2291, 2007
176. Bohler J, Schollmeyer P, Dressel B, Dobos G, Horl WH: Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. *J Am Soc Nephrol* 7:234-241, 1996
177. Bohmig GA, Schmaldienst S, Horl WH, Mayer G: Iatrogenic hypercalcaemia, hypokalaemia and metabolic alkalosis in a lady with vena cava thrombosis--beware of overzealous diuretic treatment. *Nephrol Dial Transplant* 14:782-784, 1999
178. Bohmig GA, Saemann MD, Bergmann M, Watschinger B, Regele H, Windhager T, Muhlbacher F, Horl WH, Zlabinger GJ: Long-term evaluation of proliferative donor antigen-specific reactivity in cadaveric kidney transplant recipients. *Transpl Int* 13:187-193, 2000
179. Bohmig GA, Regele H, Saemann MD, Exner M, Druml W, Kovarik J, Horl WH, Zlabinger GJ, Watschinger B: Role of humoral immune reactions as target for antirejection therapy in recipients of a spousal-donor kidney graft. *Am J Kidney Dis* 35:667-673, 2000
180. Bohmig GA, Regele H, Exner M, Derhartunian V, Kletzmayer J, Saemann MD, Horl WH, Druml W, Watschinger B: C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. *J Am Soc Nephrol* 12:2482-2489, 2001
181. Bohmig GA, Exner M, Watschinger B, Wenter C, Wahrmann M, Osterreicher C, Saemann MD, Mersich N, Horl WH, Zlabinger GJ, Regele H: C4d deposits in renal allografts are associated with inferior graft outcome. *Transplant Proc* 33:1151-1152, 2001
182. Bohmig GA, Exner M, Habicht A, Schillinger M, Lang U, Kletzmayer J, Saemann MD, Horl WH, Watschinger B, Regele H: Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. *J Am Soc Nephrol* 13:1091-1099, 2002
183. Bohmig GA, Regele H, Horl WH: Protocol biopsies after kidney transplantation. *Transpl Int* 18:131-139, 2005
184. Bokenkamp A, Herget-Rosenthal S: Urinary cystatin C as a marker of GFR? A word of caution. *Pediatr Nephrol* 19:1429, 2004
185. Bokenkamp A, Herget-Rosenthal S, Bokenkamp R: Cystatin C, kidney function and cardiovascular disease. *Pediatr Nephrol* 21:1223-1230, 2006
186. Bolbrinker J, Beige J, Huber M, Sharma AM, Thomas A, Deter HC, Kreutz R: Role of cyp2c9 genetic variants for salt sensitivity and the regulation of the renin-angiotensin-aldosterone system in normotensive men. *J Hypertens* 29:56-61, 2010
187. Bonne JF, Fournier A, Massy Z, Choukroun G, Fournier A: Overview of randomised trials of ACE inhibitors. *Lancet* 368:1152-1153, 2006
188. Bonne JF, Shahapuni I, Mailliez S, Oprisiu R, Temmar M, Choukroun G, Massy ZA, Fournier A: [Which optimal antihypertensive bitherapy for kidney patients?]. *Nephrol Ther* 3:79-88, 2007
189. Bonne JF, Shahapuni I, Massy Z, Choukroun G, Fournier A: Letter on the relation between serum Ca, PO<sub>4</sub>, and PTH with mortality in dialysis patients. *Kidney Int* 71:178, 2007
190. Borchhardt KA, Horl WH, Sunder-Plassmann G: Reversibility of 'secondary hypercalcaemia' after kidney transplantation. *Am J Transplant* 5:1757-1763, 2005
191. Borchhardt KA, Heinzl H, Gessl A, Horl WH, Kaserer K, Sunder-Plassmann G: Calcitonin concentrations in patients with chronic kidney disease and medullary thyroid carcinoma or c-cell hyperplasia. *Kidney Int* 70:2014-2020,
192. Bosch T, Schmidt B, Kleophas W, Gillen C, Otto V, Passlick-Deetjen J, Gurland HJ: LDL hemoperfusion--a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. *Artif Organs* 21:977-982, 1997
193. Bossenmaier B, Mosthaf L, Mischak H, Ullrich A, Haring HU: Protein kinase C isoforms beta 1 and beta 2 inhibit the tyrosine kinase activity of the insulin receptor. *Diabetologia* 40:863-866, 1997
194. Bostom AG, Shemin D, Bagley P, Massy ZA, Zanolli A, Christopher K, Spiegel P, Jacques PF, Dworkin L, Selhub J: Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. *Circulation* 101:2829-2832, 2000

195. Bostom AG, Shemin D, Gohh RY, Beaulieu AJ, Bagley P, Massy ZA, Jacques PF, Dworkin L, Selhub J: Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. *Kidney Int Suppl* 78:S246-S252, 2001
196. Boure T, Vanholder R: Biochemical and clinical evidence for uremic toxicity. *Artif Organs* 28:248-253, 2004
197. Boure T, Vanholder R: Which dialyser membrane to choose? *Nephrol Dial Transplant* 19:293-296, 2004
198. Brand E, Schorr U, Ringel J, Beige J, Distler A, Sharma AM: Aldosterone synthase gene (CYP11B2) C-344T polymorphism in Caucasians from the Berlin Salt-Sensitivity Trial (BeSST). *J Hypertens* 17:1563-1567, 1999
199. Brandstrom H, Rydvall A, Stegmayr B, Soderberg-Svanstrom J, Wikdahl AM: [A killer bacteria caused fasciitis with sepsis. Prompt handling saved the patient's life]. *Lakartidningen* 93:3687-3689, 1996
200. Brandt D, Gimona M, Hillmann M, Haller H, Mischak H: Protein kinase C induces actin reorganization via a Src-and Rho-dependent pathway. *J Biol Chem* 277:20903-20910, 2002
201. Brandt DT, Goerke A, Heuer M, Gimona M, Leitges M, Kremmer E, Lammers R, Haller H, Mischak H: Protein kinase C delta induces Src kinase activity via activation of the protein tyrosine phosphatase PTP alpha. *J Biol Chem* 278:34073-34078, 2003
202. Bratel T, Ljungman S, Runold M, Stenvinkel P: Renal function in hypoxaemic chronic obstructive pulmonary disease: effects of long-term oxygen treatment. *Respir Med* 97:308-316, 2003
203. Braun J, Hammerschmidt M, Schreiber M, Heidler R, Horl WH: Is zinc protoporphyrin an indicator of iron-deficient erythropoiesis in maintenance haemodialysis patients? *Nephrol Dial Transplant* 11:492-497, 1996
204. Braun J, Lindner K, Schreiber M, Heidler RA, Horl WH: Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. *Nephrol Dial Transplant* 12:1173-1181, 1997
205. Braun N, Rosenfeld S, Giolai M, Banzhaf W, Fretschner R, Warth H, Weinstock C, Deppisch R, Erley CM, Muller GA, .: Effect of continuous hemodiafiltration on IL-6, TNF-alpha, C3a, and TCC in patients with SIRS/septic shock using two different membranes. *Contrib Nephrol* 116:89-98, 1995
206. Bretschneider F, Jankowski V, Gunthner T, Salem S, Nierhaus M, Schulz A, Zidek W, Jankowski J: Replacement of acetonitrile by ethanol as solvent in reversed phase chromatography of biomolecules. *J Chromatogr B Analyt Technol Biomed Life Sci* 878:763-768, 2011
207. Bronnick K, Ehrt U, Emre M, De Deyn PP, Wesnes K, Tekin S, Aarsland D: Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. *J Neurol Neurosurg Psychiatry* 77:1136-1142, 2006
208. Brouckaert P, Libert C, Cauwels A, Everaerd B, Van MW, Ameloot P, Gansemans Y, Grijalba B, Takahashi N, Truong MJ, Van LP, Fiers W: Inhibition of and sensitization to the lethal effects of tumor necrosis factor. *J Inflamm* 47:18-26, 1995
209. Brouckaert P, Fiers W: Tumor necrosis factor and the systemic inflammatory response syndrome. *Curr Top Microbiol Immunol* 216:167-187, 1996
210. Brouckaert P, Takahashi N, van Tiel ST, Hostens J, Eggermont AM, Seynhaeve AL, Fiers W, ten Hagen TL: Tumor necrosis factor-alpha augmented tumor response in B16BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil pharmacokinetics. *Int J Cancer* 109:442-448, 2004
211. Brouns R, De Deyn PP: Neurological complications in renal failure: a review. *Clin Neurol Neurosurg* 107:1-16, 2004
212. Brouns R, Crols R, Engelborghs S, De Deyn PP: Pituitary apoplexy presenting as chemical meningitis. *Lancet* 364:502, 2004
213. Brouns R, De SD, Neetens I, De Deyn PP: Fatal venous cerebral air embolism secondary to a disconnected central venous catheter. *Cerebrovasc Dis* 21:212-214, 2006
214. Brouns R, Sheorajpanday R, Braxel E, Eyskens F, Baker R, Hughes D, Mehta A, Timmerman T, Vincent MF, De Deyn PP: Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. *Clin Neurol Neurosurg* 109:479-484, 2007
215. Brouwers N, Slegers K, Engelborghs S, Bogaerts V, van Duijn CM, De Deyn PP, Van BC, Dermaut B: The UBQLN1 polymorphism, UBQ-8i, at 9q22 is not associated with Alzheimer's disease with onset before 70 years. *Neurosci Lett* 392:72-74, 2006
216. Brouwers N, Slegers K, Engelborghs S, Bogaerts V, Serneels S, Kamali K, Corsmit E, De LE, Martin JJ, De Deyn PP, Van BC, Theuns J: Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease. *Brain* 129:2984-2991, 2006
217. Brouwers N, Nuytemans K, van der ZJ, Gijssels I, Engelborghs S, Theuns J, Kumar-Singh S, Pickut BA, Pals P, Dermaut B, Bogaerts V, De PT, Serneels S, Van den BM, Cuijt I, Matheijssens M, Peeters K, Sciot R, Martin JJ, Cras P, Santens P, Vandenberghe R, De Deyn PP, Cruts M, Van BC, Slegers K: Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. *Arch Neurol* 64:1436-1446, 2007
218. Brown SB, Brierley TT, Palanisamy N, Salusky IB, Goodman W, Brandt ML, Drueke TB, Sarfati E, Urena P, Chaganti RS, Pike JW, Arnold A: Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia. *J Clin Endocrinol Metab* 85:868-872, 2000
219. Bruchfeld A, Carrero JJ, Qureshi AR, Lindholm B, Barany P, Heimbürger O, Hu M, Lin X, Stenvinkel P, Miller EJ: Elevated serum macrophage migration inhibitory factor (mif) concentrations in chronic kidney disease (ckd) are associated with markers of oxidative stress and endothelial activation. *Mol Med* 15:70-75, 2009
220. Brunet P, Rigot JM, Coupez B, Mazeman E: [Extracorporeal shockwave lithotripsy and hemophilia: apropos of a case]. *Prog Urol* 5:99-101, 1995
221. Brunet P, Aillaud MF, San MM, Philip-Joet C, Dussol B, Bernard D, Juhan-Vague I, Berland Y: Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. *Kidney Int* 48:794-800, 1995
222. Brunet P, Saingra Y, Leonetti F, Vacher-Coconat H, Ramanarivo P, Berland Y: Tolerance of haemodialysis: a randomized cross-over trial of 5-h versus 4-h treatment time. *Nephrol Dial Transplant* 11 Suppl 8:46-51, 1996
223. Brunet P, Leroy J, Danjou P: [Eight cases of pyelo-ureteral junction syndrome treated by laparoscopic surgery]. *Chirurgie* 121:415-417, 1996
224. Brunet P, Wuest JD: Conversion of Macrocylic Polyamines into Carbon-Substituted Derivatives. Synthesis of Derivatives of 1,5,9-Triazacyclododecane-2-carbonitrile. *J Org Chem* 61:1847-1849, 1996
225. Brunet P, Capo C, Dellacasagrande J, Thirion X, Mege JL, Berland Y: IL-10 synthesis and secretion by peripheral blood mononuclear cells in haemodialysis patients. *Nephrol Dial Transplant* 13:1745-1751, 1998

226. Brunet P, Berland Y: Water quality and complications of haemodialysis. *Nephrol Dial Transplant* 15:578-580, 2000
227. Brunet P, Meria P, Mahe P, Danjou P: Laparoscopically-assisted percutaneous nephrolithotomy for the treatment of anterior calyceal diverticula. *BJU Int* 86:1088-1089, 2000
228. Brunet P, Dou L, Cerini C, Berland Y: Protein-bound uremic retention solutes. *Adv Ren Replace Ther* 10:310-320, 2003
229. Brunet P, Demers E, Maris T, Enright GD, Wuest JD: Designing permeable molecular crystals that react with external agents to give crystalline products. *Angew Chem Int Ed Engl* 42:5303-5306, 2003
230. Brunet P, Moineau G, Liot M, Burgaud A, Dubrana F, Le ND: [Radiological and clinical study of the ulna's end instability after Sauve-Kapandji procedure]. *Chir Main* 23:178-183, 2004
231. Brunet P, Limat L: Defects and spatiotemporal disorder in a pattern of falling liquid columns. *Phys Rev E Stat Nonlin Soft Matter Phys* 70:046207, 2004
232. Brunet P, Charrois O, Degeorges R, Boisrenoult P, Beaufilets P: [Reconstruction of acute posterior cruciate ligament tears using a synthetic ligament]. *Rev Chir Orthop Reparatrice Appar Mot* 91:34-43, 2005
233. Brunet P, Descamps PM, Meria P: [Laparoscopic pyeloureteral anastomosis for ureteropelvic junction repair]. *Ann Urol (Paris)* 39:257-260, 2005
234. Brunet P, Frenkian G, Girard AM, Gombert F, Petitclerc T, Reach I, Colas S: [Backward flow of blood in the extracorporeal circuit pressure transducers of the generator-monitors of hemodialysis]. *Nephrol Ther* 1:157-160, 2005
235. Brunet P, Eggers J, Deegan RD: Vibration-induced climbing of drops. *Phys Rev Lett* 99:144501, 2007
236. Brunet P, Oddeze C, Paganelli F, Andreies M, Faure V, Opris-Saveanu A, Morange S, Portugal H, Dussol B, Berland Y: Cardiac troponins I and T in hemodialysis patients without acute coronary syndrome. *Int J Cardiol* 2007
237. Brunet P: Stabilized Kuramoto-Sivashinsky equation: a useful model for secondary instabilities and related dynamics of experimental one-dimensional cellular flows. *Phys Rev E Stat Nonlin Soft Matter Phys* 76:017204, 2007
238. Brunet P, Gondouin B, Duval-Sabatier A, Dou L, Cerini C, Dignat-George F, Jourde-Chiche N, Argiles A, Burtsey S: Does uremia cause vascular dysfunction? *Kidney Blood Press Res* 34:284-290, 2011
239. Bruylant K, Crols R, Humbel RL, Appel B, De Deyn PP: Probably anti-Tr associated paraneoplastic cerebellar degeneration as initial presentation of a squamous cell carcinoma of the lung. *Clin Neurol Neurosurg* 108:415-417, 2006
240. Buchmayer H, Sunder-Plassmann G, Hirschl MM, Kletzmayer J, Woisetschlager C, Laggner AN, Horl WH, Fodinger M: G-protein beta3 subunit gene (GNB3) polymorphism 825C-->T in patients with hypertensive crisis. *Crit Care Med* 28:3203-3206, 2000
241. Buhlin K, Barany P, Heimburger O, Stenvinkel P, Gustafsson A: Oral health and pro-inflammatory status in end-stage renal disease patients. *Oral Health Prev Dent* 5:235-244, 2007
242. Bugnicourt JM, Da Silveira C, Bengrine A, Godefroy O, Baumbach G, Sevestre H, Bode-Boeger SM, Kielstein JT, Massy ZA, Chillon JM: Chronic renal failure alters endothelial function in cerebral circulation in mice. *Am J Physiol Heart Circ Physiol* 301:H1143-1152, 2011
243. Bugnicourt JM, Leclercq C, Chillon JM, Diouf M, Deramond H, Canaple S, Lamy C, Massy ZA, Godefroy O: Presence of intracranial artery calcification is associated with mortality and vascular events in patients with ischemic stroke after hospital discharge: A cohort study. *Stroke* 42:3447-3453, 2011
244. Bultinck J, Sips P, Vakaet L, Brouckaert P, Cauwels A: Systemic NO production during (septic) shock depends on parenchymal and not on hematopoietic cells: in vivo iNOS expression pattern in (septic) shock. *FASEB J* 20:2363-2365, 2006
245. Bultinck J, Brouckaert P, Cauwels A: The in vivo contribution of hematopoietic cells to systemic TNF and IL-6 production during endotoxemia. *Cytokine* 36:160-166, 2006
246. Burgelman M, Vanholder R, Fostier H, Ringoir S: Estimation of parameters in a two-pool urea kinetic model for hemodialysis. *Med Eng Phys* 19:69-76, 1997
247. Burger H, Grobbee DE, Druke T: Osteoporosis and salt intake. *Nutr Metab Cardiovasc Dis* 10:46-53, 2000
248. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R: Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. *Mov Disord* 21:1899-1907, 2006
249. Burns A, De Deyn PP: Risperidone for the treatment of neuropsychiatric features in dementia. *Drugs Aging* 23:887-896, 2006
250. Buyle M, Engelborghs S, Kunnen J, De Deyn PP: Headache as only symptom in multiple cervical artery dissection. *Headache* 41:509-511, 2001
251. Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P: Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. *Clin J Am Soc Nephrol* 3:61-68, 2008
252. Cairns TM, Friedman LS, Lou H, Whitbeck JC, Shaner MS, Cohen GH, Eisenberg RJ: N-terminal mutants of herpes simplex virus type 2 gH are transported without gL but require gL for function. *J Virol* 81:5102-5111, 2007
253. Calaf R, Cerini C, Genovesio C, Verhaeghe P, Jourde-Chiche N, Berge-LeFranc D, Gondouin B, Dou L, Morange S, Argiles A, Rathelot P, Dignat-George F, Brunet P, Charpiot P: Determination of uremic solutes in biological fluids of chronic kidney disease patients by hplc assay. *J Chromatogr B Analyt Technol Biomed Life Sci* 879:2281-2286, 2011
254. Caloca MJ, Garcia-Bermejo ML, Blumberg PM, Lewin NE, Kremmer E, Mischak H, Wang S, Nacro K, Bienfait B, Marquez VE, Kazanietz MG: beta2-chimaerin is a novel target for diacylglycerol: binding properties and changes in subcellular localization mediated by ligand binding to its C1 domain. *Proc Natl Acad Sci U S A* 96:11854-11859, 1999
255. Campbell M, Sonkodi S, Soucek M, Wiecek A: A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy. *Clin Exp Hypertens* 23:345-355, 2001
256. Campistol JM, Argiles A: Dialysis-related amyloidosis: visceral involvement and protein constituents. *Nephrol Dial Transplant* 11 Suppl 3:142-145, 1996
257. Canagarajah B, Leskow FC, Ho JY, Mischak H, Saidi LF, Kazanietz MG, Hurley JH: Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin. *Cell* 119:407-418, 2004
258. Canalejo A, Almaden Y, De SR, Glorieux G, Garfia B, Luque F, Vanholder R, Rodriguez M: Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol. *Kidney Int* 63:732-737, 2003



259. Canaud B, Garred LJ, Argiles A, Flavier JL, Bouloux C, Mion C: Creatinine kinetic modelling: a simple and reliable tool for the assessment of protein nutritional status in haemodialysis patients. *Nephrol Dial Transplant* 10:1405-1410, 1995
260. Canaud B, Leblanc M, Garred LJ, Bosc JY, Argiles A, Mion C: Protein catabolic rate over lean body mass ratio: a more rational approach to normalize the protein catabolic rate in dialysis patients. *Am J Kidney Dis* 30:672-679, 1997
261. Canaud B, Bosc JY, Leray H, Stec F, Argiles A, Leblanc M, Mion C: On-line haemodiafiltration: state of the art. *Nephrol Dial Transplant* 13 Suppl 5:3-11, 1998
262. Canaud B, Bosc JY, Leray-Moragues H, Stec F, Argiles A, Leblanc M, Mion C: On-line haemodiafiltration. Safety and efficacy in long-term clinical practice. *Nephrol Dial Transplant* 15 Suppl 1:60-67, 2000
263. Cancarini GC, Faict D, De VC, Guiberteau R, Tranaeus A, Minetti L, Maiorca R: Clinical evaluation of a peritoneal dialysis solution with 33 mmol/L bicarbonate. *Perit Dial Int* 18:576-582, 1998
264. Cano N, Fiaccadori E, Tesinsky P, Toigo G, Druml W, Kuhlmann M, Mann H, Horl WH: ESPEN Guidelines on Enteral Nutrition: Adult renal failure. *Clin Nutr* 25:295-310, 2006
265. Canova NK, Kmonickova E, Martinek J, Zidek Z, Farghali H: Thapsigargin, a selective inhibitor of sarco-endoplasmic reticulum Ca<sup>2+</sup>-ATPases, modulates nitric oxide production and cell death of primary rat hepatocytes in culture. *Cell Biol Toxicol* 23:337-354, 2007
266. Capasso G, Gennaro CI, Ragione FD, Manna C, Ciarcia R, Florio S, Perna A, Pollastro RM, Damiano S, Mazzoni O, Galletti P, Zappia V: In vivo Effect of the Natural Antioxidant Hydroxytyrosol on Cyclosporine Nephrotoxicity in Rats. *Nephrol Dial Transplant* 2007
267. Capeillere-Blandin C, Gausson V, Nguyen AT, scamps-Latscha B, Druke T, Witko-Sarsat V: Respective role of uraemic toxins and myeloperoxidase in the uraemic state. *Nephrol Dial Transplant* 21:1555-1563, 2006
268. Carder M, McNamee R, Beverland I, Elton R, Van TM, Cohen GR, Boyd J, Macnee W, Agius RM: Interacting effects of particulate pollution and cold temperature on cardiorespiratory mortality in Scotland. *Occup Environ Med* 65:197-204, 2008
269. Carrega L, Giaime P, Montserrat C, Vincente O, Brunet P, Dussol B, Berland Y, Guieu R: Influence of the dialysis membrane on markers of tissue ischemia. *J Investig Med* 54:62-66, 2006
270. Carrero JJ, Axelsson J, Avesani CM, Heimbürger O, Lindholm B, Stenvinkel P: Being an inflamed peritoneal dialysis patient -a Dante's journey. *Contrib Nephrol* 150:144-151, 2006
271. Carrero JJ, Qureshi AR, Axelsson J, Avesani CM, Suliman ME, Kato S, Barany P, Snaedal-Jonsdottir S, Alvestrand A, Heimbürger O, Lindholm B, Stenvinkel P: Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. *Am J Clin Nutr* 85:695-701, 2007
272. Carrero JJ, Qureshi AR, Axelsson J, Yilmaz MI, Rehnmark S, Witt MR, Barany P, Heimbürger O, Suliman ME, Alvestrand A, Lindholm B, Stenvinkel P: Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. *J Intern Med* 262:690-701, 2007
273. Carrero JJ, Stenvinkel P, Fellstrom B, Qureshi AR, Lamb K, Heimbürger O, Barany P, Radhakrishnan K, Lindholm B, Soveri I, Nordfors L, Shiels PG: Telomere attrition is associated with inflammation, low fetuin-A levels and high mortality in prevalent haemodialysis patients. *J Intern Med* 263:302-312, 2008
274. Carrero JJ, Brodin L, Lindholm B, Stenvinkel P: Adiponectin in chronic kidney disease: Dr jekyll and mr hyde. *Kidney Int* 75:120-121, 2009
275. Carrero JJ, Hua X, Stenvinkel P, Qureshi AR, Heimbürger O, Barany P, Lindholm B, Frostegard J: Low levels of igr antibodies against phosphorylcholine-a increase mortality risk in patients undergoing haemodialysis. *Nephrol Dial Transplant* 24:3454-3460, 2009
276. Carrero JJ, Ortiz A, Qureshi AR, Martin-Ventura JL, Barany P, Heimbürger O, Marron B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM: Additive effects of soluble tweak and inflammation on mortality in hemodialysis patients. *Clin J Am Soc Nephrol* 4:110-118, 2009
277. Carrero JJ, Park SH, Axelsson J, Lindholm B, Stenvinkel P: Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: A dreadful triad. *Semin Dial* 22:381-386, 2009
278. Carrero JJ, Qureshi AR, Parini P, Arver S, Lindholm B, Barany P, Heimbürger O, Stenvinkel P: Low serum testosterone increases mortality risk among male dialysis patients. *J Am Soc Nephrol* 20:613-620, 2009
279. Carrero JJ, Stenvinkel P: Nutrition: Can ghrelin improve appetite in uremic wasting? *Nat Rev Nephrol* 5:672-673, 2009
280. Carrero JJ, Stenvinkel P: Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: A hypothesis proposal. *Clin J Am Soc Nephrol* 4 Suppl 1:S49-55, 2009
281. Carrero JJ, Witasz A, Stenvinkel P, Qureshi AR, Heimbürger O, Barany P, Suliman ME, Anderstam B, Lindholm B, Nordfors L, Schalling M, Axelsson J: Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. *Nephrol Dial Transplant* 25:901-906, 2009
282. Carrero JJ, Stenvinkel P, Cuppari L, Ikizler TA, Kalantar-Zadeh K, Kaysen G, Mitch WE, Price SR, Wanner C, Wang AY, ter Wee P, Franch HA: Etiology of the protein-energy wasting syndrome in chronic kidney disease: A consensus statement from the international society of renal nutrition and metabolism (isrnm). *J Ren Nutr* 23:77-90, 2013
283. Cattani P, Halimi B, Aidan K, Billotey C, Tamas C, Druke TB, Sarfati E: Reoperation for secondary uremic hyperparathyroidism: are technical difficulties influenced by initial surgical procedure? *Surgery* 127:562-565, 2000
284. Cauwels A, Brouckaert P, Grooten J, Huang S, Aguet M, Fiers W: Involvement of IFN-gamma in Bacillus Calmette-Guerin-induced but not in tumor-induced sensitization to TNF-induced lethality. *J Immunol* 154:2753-2763, 1995
285. Cauwels A, Fiers W, Brouckaert P: Murine IL-12 is involved in Calmette-Guerin bacillus-induced sensitization and is by itself sufficient to sensitize mice to the lethal effects of human TNF1. *J Immunol* 156:4686-4690, 1996
286. Cauwels A, Van MW, Janssen B, Everaerd B, Huang P, Fiers W, Brouckaert P: Protection against TNF-induced lethal shock by soluble guanylate cyclase inhibition requires functional inducible nitric oxide synthase. *Immunity* 13:223-231, 2000
287. Cauwels A, Janssen B, Waeytens A, Cuvelier C, Brouckaert P: Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. *Nat Immunol* 4:387-393, 2003
288. Cauwels A, Bultinck J, Brouckaert P: Dual role of endogenous nitric oxide in tumor necrosis factor shock: induced NO tempers oxidative stress. *Cell Mol Life Sci* 62:1632-1640, 2005
289. Cauwels A, Janssen B, Buys E, Sips P, Brouckaert P: Anaphylactic shock depends on PI3K and eNOS-derived NO. *J Clin Invest* 116:2244-2251, 2006
290. Cauwels A, Brouckaert P: Survival of TNF toxicity: Dependence on caspases and NO. *Arch Biochem Biophys* 2007

291. Cauwels A, Brouckaert P: CRITICAL ROLE FOR SMALL AND LARGE CONDUCTANCE CALCIUM-DEPENDENT POTASSIUM CHANNELS IN ENDOTOXEMIA AND TNF TOXICITY. Shock Publish Ahead of Print: 2007
292. Cauwels A, Brouckaert P: Survival of TNF toxicity: dependence on caspases and NO. Arch Biochem Biophys 462:132-139, 2007
293. Cederholm T, Persson M, Andersson P, Stenvinkel P, Nordfors L, Madden J, Vedin I, Wretling B, Grimble RF, Palmblad J: Polymorphisms in cytokine genes influence long-term survival differently in elderly male and female patients. J Intern Med 262:215-223, 2007
294. Cerini C, Dou L, Anfosso F, Sabatier F, Moal V, Glorieux G, De SR, Vanholder R, gnat-George F, Sampol J, Berland Y, Brunet P: P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 92:140-150, 2004
295. Cesnek M, Holy A, Masojdikova M, Kmonickova E, Zidek Z: Synthesis of guanidino analogues of PMPDAP and their immunobiological activity. Bioorg Med Chem 16:965-980, 2008
296. Chalfant CE, Mischak H, Watson JE, Winkler BC, Goodnight J, Farese RV, Cooper DR: Regulation of alternative splicing of protein kinase C beta by insulin. J Biol Chem 270:13326-13332, 1995
297. Chalmers MJ, Quinn JP, Blakney GT, Emmett MR, Mischak H, Gaskell SJ, Marshall AG: Liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometric characterization of protein kinase C phosphorylation. J Proteome Res 2:373-382, 2003
298. Chalmers MJ, Kolch W, Emmett MR, Marshall AG, Mischak H: Identification and analysis of phosphopeptides. J Chromatogr B Analyt Technol Biomed Life Sci 803:111-120, 2004
299. Chalmers MJ, Mackay CL, Hendrickson CL, Wittke S, Walden M, Mischak H, Fliser D, Just I, Marshall AG: Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal Chem 77:7163-7171, 2005
300. Chanard J, Drueke TB: [Salt consumption, arterial pressure, morbidity, and mortality]. Servir 50:26-30, 2002
301. Chasseraud M, Liabeuf S, Mozar A, Mentaverri R, Brazier M, Massy ZA, Kamel S: Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification. Ther Apher Dial 15:140-146, 2011
302. Chen Z, Earl P, Americo J, Damon I, Smith SK, Yu F, Sebrell A, Emerson S, Cohen G, Eisenberg RJ, Gorshkova I, Schuck P, Satterfield W, Moss B, Purcell R: Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol 81:8989-8995, 2007
303. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P: Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2:898-905, 2007
304. Chmiel B, Karkoszka H, Cierpka L, Wiecek A: Rheological properties of red blood cells in kidney transplant recipients: the role of lipid profile and type of immunosuppression. Transplant Proc 37:1885-1888, 2005
305. Chmielewski M, Carrero JJ, Qureshi AR, Axelsson J, Heimbürger O, Berglund L, Barany P, Rutkowski B, Lindholm B, Stenvinkel P: Temporal discrepancies in the association between the apob/apoa-i ratio and mortality in incident dialysis patients. J Intern Med 265:708-716, 2009
306. Chmielewski M, Carrero JJ, Stenvinkel P, Lindholm B: Metabolic abnormalities in chronic kidney disease that contribute to cardiovascular disease, and nutritional initiatives that may diminish the risk. Curr Opin Lipidol 20:3-9, 2009
307. Choukroun G, Schmitt F, Martinez F, Drueke TB, Bankir L: Low urine flow reduces the capacity to excrete a sodium load in humans. Am J Physiol 273:R1726-R1733, 1997
308. Chudek J, Wiecek A, Kokot F: [The influence of water immersion on serum erythropoietin concentration in patients with essential arterial hypertension]. Pol Arch Med Wewn 96:427-434, 1996
309. Chudek J, Wiecek A, Kokot F: Influence of water immersion on plasma erythropoietin concentration in patients with essential hypertension. Kidney Blood Press Res 20:406-410, 1997
310. Chudek J, Karkoszka H, Wiecek A, Kovacs G, Ritz E, Kokot F: Secondary hyperparathyroidism resistant to active vitamin D is not unique to renal failure--observation in a patient with distal tubular acidosis and pancreatic malabsorption. Nephrol Dial Transplant 13:776-778, 1998
311. Chudek J, Wiecek A, Kokot F, Grochal A, Switala J, Kanwischer J: [Serum erythropoietin concentration in women with uterine or ovarian tumors]. Przegl Lek 55:47-50, 1998
312. Chudek J, Adamczak M, Kokot F, Karkoszka H, Ignacy W, Klimek D, Wiecek A: Relationship between body composition, sex hormones and leptinemia in hemodialyzed patients with chronic renal failure. Clin Nephrol 58:431-437, 2002
313. Chudek J, Adamczak M, Karkoszka H, Budzinski G, Ignacy W, Funahashi T, Matsuzawa Y, Cierpka L, Kokot F, Wiecek A: Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc 35:2186-2189, 2003
314. Chudek J, Piecha G, Kokot F, Wiecek A: Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients. J Nephrol 16:710-715, 2003
315. Chudek J, Adamczak M, Kania M, Holowiecka A, Rozmus W, Kokot F, Wiecek A: Does plasma leptin concentration predict the nutritional status of hemodialyzed patients with chronic renal failure? Med Sci Monit 9:CR377-CR382, 2003
316. Chudek J, Budzinski G, Karkoszka H, Marcinkowski W, Holowiecka A, Kusmierski S, Kokot F, Cierpka L, Wiecek A: [Outcome assessment of kidney transplantation in Katowice in years 1983-2000]. Wiad Lek 57:206-211, 2004
317. Chudek J, Kolonko A, Krol R, Ziaja J, Cierpka L, Wiecek A: The intrarenal vascular resistance parameters measured by duplex Doppler ultrasound shortly after kidney transplantation in patients with immediate, slow, and delayed graft function. Transplant Proc 38:42-45, 2006
318. Chudek J, Piecha G, Nieszporek T, Marini F, Brandi ML, Wiecek A: Novel 1113delC menin gene mutation in a Polish family with multiple endocrine neoplasia type 1 syndrome. Eur J Intern Med 17:447-449, 2006
319. Chudek J, Adamczak M, Nieszporek T, Wiecek A: The adipose tissue as an endocrine organ--a nephrologists' perspective. Contrib Nephrol 151:70-90, 2006
320. Chudek J, Wiecek A: Adipose tissue, inflammation and endothelial dysfunction. Pharmacol Rep 58 Suppl:81-88, 2006
321. Chudek J, Nagy A, Kokot F, Podwinski A, Wiecek A, Ritz E, Kovacs G: Phosphatemia is related to chromosomal aberrations of parathyroid glands in patients with hyperparathyroidism. J Nephrol 20:164-172, 2007

322. Chung SH, Stenvinkel P, Bergstrom J, Lindholm B: Biocompatibility of new peritoneal dialysis solutions: what can we hope to achieve? *Perit Dial Int* 20 Suppl 5:S57-S67, 2000
323. Chung SH, Stenvinkel P, Heimbürger O, Bergstrom J, Lindholm B: Prevention and treatment of the malnutrition, inflammation and atherosclerosis (MIA) syndrome in uremic patients. *Pol Arch Med Wewn* 104:645-654, 2000
324. Chung SH, Heimbürger O, Stenvinkel P, Bergstrom J, Lindholm B: Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. *Nephrol Dial Transplant* 16:2240-2245, 2001
325. Chung SH, Heimbürger O, Stenvinkel P, Qureshi AR, Lindholm B: Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. *Nephrol Dial Transplant* 18:590-597, 2003
326. Chung SH, Heimbürger O, Stenvinkel P, Wang T, Lindholm B: Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. *Perit Dial Int* 23:174-183, 2003
327. Chung SH, Heimbürger O, Lindholm B, Stenvinkel P: Chronic inflammation in PD patients. *Contrib Nephrol* 104-111, 2003
328. Chung SH, Stenvinkel P, Lindholm B, Avesani CM: Identifying and managing malnutrition stemming from different causes. *Perit Dial Int* 27 Suppl 2:S239-S244, 2007
329. Clodi M, Kotzmann H, Riedl M, Schmidt A, Barnas U, Muhlbacher F, Mustafa G, Horl WH, Waldhausl W, Mayer G, Luger A: The long-acting dopamine agonist bromocriptine mesylate as additive immunosuppressive drug after kidney transplantation. *Nephrol Dial Transplant* 12:748-752, 1997
330. Cigarran S, Pousa M, Castro MJ, Gonzalez B, Martinez A, Barril G, Aguilera A, Coronel F, Stenvinkel P, Carrero JJ: Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease. *J Ren Nutr* 2012;23:e89-95, 2012
331. Cohen G, Haag-Weber M, Mai B, Deicher R, Horl WH: Effect of immunoglobulin light chains from hemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. *J Am Soc Nephrol* 6:1592-1599, 1995
332. Cohen G, Haag-Weber M, Horl WH: Immune dysfunction in uremia. *Kidney Int Suppl* 62:S79-S82, 1997
333. Cohen G, Rudnicki M, Horl WH: A peptide isolated from a patient on continuous ambulatory peritoneal dialysis has homology to ubiquitin and inhibits the chemotactic response of polymorphonuclear leukocytes. *Miner Electrolyte Metab* 23:210-213, 1997
334. Cohen G, Rudnicki M, Horl WH: Isolation of modified ubiquitin as a neutrophil chemotaxis inhibitor from uremic patients. *J Am Soc Nephrol* 9:451-456, 1998
335. Cohen G, Rudnicki M, Horl WH: Uremic toxins modulate the spontaneous apoptotic cell death and essential functions of neutrophils. *Kidney Int Suppl* 78:S48-S52, 2001
336. Cohen G, Rudnicki M, Walter F, Niwa T, Horl WH: Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. *J Am Soc Nephrol* 12:1264-1271, 2001
337. Cohen G, Rudnicki M, Schmaldienst S, Horl WH: Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients. *Nephrol Dial Transplant* 17:879-883, 2002
338. Cohen G, Rudnicki M, Deicher R, Horl WH: Immunoglobulin light chains modulate polymorphonuclear leukocyte apoptosis. *Eur J Clin Invest* 33:669-676, 2003
339. Cohen G, Horl WH: Retinol binding protein isolated from acute renal failure patients inhibits polymorphonuclear leukocyte functions. *Eur J Clin Invest* 34:774-781, 2004
340. Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, Rincheval N, Combe B: Radiological damage in patients with rheumatoid arthritis on sustained remission. *Ann Rheum Dis* 66:358-363, 2007
341. Cohen G, Riahi Y, Alpert E, Gruzman A, Sasson S: The roles of hyperglycaemia and oxidative stress in the rise and collapse of the natural protective mechanism against vascular endothelial cell dysfunction in diabetes. *Arch Physiol Biochem* 113:259-267, 2007
342. Cohen G, Lagercrantz H, Katz-Salamon M: Abnormal circulatory stress responses of preterm graduates. *Pediatr Res* 61:329-334, 2007
343. Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, Jankowski J, Jankowski V, Argiles A, Anderstam B, Brunet P, Cerini C, Dou L, Deppisch R, Marescau B, Massy Z, Perna A, Raupachova J, Rodriguez M, Stegmayr B, Vanholder R, Horl WH: Review on uraemic toxins III: recommendations for handling uraemic retention solutes in vitro--towards a standardized approach for research on uraemia. *Nephrol Dial Transplant* 22:3381-3390, 2007
344. Cohen GA, Stevenson JG: Intraoperative echocardiography for atrioventricular canal: decision-making for surgeons. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu* 47-50, 2007
345. Cohen GL, Sherman DK, Bastardi A, Hsu L, McGoey M, Ross L: Bridging the partisan divide: Self-affirmation reduces ideological closed-mindedness and inflexibility in negotiation. *J Pers Soc Psychol* 93:415-430, 2007
346. Cohen GM: Access to diagnostics in support of HIV/AIDS and tuberculosis treatment in developing countries. *AIDS* 21 Suppl 4:S81-S87, 2007
347. Cohen GN: Early and advanced molecular biology of amino acid biosynthetic pathways and regulation. *Res Microbiol* 159:21-22, 2008
348. Cohen JL, Cohen G, Solish N, Murray CA: Diagnosis, impact, and management of focal hyperhidrosis: treatment review including botulinum toxin therapy. *Facial Plast Surg Clin North Am* 15:17-vi, 2007
349. Compton F, Hoffmann C, Zidek W, Schmidt S, Schaefer JH: Volumetric hemodynamic parameters to guide fluid removal on hemodialysis in the intensive care unit. *Hemodial Int* 11:231-237, 2007
350. Cook LJ, Davies J, Yates AP, Elliott AC, Lovell J, Joule JA, Pemberton P, Thornalley PJ, Best L: Effects of methylglyoxal on rat pancreatic beta-cells. *Biochem Pharmacol* 55:1361-1367, 1998
351. Cooker LA, Luneburg P, Faict D, Choo C, Holmes CJ: Reduced glucose solutions produced in two-chambered bags. *Perit Dial Int* 17:373-378, 1997
352. Cooker LA, Choo CG, Luneburg P, Lamela J, Holmes CJ: Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro. *Adv Perit Dial* 15:17-20, 1999
353. Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N: Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. *Perit Dial Int* 21 Suppl 3:S102-S107, 2001
354. Cooker LA, Holmes CJ, Hoff CM: Biocompatibility of icodextrin. *Kidney Int Suppl* S34-S45, 2002
355. Coon JJ, Zurbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, Frommberger M, Golovko I, Good DM, Hergert-Rosenthal S, Jankowski J, Julian BA, Kellmann M, Kolch W, Massy Z, Novak J, Rossing K, Schanstra JP, Schiffer E, Theodorescu D, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P: CE-MS analysis of the human

- urinary proteome for biomarker discovery and disease diagnostics. *Proteomics Clin Appl* in press: 2008
356. Cooper DR, Watson JE, Patel N, Illingworth P, Cevedo-Duncan M, Goodnight J, Chalfant CE, Mischak H: Ectopic expression of protein kinase C $\beta$ 1, - $\delta$ , and - $\epsilon$ , but not - $\beta$ 2 or - $\zeta$ , provide for insulin stimulation of glucose uptake in NIH-3T3 cells. *Arch Biochem Biophys* 372:69-79, 1999
  357. Cooper RS, Wolf-Maier K, Luke A, Adeyemo A, Banegas JR, Forrester T, Giampaoli S, Joffres M, Kastarinen M, Primatesta P, Stegmayr B, Thamm M: An international comparative study of blood pressure in populations of European vs. African descent. *BMC Med* 3:2, 2005
  358. Couser W, Druke T, Halloran P, Kasiske B, Klahr S, Morris P: Trial registry policy: common editorial statement a uniform clinical trial registration policy for journals of kidney diseases, dialysis and transplantation. *Nephrol Dial Transplant* 20:691, 2005
  359. Couser W, Druke T, Halloran P, Kasiske B, Klahr S, Morris P: A uniform clinical trial registration policy for journals of kidney diseases, dialysis, and transplantation. *Transplantation* 79:751, 2005
  360. Couser WG, Druke TB, Halloran PF, Kasiske BL, Klahr S, Morris P: A uniform clinical trial registration policy for journals of kidney diseases, dialysis and transplantation. *Am J Transplant* 5:643, 2005
  361. Crespo P, Mischak H, Gutkind JS: Overexpression of mammalian protein kinase C- $\zeta$  does not affect the growth characteristics of NIH 3T3 cells. *Biochem Biophys Res Commun* 213:266-272, 1995
  362. Cordeiro AC, Carrero JJ, Abensur H, Lindholm B, Stenvinkel P: Systemic and local inflammation in peritoneal dialysis: Mechanisms, biomarkers and effects on outcome. *Contrib Nephrol* 163:132-139, 2009
  363. Cordeiro AC, Qureshi AR, Stenvinkel P, Heimbürger O, Axelsson J, Barany P, Lindholm B, Carrero JJ: Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. *Nephrol Dial Transplant* 25:562-568, 2009
  364. Cromphout K, Vleugels W, Heykants L, Schollen E, Keldermans L, Sciôt R, D'Hooge R, De Deyn PP, von FK, Hartmann D, Korner C, Matthijs G: The normal phenotype of Pmm1-deficient mice suggests that Pmm1 is not essential for normal mouse development. *Mol Cell Biol* 26:5621-5635, 2006
  365. Cruts M, Gijssels I, van der ZJ, Engelborghs S, Wils H, Pirici D, Rademakers R, Vandenbergh R, Dermaut B, Martin JJ, van DC, Peeters K, Sciôt R, Santens P, De PT, Mattheijssens M, Van den BM, Cuijt I, Vennekens K, De Deyn PP, Kumar-Singh S, Van BC: Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. *Nature* 442:920-924, 2006
  366. Custodio HM, Broberg K, Wennberg M, Jansson JH, Vessby B, Hallmans G, Stegmayr B, Skerfving S: Polymorphisms in glutathione-related genes affect methylmercury retention. *Arch Environ Health* 59:588-595, 2004
  367. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, Rantapää-Dahlqvist S, Lefvert AK: Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF- $\alpha$ , IL-1 $\beta$ , and IL-1Ra genes. *J Rheumatol* 29:212-219, 2002
  368. Czerwińska B, Kokot F, Franek E, Irzyniec T, Wiecek A: [Effect of orlistat therapy on carbohydrate, lipid, vitamin and hormone plasma levels in obese subjects]. *Pol Arch Med Wewn* 112:1415-1423, 2004
  369. Czerwińska B, Wstrychowski A, Wiecek A: [Osteopoikilosis--rare, hereditary determined, benign bone dysplasia. case report]. *Pol Arch Med Wewn* 113:466-470, 2005
  370. D'Aniello A, Di Fiore MM, Fisher GH, Milone A, Seleni A, D'Aniello S, Perna AF, Ingrosso D: Occurrence of D-aspartic acid and N-methyl-D-aspartic acid in rat neuroendocrine tissues and their role in the modulation of luteinizing hormone and growth hormone release. *FASEB J* 14:699-714, 2000
  371. d'Asseler YM, Koole M, Lemahieu I, Achten E, Boon P, De Deyn PP, Dierckx RA: Recent and future evolutions in NeuroSPECT with particular emphasis on the synergistic use and fusion of imaging modalities. *Acta Neurol Belg* 97:154-162, 1997
  372. D'Haese PC, Shaheen FA, Huraib SO, Djukanovic L, Polenakovic MH, Spasovski G, Shikole A, Schurgers ML, Daneels RF, Lamberts LV, .: Increased silicon levels in dialysis patients due to high silicon content in the drinking water, inadequate water treatment procedures, and concentrate contamination: a multicentre study. *Nephrol Dial Transplant* 10:1838-1844, 1995
  373. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejjanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME: A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. *Kidney Int Suppl*S73-S78, 2003
  374. D'Hooge D, Leher P, Clement DL: Naftidrofuryl in quality of life (NIQOL). A Belgian study. *Int Angiol* 20:288-294, 2001
  375. D'Hooge R, Nagels G, Westland CE, Mucke L, De Deyn PP: Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor protein. *Neuroreport* 7:2807-2811, 1996
  376. D'Hooge R, Raes A, Lebrun P, Diltoer M, Van Bogaert PP, Manil J, Colin F, De Deyn PP: N-methyl-D-aspartate receptor activation by guanidinosuccinate but not by methylguanidine: behavioural and electrophysiological evidence. *Neuropharmacology* 35:433-440, 1996
  377. D'Hooge R, Pei YQ, Raes A, Lebrun P, Van Bogaert PP, De Deyn PP: Anticonvulsant activity of piperine on seizures induced by excitatory amino acid receptor agonists. *Arzneimittelforschung* 46:557-560, 1996
  378. D'Hooge R, Nagels G, Franck F, Bakker CE, Reyniers E, Storm K, Kooy RF, Oostra BA, Willems PJ, De Deyn PP: Mildly impaired water maze performance in male Fmr1 knockout mice. *Neuroscience* 76:367-376, 1997
  379. D'Hooge R, Raes A, Van Bogaert PP, Geelhand M, De Deyn PP: Selective block of N-methyl-D-aspartate (NMDA)-evoked whole-cell currents in mouse cultured spinal neurones by CGP 40116. *Br J Pharmacol* 120:211-214,
  380. D'Hooge R, Raes A, Hiramatsu M, Mori A, Van Bogaert PP, De Deyn PP: Effects of the competitive N-methyl-D-aspartate antagonist CGP 37849 and its ethylester CGP 39551 on N-methyl-D-aspartate-evoked whole-cell currents in cultured spinal neurones and on vestibular stimulation-induced seizures in EL mice. *Arzneimittelforschung* 48:1121-1125, 1998
  381. D'Hooge R, Franck F, Mucke L, De Deyn PP: Age-related deficits in transgenic mice expressing the HIV-1 coat protein gp120. *Eur J Neurosci* 11:4398-4402, 1999
  382. D'Hooge R, Hartmann D, Manil J, Colin F, Gieselmann V, De Deyn PP: Neuromotor alterations and cerebellar deficits in aged arylsulfatase A-deficient transgenic mice. *Neurosci Lett* 273:93-96, 1999
  383. D'Hooge R, Raes A, Van d, V, Van Bogaert PP, De Deyn PP: Effects of competitive NMDA receptor antagonists on excitatory amino acid-evoked currents in mouse spinal cord neurones. *Fundam Clin Pharmacol* 13:67-74, 1999
  384. D'Hooge R, Coenen R, Gieselmann V, Lullmann-Rauch R, De Deyn PP: Decline in brainstem auditory-evoked potentials coincides with loss of spiral ganglion cells in arylsulfatase A-deficient mice. *Brain Res* 847:352-356, 1999

385. D'Hooge R, De Deyn PP, Van d, V, Antoons G, Raes A, Van Bogaert PP: Uraemic guanidino compounds inhibit gamma-aminobutyric acid-evoked whole cell currents in mouse spinal cord neurones. *Neurosci Lett* 265:83-86, 1999
386. D'Hooge R, Marescau B, Qureshi IA, De Deyn PP: Impaired cognitive performance in ornithine transcarbamylase-deficient mice on arginine-free diet. *Brain Res* 876:1-9, 2000
387. D'Hooge R, Van DD, Franck F, Gieselmann V, De Deyn PP: Hyperactivity, neuromotor defects, and impaired learning and memory in a mouse model for metachromatic leukodystrophy. *Brain Res* 907:35-43, 2001
388. D'Hooge R, De Deyn PP: Applications of the Morris water maze in the study of learning and memory. *Brain Res Brain Res Rev* 36:60-90, 2001
389. D'Hooge R, Van d, V, Van Bogaert PP, Marescau B, Vanholder R, De Deyn PP: Involvement of voltage-and ligand-gated Ca<sup>2+</sup> channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. *Kidney Int* 63:1764-1775, 2003
390. D'Hulst C, De GN, Reeve SP, Van DD, De Deyn PP, Hassan BA, Kooy RF: Decreased expression of the GABAA receptor in fragile X syndrome. *Brain Res* 1121:238-245, 2006
391. Dagher PC, Herget-Rosenthal S, Ruehm SG, Jo SK, Star RA, Agarwal R, Molitoris BA: Newly developed techniques to study and diagnose acute renal failure. *J Am Soc Nephrol* 14:2188-2198, 2003
392. Dameche L, Brunet P, George F, ndre-Pinon S, Bernard D, Sampol J, Berland Y: Meltspun cellulose diacetate and polysulfone membranes have the same effect on complement activation and expression of leukocyte adhesion molecules and complement receptors. *Nephrol Dial Transplant* 10 Suppl 10:33-38, 1995
393. Dammeier S, Lovric J, Eulitz M, Kolch W, Mushinski JF, Mischak H: Identification of the smooth muscle-specific protein, sm22, as a novel protein kinase C substrate using two-dimensional gel electrophoresis and mass spectrometry. *Electrophoresis* 21:2443-2453, 2000
394. Dani C, Pavoni V, Corsini I, Longini M, Gori G, Giannesello L, Perna A, Gritti G, Paternostro F, Forestieri A, Buonocore G, Rubatelli FF: Inhaled nitric oxide combined with prostacyclin and adrenomedullin in acute respiratory failure with pulmonary hypertension in piglets. *Pediatr Pulmonol* 42:1048-1056, 2007
395. Daniel L, Brunet P, Berland Y, Pellissier JF: [Chronic glomerular rejection of a renal graft]. *Ann Pathol* 19:143-144, 1999
396. Danjou P, Leroy J, Brunet P, Lemaitre L: [Congenital pyeloureteral junction syndrome in adults treated with laparoscopic surgery]. *Prog Urol* 5:946-950, 1995
397. Dathe C, Daigeler AL, Seifert W, Jankowski V, Mrowka R, Kalis R, Wanker E, Mutig K, Bachmann S, Paliege A: Annexin a2 mediates apical trafficking of renal na<sup>+</sup>-k<sup>+</sup>-2cl<sup>-</sup>-cotransporter. *J Biol Chem* 2014
398. David S, Kumpers P, Shin H, Haller H, Fliser D: Everolimus-associated interstitial pneumonitis in a patient with a heart transplant. *Nephrol Dial Transplant* 22:3363-3364, 2007
399. David S, Kumpers P, Seidler V, Biertz F, Haller H, Fliser D: Diagnostic Value of N-Terminal Pro-B-Type Natriuretic Peptide (NT-ProBNP) for Left Ventricular Dysfunction in Patients with Chronic Kidney Disease Stage 5 on behavioural Haemodialysis. *Nephrol Dial Transplant* 2007
400. David S, Kumpers P, Lukasz A, Fliser D, Martens-Lobenhoffer J, Bode-Boger SM, Kliem V, Haller H, Kielstein JT: Circulating angiotensin-2 levels increase with progress of chronic kidney disease. *Nephrol Dial Transplant* 25:2571-2576, 2010
401. David S, Kumpers P, Seidler V, Biertz F, Haller H, Fliser D: Diagnostic value of n-terminal pro-b-type natriuretic peptide (nt-probnp) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. *Nephrol Dial Transplant* 23:1370-1377, 2008
402. daz-Carroll L, Xiao Y, Whitbeck JC, de Leon MP, Lou H, Kim M, Yu J, Reinherz EL, Isaacs SN, Eisenberg RJ, Cohen GH: Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6. *J Virol* 81:8131-8139, 2007
403. De Corte W, Vanholder R, Dhondt AW, De Waele JJ, Decruyenaere J, Danneels C, Claus S, Hoste EA: Serum urea concentration is probably not related to outcome in icu patients with aki and renal replacement therapy. *Nephrol Dial Transplant* 26:3211-3218, 2011
404. De Deyn PP, Ceuterick C, Saxena V, Crols R, Chappel R, Martin JJ: Chronic colchicine-induced myopathy and neuropathy. *Acta Neurol Belg* 95:29-32, 1995
405. De Deyn PP: On the ethical acceptability of placebo application in neuropsychiatric research. *Acta Neurol Belg* 95:8-17, 1995
406. De Deyn PP, Robitaille P, Vanasse M, Qureshi IA, Marescau B: Serum guanidino compound levels in uremic pediatric patients treated with hemodialysis or continuous cycle peritoneal dialysis. Correlations between nerve conduction velocities and altered guanidino compound concentrations. *Nephron* 69:411-417, 1995
407. De Deyn PP, Marescau B, D'Hooge R, Possemiers I, Nagler J, Mahler C: Guanidino compound levels in brain regions of non-dialyzed uremic patients. *Neurochem Int* 27:227-237, 1995
408. De Deyn PP, D'Hooge R: Placebos in clinical practice and research. *J Med Ethics* 22:140-146, 1996
409. De Deyn PP, Reuck JD, Deberdt W, Vlietinck R, Orgogozo JM: Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group. *Stroke* 28:2347-2352, 1997
410. De Deyn PP, Martin JJ: [The loss of autonomy in disabling neurologic diseases. Ethical considerations]. *Rev Med Liege* 52:403-412, 1997
411. De Deyn PP, Orgogozo JM, De RJ: Acute treatment of stroke. PASS group. Piracetam Acute Stroke Study. *Lancet* 352:326, 1998
412. De Deyn PP, Hiramatsu M, Borggreve F, Goeman J, D'Hooge R, Saerens J, Mori A: Superoxide dismutase activity in cerebrospinal fluid of patients with dementia and some other neurological disorders. *Alzheimer Dis Assoc Disord* 12:26-32, 1998
413. De Deyn PP, Van den Broucke PW, Pickut BA, Appel B, Crols R, Cras P, Martin JJ: Perfusion and thallium single photon emission computed tomography in herpes simplex encephalitis. *J Neurol Sci* 157:96-99, 1998
414. De Deyn PP, Goeman J, Engelborghs S, Hauben U, D'Hooge R, Baro F, Pickut BA: From neuronal and vascular impairment to dementia. *Pharmacopsychiatry* 32 Suppl 1:17-24, 1999
415. De Deyn PP, D'Hooge R: Animal models of focal epilepsy. *Acta Neurol Belg* 99:222-225, 1999
416. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, Lawlor BA: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. *Neurology* 53:946-955, 1999
417. De Deyn PP: Treatment of Alzheimer's disease. *N Engl J Med* 342:821-822, 2000
418. De Deyn PP, Katz IR: Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone. *Int J Geriatr Psychiatry* 15 Suppl 1:S14-S22, 2000

419. De Deyn PP, Katz IR: Appendices. *Int J Geriatr Psychiatry* 15 Suppl 1:S24-S30, 2000
420. De Deyn PP, Wirshing WC: Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. *J Clin Psychiatry* 62 Suppl 21:19-22, 2001
421. De Deyn PP, D'Hooge R, Van Bogaert PP, Marescau B: Endogenous guanidino compounds as uremic neurotoxins. *Kidney Int Suppl* 78:S77-S83, 2001
422. De Deyn PP, Vanholder R, D'Hooge R: Nitric oxide in uremia: effects of several potentially toxic guanidino compounds. *Kidney Int Suppl* S25-S28, 2003
423. De Deyn PP: *Clinical Neurology and Neurosurgery*. *Clin Neurol Neurosurg* 105:v-vi, 2003
424. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, Young CA, Lehman DL, Breier A: Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. *Int J Geriatr Psychiatry* 19:115-126, 2004
425. De Deyn PP, Engelborghs S, Saerens J, Goeman J, Marien P, Maertens K, Nagels G, Martin JJ, Pickut BA: The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease. *Int J Geriatr Psychiatry* 20:70-79, 2005
426. De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A: Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. *Clin Neurol Neurosurg* 107:497-508, 2005
427. De Deyn PP, Buitelaar J: Risperidone in the management of agitation and aggression associated with psychiatric disorders. *Eur Psychiatry* 21:21-28, 2006
428. de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, Dougherty FC, Oguey D: Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. *Int J Clin Pract* 60:1687-1696, 2006
429. de Francisco AL, Stenvinkel P, Vaulont S: Inflammation and its impact on anaemia in chronic kidney disease: From haemoglobin variability to hyporesponsiveness. *NDT Plus* 2:i18-i26, 2009
430. de Jonge WJ, Marescau B, D'Hooge R, De Deyn PP, Hallemeesch MM, Deutz NE, Ruijter JM, Lamers WH: Overexpression of arginase alters circulating and tissue amino acids and guanidino compounds and affects neuromotor behavior in mice. *J Nutr* 131:2732-2740, 2001
431. de Jonge WJ, Hallemeesch MM, Kwikkers KL, Ruijter JM, de Gier-de VC, van Roon MA, Meijer AJ, Marescau B, De Deyn PP, Deutz NE, Lamers WH: Overexpression of arginase I in enterocytes of transgenic mice elicits a selective arginine deficiency and affects skin, muscle, and lymphoid development. *Am J Clin Nutr* 76:128-140, 2002
432. De Keyzer K, Van Laecke S, Peeters P, Vanholder R: Human cytomegalovirus and kidney transplantation: A clinician's update. *Am J Kidney Dis* 58:118-126, 2011
433. de Kreuk AM, Zevenbergen A, Jonuleit T, Schuurhuis GJ, Huijgens PC, Hendriks EC, van Oostveen JW, Lemke HD, Jonkhoff AR: Preservation of G-CSF mobilized whole blood in an automated closed hollow-fiber bioreactor system. *Cytotherapy* 6:380-384, 2004
434. de la MS, Plum J, Passlick-Deetjen J, Grabensee B: One-compartment model for amino acids and other biological molecules in peritoneal dialysis. *Int J Clin Pharmacol Ther* 40:60-68, 2002
435. De Santo NG, Cirillo M, Kirsch KA, Correale G, Drummer C, Frassl W, Perna AF, Di SE, Bellini L, Gunga HC: Anemia and erythropoietin in space flights. *Semin Nephrol* 25:379-387, 2005
436. De Santo NG, Perna AF: Do elevated homocysteine levels predict mortality in chronic kidney disease stages 3-4? *Nat Clin Pract Nephrol* 2:614-615, 2006
437. De Santo NG, Bisaccia C, De Santo RM, Perna AF, Manzo M, Di SE, Cirillo M: Mariano Semmola (1831-1895): the effect of low protein diet in primary albuminuria. *J Nephrol* 19 Suppl 10:S48-S57, 2006
438. De Smet HJ, Baillieux H, Catsman-Berrevoets C, De Deyn PP, Marien P, Paquier PF: Postoperative motor speech production in children with the syndrome of 'cerebellar' mutism and subsequent dysarthria: a critical review of the literature. *Eur J Paediatr Neurol* 11:193-207, 2007
439. De Smet HJ, Baillieux H, De Deyn PP, Marien P, Paquier P: The cerebellum and language: the story so far. *Folia Phoniatr Logop* 59:165-170, 2007
440. De Smet HJ, Baillieux H, Catsman-Berrevoets C, De Deyn PP, Marien P, Paquier PF: Postoperative motor speech production in children with the syndrome of 'cerebellar' mutism and subsequent dysarthria: A critical review of the literature. *Eur J Paediatr Neurol* 2007
441. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Druke TB, Massy ZA: Fgf23 is independently associated with vascular calcification but not bone mineral density in patients at various ckd stages. *Osteoporos Int* 2011
442. De Vriese AS, Vanholder RC, De Sutter JH, Colardyn FA, Lameire NH: Continuous renal replacement therapies in sepsis: where are the data? *Nephrol Dial Transplant* 13:1362-1364, 1998
443. De Vriese AS, Robbrecht DL, Vanholder RC, Vogelaers DP, Lameire NH: Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. *Am J Kidney Dis* 31:108-115, 1998
444. De Vriese AS, Vanholder RC, Pascual M, Lameire NH, Colardyn FA: Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? *Intensive Care Med* 25:903-910, 1999
445. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter JH, Lameire NH: Cytokine removal during continuous hemofiltration in septic patients. *J Am Soc Nephrol* 10:846-853, 1999
446. De Vriese AS, Stoenoiu MS, Elger M, Devuyt O, Vanholder R, Kriz W, Lameire NH: Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. *Kidney Int* 60:202-210, 2001
447. De Wachter DS, Brems S, Vanholder R, Verdonck PR, Hombrouckx RO: Predialysis urea concentration is sufficient to characterize hemodialysis adequacy. *ASAIO J* 44:M670-M676, 1998
448. De BT, Claeys G, Verschraegen G, Devriese LA, Baelle M, Van VB, Vanholder R, Dequidt C, Vaneechoutte M: Continuous ambulatory peritoneal dialysis peritonitis due to *Enterococcus cecorum*. *J Clin Microbiol* 38:3511-3512, 2000
449. De CK, Cornelis R, Strijckmans K, Dams R, Lameire N, Vanholder R: Non-ideal behaviour of free vanadate on a Superose 12 size-exclusion column. Application to in vivo 48V-labelled rat spleen homogenate. *J Chromatogr B Biomed Sci Appl* 757:21-29, 2001
450. De CK, Cornelis R, Strijckmans K, Dams R, Lameire N, Vanholder R: Behaviour of vanadate and vanadium-transferrin complex on different anion-exchange columns. Application to in vivo 48V-labelled rat serum. *J Chromatogr B Analyt Technol Biomed Life Sci* 775:143-152, 2002
451. De CK, Van HM, Chery C, Cornelis R, Strijckmans K, Dams R, Lameire N, Vanholder R: Fractionation of vanadium complexes in serum, packed cells and tissues of Wistar rats by means of gel filtration and anion-exchange chromatography. *J Biol Inorg Chem* 7:884-890, 2002

452. De CK, Cornelis R, Strijckmans K, Dams R, Lameire N, Vanholder R: Fractionation of vanadium in urine of Wistar rats as a function of time after intraperitoneal injection. *J Inorg Biochem* 90:71-77, 2002
453. De FM, Cobellis L, Giraldi D, Mastrogiacomo A, Perna A, Colacurci N, Miele L, De LA: Expression and distribution of notch protein members in human placenta throughout pregnancy. *Placenta* 28:118-126, 2007
454. de GK, Bahlmann FH, Sowa J, Koenig J, Menne J, Haller H, Fliser D: Uremia causes endothelial progenitor cell deficiency. *Kidney Int* 66:641-646, 2004
455. de GK, Bahlmann FH, Bahlmann E, Menne J, Haller H, Fliser D: Kidney graft function determines endothelial progenitor cell number in renal transplant recipients. *Transplantation* 79:941-945, 2005
456. de GK, Goldberg C, Bahlmann FH, Woywodt A, Haller H, Fliser D, Haubitz M: Vascular endothelial damage and repair in antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 56:3847-3853, 2007
457. De KJ, Cornelis R, Mees L, Vanholder R, Verhoeven G: 74As-arsenate metabolism in Flemish Giant rabbits with renal insufficiency. *J Trace Elem Med Biol* 13:7-14, 1999
458. De KJ, Cornelis R, Vanholder R: In vitro methylation of arsenite by rabbit liver cytosol: effect of metal ions, metal chelating agents, methyltransferase inhibitors and uremic toxins. *Drug Chem Toxicol* 22:613-628, 1999
459. De KJ, Cornelis R, Wittevrongel L, Vanholder R: Dose dependent changes in 74As-arsenate metabolism of Flemish Giant rabbits. *J Trace Elem Med Biol* 12:193-200, 1999
460. De SG, Lameire N, Dhondt A, Van LA, Van der GJ, Duym P, Vanholder R: The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). *Nephrol Dial Transplant* 13:1770-1775, 1998
461. De SG, Vanholder R, Rottey S, Duym P, Lameire N: Relationship between gastric emptying and clinical and biochemical factors in chronic haemodialysis patients. *Nephrol Dial Transplant* 16:1850-1855, 2001
462. De SR, Glorieux G, Hsu C, Vanholder R: p-cresol and uric acid: two old uremic toxins revisited. *Kidney Int Suppl* 62:S8-11, 1997
463. De SR, David F, Sandra P, Van KJ, Lesaffer G, Dhondt A, Lameire N, Vanholder R: A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. *Clin Chim Acta* 278:1-21, 1998
464. De SR, Vogeleere P, Van KJ, Lameire N, Vanholder R: Identification by HPLC of uraemic retention solutes decreasing theophylline protein binding. *Nephrol Dial Transplant* 14 Suppl 4:11-12, 1999
465. De SR, Vogeleere P, Van KJ, Lameire N, Vanholder R: Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients. *J Chromatogr A* 847:141-153, 1999
466. De SR, Van KJ, Liebich H, Lesaffer G, Verstraete A, Dhondt A, Duym P, Lameire N, Vanholder R: Heparin-induced release of protein-bound solutes during hemodialysis is an in vitro artifact. *Clin Chem* 47:901-909, 2001
467. De SR, Van KJ, Van VB, De CA, Brunet P, Lameire N, Vanholder R: Toxicity of free p-cresol: a prospective and cross-sectional analysis. *Clin Chem* 49:470-478, 2003
468. De SR, Dhondt A, Eloit S, Galli F, Waterloos MA, Vanholder R: Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. *Nephrol Dial Transplant* 22:2006-2012, 2007
469. De VA, Vanholder R, Lameire N: Severe acute renal failure due to bromate intoxication: report of a case and discussion of management guidelines based on a review of the literature. *Nephrol Dial Transplant* 12:204-209, 1997
470. De WL, Wilssens I, Engelborghs S, De Deyn PP, Marien P: Impairment of syntax and lexical semantics in a patient with bilateral paramedian thalamic infarction. *Brain Lang* 96:69-77, 2006
471. Decramer S, Wittke S, Mischak H, Zurbig P, Walden M, Bouissou F, Bascands JL, Schanstra JP: Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. *Nat Med* 12:398-400, 2006
472. Deicher R, Exner M, Cohen G, Haag-Weber M, Horl WH: Neutrophil beta(2)-microglobulin and lactoferrin content in renal failure patients. *Am J Kidney Dis* 35:1117-1126, 2000
473. Deicher R, Horl WH: Intravenous iron: the iatrogenic kick to lose control over oxygen? *Kidney Blood Press Res* 25:284-288, 2002
474. Deicher R, Horl WH: Anaemia as a risk factor for the progression of chronic kidney disease. *Curr Opin Nephrol Hypertens* 12:139-143, 2003
475. Deicher R, Ziai F, Cohen G, Mullner M, Horl WH: High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. *Kidney Int* 64:728-736, 2003
476. Deicher R, Horl WH: Vitamin C in chronic kidney disease and hemodialysis patients. *Kidney Blood Press Res* 26:100-106, 2003
477. Deicher R, Horl WH: Vitamin C for hyporesponsiveness to EPO: a cure for all? *Am J Kidney Dis* 42:848-849, 2003
478. Deicher R, Horl WH: Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anaemia of chronic kidney disease. *Drugs* 64:499-509, 2004
479. Deicher R, Horl WH: Hepcidin: a molecular link between inflammation and anaemia. *Nephrol Dial Transplant* 19:521-524, 2004
480. Deicher R, Ziai F, Habicht A, Bieglmayer C, Schillinger M, Horl WH: Vitamin C plasma level and response to erythropoietin in patients on maintenance haemodialysis. *Nephrol Dial Transplant* 19:2319-2324, 2004
481. Deicher R, Kirsch B, Mullner M, Kaczirek K, Niederle B, Horl WH: Impact of parathyroidectomy on neutrophil cytosolic calcium in chronic kidney disease patients: a prospective parallel group trial. *J Intern Med* 258:67-76, 2005
482. Deicher R, Horl WH: Hormonal adjuvants for the treatment of renal anaemia. *Eur J Clin Invest* 35 Suppl 3:75-84, 2005
483. Deicher R, Ziai F, Bieglmayer C, Schillinger M, Horl WH: Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. *J Am Soc Nephrol* 16:1811-1818, 2005
484. Deicher R, Horl WH: New insights into the regulation of iron homeostasis. *Eur J Clin Invest* 36:301-309, 2006
485. Deignan JL, Marescau B, Livesay JC, Iyer RK, De Deyn PP, Cederbaum SD, Grody WW: Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia. *Mol Genet Metab* 93:172-178, 2008
486. della FD, Schmelzer B, Hartoko T, Vandenbroucke M, Brands C, De Deyn PP: Securing nasogastric tubes in non-cooperative patients. *Acta Otorhinolaryngol Belg* 50:195-197, 1996

487. della FD, Hartoko T, Vandenbroucke M, Brands C, Schmelzer B, De Deyn PP: [Fixation of nasogastric tubes in agitated and uncooperative patients]. *Rev Laryngol Otol Rhinol (Bord)* 119:59-61, 1998
488. Demeester N, Castro G, Desrumaux C, De GC, Fruchart JC, Santens P, Mulleners E, Engelborghs S, De Deyn PP, Vandekerckhove J, Rosseneu M, Labeur C: Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. *J Lipid Res* 41:963-974, 2000
489. Demetriou D, Shabpar A, Bohmig G, Schmaldienst S, Horl WH, Watschinger B: Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation. *Wien Klin Wochenschr* 112:358-361, 2000
490. Demetriou D, Habicht A, Schillinger M, Horl WH, Vychytil A: Adequacy of automated peritoneal dialysis with and without manual daytime exchange: A randomized controlled trial. *Kidney Int* 70:1649-1655, 2006
491. Depner TA, Vanholder R, Dhondt AM, Van BW, Gotch FA, Casino FG: Is Kt/V urea a satisfactory measure for dosing the newer dialysis regimens? *Semin Dial* 14:8-21, 2001
492. Deppisch R, Gohl H, Smeby L: Microdomain structure of polymeric surfaces--potential for improving blood treatment procedures. *Nephrol Dial Transplant* 13:1354-1359, 1998
493. Deppisch RM, Beck W, Goehl H, Ritz E: Complement components as uremic toxins and their potential role as mediators of microinflammation. *Kidney Int Suppl* 78:S271-S277, 2001
494. Derave W, Marescau B, Vanden EE, Eijnde BO, De Deyn PP, Hespel P: Plasma guanidino compounds are altered by oral creatine supplementation in healthy humans. *J Appl Physiol* 97:852-857, 2004
495. Dermaut B, Kumar-Singh S, De JC, Cruts M, Lofgren A, Lubke U, Cras P, Dom R, De Deyn PP, Martin JJ, Van BC: Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation. *Brain* 124:2383-2392, 2001
496. Dermaut B, Kumar-Singh S, Engelborghs S, Theuns J, Rademakers R, Saerens J, Pickut BA, Peeters K, Van den BM, Vennekens K, Claes S, Cruts M, Cras P, Martin JJ, Van BC, De Deyn PP: A novel presenilin 1 mutation associated with Pick's disease but not beta-amyloid plaques. *Ann Neurol* 55:617-626, 2004
497. Derwa A, Peeters P, Vanholder R: Calcium channel blockers in the prevention of end stage renal disease: a review. *Acta Clin Belg* 59:44-56, 2004
498. Deshmukh DR, Ghole VS, Marescau B, De Deyn PP: Effect of endotoxemia on plasma and tissue levels of nitric oxide metabolites and guanidino compounds. *Arch Physiol Biochem* 105:32-37, 1997
499. Develter W, De CA, Van BW, Vanholder R, Lameire N: Survival and complications of indwelling venous catheters for permanent use in hemodialysis patients. *Artif Organs* 29:399-405, 2005
500. Dhillon AS, Pollock C, Steen H, Shaw PE, Mischak H, Kolch W: Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. *Mol Cell Biol* 22:3237-3246, 2002
501. Dhillon AS, Meikle S, Peyssonnaud C, Grindlay J, Kaiser C, Steen H, Shaw PE, Mischak H, Eychene A, Kolch W: A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. *Mol Cell Biol* 23:1983-1993, 2003
502. Dhondt A, Vanholder R, Waterloos MA, Glorieux G, De SR, Lameire N: Citrate anticoagulation does not correct cuprophane bioincompatibility as evaluated by the expression of leukocyte surface molecules. *Nephrol Dial Transplant* 13:1752-1758, 1998
503. Dhondt A, Vanholder R, Lameire N: Hemodialysis-related bioincompatibility and adhesion molecules. *Int J Artif Organs* 21:501-505, 1998
504. Dhondt A, Vanholder R, Waterloos MA, Glorieux G, De SR, Ringoir S: In vitro effect of cefodizime, imipenem/cilastatin and co-trimoxazole on dexamethasone and cyclosporin A depressed phagocytosis. *Infection* 26:120-125, 1998
505. Dhondt A, Vanholder R, Van BW, Lameire N: The removal of uremic toxins. *Kidney Int Suppl* 76:S47-S59, 2000
506. Dhondt A, Vanholder R, Tielemans C, Glorieux G, Waterloos MA, De SR, Lameire N: Effect of regional citrate anticoagulation on leukopenia, complement activation, and expression of leukocyte surface molecules during hemodialysis with unmodified cellulose membranes. *Nephron* 85:334-342, 2000
507. Dhondt A, Vanholder R, Glorieux G, Waterloos MA, De SR, Lesaffer G, Lameire N: Vitamin E-bonded cellulose membrane and hemodialysis bioincompatibility: absence of an acute benefit on expression of leukocyte surface molecules. *Am J Kidney Dis* 36:1140-1146, 2000
508. Dhondt A, Van BW, Vanholder R, Lameire N: Selected practical aspects of intermittent hemodialysis in acute renal failure patients. *Contrib Nephrol* 222-235, 2001
509. Dhondt A, Eloit S, Wachter DD, Smet RD, Waterloos MA, Glorieux G, Lameire N, Verdonck P, Vanholder R: Dialysate partitioning in the Genius batch hemodialysis system: effect of temperature and solute concentration. *Kidney Int* 67:2470-2476, 2005
510. Dhondt A, Verstraete A, Vandewoude K, Segers H, Eloit S, Decruyenaere J, Vanholder R: Efficiency of the Genius batch hemodialysis system with low serum solute concentrations: the case of lithium intoxication therapy. *Am J Kidney Dis* 46:e95-e99, 2005
511. Dhondt AW, Vanholder RC, Ringoir SM: Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. *Nephrol Dial Transplant* 10:2107-2109, 1995
512. Dhondt AW, Vanholder RC, Waterloos MA, Glorieux GL, Ringoir SM: Leukocyte CD14 and CD45 expression during hemodialysis: polysulfone versus cuprophane. *Nephron* 74:342-348, 1996
513. Dhondt AW, Vanholder RC, De Smet RV, Claus SA, Waterloos MA, Glorieux GL, Delanghe JR, Lameire NH: Studies on dialysate mixing in the Genius single-pass batch system for hemodialysis therapy. *Kidney Int* 63:1540-1547, 2003
514. Di MG, Gambardella A, Labate A, Perna A, Ricci P, Quattrone A: Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients. *Seizure* 16:653-656, 2007
515. Dick JM, Van MW, Brouckaert P, Lefebvre RA: Relaxation by vasoactive intestinal polypeptide in the gastric fundus of nitric oxide synthase-deficient mice. *J Physiol* 538:133-143, 2002
516. Dierckx E, Engelborghs S, De RR, De Deyn PP, Ponjaert-Kristoffersen I: Differentiation between mild cognitive impairment, Alzheimer's disease and depression by means of cued recall. *Psychol Med* 37:747-755, 2007
517. Dierckx E, Engelborghs S, De RR, De Deyn PP, Ponjaert-Kristoffersen I: Mild cognitive impairment: what's in a name? *Gerontology* 53:28-35, 2007
518. Dierckx RA, Dobbeleir A, Pickut BA, Timmermans L, Dierckx I, Vervaeke A, Vandevivere J, Deberdt W, De Deyn PP: Technetium-99m HMPAO SPET in acute supratentorial ischaemic infarction, expressing deficits as millilitre of zero perfusion. *Eur J Nucl Med* 22:427-433, 1995



519. Dittrich E, Puttinger H, Schneider B, Horl WH, Haag-Weber M, Vychytil A: Is absorption of high-dose oral iron sufficient in peritoneal dialysis patients? *Perit Dial Int* 20:667-673, 2000
520. Dittrich E, Schillinger M, Sunder-Plassmann G, Horl WH, Vychytil A: Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients. *Perit Dial Int* 22:60-66, 2002
521. Dittrich E, Schmaldienst S, Langer M, Jansen M, Horl WH, Derfler K: Immunoabsorption and plasma exchange in pregnancy. *Kidney Blood Press Res* 25:232-239, 2002
522. Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E: Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. *Transpl Int* 17:215-220, 2004
523. Dittrich E, Puttinger H, Schillinger M, Lang I, Stefanelli T, Horl WH, Vychytil A: Effect of radio contrast media on residual renal function in peritoneal dialysis patients--a prospective study. *Nephrol Dial Transplant* 21:1334-1339, 2006
524. Dobler D, Ahmed N, Song L, Eboigbodin KE, Thornalley PJ: Increased dicarbonyl metabolism in endothelial cells in hyperglycemia induces anoikis and impairs angiogenesis by RGD and GFOGER motif modification. *Diabetes* 55:1961-1969, 2006
525. Dobos GJ, Burger M, Kuhlmann J, Passlick-Deetjen J, Schollmeyer P, Bohler J: Improved cytosolic free calcium mobilization and superoxide production in bicarbonate-based peritoneal dialysis solution. *Nephrol Dial Transplant* 12:973-977, 1997
526. Dolhofer-Bliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz KD: Immunological determination of advanced glycosylation end-products in human blood and urine. *Nephrol Dial Transplant* 10:657-664, 1995
527. Dortet L, Nguyen-Khoa T, Kebede M, Couloc'h J, Massy Z, Lacour B: [Evaluation of lipoperoxidation in hemodialysis patients with a simple test using the "Free Oxygen Radical Monitor"]. *Ann Biol Clin (Paris)* 62:707-711, 2004
528. Dou L, Brunet P, gnat-George F, Sampol J, Berland Y: Effect of uremia and hemodialysis on soluble L-selectin and leukocyte surface CD11b and L-selectin. *Am J Kidney Dis* 31:67-73, 1998
529. Dou L, Cerini C, Brunet P, Guilianelli C, Moal V, Grau G, De SR, Vanholder R, Sampol J, Berland Y: P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. *Kidney Int* 62:1999-2009, 2002
530. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. *Kidney Int* 65:442-451, 2004
531. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, gnat-George F, Brunet P: The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. *J Thromb Haemost* 5:1302-1308, 2007
532. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, gnat-George F, Brunet P: The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. *J Thromb Haemost* 2007
533. Dougherty FC, Donovan FM, Jr., Townsley MI: Harmonic analysis of perfusion pumps. *J Biomech Eng* 125:814-822, 2003
534. Drancourt M, Moal V, Brunet P, Dussol B, Berland Y, Raoult D: Bartonella (Rochalimaea) quintana infection in a seronegative hemodialyzed patient. *J Clin Microbiol* 34:1158-1160, 1996
535. Druke T, Touam M, Zingraff J: Dialysis-associated amyloidosis. *Adv Ren Replace Ther* 2:24-39, 1995
536. Druke T: Pathogenesis of secondary hyperparathyroidism. *Kidney Blood Press Res* 20:154-156, 1997
537. Druke T, Ritz E: To the birthday of professor A. M. Davison, editor emeritus of NDT. *Nephrol Dial Transplant* 15:128, 2000
538. Druke T, Sketch M: NDT online. *Nephrol Dial Transplant* 15:447, 2000
539. Druke T: Professor F. Kokot, Katowice, Poland. *Nephrol Dial Transplant* 15:279, 2000
540. Druke T: Hyporesponsiveness to recombinant human erythropoietin. *Nephrol Dial Transplant* 16 Suppl 7:25-28, 2001
541. Druke T, Witko-Sarsat V, Massy Z, Scamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. *Circulation* 106:2212-2217, 2002
542. Druke T, Foley RN: Introduction: improving outcomes in chronic kidney disease. *Kidney Int Suppl* S1-S4, 2006
543. Druke T, Martin D, Rodriguez M: Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. *Nephrol Dial Transplant* 22:1828-1839, 2007
544. Druke TB: The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. *Kidney Int* 48:259-272, 1995
545. Druke TB: Will bone disease still remain one of the most serious complications in dialysis patients? *Nephrol Dial Transplant* 10 Suppl 7:16-19, 1995
546. Druke TB: R-HuEPO hyporesponsiveness--who and why? *Nephrol Dial Transplant* 10 Suppl 2:62-68, 1995
547. Druke TB: A clinical approach to the uremic patient with extraskeletal calcifications. *Nephrol Dial Transplant* 11 Suppl 3:37-42, 1996
548. Druke TB: Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia. *Pediatr Nephrol* 10:348-350, 1996
549. Druke TB, Sonikian M, Zingraff J: Control of severe hyperparathyroidism and regression of a brown tumour after treatment with i.v. alfacalcidol in a uremic patient. *Nephrol Dial Transplant* 11:221-223, 1996
550. Druke TB: Treatment of beta 2-microglobulin amyloidosis by extracorporeal therapies other than haemodialysis, by medication and by surgery. *Nephrol Dial Transplant* 11 Suppl 2:150-153, 1996
551. Druke TB: Mineral metabolism: new aspects and perspectives. *Curr Opin Nephrol Hypertens* 5:297-299, 1996
552. Druke TB: Calcium-sensing receptors and associated pathological conditions. *Rev Rhum Engl Ed* 63:305-308, 1996
553. Druke TB, Jouhanneau P, Banide H, Lacour B, Yiu F, Raisbeck G: Effects of silicon, citrate and the fasting state on the intestinal absorption of aluminium in rats. *Clin Sci (Lond)* 92:63-67, 1997
554. Druke TB, Zhang P, Gogusev J: Apoptosis: background and possible role in secondary hyperparathyroidism. *Nephrol Dial Transplant* 12:2228-2233, 1997
555. Druke TB, Barany P, Cazzola M, Eschbach JW, Grutzmacher P, Kaltwasser JP, Macdougall IC, Pippard MJ, Shaldon S, van WD: Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. *Clin Nephrol* 48:1-8, 1997
556. Druke TB, Silver J: Mineral metabolism. *Curr Opin Nephrol Hypertens* 6:305-307, 1997
557. Druke TB: Dialysis-related amyloidosis. *Nephrol Dial Transplant* 13 Suppl 1:58-64, 1998

558. Drueke TB, Cattani P, Zingraff J, Sarfati E: Endocrine-cell allotransplantation. *Lancet* 351:597-598, 1998
559. Drueke TB: [Anomalies of phosphate and calcium metabolism in chronic renal insufficiency]. *Rev Prat* 48:1207-1212, 1998
560. Drueke TB: Primary and secondary uraemic hyperparathyroidism: from initial clinical observations to recent findings. *Nephrol Dial Transplant* 13:1384-1387, 1998
561. Drueke TB: Medical management of secondary hyperparathyroidism in uremia. *Am J Med Sci* 317:383-389, 1999
562. Drueke TB: Extraskeletal problems and amyloid. *Kidney Int Suppl* 73:S89-S93, 1999
563. Drueke TB: Dietary calcium and blood pressure. *Am J Hypertens* 12:96-98, 1999
564. Drueke TB: Genesis of atherosclerosis in uremic patients. *Miner Electrolyte Metab* 25:251-257, 1999
565. Drueke TB, Eckardt KU, Frei U, Jacobs C, Kokot F, McMahon LP, Schaefer RM: Does early anemia correction prevent complications of chronic renal failure? *Clin Nephrol* 51:1-11, 1999
566. Drueke TB, Touam M, Thornley-Brown D, Rostand SG: Extraskeletal calcification in patients with chronic kidney failure. *Adv Nephrol Neckar Hosp* 30:333-356, 2000
567. Drueke TB: Cell biology of parathyroid gland hyperplasia in chronic renal failure. *J Am Soc Nephrol* 11:1141-1152, 2000
568. Drueke TB: Beta2-microglobulin and amyloidosis. *Nephrol Dial Transplant* 15 Suppl 1:17-24, 2000
569. Drueke TB: Aspects of cardiovascular burden in pre-dialysis patients. *Nephron* 85 Suppl 1:9-14, 2000
570. Drueke TB, Suter PM: [The salt-free diet]. *Ther Umsch* 57:161-166, 2000
571. Drueke TB: Renal osteodystrophy: management of hyperphosphataemia. *Nephrol Dial Transplant* 15 Suppl 5:32-33, 2000
572. Drueke TB: Parathyroid gland hyperplasia in uremia. *Kidney Int* 59:1182-1183, 2001
573. Drueke TB, Nguyen KT, Massy ZA, Witko-Sarsat V, Lacour B, Scamps-Latscha B: Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. *Kidney Int Suppl* 78:S114-S119, 2001
574. Drueke TB: The place of calcium and calcimimetics in the treatment of secondary hyperparathyroidism. *Nephrol Dial Transplant* 16 Suppl 6:15-17, 2001
575. Drueke TB: Genetic aspects of secondary hyperparathyroidism in uremia. *Am J Kidney Dis* 38:S143-S146, 2001
576. Drueke TB: Control of secondary hyperparathyroidism by vitamin D derivatives. *Am J Kidney Dis* 37:S58-S61, 2001
577. Drueke TB, Eckardt KU: Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. *Nephrol Dial Transplant* 17 Suppl 5:28-31, 2002
578. Drueke TB, Massy ZA: Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia. *Blood Purif* 20:494-497, 2002
579. Drueke TB: [Dietary sodium: beyond blood pressure, what relationship with morbidity and life expectancy?]. *Nephrologie* 23:67-69, 2002
580. Drueke TB: Foreword: extraskeletal calcifications in patients with chronic renal failure. *Nephrol Dial Transplant* 17:330-331, 2002
581. Drueke TB: Sixth symposium of the Japan-France Nephrology Exchange Association. *Nephrol Dial Transplant* 17:1887, 2002
582. Drueke TB: Intestinal absorption of aluminium in renal failure. *Nephrol Dial Transplant* 17 Suppl 2:13-16, 2002
583. Drueke TB, Rostand SG: Progression of vascular calcification in uraemic patients: can it be stopped? *Nephrol Dial Transplant* 17:1365-1368, 2002
584. Drueke TB: Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysis. *Nephrol Dial Transplant* 17 Suppl 11:20-22, 2002
585. Drueke TB, McCarron DA: Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. *N Engl J Med* 349:496-499, 2003
586. Drueke TB, Scamps-Latscha B, Locatelli F: Stopping a medical research project for financial reasons. *Nephrol Dial Transplant* 18:1982-1983, 2003
587. Drueke TB: Calcimimetics versus vitamin D: what are their relative roles? *Blood Purif* 22:38-43, 2004
588. Drueke TB, Moe SM: Disturbances of bone and mineral metabolism in chronic kidney disease: an international initiative to improve diagnosis and treatment. *Nephrol Dial Transplant* 19:534-536, 2004
589. Drueke TB: Modulation and action of the calcium-sensing receptor. *Nephrol Dial Transplant* 19 Suppl 5:V20-V26, 2004
590. Drueke TB, Massy ZA: Intravenous iron: how much is too much? *J Am Soc Nephrol* 16:2833-2835, 2005
591. Drueke TB: Which vitamin D derivative to prescribe for renal patients. *Curr Opin Nephrol Hypertens* 14:343-349, 2005
592. Drueke TB: Pathophysiological aspects of vascular calcification in chronic renal failure. *Nefrologia* 25 Suppl 2:96-99, 2005
593. Drueke TB: Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means. *Pediatr Nephrol* 20:399-403, 2005
594. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med* 355:2071-2084, 2006
595. Drueke TB, Landais P: Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients. *Am J Kidney Dis* 47:1083-1084, 2006
596. Drueke TB: Haematopoietic stem cells--role of calcium-sensing receptor in bone marrow homing. *Nephrol Dial Transplant* 21:2072-2074, 2006
597. Drueke TB: Therapeutic failure of cinacalcet in a renal transplant patient. *Nephrol Dial Transplant* 21:824-825, 2006
598. Drueke TB, Lacour B: Racial differences in calcium retention in response to dietary salt. *Am J Clin Nutr* 83:170, 2006
599. Drueke TB, Prie D: Klotho spins the thread of life--what does Klotho do to the receptors of fibroblast growth factor-23 (FGF23)? *Nephrol Dial Transplant* 2007
600. Drueke TB: [Hemoglobin target for chronic kidney disease patients?]. *Nephrol Ther* 3:369-371, 2007

601. Druke TB: Lanthanum carbonate as a first-line phosphate binder: the "cons". *Semin Dial* 20:329-332, 2007
602. Druke TB: Target haemoglobin concentrations in chronic kidney disease. *Lancet* 369:1516-1517, 2007
603. Druke TB, Prie D: Klotho spins the thread of life--what does Klotho do to the receptors of fibroblast growth factor-23 (FGF23)? *Nephrol Dial Transplant* 22:1524-1526, 2007
604. Druke TB, Fukagawa M: Whole or fragmentary information on parathyroid hormone? *Clin J Am Soc Nephrol* 2:1106-1107, 2007
605. Druke TB, Massy ZA: Chronic kidney disease: Medial or intimal calcification in ckd--does it matter? *Nat Rev Nephrol* 7:250-251, 2011
606. Druml W, Horl WH, Stevens PE: Practical guide to diagnosis and differential diagnosis of ARF in the ICU. *Int J Artif Organs* 19:87-89, 1996
607. Druml W, Schwarzenhofer M, Apsner R, Horl WH: Fat-soluble vitamins in patients with acute renal failure. *Miner Electrolyte Metab* 24:220-226, 1998
608. Ducloux D, Motte G, Massy ZA: Hyperhomocyst(e)inemia as a risk factor after renal transplantation. *Ann Transplant* 6:40-42, 2001
609. Ducloux D, Aboubakr A, Motte G, Toubin G, Fournier V, Chalopin JM, Druke T, Massy ZA: Hyperhomocysteinemia therapy in haemodialysis patients: folic versus folic acid in combination with vitamin B6 and B12. *Nephrol Dial Transplant* 17:865-870, 2002
610. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. *J Am Soc Nephrol* 2012
611. Dussol B, Tsimeratos M, Lerda D, Casanova P, Brunet P, Berland Y: [Viral hepatitis C and membranoproliferative glomerulonephritis in a renal transplant patient]. *Nephrologie* 16:223-226, 1995
612. Dussol B, Bernard O, Xerri L, Stoppa AM, Brunet P, Maraninchi D, Berland Y: [Lymphoproliferative syndrome induced by Epstein-Barr virus after kidney transplantation: value of genotypic analysis]. *Presse Med* 24:1033-1035, 1995
613. Dussol B, Brunet P, Cantaloube JF, Schleinitz N, Biagini P, Berland Y: Hepatitis C virus infection contracted just before kidney transplantation. *Nephron* 71:229, 1995
614. Dussol B, Berthezene P, Brunet P, Berland Y: Hepatitis C virus infection among chronic dialysis patients in the southeast of France. Provence-Alpes-Cote d'Azur Nephrologists Group. *Nephrol Dial Transplant* 10:477-478, 1995
615. Dussol B, Berthezene P, Brunet P, Roubicek C, Berland Y: Hepatitis C virus infection among chronic dialysis patients in the south of France: a collaborative study. *Am J Kidney Dis* 25:399-404, 1995
616. Dussol B, De L, X, Brunet P, Roubicek C, Chicheportiche C, Cantaloube JF, Biagini P, De MP, Berland Y: Is hepatitis C virus-RNA detection by nested polymerase chain reaction clinically relevant in hemodialysis patients? *Clin Nephrol* 45:257-260, 1996
617. Dussol B, Charrel R, De L, X, Berthezene P, Brunet P, De MP, Raoult D, Berland Y: Prevalence of hepatitis G virus infection in kidney transplant recipients. *Transplantation* 64:537-539, 1997
618. Dussol B, Brunet P, Vacher-Coponat H, Bouabdallah R, Chetaille P, Berland Y: Crescentic glomerulonephritis with antineutrophil cytoplasmic antibodies associated with chronic lymphocytic leukaemia. *Nephrol Dial Transplant* 12:785-786, 1997
619. Dussol B, Kaplanski G, Daniel L, Brunet P, Pellissier JF, Berland Y: Simultaneous occurrence of fibrillary glomerulopathy and AL amyloid. *Nephrol Dial Transplant* 13:2630-2632, 1998
620. Dussol B, Fenouillet E, Brunet P, Purgus R, Sauze N, Carrega L, Mercier L, Zouher I, Bechis G, Berland Y, Guieu R: Kinetic study of adenosine concentrations and the expression of adenosine deaminase in mononuclear cells during hemodialysis. *Kidney Int* 66:1640-1646, 2004
621. Dussol B, Morand P, Martinat C, Lombard E, Portugal H, Brunet P, Berland Y: Influence of parathyroidectomy on mortality in hemodialysis patients: a prospective observational study. *Ren Fail* 29:579-586, 2007
622. Duval-Sabatier A, Brunet P, Seck SM, Haddad F, Giaime P, Ramanarivo P, Bouchouareb D, Berland Y: [experiment of self blood pressure measurement at home in haemodialysis patients in a hospital unit]. *Nephrol Ther* 7:544-548, 2011
623. Dyer MJ, MacFarlane M, Cohen GM: Barriers to effective TRAIL-targeted therapy of malignancy. *J Clin Oncol* 25:4505-4506, 2007
624. Dyess DL, Hunter JL, Lakey JR, Moyer D, Dougherty FC, Townsley MI: Attenuation of histamine-induced endothelial permeability responses after pacing-induced heart failure: role for endogenous catecholamines. *Microcirculation* 7:307-315, 2000
625. Dyjas R, Wiecek A, Kokot F: [Treatment of non-renal anemia with human recombinant erythropoietin (rHu-EPO)]. *Przegl Lek* 53:486-490, 1996
626. Dyjas R, Bulanowski M, Ficek R, Witkowicz J, Chudek J, Wiecek A: [Influence of recombinant human erythropoietin (rHuEPO) on plasma levels of selected hormones in females with rheumatoid arthritis]. *Pol Arch Med Wewn* 114:731-737, 2005
627. Dzielinska Z, Januszewicz A, Wiecek A, Demkow M, Makowiecka-Ciesla M, Prejbisz A, Kadziela J, Mielniczuk R, Florczak E, Janas J, Januszewicz M, Ruzyllo W: Decreased plasma concentration of a novel anti-inflammatory protein--adiponectin--in hypertensive men with coronary artery disease. *Thromb Res* 110:365-369, 2003
628. Edwards LG, Adesida A, Thornalley PJ: Inhibition of human leukaemia 60 cell growth by S-D-lactoylglutathione in vitro. Mediation by metabolism to N-D-lactoylcysteine and induction of apoptosis. *Leuk Res* 20:17-26, 1996
629. Efendic E, Lindholm B, Bergstrom J, Stenvinkel P: [Strong connection between malnutrition, inflammation and arteriosclerosis. Improved treatment of renal failure if underlying factors are attacked]. *Lakartidningen* 96:4538-4542,
630. Eggertsen G, Heimbürger O, Stenvinkel P, Berglund L: Influence of variation at the apolipoprotein E locus on lipid and lipoprotein levels in CAPD patients. *Nephrol Dial Transplant* 12:141-144, 1997
631. Ehart U, Bronnick K, De Deyn PP, Emre M, Tekin S, Lane R, Aarsland D: Subthreshold depression in patients with Parkinson's disease and dementia--clinical and demographic correlates. *Int J Geriatr Psychiatry* 2007
632. Ehart U, Bronnick K, De Deyn PP, Emre M, Tekin S, Lane R, Aarsland D: Subthreshold depression in patients with Parkinson's disease and dementia--clinical and demographic correlates. *Int J Geriatr Psychiatry* 22:980-985, 2007
633. Einbinder T, Sufaro Y, Yusim I, Byk G, Passlick-Deetjen J, Chaimovitz C, Douvdevani A: Correction of anemia in uremic mice by genetically modified peritoneal mesothelial cells. *Kidney Int* 63:2103-2112, 2003
634. Eisses MJ, Geiduschek JM, Jonmarker C, Cohen GA, Chandler WL: Effect of polymer coating (poly 2-methoxyethylacrylate) of the

- oxygenator on hemostatic markers during cardiopulmonary bypass in children. *J Cardiothorac Vasc Anesth* 21:28-34, 2007
635. Eitel K, Staiger H, Rieger J, Mischak H, Brandhorst H, Brendel MD, Bretzel RG, Haring HU, Kellerer M: Protein kinase C delta activation and translocation to the nucleus are required for fatty acid-induced apoptosis of insulin-secreting cells. *Diabetes* 52:991-997, 2003
636. Ekblom K, Hultdin J, Stegmayr B, Johansson I, Van GB, Hallmans G, Weinehall L, Johansson L, Wiklund PG, Marklund SL: Iron stores and HFE genotypes are not related to increased risk of ischemic stroke. A prospective nested case-referent study. *Cerebrovasc Dis* 24:405-411, 2007
637. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod A, Vanholder R, Walker R, Wang H: The burden of kidney disease: improving global outcomes. *Kidney Int* 66:1310-1314, 2004
638. Ekstrom TJ, Stenvinkel P: The epigenetic conductor: A genomic orchestrator in chronic kidney disease complications? *J Nephrol* 22:442-449, 2009
639. Eliasson M, Lindahl B, Lundberg V, Stegmayr B: No increase in the prevalence of known diabetes between 1986 and 1999 in subjects 25-64 years of age in northern Sweden. *Diabet Med* 19:874-880, 2002
640. Eliasson M, Lindahl B, Lundberg V, Stegmayr B: Diabetes and obesity in Northern Sweden: occurrence and risk factors for stroke and myocardial infarction. *Scand J Public Health Suppl* 61:70-77, 2003
641. Eliasson M, Janlert U, Jansson JH, Stegmayr B: Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. *J Intern Med* 260:551-559, 2006
642. Eliasson MC, Jansson JH, Lindahl B, Stegmayr B: High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. *Cardiovasc Diabetol* 2:19, 2003
643. Elinder CG, Stenvinkel P, Heimbürger O: [Dialysis is life-sustaining--but when to initiate it?]. *Lakartidningen* 99:520-521, 2002
644. Eloit S, Torremans A, De SR, Marescau B, De WD, De Deyn PP, Lameire N, Verdonck P, Vanholder R: Kinetic behavior of urea is different from that of other water-soluble compounds: the case of the guanidino compounds. *Kidney Int* 67:1566-1575, 2005
645. Eloit S, Dhondt A, Vierendeels J, De WD, Verdonck P, Vanholder R: Temperature and concentration distribution within the Genius dialysate container. *Nephrol Dial Transplant* 22:2962-2969, 2007
646. Eloit S, Torremans A, De SR, Marescau B, De Deyn PP, Verdonck P, Vanholder R: Complex compartmental behavior of small water-soluble uremic retention solutes: evaluation by direct measurements in plasma and erythrocytes. *Am J Kidney Dis* 50:279-288, 2007
647. Eloit S, Van BW, Dhondt A, Van de WH, Glorieux G, Verdonck P, Vanholder R: Impact of hemodialysis duration on the removal of uremic retention solutes. *Kidney Int* 73:765-770, 2008
648. Eloit S, Schepers E, Barreto DV, Barreto FC, Liabeuf S, Van Biesen W, Verbeke F, Glorieux G, Choukroun G, Massy Z, Vanholder R: Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. *Clin J Am Soc Nephrol* 6:1266-1273, 2011
649. Eloit S, Van Biesen W, Glorieux G, Neiryck N, Dhondt A, Vanholder R: Does the adequacy parameter  $kt/v(\text{urea})$  reflect uremic toxin concentrations in hemodialysis patients? *PLoS One* 2013;8:e76838.
650. Eloit S, Vanholder R, Van Biesen W, Lameire N: The patient as a limit to dialysis technology. *Clin J Am Soc Nephrol* 6:2105-2107, 2011
651. Emmelin M, Weinehall L, Stegmayr B, Dahlgren L, Stenlund H, Wall S: Self-rated ill-health strengthens the effect of biomedical risk factors in predicting stroke, especially for men --an incident case referent study. *J Hypertens* 21:887-896, 2003
652. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van LT, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease. *N Engl J Med* 351:2509-2518, 2004
653. Engelborghs S, De Deyn PP: The neurochemistry of Alzheimer's disease. *Acta Neurol Belg* 97:67-84, 1997
654. Engelborghs S, Borggreve F, Pickut BA, Michiels K, Van de MW, De Deyn PP: Case report of a patient with complex partial frontal lobe seizures as a complication of bifrontal lobotomy. *Acta Neurol Belg* 98:199-203, 1998
655. Engelborghs S, Marien P, Martin JJ, De Deyn PP: Functional anatomy, vascularisation and pathology of the human thalamus. *Acta Neurol Belg* 98:252-265, 1998
656. Engelborghs S, Pickut BA, D'Hooge R, Wiechert P, Haeghele K, De Deyn PP: Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats. *Arzneimittelforschung* 48:713-716, 1998
657. Engelborghs S, De BM, De CJ, D'Hooge R, Geerts H, Verhaegen H, De Deyn PP: Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. *Neurochem Int* 34:523-530, 1999
658. Engelborghs S, Marien P, Pickut BA, Verstraeten S, De Deyn PP: Loss of psychic self-activation after paramedian bithalamic infarction. *Stroke* 31:1762-1765, 2000
659. Engelborghs S, Pickut BA, Marien P, Opsomer F, De Deyn PP: Crossed cerebellar diaschisis and hemiataxia after thalamic hemorrhage. *J Neurol* 247:476-477, 2000
660. Engelborghs S, D'Hooge R, De Deyn PP: Pathophysiology of epilepsy. *Acta Neurol Belg* 100:201-213, 2000
661. Engelborghs S, Marien P, De Deyn PP: Gelastic epilepsy caused by hypothalamic hamartoma. *Lancet* 356:940, 2000
662. Engelborghs S, De Deyn PP: Biological and genetic markers of sporadic Alzheimer's disease. *Acta Med Okayama* 55:55-63, 2001
663. Engelborghs S, Dermaut B, Goeman J, Saerens J, Marien P, Pickut BA, Van den BM, Serneels S, Cruts M, Van BC, De Deyn PP: Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. *J Neurol Neurosurg Psychiatry* 74:1148-1151, 2003
664. Engelborghs S, Pickut BA, De Deyn PP: Recurrent transient ischemic attacks in a 15-year-old boy with beta-thalassemia minor and thrombophilia. Contribution of perfusion SPECT to clinical diagnosis. *Acta Neurol Belg* 103:99-102, 2003
665. Engelborghs S, Marescau B, De Deyn PP: Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. *Neurochem Res* 28:1145-1150, 2003
666. Engelborghs S, Vloeberghs E, Maertens K, Marien P, Somers N, Symons A, Clement F, Ketels V, Saerens J, Goeman J, Pickut BA, Vandevivere J, De Deyn PP: Correlations between cognitive, behavioural and psychological findings and levels of vitamin B12 and folate in patients with dementia. *Int J Geriatr Psychiatry* 19:365-370, 2004

667. Engelborghs S, Vloeberghs E, Maertens K, Marescau B, De Deyn PP: Evidence for an association between the CSF HVA:5-HIAA ratio and aggressiveness in frontotemporal dementia but not in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 75:1080, 2004
668. Engelborghs S, Holmes C, McCulley M, De Deyn PP: 5-HT2A receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease. *Int J Geriatr Psychiatry* 19:1108-1109, 2004
669. Engelborghs S, Maertens K, Nagels G, Vloeberghs E, Marien P, Symons A, Ketels V, Estercam S, Somers N, De Deyn PP: Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. *Int J Geriatr Psychiatry* 20:1028-1037, 2005
670. Engelborghs S, Maertens K, Marien P, Vloeberghs E, Somers N, Nagels G, De Deyn PP: Behavioural and neuropsychological correlates of frontal lobe features in dementia. *Psychol Med* 36:1173-1182, 2006
671. Engelborghs S, Dermaut B, Marien P, Symons A, Vloeberghs E, Maertens K, Somers N, Goeman J, Rademakers R, Van den BM, Pickut B, Cruts M, Van BC, De Deyn PP: Dose dependent effect of APOE epsilon4 on behavioral symptoms in frontal lobe dementia. *Neurobiol Aging* 27:285-292, 2006
672. Engelborghs S, Maertens K, Vloeberghs E, Aerts T, Somers N, Marien P, De Deyn PP: Neuropsychological and behavioural correlates of CSF biomarkers in dementia. *Neurochem Int* 48:286-295, 2006
673. Engelborghs S, De VK, Van de CT, Vanderstichele H, Van EB, Cras P, Martin JJ, Vanmechelen E, De Deyn PP: Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. *Neurobiol Aging* 2007
674. Engelborghs S, Vloeberghs E, Le BN, Van BM, Marien P, Somers N, Nagels G, Pickut BA, De Deyn PP: The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. *Neurochem Int* 2007
675. Engelborghs S, Slegers K, Cras P, Brouwers N, Serneels S, De LE, Martin JJ, Vanmechelen E, Van BC, De Deyn PP: No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. *Brain* 130:2320-2326, 2007
676. Ereik E, Sever MS, Serdengecti K, Vanholder R, Akoglu E, Yavuz M, Ergin H, Tekce M, Duman N, Lameire N: An overview of morbidity and mortality in patients with acute renal failure due to crush syndrome: the Marmara earthquake experience. *Nephrol Dial Transplant* 17:33-40, 2002
677. Eriksson M, Stegmayr B, Lundberg V: MONICA quality assessments. *Scand J Public Health Suppl* 61:25-30, 2003
678. Eriksson M, Asplund K, Glader EL, Norrvig B, Stegmayr B, Terent A, Asberg KH, Wester PO: Self-reported depression and use of antidepressants after stroke: a national survey. *Stroke* 35:936-941, 2004
679. Eriksson M, Appelros P, Norrvig B, Terent A, Stegmayr B: Assessment of functional outcome in a national quality register for acute stroke: can simple self-reported items be transformed into the modified Rankin Scale? *Stroke* 38:1384-1386, 2007
680. Eriksson UJ, Wentzel P, Minhas HS, Thornalley PJ: Teratogenicity of 3-deoxyglucosone and diabetic embryopathy. *Diabetes* 47:1960-1966, 1998
681. Errjgers V, Van DD, Gantois I, Van Ginneken CJ, Grossman AW, D'Hooge R, De Deyn PP, Kooy RF: FVB.129P2-Pde6b(+) Tyr(c-ch)/Ant, a sighted variant of the FVB/N mouse strain suitable for behavioral analysis. *Genes Brain Behav* 2006
682. Errjgers V, Van DD, Gantois I, Van Ginneken CJ, Grossman AW, D'Hooge R, De Deyn PP, Kooy RF: FVB.129P2-Pde6b(+) Tyr(c-ch)/Ant, a sighted variant of the FVB/N mouse strain suitable for behavioral analysis. *Genes Brain Behav* 6:552-557, 2007
683. Exner M, Bohmig GA, Schillinger M, Regele H, Watschinger B, Horl WH, Raith M, Mannhalter C, Wagner OF: Donor heme oxygenase-1 genotype is associated with renal allograft function. *Transplantation* 77:538-542, 2004
684. Fabrizii V, Thalhammer F, Horl WH: [Aminoglycoside-induced nephrotoxicity]. *Wien Klin Wochenschr* 109:830-835, 1997
685. Fabrizii V, Horl WH: Renal transplantation in the elderly. *Curr Opin Urol* 11:159-163, 2001
686. Fabrizii V, Winkelmayr WC, Klausner R, Kletzmayer J, Saemann MD, Steininger R, Kramar R, Horl WH, Kovarik J: Patient and graft survival in older kidney transplant recipients: does age matter? *J Am Soc Nephrol* 15:1052-1060, 2004
687. Fabrizii V, Kovarik J, Bodingbauer M, Kramar R, Horl WH, Winkelmayr WC: Long-term patient and graft survival in the eurotransplant senior program: a single-center experience. *Transplantation* 80:582-589, 2005
688. Fagugli RM, Vanholder R, De SR, Selvi A, Antolini F, Lameire N, Floridi A, Buoncristiani U: Advanced glycation end products: specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis. *Int J Artif Organs* 24:256-262, 2001
689. Fagugli RM, De SR, Buoncristiani U, Lameire N, Vanholder R: Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. *Am J Kidney Dis* 40:339-347, 2002
690. Faller B, Aparicio M, Faict D, De VC, de P, V, Larroumet N, Guiberteau R, Jones M, Peluso F: Clinical evaluation of an optimized 1.1% amino acid solution for peritoneal dialysis. *Nephrol Dial Transplant* 10:1432-1437, 1995
691. Faragher AJ, Sun XM, Butterworth M, Harper N, Mulheran M, Ruchaud S, Earnshaw WC, Cohen GM: Death receptor-induced apoptosis reveals a novel interplay between the chromosomal passenger complex and CENP-C during interphase. *Mol Biol Cell* 18:1337-1347, 2007
692. Farghali H, Hodis J, Kutinova-Canova N, Potmesil P, Krmnickova E, Zidek Z: Glucose release as a response to glucagon in rat hepatocyte culture: involvement of NO signaling. *Physiol Res* 2007
693. Farnsworth A, Wisner TW, Webb M, Roller R, Cohen G, Eisenberg R, Johnson DC: Herpes simplex virus glycoproteins gB and gH function in fusion between the virion envelope and the outer nuclear membrane. *Proc Natl Acad Sci US A* 104:10187-10192, 2007
694. Faure V, Cerini C, Paul P, Berland Y, gnat-George F, Brunet P: The uremic solute p-cresol decreases leukocyte transendothelial migration in vitro. *Int Immunol* 18:1453-1459, 2006
695. Faure V, Dou L, Sabatier F, Cerini C, Sampol J, Berland Y, Brunet P, gnat-George F: Elevation of circulating endothelial microparticles in patients with chronic renal failure. *J Thromb Haemost* 4:566-573, 2006
696. Faulhaber-Walter R, Hafer C, Jahr N, Vahlbruch J, Hoy L, Haller H, Fliser D, Kielstein JT: The hannover dialysis outcome study: Comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. *Nephrol Dial Transplant* 24:2179-2186, 2009
697. Feix A, Fritsche-Polanz R, Kletzmayer J, Vychytil A, Horl WH, Sunder-Plassmann G, Fodinger M: Increased prevalence of combined MTR and MTHFR genotypes among individuals with severely elevated total homocysteine plasma levels. *Am J Kidney Dis* 38:956-964, 2001
698. Feldkamp T, Baumgart D, Elsner M, Herget-Rosenthal S, Pietruck F, Erbel R, Philipp T, Kribben A: Nephrotoxicity of iso-osmolar versus low-

- osmolar contrast media is equal in low risk patients. *Clin Nephrol* 66:322-330, 2006
699. Fellah H, Feki M, Hsairi M, Sanhaji H, Kaabachi N, Ben AT, Massy ZA, Ben MH, Lacour B, Mebazaa A: Hyperhomocysteinemia and end-stage renal disease: determinants and association with cardiovascular disease in Tunisian patients. *Clin Chem Lab Med* 41:675-680, 2003
700. Fellah H, Feki M, Feki H, Souissi M, Kaabachi N, Ben AT, Massy ZA, Ben MH, Lacour B, Mebazaa A: Classical and "non-classical" cardiovascular risk factors in Tunisian patients with end stage renal disease: prevalence and association with cardiovascular events. *Clin Lab* 50:447-453, 2004
701. Fellah H, Feki M, Souissi M, Ghorbel H, Ben AT, Massy Z, Hedhili A, Ben MH, Lacour B, Kaabachi N, Mebazaa A: [Oxidative stress in end stage renal disease: evidence and association with cardiovascular events in Tunisian patients]. *Tunis Med* 84:724-729, 2006
702. Fenchel M, Nael K, Herget-Rosenthal S, Krishnam M, Ruehm SG: Magnetic resonance imaging of renal disease: recent developments and future applications. *Nephron Clin Pract* 103:c37-c44, 2006
703. Feriani M, Passlick-Deetjen J, La GG: Factors affecting bicarbonate transfer with bicarbonate-containing CAPD solution. *Perit Dial Int* 15:336-341, 1995
704. Feriani M, Carobi C, La GG, Buoncristiani U, Passlick-Deetjen J: Clinical experience with a 39 mmol/L bicarbonate-buffered peritoneal dialysis solution. *Perit Dial Int* 17:17-21, 1997
705. Feriani M, Kirchgessner J, La GG, Passlick-Deetjen J: Randomized long-term evaluation of bicarbonate-buffered CAPD solution. *Kidney Int* 54:1731-1738, 1998
706. Feriani M, Passlick-Deetjen J, Jaeckle-Meyer I, La GG: Individualized bicarbonate concentrations in the peritoneal dialysis fluid to optimize acid-base status in CAPD patients. *Nephrol Dial Transplant* 19:195-202, 2004
707. Ferrannini E, Camastra S, Coppack SW, Fliser D, Golay A, Mitrakou A: Insulin action and non-esterified fatty acids. The European Group for the Study of Insulin Resistance (EGIR). *Proc Nutr Soc* 56:753-761, 1997
708. Ferreira A, Urena P, Ang KS, Simon P, Morieux C, Souberbielle JC, de Vernejoul MC, Druke TB: Relationship between serum beta 2-microglobulin, bone histology, and dialysis membranes in uraemic patients. *Nephrol Dial Transplant* 10:1701-1707, 1995
709. Ferreira A, Simon P, Druke TB, schamps-Latscha B: Potential role of cytokines in renal osteodystrophy. *Nephrol Dial Transplant* 11:399-400, 1996
710. Ferreira A, Druke TB: Biological markers in the diagnosis of the different forms of renal osteodystrophy. *AmJ MedSci* 320:85-89, 2000
711. Ferreira A, Ghazali A, Galvao J, Souberbielle JC, Jehle PM, Mohan S, scamps-Latscha B, Oprisiu R, Fournier A, Druke TB: Effect of type of dialysis membrane on bone in haemodialysis patients. *Nephrol Dial Transplant* 16:1230-1238, 2001
712. Ficek J, Kokot F, Chudek J, Adamczak M, Ficek R, Wiecek A: Influence of antihypertensive treatment with perindopril, pindolol or felodipinon plasma leptin concentration in patients with essential hypertension. *Horm Metab Res* 34:703-708, 2002
713. Ficek R, Kokot F, Chudek J, Adamczak M, Ficek J, Wiecek A: Plasma leptin concentration in patients with acute renal failure. *Clin Nephrol* 62:84-91, 2004
714. Ficek R, Kokot F, Chudek J, Adamczak M, Ficek J, Wiecek A: Plasma concentrations of tumor necrosis factor alpha may predict the outcome of patients with acute renal failure. *Kidney Blood Press Res* 29:203-209, 2006
715. Fichera A, Little N, Jagadeeswaran S, Dougherty U, Sehdev A, Mustafi R, Cerda S, Yuan W, Khare S, Tretiakova M, Gong C, Tallerico M, Cohen G, Joseph L, Hart J, Turner JR, Bissonnette M: Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. *Cancer Res* 67:827-835, 2007
716. Fichoux A, Argiles A, Bosc JY, Mion C: Analysis of the influence of the infusion site on dialyser clearances measured in an in vitro system mimicking haemodialysis and haemodiafiltration. *Blood Purif* 17:10-18, 1999
717. Fichoux A, Argiles A, Mion H, Mion CM: Influence of convection on small molecule clearances in online hemodiafiltration. *Kidney Int* 57:1755-1763, 2000
718. Fichoux A, Gayraud N, Szwarc I, Andress D, Soullier S, Duny Y, Goubert G, Thomas M, Bismuth-Mondolfo J, Daures JP, Brunet P, Servel MF, Argiles A: The use of sds-page scanning of spent dialysate to assess uraemic toxin removal by dialysis. *Nephrol Dial Transplant* 26:2281-2289, 2011
719. Fichoux A, Kerr PG, Brunet P, Argiles A: The ultrafiltration coefficient of a dialyser (kuf) is not a fixed value, and it follows a parabolic function: The new concept of kuf max. *Nephrol Dial Transplant* 26:636-640, 2011
720. Filee P, Vreuls C, Herman R, Thamm I, Aerts T, De Deyn PP, Frere JM, Joris B: Dimerization and DNA binding properties of the *Bacillus licheniformis* 749/I Blal repressor. *J Biol Chem* 278:16482-16487, 2003
721. Flipon E, Liabeuf S, Fardellone P, Mentaverri R, Ryckelynck T, Grados F, Kamel S, Massy ZA, Dargent-Molina P, Brazier M: Is vascular calcification associated with bone mineral density and osteoporotic fractures in ambulatory, elderly women? *Osteoporos Int* 23:1533-1539, 2012
722. Fliser D, Fode P, Arnold U, Nowicki M, Kohl B, Ritz E: The effect of dietary salt on insulin sensitivity. *Eur J Clin Invest* 25:39-43, 1995
723. Fliser D, Ritz E, Franek E: Renal reserve in the elderly. *Semin Nephrol* 15:463-467, 1995
724. Fliser D, Rett K, Hubinger A, Ritz E: Influence of ACE inhibition on glucose tolerance in patients with stable chronic renal failure. *Nephrol Dial Transplant* 10:643-647, 1995
725. Fliser D: Loop diuretics and thiazides--the case for their combination in chronic renal failure. *Nephrol Dial Transplant* 11:408-410, 1996
726. Fliser D, Ritz E: Renal haemodynamics in the elderly. *Nephrol Dial Transplant* 11 Suppl 9:2-8, 1996
727. Fliser D, Franek E, Fode P, Stefanski A, Schmitt CP, Lyons M, Ritz E: Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. *Nephrol Dial Transplant* 12:933-938, 1997
728. Fliser D, Keller C, Bahrmann P, Franek E, Schreckling H, Bergis K, Ritz E: Altered action of angiotensin II in patients with type 2 diabetes mellitus of recent onset. *J Hypertens* 15:293-299, 1997
729. Fliser D, Schaefer F, Schmid D, Veldhuis JD, Ritz E: Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans. *Hypertension* 30:1156-1161, 1997
730. Fliser D, Franek E, Ritz E: Renal function in the elderly--is the dogma of an inexorable decline of renal function correct? *Nephrol Dial Transplant* 12:1553-1555, 1997
731. Fliser D, Stefanski A, Franek E, Fode P, Gudarzy A, Ritz E: No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects. *Eur J Clin Invest* 27:629-633, 1997

732. Fliser D, Franek E, Joest M, Block S, Mutschler E, Ritz E: Renal function in the elderly: impact of hypertension and cardiac function. *Kidney Int* 51:1196-1204, 1997
733. Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. *Kidney Int* 53:1343-1347, 1998
734. Fliser D, Ritz E: Relationship between hypertension and renal function and its therapeutic implications in the elderly. *Gerontology* 44:123-131, 1998
735. Fliser D, Ritz E: [Disorders of calcium and phosphate homeostasis]. *Internist (Berl)* 39:825-830, 1998
736. Fliser D, Veldhuis JD, Dikow R, Schmidt-Gayk H, Ritz E: Effects of acute ACE inhibition on pulsatile renin and aldosterone secretion and their synchrony. *Hypertension* 32:929-934, 1998
737. Fliser D, Ritz E: Does essential hypertension cause progressive renal disease? *J Hypertens Suppl* 16:S13-S15, 1998
738. Fliser D, Ritz E: [Disorders of calcium and phosphate homeostasis]. *Urologe A* 38:285-295, 1999
739. Fliser D, Bischoff I, Hanses A, Block S, Joest M, Ritz E, Mutschler E: Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. *Eur J Clin Pharmacol* 55:205-211, 1999
740. Fliser D, Zurbruggen I, Mutschler E, Bischoff I, Nussberger J, Franek E, Ritz E: Coadministration of albumin and furosemide in patients with the nephrotic syndrome. *Kidney Int* 55:629-634, 1999
741. Fliser D, Haller H: [Nephropathy in type 2 diabetes mellitus]. *Internist (Berl)* 41:1363-1373, 2000
742. Fliser D, Dikow R, Demukaj S, Ritz E: Opposing effects of angiotensin II on muscle and renal blood flow under euglycemic conditions. *J Am Soc Nephrol* 11:2001-2006, 2000
743. Fliser D, Ritz E: Serum cystatin C concentration as a marker of renal dysfunction in the elderly. *Am J Kidney Dis* 37:79-83, 2001
744. Fliser D, Haller H: Angiotensin II subtype 1-receptor antagonists in the treatment of diabetic nephropathy. *J Hypertens Suppl* 19:S57-S60, 2001
745. Fliser D: Renal replacement therapy in the intensive care unit with a single-pass batch system. *EDTNA ERCA J Suppl* 2:8, 2002
746. Fliser D, Kielstein JT, Haller H, Bode-Boger SM: Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease? *Kidney Int Suppl* S37-S40, 2003
747. Fliser D, Kielstein JT: A single-pass batch dialysis system: an ideal dialysis method for the patient in intensive care with acute renal failure. *Curr Opin Crit Care* 10:483-488, 2004
748. Fliser D, Haller H: [Modern differential therapy with diuretics]. *Internist (Berl)* 45:598-605, 2004
749. Fliser D, Buchholz K, Haller H: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. *Circulation* 110:1103-1107, 2004
750. Fliser D, de GK, Bahlmann FH, Haller H: Cardiovascular disease in renal patients--a matter of stem cells? *Nephrol Dial Transplant* 19:2952-2954, 2004
751. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H: Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. *J Am Soc Nephrol* 16:1135-1140, 2005
752. Fliser D: Ren sanus in corpore sano: the myth of the inexorable decline of renal function with senescence. *Nephrol Dial Transplant* 20:482-485, 2005
753. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E: Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. *J Am Soc Nephrol* 16:2456-2461, 2005
754. Fliser D, Wittke S, Mischak H: Capillary electrophoresis coupled to mass spectrometry for clinical diagnostic purposes. *Electrophoresis* 26:2708-2716, 2005
755. Fliser D: Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule. *Eur J Clin Invest* 35:71-79, 2005
756. Fliser D, Bahlmann FH, deGroot K, Haller H: Mechanisms of disease: erythropoietin--an old hormone with a new mission? *Nat Clin Pract Cardiovasc Med* 3:563-572, 2006
757. Fliser D, Bahlmann FH, Haller H: EPO: renoprotection beyond anemia correction. *Pediatr Nephrol* 21:1785-1789, 2006
758. Fliser D, Kielstein JT: Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis. *Nat Clin Pract Nephrol* 2:32-39, 2006
759. Fliser D, Kielstein JT, Menne J: Insulin resistance and renal disease. *Contrib Nephrol* 151:203-211, 2006
760. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. *J Am Soc Nephrol* 18:2600-2608, 2007
761. Fliser D, Haller H: Erythropoietin and treatment of non-anemic conditions--cardiovascular protection. *Semin Biomarker discovery. J Am Soc Nephrol* 18:1057-1071, 2007
762. Fliser D: Perspectives in renal disease progression: The endothelium as a treatment target in chronic kidney disease. *J Nephrol* 23:369-376, 2010
763. Fliser D, Dellanna F, Koch M, Seufert J, Witzke O, Hauser IA: The primavera study protocol design: Evaluating the effect of continuous erythropoiesis receptor activator (c.E.R.A.) on renal function in non-anemic patients with chronic kidney disease. *Contemp Clin Trials* 32:786-792, 2011
764. Fliser D, Laville M, Covic A, Fouque D, Vanholder R, Juillard L, Van Biesen W: A european renal best practice (erbp) position statement on the kidney disease improving global outcomes (kdigo) clinical practice guidelines on acute kidney injury: Part 1: Definitions, conservative management and contrast-induced nephropathy. *Nephrol Dial Transplant* 27:4263-4272, 2012
765. Fodinger M, Mannhalter C, Pabinger I, Koizar D, Rintelen C, Horl WH, Sunder-Plassmann G: Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients. *Nephrol Dial Transplant* 11:668-672, 1996
766. Fodinger M, Mannhalter C, Wolff G, Pabinger I, Muller E, Schmid R, Horl WH, Sunder-Plassmann G: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. *Kidney Int* 52:517-523, 1997
767. Fodinger M, Hirschl MM, Schedler D, Herkner H, Bur A, Laggner AN, Horl WH, Sunder-Plassmann G: Mutations in the carboxy terminus of the beta and gamma subunits of the epithelial sodium channel are not

- present in patients with hypertensive crisis. *Eur J Clin Invest* 28:707-711, 1998
768. Fodinger M, Fritsche-Polanz R, Schedler D, Horl WH, Sunder-Plassmann G: Two novel mutations in the beta subunit of the human epithelial sodium channel. *Kidney Int* 55:2530-2531, 1999
769. Fodinger M, Wolff G, Fischer G, Rasoul-Rockenschaub S, Schmid R, Horl WH, Sunder-Plassmann G: Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients. *Kidney Int* 55:1072-1080, 1999
770. Fodinger M, Schedler D, Fritsche-Polanz R, Horl WH, Sunder-Plassmann G: Molecular analysis of the carboxy terminus of the beta and gamma subunits of the epithelial sodium channel in patients with end-stage renal disease. *Nephron* 81:381-386, 1999
771. Fodinger M, Buchmayer H, Heinz G, Papagiannopoulos M, Kletzmayer J, Rasoul-Rockenschaub S, Horl WH, Sunder-Plassmann G: Effect of MTHFR 1298A-->C and MTHFR 677C-->T genotypes on total homocysteine, folate, and vitamin B(12) plasma concentrations in kidney graft recipients. *J Am Soc Nephrol* 11:1918-1925, 2000
772. Fodinger M, Fritsche-Polanz R, Buchmayer H, Skoupy S, Sengoelge G, Horl WH, Sunder-Plassmann G: Erythropoietin-inducible immediate-early genes in human vascular endothelial cells. *J Investig Med* 48:137-149, 2000
773. Fodinger M, Horl WH, Sunder-Plassmann G: Molecular biology of 5,10-methylenetetrahydrofolate reductase. *J Nephrol* 13:20-33, 2000
774. Fodinger M, Buchmayer H, Heinz G, Papagiannopoulos M, Kletzmayer J, Perschl A, Vychytil A, Horl WH, Sunder-Plassmann G: Association of two MTHFR polymorphisms with total homocysteine plasma levels in dialysis patients. *Am J Kidney Dis* 38:77-84, 2001
775. Fodinger M, Wagner OF, Horl WH, Sunder-Plassmann G: Recent insights into the molecular genetics of the homocysteine metabolism. *Kidney Int Suppl* 78:S238-S242, 2001
776. Formigli L, Perna AM, Meacci E, Cinci L, Margheri M, Nistri S, Tani A, Silvertown J, Orlandini G, Porciani C, Zecchi-Orlandini S, Medin J, Bani D: Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodelling. *J Cell Mol Med* 11:1087-1100, 2007
777. Forsberg L, de FU, Marklund SL, Andersson PM, Stegmayr B, Morgenstern R: Phenotype determination of a common Pro-Leu polymorphism in human glutathione peroxidase 1. *Blood Cells Mol Dis* 26:423-426, 2000
778. Forster PB, Deppisch R, Furst P, Schneider H: Immunophenotyping and LDL receptor activity analysis in monocytes/macrophages during low-and high-flux haemodialysis. *Nephrol Dial Transplant* 14 Suppl 4:49-51, 1999
779. Fouque D, Vennegoor M, ter WP, Wanner C, Basci A, Canaud B, Haage P, Konner K, Kooman J, Martin-Malo A, Pedrini L, Pizzarelli F, Tattersall J, Tordoir J, Vanholder R: EBPG guideline on nutrition. *Nephrol Dial Transplant* 22 Suppl 2:ii45-ii87, 2007
780. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Trevinho-Becerra A, Wanner C: A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. *Hematol* 44:212-217, 2007
781. Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami MA, Jankowski J, Mischak H: Advances in urinary proteome analysis and biomarkers discovery *J Am Soc Nephrol*. 18:1057-71,
782. Franek E, Bar A, Kokot F, Dulawa J, Wiecek A, Kochanska-Dziurawicz A, Bar K, Szkodny A, Pawlowski W, Myrta J: Abnormal function of renal tubules in patients with simple renal cysts. *Int Urol Nephrol* 27:679-685, 1995
783. Franek E, Wiecek A, Kozielski J, Rauer R, Kokot M, Kokot F, Oklek K: [Half-time of erythropoietin in patients with chronic obstructive pulmonary diseases]. *Przegl Lek* 53:592-594, 1996
784. Franek E, Blach A, Witula A, Kolonko A, Chudek J, Drugacz J, Wiecek A: Association between chronic periodontal disease and left ventricular hypertrophy in kidney transplant recipients. *Transplantation* 80:3-5, 2005
785. Franek E, Blaschky R, Kolonko A, Mazur-Psonka L, Langowska-Adamczyk H, Drugacz J, Kokot F, Wiecek A: [Oral hygiene in haemodialyzed patients with chronic renal failure]. *Wiad Lek* 59:184-188, 2006
786. Franek E, Blaschky R, Kolonko A, Mazur-Psonka L, Langowska-Adamczyk H, Kokot F, Wiecek A: Chronic periodontitis in hemodialysis patients with chronic kidney disease is associated with elevated serum C-reactive protein concentration and greater intima-media thickness of the carotid artery. *J Nephrol* 19:346-351, 2006
787. Franken S, Wittke D, Mansson JE, D'Hooge R, De Deyn PP, Lullmann-Rauch R, Matzner U, Gieselmann V: Modest phenotypic improvements in ASA-deficient mice with only one UDP-galactose:ceramide-galactosyltransferase gene. *Lipids Health Dis* 5:21, 2006
788. Fraune C, Lange S, Krebs C, Holzel A, Baucke J, Divac N, Schwedhelm E, Streichert T, Velden J, Garrelts IM, Danser AH, Frenay AR, van Goor H, Jankowski V, Stahl R, Nguyen G, Wenzel UO: A11 antagonism and renin inhibition in mice: Pivotal role of targeting angiotensin ii in chronic kidney disease. *Am J Physiol Renal Physiol* 303:F1037-1048, 2012
789. Franssen E, D'Hooge R, Van CG, Verhoye M, Sijbers J, Reyniers E, Soriano P, Kamiguchi H, Willemsen R, Koekkoek SK, De Zeeuw CI, De Deyn PP, Van der LA, Lemmon V, Kooy RF, Willems PJ: L1 knockout mice show dilated ventricles, vermiform hypoplasia and impaired exploration patterns. *Hum Mol Genet* 7:999-1009, 1998
790. Franz M, Regele H, Kirchmair M, Kletzmayer J, Sunder-Plassmann G, Horl WH, Pohanka E: Magic mushrooms: hope for a 'cheap high' resulting in end-stage renal failure. *Nephrol Dial Transplant* 11:2324-2327, 1996
791. Franz M, Horl WH: [Value of diuretics in hypertension]. *Wien Med Wochenschr* 146:432-435, 1996
792. Franz M, Horl WH: Protein catabolism in acute renal failure. *Miner Electrolyte Metab* 23:189-193, 1997
793. Franz M, Pohanka E, Tribl B, Woloszczuk W, Horl WH: Living on chronic hemodialysis between dryness and fluid overload. *Kidney Int Suppl* 59:S39-S42, 1997
794. Franz M, Horl WH: The patient with end-stage renal failure and ascites. *Nephrol Dial Transplant* 12:1070-1078, 1997
795. Franz M, Regele H, Schmaldienst S, Stummvoll HK, Horl WH, Pohanka E: Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? *Transplantation* 66:1258-1262, 1998
796. Franz M, Horl WH: Common errors in diagnosis and management of urinary tract infection. II: clinical management. *Nephrol Dial Transplant* 14:2754-2762, 1999
797. Franz M, Geppert A, Kain R, Horl WH, Pohanka E: Acute renal failure after ibutilide. *Lancet* 353:467, 1999
798. Franz M, Horl WH: Common errors in diagnosis and management of urinary tract infection. I: pathophysiology and diagnostic techniques. *Nephrol Dial Transplant* 14:2746-2753, 1999



799. Franz M, Woloszczuk W, Horl WH: N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. *Kidney Int* 58:374-383, 2000
800. Franz M, Woloszczuk W, Horl WH: N-terminal fragments of the proatrial natriuretic peptide in plasma and urine of kidney graft recipients. *Transplantation* 72:89-94, 2001
801. Franz M, Woloszczuk W, Horl WH: Adsorption of natriuretic factors in uremia. *Semin Nephrol* 21:298-302, 2001
802. Franz M, Woloszczuk W, Horl WH: Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. *Kidney Int* 59:1928-1934, 2001
803. Fried L, Hutchison A, Stegmayr B, Prichard S, Bargman JM: Recommendations for the treatment of lipid disorders in patients on peritoneal dialysis. ISPD guidelines/recommendations. International Society for Peritoneal Dialysis. *Perit Dial Int* 19:7-16, 1999
804. Friedrich B, Alexander D, Aicher WK, Duszenko M, Schaub TP, Passlick-Deetjen J, Waldegger S, Wolf S, Risler T, Lang F: Influence of standard haemodialysis treatment on transcription of human serum- and glucocorticoid-inducible kinase SGK1 and taurine transporter TAUT in blood leukocytes. *Nephrol Dial Transplant* 20:768-774, 2005
805. Frints SG, Marynen P, Hartmann D, Fryns JP, Steyaert J, Schachner M, Rolf B, Craessaerts K, Snellinx A, Hollanders K, D'Hooge R, De Deyn PP, Froyen G: CALL interrupted in a patient with non-specific mental retardation: gene dosage-dependent alteration of murine brain development and behavior. *Hum Mol Genet* 12:1463-1474, 2003
806. Frommberger M, Zuerbig P, Jantos J, Krahn T, Mischak H, Pich A, Just I, Schmitt-Kopplin P, Schiffer E: Peptidomic analysis of rat urine using capillary electrophoresis coupled to mass spectrometry. *Proteomics Clin Appl* 1:650-660, 2007
807. Fujigasaki H, Martin JJ, De Deyn PP, Camuzat A, Deffond D, Stevanin G, Dermaut B, Van BC, Durr A, Brice A: CAG repeat expansion in the TATA box-binding protein gene causes autosomal dominant cerebellar ataxia. *Brain* 124:1939-1947, 2001
808. Fumeron C, Nguyen-Khoa T, Salties C, Kebede M, Buisson C, Druke TB, Lacour B, Massy ZA: Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. *Nephrol Dial Transplant* 20:1874-1879, 2005
809. Gahl GM, Jorres A: Nightly intermittent peritoneal dialysis: targets and prescriptions. *Perit Dial Int* 20 Suppl 2:S89-S92, 2000
810. Gallice PM, Kovacic HN, Brunet PJ, Berland YF, Crevat AD: A non ouabain-like inhibitor of the sodium pump in uremic plasma ultrafiltrates and urine from healthy subjects. *Clin Chim Acta* 273:149-160, 1998
811. Galzin M, Brunet P, Burtey S, Dussol B, Berland Y: [Tubular necrosis after non-steroidal anti-inflammatory agents and acute alcoholic intoxication]. *Nephrologie* 18:113-115, 1997
812. Gama-Axelsson T, Lindholm B, Barany P, Heimbürger O, Stenvinkel P, Qureshi AR: Self-rated appetite as a predictor of mortality in patients with stage 5 chronic kidney disease. *J Ren Nutr* 23:106-113, 2012
813. Gamp AC, Tanaka Y, Lullmann-Rauch R, Wittke D, D'Hooge R, De Deyn PP, Moser T, Maier H, Hartmann D, Reiss K, Illert AL, von FK, Saftig P: LIMP-2/LGP85 deficiency causes ureteric pelvic junction obstruction, deafness and peripheral neuropathy in mice. *Hum Mol Genet* 12:631-646, 2003
814. Gantois I, Bakker CE, Reyniers E, Willemsen R, D'Hooge R, De Deyn PP, Oostra BA, Kooy RF: Restoring the phenotype of fragile X syndrome: insight from the mouse model. *Curr Mol Med* 1:447-455, 2001
815. Garcia-Garcia M, Garcia-Valero J, Mourad G, Argiles A: Urinary and serum beta 2-microglobulin in living related kidney donors and in renal failure. *Contrib Nephrol* 112:77-82, 1995
816. Garcia-Garcia M, Gouin-Charnet A, Mourad G, Argiles A: Monomeric and dimeric beta 2-microglobulin may be extracted from amyloid deposits in vitro. *Nephrol Dial Transplant* 12:1192-1198, 1997
817. Garcia-Garcia M, Mourad G, Durfort M, Garcia-Valero J, Argiles A: Vascular involvement and cell damage in experimental AA and clinical beta(2)-microglobulin amyloidosis. *Nephrol Dial Transplant* 17:1450-1456, 2002
818. Garcia-Lopez E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P: Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. *Perit Dial Int* 27 Suppl 2:S205-S209, 2007
819. Garred LJ, Canaud B, Argiles A, Flavier JL, Mion C: Protein catabolic rate determination from a single measurement of dialyzed urea. *ASAIO J* 41:M804-M809, 1995
820. Garrigue V, Lorho R, Canet S, Augias D, Serval MF, Canaud B, Albat B, Mourad G, Argiles A: Necrotic skin lesions in a dialysis patient: a multifactorial entity. *Clin Nephrol* 57:163-166, 2002
821. Garzoni D, Keusch G, Kleinoeder T, Martin H, Dhondt A, Cremaschi L, Tatsis E, Ibrahim N, Boer W, Kuehne S, Claus M, Zahn M, Schuemann E, Engelmann J, Hickstein H, Wojke R, Gaulty A, Passlick-Deetjen J: Reduced complications during hemodialysis by automatic blood volume controlled ultrafiltration. *Int J Artif Organs* 30:16-24, 2007
822. Gebruers N, Truijien S, Engelborghs S, De Deyn PP: Volumetric evaluation of upper extremities in 250 healthy persons. *Clin Physiol Funct Imaging* 27:17-22, 2007
823. Gerdemann A, Lemke HD, Nothdurft A, Heidland A, Munch G, Bahner U, Schinzel R: Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. *Clin Nephrol* 54:276-283, 2000
824. Gerlach J, Jorres A, Berger A, Schon M, Smith MD, Nohr R, Neuhaus P: Systemic liberation of interleukin-1 beta and interleukin-1 receptor antagonist in the perioperative phase of liver transplantation. *Transpl Int* 9:408-414, 1996
825. Gerlach J, Jorres A, Schon M, Nohr R, Berger A, Spatkowski G, Smith MD, Neuhaus P: Systemic liberation of interleukin-8 in the perioperative phase of liver transplantation. *Transpl Int* 10:401-404, 1997
826. Gerlach J, Jorres A, Nohr R, Zeilinger K, Spatkowski G, Neuhaus P: Local liberation of cytokines during liver preservation. *Transpl Int* 12:261-265, 1999
827. Ghanavati S, My Diep L, Barany P, Heimbürger O, Seeberger A, Stenvinkel P, Rohani M, Agewall S: Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4. *Angiology* 2013
828. Giaime P, Carrega L, Fenouillet E, Mercier L, Gerolami V, Ruf J, Sauze N, Brunet P, Saadjian A, Berland Y, Dussol B, Guieu R: Relationship between A2A adenosine receptor expression and intradialytic hypotension during hemodialysis. *J Investig Med* 54:473-477, 2006
829. Giampaoli S, Capewell S, Shelley E, Allender S, Briggs A, Jorgensen T, Labarthe D, Marques-Vidal P, Stegmayr B, Verschuren WM, Zdrojewski T: Foreword. *Eur J Cardiovasc Prev Rehabil* 14 Suppl 3:S1, 2007
830. Gierek T, Kokot F, Pilch J, Wiecek A, Paluch J, Franek E: [The concentration of ferritin in blood serum of patients with neoplasms of the larynx and the maxillary-ethmoidal complex]. *Otolaryngol Pol* 49 Suppl 20:81-83, 1995

831. Gierek T, Markowski J, Kokot F, Paluch J, Wiecek A, Klimek D: [Electrophysiological examinations (ABR and DPOAE) of hearing organ in hemodialysed patients suffering from chronic renal failure]. *Otolaryngol Pol* 56:189-194, 2002
832. Gieselmann V, Franken S, Klein D, Mansson JE, Sandhoff R, Lullmann RR, Hartmann D, Saravanan VP, De Deyn PP, D'Hooge R, Van Der Linden AM, Schaeren-Wiemers N: Metachromatic leukodystrophy: consequences of sulphatide accumulation. *Acta Paediatr Suppl* 92:74-79, 2003
833. Gijssels I, Slegers K, Engelborghs S, Robberecht W, Martin JJ, Vandenberghe R, Sciot R, Dermaut B, Goossens D, van der ZJ, De PT, Del-Favero J, Santens P, De JP, De Deyn PP, Van BC, Cruts M: Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS. *Neurobiol Aging* 2007
834. Gillert G, Goffin E, Michel C, Evenepoel P, Biesen WV, Tintillier M, Stenvinkel P, Heimbürger O, Lindholm B, Nordfors L, Robert A, Devuyst O: Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. *Kidney Int* 67:2477-2487, 2005
835. Girndt M, Stenvinkel P, Ulrich C, Axelsson J, Nordfors L, Barany P, Carrero JJ, Heine GH, Kaul H, Kohler H: Influence of cytokine gene polymorphisms on erythropoietin dose requirements in chronic haemodialysis patients. *Nephrol Dial Transplant* 22:3586-3592, 2007
836. Gjurchinov D, Stojanovska-Nojkova J, Grunevski M, Nikolov V, Spasovski G: Radiological and "imaging" methods in TNM classification of non-small-cell lung cancer. *Prilozi* 28:155-167, 2007
837. Glader CA, Stegmayr B, Boman J, Stenlund H, Weinehall L, Hallmans G, Dahlen GH: Chlamydia pneumoniae antibodies and high lipoprotein(a) levels do not predict ischemic cerebral infarctions. Results from a nested case-control study in Northern Sweden. *Stroke* 30:2013-2018, 1999
838. Glader EL, Stegmayr B: Declining prevalence of angina pectoris in middle-aged men and women. A population-based study within the Northern Sweden MONICA Project. *Multinational Monitoring of Trends and Cardiovascular Disease. J Intern Med* 246:285-291, 1999
839. Glader EL, Stegmayr B, Johansson L, Hulter-Asberg K, Wester PO: Differences in long-term outcome between patients treated in stroke units and in general wards: a 2-year follow-up of stroke patients in Sweden. *Stroke* 32:2124-2130, 2001
840. Glader EL, Stegmayr B, Johansson L, Hulter-Asberg K, Staaf A, Wester PO: [Stroke--and then? Considerable need of assistance two year after stroke according to a large nation-wide study]. *Lakartidningen* 98:4462-4467, 2001
841. Glader EL, Stegmayr B, Asplund K: Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden. *Stroke* 33:1327-1333, 2002
842. Glader EL, Stegmayr B, Norrving B, Terent A, Hulter-Asberg K, Wester PO, Asplund K: Sex differences in management and outcome after stroke: a Swedish national perspective. *Stroke* 34:1970-1975, 2003
843. Glader EL, Stegmayr B, Norrving B, Terent A, Hulter-Asberg K, Wester PO, Asplund K: Large variations in the use of oral anticoagulants in stroke patients with atrial fibrillation: a Swedish national perspective. *J Intern Med* 255:22-32, 2004
844. Gloeckner H, Jonuleit T, Lemke HD: Monitoring of cell viability and cell growth in a hollow-fiber bioreactor by use of the dye Alamar Blue. *J Immunol Methods* 252:131-138, 2001
845. Gloeckner H, Lemke HD: New miniaturized hollow-fiber bioreactor for in vivo like cell culture, cell expansion, and production of cell-derived products. *Biotechnol Prog* 17:828-831, 2001
846. Glorieux G, Hsu CH, De SR, Dhondt A, Van KJ, Vogeleere P, Lameire N, Vanholder R: Inhibition of calcitriol-induced monocyte CD14 expression by uremic toxins: role of purines. *J Am Soc Nephrol* 9:1826-1831, 1998
847. Glorieux G, Vanholder R: Blunted response to vitamin D in uremia. *Kidney Int Suppl* 78:S182-S185, 2001
848. Glorieux G, Vanholder R, Lameire N: Advanced glycation and the immune system: stimulation, inhibition or both? *Eur J Clin Invest* 31:1015-1018, 2001
849. Glorieux G, Hsu C, De SR, Dhondt A, van EJ, Waterloos MA, Lameire N, Plum J, Vanholder R: The anti-proliferative effect of calcitriol on HL-60 cells is neutralized by uraemic biological fluids. *Nephrol Dial Transplant* 16:246-252, 2001
850. Glorieux G, Lameire N, Van BW, Dequidt C, Vanholder R: Specific characteristics of peritoneal leucocyte populations during sterile peritonitis associated with icodextrin CAPD fluids. *Nephrol Dial Transplant* 18:1648-1653, 2003
851. Glorieux G, Vanholder R, Lameire N: Uraemic retention and apoptosis: what is the balance for the inflammatory status in uraemia? *Eur J Clin Invest* 33:631-634, 2003
852. Glorieux G, Helling R, Henle T, Brunet P, Deppisch R, Lameire N, Vanholder R: In vitro evidence for immune activating effect of specific AGE structures retained in uremia. *Kidney Int* 66:1873-1880, 2004
853. Glorieux G, Schepers E, Vanholder RC: Uremic toxins in chronic renal failure. *Prilozi* 28:173-204, 2007
854. Glorieux GL, Dhondt AW, Jacobs P, Van LJ, Lameire NH, De Deyn PP, Vanholder RC: In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. *Kidney Int* 65:2184-2192, 2004
855. Glorieux G, Cohen G, Jankowski J, Vanholder R: Platelet/leukocyte activation, inflammation, and uremia. *Semin Dial* 22:423-427, 2009
856. Glorieux G, Schepers E, Schindler R, Lemke HD, Verbeke F, Dhondt A, Lameire N, Vanholder R: A novel bio-assay increases the detection yield of microbiological impurity of dialysis fluid, in comparison to the lal-test. *Nephrol Dial Transplant* 24:548-554, 2009
857. Glorieux G, Vanholder R: New uremic toxins - which solutes should be removed? *Contrib Nephrol* 168:117-128, 2011
858. Godfraind JM, Reyniers E, De BK, D'Hooge R, De Deyn PP, Bakker CE, Oostra BA, Kooy RF, Willems PJ: Long-term potentiation in the hippocampus of fragile X knockout mice. *Am J Med Genet* 64:246-251, 1996
859. Goeman J, Hoksbergen I, Pickut BA, Dom L, Crols R, De Deyn PP: Dementia paralytica in a fifteen-year-old boy. *J Neurol Sci* 144:214-217, 1996
860. Goerke A, Sakai N, Gutjahr E, Schlapkohl WA, Mushinski JF, Haller H, Kolch W, Saito N, Mischak H: Induction of apoptosis by protein kinase C delta is independent of its kinase activity. *J Biol Chem* 277:32054-32062, 2002
861. Gogusev J, Duchambon P, Stoermann-Chopard C, Giovannini M, Sarfati E, Druke TB: De novo expression of transforming growth factor-alpha in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. *Nephrol Dial Transplant* 11:2155-2162, 1996
862. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Druke TB: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. *Kidney Int* 51:328-336, 1997

863. Gokal R, Alexander S, Ash S, Chen TW, Danielson A, Holmes C, Joffe P, Moncrief J, Nichols K, Piraino B, Prowant B, Slingeneyer A, Stegmayr B, Twardowski Z, Vas S: Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. (Official report from the International Society for Peritoneal Dialysis). *Perit Dial Int* 18:11-33, 1998
864. Gokal R, Blake PG, Passlick-Deetjen J, Schaub TP, Prichard S, Burkart JM: What is the evidence that peritoneal dialysis is underutilized as an ESRD therapy? *Semin Dial* 15:149-161, 2002
865. Goldammer A, Wiltschnig S, Heinz G, Jansen M, Stulnig T, Horl WH, Derfler K: Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia. *Metabolism* 51:976-980, 2002
866. Goldammer A, Derfler K, Herkner K, Bradwell AR, Horl WH, Haas M: Influence of plasma immunoglobulin level on antibody synthesis. *Blood* 100:353-355, 2002
867. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A: Lanthanum carbonate reduces fgf23 in chronic kidney disease stage 3 patients. *Nephrol Dial Transplant* 26:2567-2571, 2011
868. Gonzalez-Parra E, Martin-Cleary C, Martin J, Ortiz A: Calcific uremic arteriopathy while on cinacalcet. *J Postgrad Med* 57:51-52, 2011
869. Good DM, Thongboonkerd V, Novak J, Bascands JL, Schanstra JP, Coon JJ, Dominiczak A, Mischak H: Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. *J Proteome Res* 6:4549-4555, 2007
870. Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G, Coon JJ, Dakna M, Decramer S, Delles C, Dominiczak AF, Ehrlich JH, Eitner F, Fliser D, Frommberger M, Ganser A, Girolami MA, Golovko I, Gwinner W, Haubitz M, Herget-Rosenthal S, Jankowski J, Jahn H, Jerums G, Julian BA, Kellmann M, Kliem W, Kolch W, Krolewski AS, Luppi M, Massy Z, Melter M, Neuss C, Novak J, Peter K, Rossing K, Rupprecht H, Schanstra JP, Schiffer E, Stolzenburg JU, Tarnow L, Theodorescu D, Thongboonkerd V, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P: Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. *Mol Cell Proteomics* 2010;9:2424-2437, 2010
871. Goodman WG, London G, Amann K, Block GA, Giachelli C, Hruska KA, Ketteler M, Levin A, Massy Z, McCarron DA, Raggi P, Shanahan CM, Yorioka N: Vascular calcification in chronic kidney disease. *Am J Kidney Dis* 43:572-579, 2004
872. Goodnight JA, Mischak H, Kolch W, Mushinski JF: Immunocytochemical localization of eight protein kinase C isozymes overexpressed in NIH 3T3 fibroblasts. Isoform-specific association with microfilaments, Golgi, endoplasmic reticulum, and nuclear and cell membranes. *J Biol Chem* 270:9991-10001, 1995
873. Goodsaid, F., Bandow, J. E., and Mischak, H. Grand Rounds in Proteomics at the FDA. *PROTEOMICS -Clinical Applications* 1, 1526-1531. 2007. Ref Type: Journal (Full)
874. Gouin-Charnet A, Mourad G, Argiles A: Alpha 2-macroglobulin protects some of the protein constituents of dialysis-associated amyloidosis from protease degradation. *Biochem Biophys Res Commun* 231:48-51, 1997
875. Gouin-Charnet A, Laune D, Granier C, Mani JC, Pau B, Mourad G, Argiles A: alpha2-Macroglobulin, the main serum antiprotease, binds beta2-microglobulin, the light chain of the class I major histocompatibility complex, which is involved in human disease. *Clin Sci (Lond)* 98:427-433, 2000
876. Graham KA, Reaich D, Channon SM, Downie S, Gilmour E, Passlick-Deetjen J, Goodship TH: Correction of acidosis in CAPD decreases whole body protein degradation. *Kidney Int* 49:1396-1400, 1996
877. Grahl DA, Axelsson J, Nordfors L, Heimbürger O, Barany P, Qureshi AR, Kato S, Watanabe M, Suliman M, Riella MC, Lindholm B, Stenvinkel P, Pecoits-Filho R: Associations between the CYBA 242C/T and the MPO -463G/A Polymorphisms, Oxidative Stress and Cardiovascular Disease in Chronic Kidney Disease Patients. *Blood Purif* 25:210-218, 2007
878. Gray LJ, Sprigg N, Bath PM, Sorensen P, Lindenstrom E, Boysen G, De Deyn PP, Friis P, Leys D, Marttila R, Olsson JE, O'Neill D, Ringelstein B, van der Sande JJ, Turpie AG: Significant variation in mortality and functional outcome after acute ischaemic stroke between Western countries: data from the tinzaparin in acute ischaemic stroke trial (TAIST). *J Neurol Neurosurg Psychiatry* 77:327-333, 2006
879. Gray LJ, Sprigg N, Bath PM, Boysen G, De Deyn PP, Leys D, O'Neill D, Ringelstein EB: Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). *Stroke* 38:2960-2964, 2007
880. Greco AV, Mingrone G, Favuzzi A, Bertuzzi A, Gandolfi A, DeSmet R, Vanholder R, Gasbarrini G: Subclinical hepatic encephalopathy: role of tryptophan binding to albumin and the competition with indole-3-acetic acid. *J Investig Med* 48:274-280, 2000
881. Grobden B, De Deyn PP, Slegers H: Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. *Cell Tissue Res* 310:257-270, 2002
882. Grun OS, Herath E, Weihrauch A, Flugge F, Rogacev KS, Fliser D, Heine GH: Does the measurement of the difference of resistive indexes in spleen and kidney allow a selective assessment of chronic kidney injury? *Radiology* 264:894-902, 2012
883. Grunewald T, Lindner M, Weiss S, Ruf I, Treutler T, Ruf B, Beige J: Staphylococcus colonization, mortality and morbidity in hemodialysis patients: 10 years of observation. *Int J Hyg Environ Health* 216:751-754, 2013
884. Grzegorzewska AE, Wiecek A, Mariak I, Kokot F: Amino-acid-based dialysis solution changes leptinemia and leptin peritoneal clearance. *Adv Perit Dial* 16:7-14, 2000
885. Gueler F, Gwinner W, Schiborr C, Martin M, Klos A, Kirsch T, Fiebeler A, Haller H, Fliser D: Biocompatibility parameters of different dialysis membranes assessed during systemic inflammation. *Blood Purif* 23:196-202, 2005
886. Gueler F, Park JK, Rong S, Kirsch T, Lindschau C, Zheng W, Elger M, Fiebeler A, Fliser D, Luft FC, Haller H: Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. *Am J Pathol* 170:1192-1199, 2007
887. Guez M, Hildingsson C, Stegmayr B, Toolanen G: Chronic neck pain of traumatic and non-traumatic origin: a population-based study. *Acta Orthop Scand* 74:576-579, 2003
888. Guieu R, Dussol B, Devaux C, Sampol J, Brunet P, Rochat H, Bechis G, Berland YF: Interactions between cyclosporine A and adenosine in kidney transplant recipients. *Kidney Int* 53:200-204, 1998
889. Guieu R, Brunet P, Sampol J, Bechis G, Fenouillet E, Mege JL, Capo C, Vitte J, Ibrahim Z, Carrega L, Lerda D, Rochat H, Berland Y, Dussol B: Adenosine and hemodialysis in humans. *J Investig Med* 49:56-67, 2001
890. Guignonis V, Fremeaux-Bacchi V, Giraudier S, Favier R, Borderie D, Massy Z, Mougnot B, Rosenblatt DS, Deschenes G: Late-onset thrombotic microangiopathy caused by cblC disease: association with a factor H mutation. *Am J Kidney Dis* 45:588-595, 2005
891. Guijarro C, Massy ZA, Kasiske BL: Clinical correlation between renal allograft failure and hyperlipidemia. *Kidney Int Suppl* 52:S56-S59, 1995

892. Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ, Kasiske BL: Serum albumin and mortality after renal transplantation. *Am J Kidney Dis* 27:117-123, 1996
893. Guijarro C, Kim Y, Schoonover CM, Massy ZA, O'Donnell MP, Kasiske BL, Keane WF, Kashtan CE: Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. *Nephrol Dial Transplant* 11:990-996, 1996
894. Guijarro C, Kim Y, Kasiske BL, Massy ZA, O'Donnell MP, Kashtan CE, Keane WF: Central role of the transcription factor nuclear factor-kappa B in mesangial cell production of chemokines. *Contrib Nephrol* 120:210-218, 1997
895. Guijarro C, Blanco-Colio LM, Massy ZA, O'Donnell MP, Kasiske BL, Keane WF, Egido J: Lipophilic statins induce apoptosis of human vascular smooth muscle cells. *Kidney Int Suppl* 71:S88-S91, 1999
896. Guillet B, Simon N, Sampol JJ, Lorec-Penet AM, Portugal H, Berland Y, Dussol B, Brunet P: Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. *Nephrol Dial Transplant* 18:2348-2353, 2003
897. Gunthner T, Jankowski V, Kretschmer A, Nierhaus M, van der Giet M, Zidek W, Jankowski J: Endothelium and vascular smooth muscle cells in the context of uremia. *Semin Dial* 22:428-432, 2009
898. Guo Q, Barany P, Qureshi AR, Snaedal S, Heimbürger O, Stenvinkel P, Lindholm B, Axelsson J: N-terminal pro-brain natriuretic peptide independently predicts protein energy wasting and is associated with all-cause mortality in prevalent hd patients. *Am J Nephrol* 29:516-523, 2009
899. Guo Q, Carrero JJ, Yu X, Barany P, Qureshi AR, Eriksson M, Anderstam B, Chmielewski M, Heimbürger O, Stenvinkel P, Lindholm B, Axelsson J: Associations of vegf and its receptors vegfr-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. *Nephrol Dial Transplant* 24:3468-3473, 2009
900. Guz G, Glorieux GL, De SR, Waterloos MA, Vanholder RC, Dhondt AW: Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients. *Nephrol Dial Transplant* 21:2834-2840, 2006
901. Haag-Weber M, Horl WH: The immune system in uremia and during its treatment. *New Horiz* 3:669-679, 1995
902. Haag-Weber M, Horl WH: Are granulocyte inhibitory proteins contributing to enhanced susceptibility to infections in uraemia? *Nephrol Dial Transplant* 11 Suppl 2:98-100, 1996
903. Haag-Weber M, Horl WH: Dysfunction of polymorphonuclear leukocytes in uremia. *Semin Nephrol* 16:192-201, 1996
904. Haag-Weber M, Cohen G, Horl WH: Clinical significance of granulocyte-inhibiting proteins. *Nephrol Dial Transplant* 15 Suppl 1:15-16, 2000
905. Haas M, Leko-Mohr Z, Lang T, Jansen M, Knobl P, Horl WH, Druml W: The LDH ratio as a marker for response to plasma exchange in HUS/TTP of the adult. *Clin Nephrol* 57:414-420, 2002
906. Haas M, Mayer G, Wirnsberger G, Holzer H, Ratschek M, Neyer U, Neuweiler J, Kramar R, Schneider B, Breiteneder-Geleff S, Regele HM, Horl WH, Kerjaschki D: Antioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study. *Wien Klin Wochenschr* 114:143-147, 2002
907. Haas M, Bohmig GA, Leko-Mohr Z, Exner M, Regele H, Derfler K, Horl WH, Druml W: Peri-operative immunoadsorption in sensitized renal transplant recipients. *Nephrol Dial Transplant* 17:1503-1508, 2002
908. Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U, Pieper AK, Schaub TP, Passlick-Deetjen J, Mehls O, Schaefer F: Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. *J Am Soc Nephrol* 14:2632-2638, 2003
909. Habicht A, Regele H, Exner M, Soleiman A, Horl WH, Watschinger B, Derfler K, Bohmig GA: A case of severe C4d-positive kidney allograft dysfunction in the absence of histomorphologic features of rejection. *Wien Klin Wochenschr* 114:945-948, 2002
910. Hacker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB, Wagner H: CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. *EMBO J* 17:6230-6240, 1998
911. Hacker H, Mischak H, Hacker G, Eser S, Prenzel N, Ullrich A, Wagner H: Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells. *EMBO J* 18:6973-6982, 1999
912. Hafer C, Becker T, Kielstein JT, Bahlmann E, Schwarz A, Grinzoff N, Drzymala D, Bonnard I, Richter N, Lehner F, Klempnauer J, Haller H, Traeder J, Fliser D: High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation. *Kidney Int* 2011;81:314-320, 2011
913. Hagen W, Fodinger M, Heinz G, Buchmayer H, Horl WH, Sunder-Plassmann G: Effect of MTHFR genotypes and hyperhomocysteinemia on patient and graft survival in kidney transplant recipients. *Kidney Int Suppl* 78:S253-S257, 2001
914. Hagen W, Fodinger M, Horl WH, Sunder-Plassmann G: Therapy of hyperhomocysteinemia in end-stage renal disease patients. *Minerva Urol Nefrol* 53:159-170, 2001
915. Hagdoost S, Maruyama Y, Pecoits-Filho R, Heimbürger O, Seeberger A, Anderstam B, Suliman ME, Czene S, Lindholm B, Stenvinkel P, Harms-Ringdahl M: Elevated serum 8-oxo-dG in hemodialysis patients: a marker of systemic inflammation? *Antioxid Redox Signal* 8:2169-2173, 2006
916. Haidinger M, Geyeregger R, Poglitsch M, Weichhart T, Zeyda M, Vodenik B, Stulnig TM, Bohmig GA, Horl WH, Saemann MD: Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation. *Transplantation* 84:117-121, 2007
917. Hallems A, Aerts P, Otten B, De Deyn PP, De CD: Mechanical energy in toddler gait. A trade-off between economy and stability? *J Exp Biol* 207:2417-2431, 2004
918. Haller H, de GK, Bahlmann F, Elger M, Fliser D: Stem cells and progenitor cells in renal disease. *Kidney Int* 68:1932-1936, 2005
919. Haller H, Bahlmann F, Fliser D: [Regeneration of renal tissue --therapy of the future?]. *Dtsch Med Wochenschr* 131:896-898, 2006
920. Hallmans G, Agren A, Johansson G, Johansson A, Stegmayr B, Jansson JH, Lindahl B, Rolandsson O, Soderberg S, Nilsson M, Johansson I, Weinehall L: Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort -evaluation of risk factors and their interactions. *Scand J Public Health Suppl* 61:18-24, 2003
921. Hamwi A, Fodinger M, Sunder-Plassmann G, Horl WH, Vukovich TC: Disturbed latex immunoassays for C-reactive protein and ferritin in a renal transplant patient due to polyclonal IgM hypergammaglobulinaemia. *Nephrol Dial Transplant* 12:1229-1233, 1997

922. Hannah BP, Heldwein EE, Bender FC, Cohen GH, Eisenberg RJ: Mutational evidence of internal fusion loops in herpes simplex virus glycoprotein B. *J Virol* 81:4858-4865, 2007
923. Hansch GM, Karnaukhova S, Chang SH, Rus H, Nicolescu F, Deppisch R, Meissner C, Ludwig H, Ritz E: Activation of human neutrophils after contact with cellulose-based haemodialysis membranes: intracellular calcium signalling in single cells. *Nephrol Dial Transplant* 11:2453-2460, 1996
924. Hatamizadeh P, Najafi I, Vanholder R, Rashid-Farokhi F, Sanadgol H, Seyrafian S, Mooraki A, Atabak S, Samimagham H, Pourfarziani V, Broumand B, Van BW, Lameire N: Epidemiologic aspects of the Bam earthquake in Iran: the nephrologic perspective. *Am J Kidney Dis* 47:428-438, 2006
925. Hauben U, D'Hooge R, Soetens E, De Deyn PP: Effects of oral administration of the competitive N-methyl-D-aspartate antagonist, CGP 40116, on passive avoidance, spatial learning, and neuromotor abilities in mice. *Brain Res Bull* 48:333-341, 1999
926. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Haller H, Mischak H: Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. *Kidney Int* 67:2313-2320, 2005
927. Haufe CC, Eismann U, Deppisch RM, Stein G: Expression of beta2-microglobulin and c-fos mRNA: is there an influence of high-or low-flux dialyzer membranes? *Kidney Int Suppl* 78:S177-S181, 2001
928. Hauser AC, Hagen W, Rehak PH, Buchmayer H, Fodinger M, Papagiannopoulos M, Bieglmayer C, Apsner R, Koller E, Ignatescu M, Horl WH, Sunder-Plassmann G: Efficacy of folic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients. *Am J Kidney Dis* 37:758-765, 2001
929. Hauser AC, Horl WH: [Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology]. *Wien Med Wochenschr* 151:160-164, 2001
930. Hauser AC, Pabinger-Fasching I, Quehenberger P, Kettenbach J, Horl WH: A patient with sudden abdominal pain 10 years after successful renal transplantation. *Nephrol Dial Transplant* 18:1021-1025, 2003
931. Hauser AC, Hauser L, Pabinger-Fasching I, Quehenberger P, Derfler K, Horl WH: The course of anticardiolipin antibody levels under immunoadsorption therapy. *Am J Kidney Dis* 46:446-454, 2005
932. Hauser RA, Rascol O, Korczyn AD, Jon SA, Watts RL, Poewe W, De Deyn PP, Lang AE: Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. *Mov Disord* 22:2409-2417, 2007
933. Hayashi SY, Brodin LA, Alvestrand A, Lind B, Stenvinkel P, Mazza do NM, Qureshi AR, Saha S, Lindholm B, Seeberger A: Improvement of cardiac function after haemodialysis. Quantitative evaluation by colour tissue velocity imaging. *Nephrol Dial Transplant* 19:1497-1506, 2004
934. Hecking M, Kainz A, Schillinger M, Posch C, Birsan T, Rasoul-Rockenschaub S, Bohmig GA, Schmaldienst S, Watschinger B, Horl WH, Muhlbacher F, Saemann MD: Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine. *Transpl Int* 21:223-233, 2008
935. Heemann U, Abramowicz D, Spasovski G, Vanholder R: Endorsement of the kidney disease improving global outcomes (kdigo) guidelines on kidney transplantation: A european renal best practice (erbp) position statement. *Nephrol Dial Transplant* 26:2099-2106, 2011
936. Heering P, Ivens K, Thumer O, Morgera S, Heintzen M, Passlick-Deetjen J, Willers R, Strauer BE, Grabensee B: The use of different buffers during continuous hemofiltration in critically ill patients with acute renal failure. *Intensive Care Med* 25:1244-1251, 1999
937. Heimbürger O, Stenvinkel P, Berglund L, Traneus A, Lindholm B: Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. *Nephron* 72:135-144, 1996
938. Heimbürger O, Lonnqvist F, Danielsson A, Nordenstrom J, Stenvinkel P: Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. *J Am Soc Nephrol* 8:1423-1430, 1997
939. Heimbürger O, Wang T, Lonnqvist F, Stenvinkel P: Peritoneal clearance of leptin in CAPD patients: impact of local insulin administration. *Nephrol Dial Transplant* 14:723-727, 1999
940. Heimbürger O, Qureshi AR, Blauer WS, Berglund L, Stenvinkel P: Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. *Am J Kidney Dis* 36:1213-1225, 2000
941. Heimbürger O, Stenvinkel P: Adipokines in chronic kidney disease--fat tissue gives nephrologists a message. *Perit Dial Int* 25:340-342, 2005
942. Heimbürger O, Stenvinkel P: Statins to treat chronic inflammation in dialysis patients--is this feasible? *Perit Dial Int* 27:254-257, 2007
943. Heine GH, Ortiz A, Massy ZA, Lindholm B, Wiecek A, Martinez-Castelao A, Covic A, Goldsmith D, Suleymanlar G, London GM, Parati G, Sicari R, Zoccali C, Fliser D: Monocyte subpopulations and cardiovascular risk in chronic kidney disease. *Nat Rev Nephrol* 2012;8:362-369.
944. Heirman I, Ginneberge D, Brigelius-Flohe R, Hendrickx N, Agostinis P, Brouckaert P, Rottiers P, Grooten J: Blocking tumor cell eicosanoid synthesis by GP x 4 impedes tumor growth and malignancy. *Free Radic Biol Med* 40:285-294, 2006
945. Helmer C, Stengel B, Metzger M, Froissart M, Massy ZA, Tzourio C, Berr C, Dartigues JF: Chronic kidney disease, cognitive decline, and incident dementia: The 3c study. *Neurology* 2011;77:2043-2051.
946. Henle T, Deppisch R, Ritz E: The Maillard reaction--from food chemistry to uraemia research. *Nephrol Dial Transplant* 11:1718-1722, 1996
947. Henle T, Deppisch R, Beck W, Hergesell O, Hansch GM, Ritz E: Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. *Nephrol Dial Transplant* 14:1968-1975, 1999
948. Hennequin C, Lalanne V, Estepa L, Druke T, Daudon M, Lacour B: Validation by image analysis of a turbidimetric method to study calcium oxalate crystallization. *Clin Nephrol* 48:292-299, 1997
949. Hennequin C, Tardivel S, Medetognon J, Druke T, Daudon M, Lacour B: A stable animal model of diet-induced calcium oxalate crystalluria. *Urol Res* 26:57-63, 1998
950. Hennige AM, Fritsche A, Strack V, Weigert C, Mischak H, Borboni P, Renn W, Haring HU, Kellerer M: PKC zeta enhances insulin-like growth factor 1-dependent mitogenic activity in the rat clonal beta cell line RIN 1046-38. *Biochem Biophys Res Commun* 290:85-90, 2002
951. Herembert T, Gogusev J, Zhu DL, Druke TB, Marche P: Control of vascular smooth-muscle cell growth by macrophage-colony-stimulating factor. *Biochem J* 325 ( Pt 1):123-128, 1997
952. Herget-Rosenthal S, Kribben A, Pietruck F, Ross B, Philipp T: Two by two hour creatinine clearance--repeatable and valid. *Clin Nephrol* 51:348-354, 1999
953. Herget-Rosenthal S, Trabold S, Huesing J, Heemann U, Philipp T, Kribben A: Cystatin C--an accurate marker of glomerular filtration rate after renal transplantation? *Transpl Int* 13:285-289, 2000

954. Herget-Rosenthal S, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A: Cystatin C: efficacy as screening test for reduced glomerular filtration rate. *Am J Nephrol* 20:97-102, 2000
955. Herget-Rosenthal S, Uppenkamp M, Beelen D, Kohl D, Kribben A: Renal complications of high-dose chemotherapy and peripheral blood stem cell transplantation. *Nephron* 84:136-141, 2000
956. Herget-Rosenthal S, Marggraf G, Pietruck F, Husing J, Strupat M, Philipp T, Kribben A: Procalcitonin for accurate detection of infection in haemodialysis. *Nephrol Dial Transplant* 16:975-979, 2001
957. Herget-Rosenthal S, Hosford M, Kribben A, Atkinson SJ, Sandoval RM, Molitoris BA: Characteristics of EYFP-actin and visualization of actin dynamics during ATP depletion and repletion. *Am J Physiol Cell Physiol* 281:C1858-C1870, 2001
958. Herget-Rosenthal S, Gerken G, Philipp T, Holtmann G: Serum ferritin and survival of renal transplant recipients: a prospective 10-year cohort study. *Transpl Int* 16:642-647, 2003
959. Herget-Rosenthal S, Feldkamp T, Volbracht L, Kribben A: Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: precision, interferences, stability and reference range. *Ann Clin Biochem* 41:111-118, 2004
960. Herget-Rosenthal S, Poppen D, Husing J, Marggraf G, Pietruck F, Jakob HG, Philipp T, Kribben A: Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. *Clin Chem* 50:552-558, 2004
961. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, Philipp T, Kribben A: Early detection of acute renal failure by serum cystatin C. *Kidney Int* 66:1115-1122, 2004
962. Herget-Rosenthal S, Klein T, Marggraf G, Hirsch T, Jakob HG, Philipp T, Kribben A: Modulation and source of procalcitonin in reduced renal function and renal replacement therapy. *Scand J Immunol* 61:180-186, 2005
963. Herget-Rosenthal S, Pietruck F, Volbracht L, Philipp T, Kribben A: Serum cystatin C--a superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine. *Clin Nephrol* 64:41-46, 2005
964. Herget-Rosenthal S: Can serial measurements of cystatin C accurately detect early renal function decline? *Nat Clin Pract Nephrol* 1:68-69, 2005
965. Herget-Rosenthal S: One step forward in the early detection of acute renal failure. *Lancet* 365:1205-1206, 2005
966. Herget-Rosenthal S, Molitoris BA: Advances in imaging the kidney and cellular processes. *Nephron Exp Nephrol* 103:e31-e32, 2006
967. Herget-Rosenthal S, Quellmann T, Linden C, Reinhardt W, Philipp T, Kribben A: Management of advanced chronic kidney disease in primary care -current data from Germany. *Int J Clin Pract* 60:941-948, 2006
968. Herget-Rosenthal S: Thrombotic microangiopathies--an issue for intensivists? *Acta Clin Belg Suppl* 385-388, 2007
969. Herget-Rosenthal S, Bokenkamp A, Hofmann W: How to estimate GFR-serum creatinine, serum cystatin C or equations? *Clin Biochem* 40:153-161, 2007
970. Herget-Rosenthal S, van Wijk JA, Brocker-Preuss M, Bokenkamp A: Increased urinary cystatin C reflects structural and functional renal tubular impairment independent of glomerular filtration rate. *Clin Biochem* 40:946-951, 2007
971. Hermansson J, Gillander GK, Karlsson B, Lindahl B, Stegmayr B, Knutsson A: Ischemic stroke and shift work. *Scand J Work Environ Health* 33:435-439, 2007
972. Hernanz-Schulman M, Foster C, Maxa R, Battles G, Dutt P, Stratton C, Holburn G, Schulman G, Neblett WW, Shyr Y, Hakim RR, Vanholder R, Heller RM: Experimental study of mortality and morbidity of contrast media and standardized fecal dose in the peritoneal cavity. *Pediatr Radiol* 30:369-378, 2000
973. Hernanz-Schulman M, Vanholder R, Waterloos MA, Hakim R, Schulman G: Effect of radiographic contrast agents on leukocyte metabolic response. *Pediatr Radiol* 30:361-368, 2000
974. Hesse UJ, Berrevoet F, Pattyn P, Vanholder R, de HB: Donor parameters of pancreas grafts processed for islet or beta-cell isolation and transplantation. *Transplant Proc* 29:2259, 1997
975. Hesse UJ, Vermassen F, Lameire N, Vanholder R: Expanded criteria donors and dual kidney transplantation. *Transpl Int* 11:457-458, 1998
976. Hillmeister P, Lehmann KE, Bondke A, Witt H, Duelsner A, Gruber C, Busch HJ, Jankowski J, Ruiz-Noppinger P, Hossmann KA, Buschmann IR: Induction of cerebral arteriogenesis leads to early-phase expression of protease inhibitors in growing collaterals of the brain. *J Cereb Blood Flow Metab* 2008;28:1811-1823.
977. Hindricks J, Ebert T, Bachmann A, Kralisch S, Lossner U, Kratzsch J, Stolzenburg JU, Dietel A, Beige J, Anders M, Bast I, Blucher M, Stumvoll M, Fasshauer M: Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. *Clin Endocrinol (Oxf)* 2013
978. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. *Kidney Int* 62:1524-1538, 2002
979. Hocheleid T, Ameloot P, Brockaert P, Van LF, Libert C: Differential response of a(2)-macroglobulin-deficient mice in models of lethal TNF-induced inflammation. *Eur Cytokine Netw* 11:597-601, 2000
980. Hocheleid T, Wullaert A, Berger FG, Baumann H, Brockaert P, Steidler L, Libert C: Overexpression of alpha(1)-acid glycoprotein in transgenic mice leads to sensitisation to acute colitis. *Gut* 51:398-404, 2002
981. Hodis J, Kutinova-Canova N, Potmesil P, Kamenikova L, Kmonickova E, Zidek Z, Farghali H: The role of adrenergic agonists on glycogenolysis in rat hepatocyte cultures and possible involvement of NO. *Physiol Res* 56:419-425, 2007
982. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D: Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. *Kidney Int* 48:1563-1570, 1995
983. Hoffmann JN, Hartl WH, Deppisch R, Faist E, Jochum M, Inthorn D: Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis. *Intensive Care Med* 22:1360-1367, 1996
984. Hoksbergen I, Pickut BA, Marien P, Slabbynck H, Kunnen J, De Deyn PP: SPECT findings in an unusual case of visual hallucinosis. *J Neurol* 243:594-598, 1996
985. Holecki M, Zahorska-Markiewicz B, Nieszporek T, Olszanecka-Glinianowicz M, Mizia-Stec K, Zak-Golab A, Kocelak P, Fryzlewicz-Moska A, Wiecek A: [Impact of the mass-reductive therapy with orlistat on 25-(OH)-D3 and PTH concentration in sera of obese, menopausal women]. *Endokrynol Pol* 56:240-245, 2005
986. Holecki M, Zahorska-Markiewicz B, Nieszporek T, Mizia-Stec K, Olszanecka-Glinianowicz M, Zak-Golab A, Kocelak P, Wiecek A: The influence of a 3-month weight reduction therapy with Orlistat on serum

- vitamin B12 and folic acid concentration in obese women. *Int J Obes (Lond)* 30:1017-1018, 2006
987. Holecki M, Zahorska-Markiewicz B, Janowska J, Mizia-Stec K, Zak-Golab A, Olszanecka-Glinianowicz M, Wojaczynska-Stanek K, Nieszporek T, Wiecek A: Osteoprotegerin -does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women? *Endokrynol Pol* 58:7-10, 2007
988. Holecki M, Zahorska-Markiewicz B, Janowska J, Nieszporek T, Wojaczynska-Stanek K, Zak-Golab A, Wiecek A: The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women. *Obesity (Silver Spring)* 15:1925-1929, 2007
989. Holmberg B, Brannstrom M, Bucht B, Crougneau V, Dimeny E, Ekspong A, Granroth B, Grontoft KC, Hadimeri H, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Mikaelsson L, Olausson E, Persson B, Welin D, Wikdahl AM, Stegmayr BG: Safety and efficacy of atorvastatin in patients with severe renal dysfunction. *Scand J Urol Nephrol* 39:503-510, 2005
990. Holmen C, Elsheikh E, Stenvinkel P, Qureshi AR, Pettersson E, Jalkanen S, Sumitran-Holgersson S: Circulating inflammatory endothelial cells contribute to endothelial progenitor cell dysfunction in patients with vasculitis and kidney involvement. *J Am Soc Nephrol* 16:3110-3120, 2005
991. Holmes C, Mujais S: Glucose sparing in peritoneal dialysis: implications and metrics. *Kidney Int Suppl* S104-S109, 2006
992. Holmes CJ: Hemodialyzer performance: biological indices. *Artif Organs* 19:1126-1135, 1995
993. Holmes CJ: Peritoneal host defense mechanisms. *Perit Dial Int* 16 Suppl 1:S124-S125, 1996
994. Holmes CJ, Shockley TR: Strategies to reduce glucose exposure in peritoneal dialysis patients. *Perit Dial Int* 20 Suppl 2:S37-S41, 2000
995. Holmes CJ: Pre-clinical biocompatibility testing of peritoneal dialysis solutions. *Perit Dial Int* 20 Suppl 5:S5-S9, 2000
996. Holmes CJ, Faict D: Peritoneal dialysis solution biocompatibility: definitions and evaluation strategies. *Kidney Int Suppl* S50-S56, 2003
997. Holmes CJ, Degremont A, Kubey W, Straka P, Man NK: Effectiveness of various chemical disinfectants versus cleaning combined with heat disinfection on *Pseudomonas* biofilm in hemodialysis machines. *Blood Purif* 22:461-468, 2004
998. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B: Serum albumin, C-reactive protein, interleukin 6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. *Am J Kidney Dis* 47:139-148, 2006
999. Honda H, Qureshi AR, Axelsson J, Heimbürger O, Suliman ME, Barany P, Stenvinkel P, Lindholm B: Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality. *Am J Clin Nutr* 86:633-638, 2007
1000. Horl MP, Horl WH: Hemodialysis-associated hypertension: pathophysiology and therapy. *Am J Kidney Dis* 39:227-244, 2002
1001. Horl MP, Horl WH: Hypertension and dialysis. *Kidney Blood Press Res* 26:76-81, 2003
1002. Horl MP, Horl WH: Drug therapy for hypertension in hemodialysis patients. *Semin Dial* 17:288-294, 2004
1003. Horl WH: Is it necessary to treat metabolic acidosis in chronic renal insufficiency? *Nephrol Dial Transplant* 10:1542-1543, 1995
1004. Horl WH: How to get the best out of r-HuEPO. *Nephrol Dial Transplant* 10 Suppl 2:92-95, 1995
1005. Horl WH, Haag-Weber M, Mai B, Massry SG: Verapamil reverses abnormal  $[Ca^{2+}]_i$  and carbohydrate metabolism of PMNL of dialysis patients. *Kidney Int* 47:1741-1745, 1995
1006. Horl WH, Druml W, Stevens PE: Pathophysiology of ARF in the ICU. *Int J Artif Organs* 19:84-86, 1996
1007. Horl WH: [ACE inhibitors and the kidney]. *Wien Med Wochenschr* 146:450-453, 1996
1008. Horl WH: [Are ACE inhibitors nephroprotective?]. *Wien Klin Wochenschr* 108:373-377, 1996
1009. Horl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder-Plassmann G: How to diagnose and correct iron deficiency during r-huEPO therapy--a consensus report. *Nephrol Dial Transplant* 11:246-250, 1996
1010. Horl WH: [Comment on the contribution: "Usefulness of fixed analgesic combinations exemplified by thomapyrin"]. *Wien Klin Wochenschr* 109:255-256, 1997
1011. Horl WH: What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rEPO therapy? Measurement of hypochromic red blood cells is not the first line procedure to identify the patient with iron deficiency. *Nephrol Dial Transplant* 13:850-851, 1998
1012. Horl WH: Genesis of the uraemic syndrome: role of uraemic toxins. *Wien Klin Wochenschr* 110:511-520, 1998
1013. Horl WH: The medicinal use of urine. *Am J Nephrol* 19:111-113, 1999
1014. Horl WH, de AF, Williams PF: Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: access to ESRD treatments. *Nephrol Dial Transplant* 14 Suppl 6:10-15, 1999
1015. Horl WH: [Goal blood pressure values from the nephrologic viewpoint]. *Wien Med Wochenschr* 149:629-632, 1999
1016. Horl WH: Neutrophil function and infections in uremia. *Am J Kidney Dis* 33:xlx-xlviii, 1999
1017. Horl WH: [Nutrition in acute and chronic kidney replacement therapy]. *Internist (Berl)* 40:49-54, 1999
1018. Horl WH: [Diagnosis and therapy of renal anemia. Iron levels should be watched carefully: MMW Seminar on Anemia. 2]. *MMW Fortschr Med* 141:47-48, 1999
1019. Horl WH: [Renaissance of diuretics in the treatment of hypertension]. *Wien Klin Wochenschr* 111:903-907, 1999
1020. Horl WH: Is there a role for adjuvant therapy in patients being treated with epoetin? *Nephrol Dial Transplant* 14 Suppl 2:50-60, 1999
1021. Horl WH: [Invited comment on: Hans Eppinger, Karl Kloss: What should the practicing physician know about the current status of the nephritis topic?]
1022. From: *Wien med Wschr* 1920;71:38-40; *Wien med Wschr* 1920;71:145-149; *Wien med Wschr* 1920;71:194-198]. *Wien Med Wochenschr* 150:369-376, 2000
1023. Horl WH, Kerjaschki D: Membranous glomerulonephritis (MGN). *J Nephrol* 13:291-316, 2000
1024. Horl WH: Uremic toxins: new aspects. *J Nephrol* 13 Suppl 3:S83-S88, 2000

1025. Horl WH, Jacobs C, Macdougall IC, Valderrabano F, Parrondo I, Carveth BG, Thompson K: European best practice guidelines 17-18: adverse effects. *Nephrol Dial Transplant* 15 Suppl 4:51-56, 2000
1026. Horl WH, Jacobs C, Macdougall IC, Valderrabano F, Parrondo I, Thompson K, Carveth BG: European best practice guidelines 14-16: inadequate response to epoetin. *Nephrol Dial Transplant* 15 Suppl 4:43-50, 2000
1027. Horl WH: Aprotinin and renal function in patients undergoing cardiac surgery. *Br J Anaesth* 84:3-5, 2000
1028. Horl WH: Re: Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients. *Perit Dial Int* 21:527-528, 2001
1029. Horl WH: Neutrophil function in renal failure. *Adv Nephrol Necker Hosp* 31:173-192, 2001
1030. Horl WH: Intraplatelet calcium levels in patients with acute renal failure. *Nephrol Dial Transplant* 16:2275-2276, 2001
1031. Horl WH: Should we still use iron dextran in hemodialysis patients? *Am J Kidney Dis* 37:859-861, 2001
1032. Horl WH: Are new toxins appearing on the horizon? *Contrib Nephrol* 28-41, 2001
1033. Horl WH: How to induce severe electrolyte disturbances in the elderly? *Wien Klin Wochenschr* 114:885-886, 2002
1034. Horl WH: Renal medicine and renal transplantation. *Curr Opin Urol* 12:87, 2002
1035. Horl WH: Non-erythropoietin-based anaemia management in chronic kidney disease. *Nephrol Dial Transplant* 17 Suppl 11:35-38, 2002
1036. Horl WH: Secondary hyperparathyroidism: present and future therapeutic implications. *Nephrol Dial Transplant* 17:732-733, 2002
1037. Horl WH: Hemodialysis membranes: interleukins, biocompatibility, and middle molecules. *J Am Soc Nephrol* 13 Suppl 1:S62-S71, 2002
1038. Horl WH: A need for an individualized approach to end-stage renal disease patients. *Nephrol Dial Transplant* 17 Suppl 6:17-21, 2002
1039. Horl WH: ACE inhibitors in hemodialysis patients: does survival improve? *Am J Kidney Dis* 40:1100-1102, 2002
1040. Horl WH: Adjunctive therapy in anaemia management. *Nephrol Dial Transplant* 17 Suppl 5:56-59, 2002
1041. Horl WH, Holzer H, Mayer GJ: [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study]. *Wien Klin Wochenschr* 114:967-971, 2002
1042. Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP, Valderrabano F: Predialysis Survey on Anemia Management: patient referral. *Am J Kidney Dis* 41:49-61, 2003
1043. Horl WH: Renal osteodystrophy: role of calcimimetics. *Am J Kidney Dis* 41:S104-S107, 2003
1044. Horl WH: [Atherosclerosis and uremia: significance of non-traditional risk factors]. *Wien Klin Wochenschr* 115:220-234, 2003
1045. Horl WH, Cohen JJ, Harrington JT, Madias NE, Zusman CJ: Atherosclerosis and uremic retention solutes. *Kidney Int* 66:1719-1731, 2004
1046. Horl WH: The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. *Nephrol Dial Transplant* 19 Suppl 5:V2-V8, 2004
1047. Horl WH: [Tumor lysis syndrome: risk factors and treatment]. *Wien Klin Wochenschr* 117:7-17, 2005
1048. Horl WH: Natriuretic peptides in acute and chronic kidney disease and during renal replacement therapy. *J Investig Med* 53:366-370, 2005
1049. Horl WH, Vanrenterghem Y, Canaud B, Mann J, Teatini U, Wanner C, Wikstrom B: Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. *Nephrol Dial Transplant* 20 Suppl 3:iii25-iii32, 2005
1050. Horl WH, Ertl G: Anaemia and the heart. *Eur J Clin Invest* 35 Suppl 3:20-25, 2005
1051. Horl WH: [Anemia and its treatment in peritoneal dialysis patients]. *Wien Klin Wochenschr* 117 Suppl 6:69-72, 2005
1052. Horl WH: [Thrombocytopeny and blood complications in uremia]. *Wien Klin Wochenschr* 118:134-150, 2006
1053. Horl WH: [Sequela of hypertension: kidney disease]. *Internist (Berl)* 47:226, 228-226, 232, 2006
1054. Horl WH: Iron therapy for renal anemia: how much needed, how much harmful? *Pediatr Nephrol* 22:480-489, 2007
1055. Horl WH: Clinical aspects of iron use in the anemia of kidney disease. *J Am Soc Nephrol* 18:382-393, 2007
1056. Horner D, Fliser D, Klimm HP, Ritz E: Albuminuria in normotensive and hypertensive individuals attending offices of general practitioners. *J Hypertens* 14:655-660, 1996
1057. Hory B, Drueke TB: The parathyroid-bone axis in uremia: new insights into old questions. *Curr Opin Nephrol Hypertens* 6:40-48, 1997
1058. Hory B, Roussanne MC, Drueke TB, Bourdeau A: The calcium receptor in health and disease. *Exp Nephrol* 6:171-179, 1998
1059. Hory B, Drueke TB: Menin and MEN 1 gene: a model of tumour suppressor system. *Nephrol Dial Transplant* 13:2176-2179, 1998
1060. Hory BG, Roussanne MC, Rostand S, Bourdeau A, Drueke TB, Gogusev J: Absence of response to human parathyroid hormone in athymic mice grafted with human parathyroid adenoma, hyperplasia or parathyroid cells maintained in culture. *J Endocrinol Invest* 23:273-279, 2000
1061. Hoste E, Vanholder R: Acute kidney injury 2007. *Acta Clin Belg* Suppl313, 2007
1062. Hoste EA, Vanholder RC, Lameire NH, Roosens CD, Decruyenaere JM, Blot SI, Colardyn FA: No early respiratory benefit with CVVHDF in patients with acute renal failure and acute lung injury. *Nephrol Dial Transplant* 17:2153-2158, 2002
1063. Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA: Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. *J Am Soc Nephrol* 14:1022-1030, 2003
1064. Hoste EA, Blot SI, Lameire NH, Vanholder RC, De BD, Colardyn FA: Effect of nosocomial bloodstream infection on the outcome of critically ill patients with acute renal failure treated with renal replacement therapy. *J Am Soc Nephrol* 15:454-462, 2004
1065. Hoste EA, Damen J, Vanholder RC, Lameire NH, Delanghe JR, Van den HK, Colardyn FA: Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. *Nephrol Dial Transplant* 20:747-753, 2005



1066. Hoste EA, Colpaert K, Vanholder RC, Lameire NH, De Waele JJ, Blot SI, Colardyn FA: Sodium bicarbonate versus THAM in ICU patients with mild metabolic acidosis. *J Nephrol* 18:303-307, 2005
1067. Hoste EA, Vandijck DM, Vanholder RC, De Waele JJ, Lameire NH, Claus S, De SJ, Dhondt AW, Decruyenaere JM, Verschraegen G, Blot SI: Health implications of antimicrobial resistance for patients with acute kidney injury and bloodstream infection. *Infect Control Hosp Epidemiol* 28:1107-1110, 2007
1068. Hruby M, Urena P, Mannstadt M, Schmitt F, Lacour B, Druke TB: Effects of new vitamin D analogues on parathyroid function in chronically uraemic rats with secondary hyperparathyroidism. *Nephrol Dial Transplant* 11:1781-1786, 1996
1069. Huang X, Lindholm B, Stenvinkel P, Carrero JJ: Dietary fat modification in patients with chronic kidney disease: N-3 fatty acids and beyond. *J Nephrol* 2013;26:960-974.
1070. Huang X, Sjogren P, Arnlov J, Cederholm T, Lind L, Stenvinkel P, Lindholm B, Riserus U, Carrero JJ: Serum fatty acid patterns, insulin sensitivity and the metabolic syndrome in individuals with chronic kidney disease. *J Intern Med* 2013;275:71-83.
1071. Huber M, Treutler T, Martus P, Kurzidim A, Kreutz R, Beige J: Dialysis-associated hypertension treated with telmisartan--diatel: A pilot, placebo-controlled, cross-over, randomized trial. *PLoS One* 2013;8:e79322.
1072. Huber W, Ritz E, Fliser D: Does occupational exposure to toxins increase albumin excretion rate? *Kidney Int* 54:303-304, 1998
1073. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H: Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. *Neurology* 52:1555-1562, 1999
1074. Ignacy W, Wiecek A, Kokot F: [Hemodialysis--is it a method of acute intermittent porphyria treatment? Case report]. *Pol Arch Med Wewn* 101:55-58, 1999
1075. Ignacy W, Chudek J, Adamczak M, Funahashi T, Matsuzawa Y, Kokot F, Wiecek A: Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease--a follow-up study. *Nephron Clin Pract* 101:c18-c24, 2005
1076. Ignatescu MC, Fodiger M, Kletzmayer J, Bieglmayer C, Horl WH, Sunder-Plassmann G: Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells? *Kidney Int Suppl* 78:S258-S261, 2001
1077. Ignatescu MC, Kletzmayer J, Fodinger M, Bieglmayer C, Horl WH, Sunder-Plassmann G: Influence of mycophenolic acid and tacrolimus on homocysteine metabolism. *Kidney Int* 61:1894-1898, 2002
1078. Ikizler TA, Cano NJ, Franch H, Fouque D, Himmelfarb J, Kalantar-Zadeh K, Kuhlmann MK, Stenvinkel P, TerWee P, Teta D, Wang AY, Wanner C: Prevention and treatment of protein energy wasting in chronic kidney disease patients: A consensus statement by the international society of renal nutrition and metabolism. *Kidney Int* 2013;84:1096-1107.
1079. Imanishi Y, Tahara H, Palanisamy N, Spitalny S, Salusky IB, Goodman W, Brandt ML, Druke TB, Sarfati E, Urena P, Chaganti RS, Arnold A: Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. *J Am Soc Nephrol* 13:1490-1498, 2002
1080. Inagaki C, Dousseau M, Pacher N, Sarfati E, Druke TB, Gogusev J: Structural analysis of gene marker loci on chromosomes 10 and 11 in primary and secondary uraemic hyperparathyroidism. *Nephrol Dial Transplant* 13:350-357, 1998
1081. Ingrosso D, D'angelo S, Perna AF, Iolascon A, Miraglia del GE, Perrotta S, Zappia V, Galletti P: Increased membrane-protein methylation in hereditary spherocytosis. A marker of cytoskeletal disarray. *Eur J Biochem* 228:894-898, 1995
1082. Ingrosso D, D'angelo S, Perrotta S, d'Urzo G, Iolascon A, Perna AF, Galletti P, Zappia V, Miraglia del GE: Cytoskeletal behaviour in spectrin and in band 3 deficient spherocytic red cells: evidence for differentiated splenic conditioning role. *Br J Haematol* 93:38-41, 1996
1083. Ingrosso D, Perna AF: D-amino acids in aging erythrocytes. *EXS* 85:119-141, 1998
1084. Ingrosso D, D'angelo S, di CE, Perna AF, Zappia V, Galletti P: Increased methyl esterification of altered aspartyl residues in erythrocyte membrane proteins in response to oxidative stress. *Eur J Biochem* 267:4397-4405, 2000
1085. Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, Vacca M, D'Esposito M, D'Urso M, Galletti P, Zappia V: Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. *Lancet* 361:1693-1699, 2003
1086. Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM: Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. *Leukemia* 21:1773-1782, 2007
1087. Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Spasovski G, Stankov O, Stojceva-Taneva O, Paneva-Masin J: [Kidney transplantation using living donors over age 65]. *Ann Urol (Paris)* 34:302-305, 2000
1088. Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Antova Z, Spasovski G, Vlckova-Laskovska M, Zografski G: [Cancer after kidney transplantation and immunosuppression]. *Ann Urol (Paris)* 34:336-339, 2000
1089. Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Stojkovski L, Spasovski G, Paneva-Masin J: Use of advanced age donors in living renal transplantation--is it justified? *Transplant Proc* 33:1227-1228, 2001
1090. Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Spasovski G, Sikole A, Paneva-Masin J: Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation. *Transplant Proc* 33:3203-3204, 2001
1091. Ivanovski N, Popov Z, Kolevski P, Cakalaroski K, Stojkovski L, Spasovski G, Zafirovska K: Living related renal transplantation--the use of advanced age donors. *Clin Nephrol* 55:309-312, 2001
1092. Ivanovski N, Stojceva-Taneva O, Grozdanovski R, Boskovska M, Druke TB, Massy ZA: Short-term effect of folic acid supplementation in renal transplant recipients and chronic kidney disease patients with comparable renal function impairment. *Nephrologie* 25:301-303, 2004
1093. Ivanovski N, Popov Z, Cakalaroski K, Masin J, Spasovski G, Zafirovska K: Living-unrelated (paid) renal transplantation--ten years later. *Transplant Proc* 37:563-564, 2005
1094. Ivanovski O, Nguyen-Khoa T, Phan O, Massy ZA: Could proteinuria evaluation be helpful in predicting renal progression in apolipoprotein E-deficient (E-/-) mice with chronic renal failure? *Nephrol Dial Transplant* 19:1013-1014, 2004
1095. Ivanovski O, Szumilak D, Nguyen-Khoa T, Ruellan N, Phan O, Lacour B, scamps-Latscha B, Druke TB, Massy ZA: The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. *Kidney Int* 67:2288-2294, 2005
1096. Ivanovski O, Szumilak D, Nguyen-Khoa T, Dechaux M, Massy ZA, Phan O, Mothu N, Lacour B, Druke TB, Muntzel M: Dietary salt

- restriction accelerates atherosclerosis in apolipoprotein E-deficient mice. *Atherosclerosis* 180:271-276, 2005
1097. Jacobs C, Horl WH, Macdougall IC, Valderrabano F, Parrondo I, Abraham IL, Segner A: European best practice guidelines 9-13: anaemia management. *Nephrol Dial Transplant* 15 Suppl 4:33-42, 2000
1098. Jacobs C, Horl WH, Macdougall IC, Valderrabano F, Parrondo I, Segner A, Abraham IL: European best practice guidelines 5: target haemoglobin. *Nephrol Dial Transplant* 15 Suppl 4:15-19, 2000
1099. Jacobs P, Glorieux G, Vanholder R: Interleukin/cytokine profiles in haemodialysis and in continuous peritoneal dialysis. *Nephrol Dial Transplant* 19 Suppl 5:V41-V45, 2004
1100. Jadoul M, Garbar C, Noel H, Sennesael J, Vanholder R, Bernaert P, Rorive G, Hanique G, van Ypersele de SC: Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. *Kidney Int* 51:1928-1932, 1997
1101. Jadoul M, Druke T, Zingraff J, van Ypersele de SC: Does dialysis-related amyloidosis regress after transplantation? *Nephrol Dial Transplant* 12:655-657, 1997
1102. Jadoul M, Garbar C, Vanholder R, Sennesael J, Michel C, Robert A, Noel H, van Ypersele de SC: Prevalence of histological beta2-microglobulin amyloidosis in CAPD patients compared with hemodialysis patients. *Kidney Int* 54:956-959, 1998
1103. Janicki S, Jankowski J, Szulc J, Woyczkowski B, Sznitowska M: The effect of cryoprotectants on the physical properties of large liposomes containing sodium diclofenac. *Acta Pol Pharm* 59:187-191, 2002
1104. Jankowski J, Schluter H, Tepel M, Spieker C, Zidek W: Effect of diadenosine polyphosphates on Ca<sup>2+</sup> ATPase activity. *J Mol Med* 75:674-677, 1997
1105. Jankowski J, Nofer JR, Tepel M, Griewel B, Schluter H, Assmann G, Zidek W: Identification of oxidized low-density lipoprotein in human serum by NMR spectroscopy. *Clin Sci (Lond)* 95:489-495, 1998
1106. Jankowski J, Potthoff W, Zidek W, Schluter H: Purification of chemically synthesised dinucleoside(5',5') polyphosphates by displacement chromatography. *J Chromatogr B Biomed Sci Appl* 719:63-70, 1998
1107. Jankowski J, Luftmann H, Tepel M, Leibfritz D, Zidek W, Schluter H: Characterization of dimethylguanosine, phenylethylamine, and phenylacetic acid as inhibitors of Ca<sup>2+</sup> ATPase in end-stage renal failure. *J Am Soc Nephrol* 9:1249-1257, 1998
1108. Jankowski J, Potthoff W, van der GM, Tepel M, Zidek W, Schluter H: High-performance liquid chromatographic assay of the diadenosine polyphosphates in human platelets. *Anal Biochem* 269:72-78, 1999
1109. Jankowski J, Tepel M, van der GM, Tente IM, Henning L, Junker R, Zidek W, Schluter H: Identification and characterization of P(1), P(7)-Di(adenosine-5')-heptaphosphate from human platelets. *J Biol Chem* 274:23926-23931, 1999
1110. Jankowski J, Schroter A, Tepel M, van der GM, Stephan N, Luo J, Zidek W, Schluter H: Isolation and characterization of coenzyme A glutathione disulfide as a parathyroid-derived vasoconstrictive factor. *Circulation* 102:2548-2552, 2000
1111. Jankowski J, Stephan N, Knobloch M, Fischer S, Schmaltz D, Zidek W, Schluter H: Mass-spectrometry-linked screening of protein fractions for enzymatic activities--a tool for functional genomics. *Anal Biochem* 290:324-329, 2001
1112. Jankowski J, Yoon MS, Stephan N, Zidek W, Schluter H: Vasoactive diadenosine polyphosphates in human placenta: possible candidates in the pathophysiology of pre-eclampsia? *J Hypertens* 19:567-573, 2001
1113. Jankowski J, Hagemann J, Yoon MS, van der GM, Stephan N, Zidek W, Schluter H, Tepel M: Increased vascular growth in hemodialysis patients induced by platelet-derived diadenosine polyphosphates. *Kidney Int* 59:1134-1141, 2001
1114. Jankowski J, Tepel M, Stephan N, van der GM, Breden V, Zidek W, Schluter H: Characterization of p-hydroxy-hippuric acid as an inhibitor of Ca<sup>2+</sup>-ATPase in end-stage renal failure. *Kidney Int Suppl* 78:S84-S88, 2001
1115. Jankowski J, Hagemann J, Tepel M, van der GM, Stephan N, Henning L, Gouni-Berthold I, Sachinidis A, Zidek W, Schluter H: Dinucleotides as growth-promoting extracellular mediators. Presence of dinucleoside diphosphates Ap<sub>2</sub>A, Ap<sub>2</sub>G, and Gp<sub>2</sub>G in releasable granules of platelets. *J Biol Chem* 276:8904-8909, 2001
1116. Jankowski J, Grosse-Huttman P, Zidek W, Schluter H: Identification of dinucleoside polyphosphates by matrix-assisted laser desorption/ionisation post-source decay mass spectrometry. *Rapid Commun Mass Spectrom* 17:1189-1194, 2003
1117. Jankowski J, van der Giet M, Jankowski V, Schmidt S, Hemeier M, Mahn B, Giebing G, Tolle M, Luftmann H, Schluter H, Zidek W, Tepel M: Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. *J Clin Invest* 112:256-264, 2003
1118. Jankowski J, Jankowski V, Laufer U, van der GM, Henning L, Tepel M, Zidek W, Schluter H: Identification and quantification of diadenosine polyphosphate concentrations in human plasma. *Arterioscler Thromb Vasc Biol* 23:1231-1238, 2003
1119. Jankowski J, Schluter H, Henning L, van der GM, Jankowski V, Zidek W, Tepel M: The AN69 hemofiltration membrane has a decreasing effect on the intracellular diadenosine pentaphosphate concentration of platelets. *Kidney Blood Press Res* 26:50-54, 2003
1120. Jankowski J, Jankowski V, Seibt B, Henning L, Zidek W, Schluter H: Identification of dinucleoside polyphosphates in adrenal glands. *Biochem Biophys Res Commun* 304:365-370, 2003
1121. Jankowski J, Henning L, Schluter H: Analysis of the releasable nucleotides of platelets. *Methods Mol Biol* 272:97-108, 2004
1122. Jankowski J, Grosse-Huttman P, Zidek W, Schluter H: Identification of dinucleoside polyphosphates by matrix-assisted laser desorption/ionisation post-source decay mass spectrometry. *Rapid Commun Mass Spectrom* 2003;17:1189-1194.
1123. Jankowski J, Gunthner T: Does an apple a day put hypertension in play? *Kidney Int* 2008;74:409-410.
1124. Jankowski J, Hagemann J, Tepel M, van Der Giet M, Stephan N, Henning L, Gouni-Berthold I, Sachinidis A, Zidek W, Schluter H: Dinucleotides as growth-promoting extracellular mediators. Presence of dinucleoside diphosphates ap<sub>2</sub>a, ap<sub>2</sub>g, and gp<sub>2</sub>g in releasable granules of platelets. *J Biol Chem* 2001;276:8904-8909.
1125. Jankowski J, Henning L, Schluter H: Analysis of the releasable nucleotides of platelets. *Methods Mol Biol* 2004;272:97-108.
1126. Jankowski J, Jankowski V, Laufer U, van der Giet M, Henning L, Tepel M, Zidek W, Schluter H: Identification and quantification of diadenosine polyphosphate concentrations in human plasma. *Arterioscler Thromb Vasc Biol* 2003;23:1231-1238.
1127. Jankowski J, Jankowski V, Seibt B, Henning L, Zidek W, Schluter H: Identification of dinucleoside polyphosphates in adrenal glands. *Biochem Biophys Res Commun* 2003;304:365-370.
1128. Jankowski J, Schluter H, Henning L, van der Giet M, Jankowski V, Zidek W, Tepel M: The an69 hemofiltration membrane has a decreasing effect on the intracellular diadenosine pentaphosphate concentration of platelets. *Kidney Blood Press Res* 2003;26:50-54.

1129. Jankowski J, Stephan N, Knobloch M, Fischer S, Schmaltz D, Zidek W, Schluter H: Mass-spectrometry-linked screening of protein fractions for enzymatic activities--a tool for functional genomics. *Anal Biochem* 2001;290:324-329.
1130. Jankowski J, van der Giet M, Jankowski V, Schmidt S, Hemeier M, Mahn B, Giebing G, Tolle M, Luftmann H, Schluter H, Zidek W, Tepel M: Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits inos expression. *J Clin Invest* 2003;112:256-264.
1131. Jankowski J, Yoon MS, Stephan N, Zidek W, Schluter H: Vasoactive diadenosine polyphosphates in human placenta: Possible candidates in the pathophysiology of pre-eclampsia? *J Hypertens* 2001;19:567-573.
1132. Jankowski V, Tolle M, Vanholder R, Schonfelder G, van der GM, Henning L, Schluter H, Paul M, Zidek W, Jankowski J: Uridine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor. *Nat Med* 11:223-227, 2005
1133. Jankowski V, Vanholder R, van der GM, Henning L, Tolle M, Schonfelder G, Krakow A, Karadogan S, Gustavsson N, Gobom J, Webb J, Lehrach H, Giebing G, Schluter H, Hilgers KF, Zidek W, Jankowski J: Detection of angiotensin II in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. *Hypertension* 46:591-597, 2005
1134. Jankowski V, Vanholder R, Henning L, Karadogan S, Zidek W, Schluter H, Jankowski J: Isolation and quantification of dinucleoside polyphosphates by using monolithic reversed phase chromatography columns. *J Chromatogr B Analyt Technol Biomed Life Sci* 819:131-139, 2005
1135. Jankowski V, Vanholder R, van der GM, Tolle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schluter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J: Mass-spectrometric identification of a novel angiotensin peptide in human plasma. *Arterioscler Thromb Vasc Biol* 27:297-302, 2007
1136. Jankowski V, Karadogan S, Vanholder R, Nofer JR, Herget-Rosenthal S, van der GM, Tolle M, Tran TN, Zidek W, Jankowski J: Paracrine stimulation of vascular smooth muscle proliferation by diadenosine polyphosphates released from proximal tubule epithelial cells. *Kidney Int* 2007
1137. Jankowski V, Meyer AA, Schlattmann P, Gui Y, Zheng XL, Stamcou I, Radtke K, Tran TN, van der GM, Tolle M, Zidek W, Jankowski J: Increased uridine adenosine tetraphosphate concentrations in plasma of juvenile hypertensives. *Arterioscler Thromb Vasc Biol* 27:1776-1781, 2007
1138. Jankowski V, Karadogan S, Vanholder R, Nofer JR, Herget-Rosenthal S, van der GM, Tolle M, Tran TN, Zidek W, Jankowski J: Paracrine stimulation of vascular smooth muscle proliferation by diadenosine polyphosphates released from proximal tubule epithelial cells. *Kidney Int* 71:994-1000, 2007
1139. Jankowski V, Patzak A, Herget-Rosenthal S, Tran TN, Lai EY, Gunthner T, Buschmann I, Zidek W, Jankowski J: Uridine adenosine tetraphosphate acts as an autocrine hormone affecting glomerular filtration rate. *J Mol Med (Berl)* 86:333-340, 2008
1140. Jankowski V, van der Giet M, Mischak H, Morgan M, Zidek W, Jankowski J: Dinucleoside polyphosphates: Strong endogenous agonists of the purinergic system. *Br J Pharmacol* 157:1142-1153, 2009
1141. Jankowski V, Gunthner T, Herget-Rosenthal S, Zidek W, Jankowski J: Dinucleoside polyphosphates and uremia. *Semin Dial* 22:396-399, 2009
1142. Jankowski V, Gunthner T, Herget-Rosenthal S, Zidek W, Jankowski J: Dinucleoside polyphosphates and uremia. *Semin Dial* 2009;22:396-399.
1143. Jankowski V, Karadogan S, Vanholder R, Nofer JR, Herget-Rosenthal S, van der Giet M, Tolle M, Tran TN, Zidek W, Jankowski J: Paracrine stimulation of vascular smooth muscle proliferation by diadenosine polyphosphates released from proximal tubule epithelial cells. *Kidney Int* 2007;71:994-1000.
1144. Jankowski V, Meyer AA, Schlattmann P, Gui Y, Zheng XL, Stamcou I, Radtke K, Tran TN, van der Giet M, Tolle M, Zidek W, Jankowski J: Increased uridine adenosine tetraphosphate concentrations in plasma of juvenile hypertensives. *Arterioscler Thromb Vasc Biol* 2007;27:1776-1781.
1145. Jankowski V, Patzak A, Herget-Rosenthal S, Tran TN, Lai EY, Gunthner T, Buschmann I, Zidek W, Jankowski J: Uridine adenosine tetraphosphate acts as an autocrine hormone affecting glomerular filtration rate. *J Mol Med (Berl)* 2008;86:333-340.
1146. Jankowski V, Schulz A, Kretschmer A, Mischak H, Boehringer F, van der Giet M, Janke D, Schuchardt M, Herwig R, Zidek W, Jankowski J: The enzymatic activity of the vegf2 receptor for the biosynthesis of dinucleoside polyphosphates. *J Mol Med (Berl)* 2013;91:1095-1107.
1147. Jankowski V, Tolle M, Santos RA, Gunthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SV, Sampaio WO, Lautner R, Kretschmer A, van der Giet M, Zidek W, Jankowski J: Angioprotectin: An angiotensin ii-like peptide causing vasodilatory effects. *FASEB J* 2011;25:2987-2995.
1148. Jankowski V, Tolle M, Tran TN, van der Giet M, Schuchardt M, Lehmann K, Janke D, Flick B, Ortiz A, Sanchez-Nino MD, Tepel M, Zidek W, Jankowski J: Identification of a potent endothelium-derived angiogenic factor. *PLoS One* 2013;8:e68575.
1149. Jankowski V, Tolle M, Vanholder R, Schonfelder G, van der Giet M, Henning L, Schluter H, Paul M, Zidek W, Jankowski J: Uridine adenosine tetraphosphate: A novel endothelium-derived vasoconstrictive factor. *Nat Med* 2005;11:223-227.
1150. Jankowski V, van der Giet M, Mischak H, Morgan M, Zidek W, Jankowski J: Dinucleoside polyphosphates: Strong endogenous agonists of the purinergic system. *Br J Pharmacol* 2009;157:1142-1153.
1151. Jankowski V, Vanholder R, Henning L, Karadogan S, Zidek W, Schluter H, Jankowski J: Isolation and quantification of dinucleoside polyphosphates by using monolithic reversed phase chromatography columns. *J Chromatogr B Analyt Technol Biomed Life Sci* 2005;819:131-139.
1152. Jankowski V, Vanholder R, van der Giet M, Henning L, Tolle M, Schonfelder G, Krakow A, Karadogan S, Gustavsson N, Gobom J, Webb J, Lehrach H, Giebing G, Schluter H, Hilgers KF, Zidek W, Jankowski J: Detection of angiotensin ii in supernatants of stimulated mononuclear leukocytes by matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass analysis. *Hypertension* 2005;46:591-597.
1153. Jankowski V, Vanholder R, van der Giet M, Tolle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schluter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J: Mass-spectrometric identification of a novel angiotensin peptide in human plasma. *Arterioscler Thromb Vasc Biol* 2007;27:297-302.
1154. Janosch P, Schellerer M, Seitz T, Reim P, Eulitz M, Brielmeier M, Kolch W, Sedivy JM, Mischak H: Characterization of IkappaB kinases. IkappaB-alpha is not phosphorylated by Raf-1 or protein kinase C isozymes, but is a casein kinase II substrate. *J Biol Chem* 271:13868-13874, 1996
1155. Janosch P, Kieser A, Eulitz M, Lovric J, Sauer G, Reichert M, Gounari F, Buscher D, Baccarini M, Mischak H, Kolch W: The Raf-1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments. *FASEB J* 14:2008-2021, 2000

1156. Jansen M, Gabriel H, Banyai S, Pidlich J, Weidinger F, Horl WH, Derfler
1157. K: Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoabsorption therapy in a renal transplant recipient. *Wien Klin Wochenschr* 108:425-431, 1996
1158. Jansen M, Banyai S, Schmaldienst S, Goldammer A, Rohac M, Horl WH, Derfler K: Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia. *Wien Klin Wochenschr* 112:61-69, 2000
1159. Jansen M, Schmaldienst S, Banyai S, Quehenberger P, Pabinger I, Derfler K, Horl WH, Knobl P: Treatment of coagulation inhibitors with extracorporeal immunoabsorption (Ig-Therasorb). *Br J Haematol* 112:91-97, 2001
1160. Jansen S, Chmelik J, Zidek L, Padrta P, Novak P, Zdrahal Z, Picimbon JF, Lofstedt C, Sklenar V: Structure of Bombyx mori chemosensory protein 1 in solution. *Arch Insect Biochem Physiol* 66:135-145, 2007
1161. Jia T, Stenvinkel P, Lindholm B: [the triple whammy of muscle loss, osteoporosis and vascular calcification in chronic kidney disease patients calls out the need for novel treatment strategies]. *G Ital Nefrol* 2013;30
1162. Jing L, Chong TM, Byrd B, McClurkan CL, Huang J, Story BT, Dunkley KM, daz-Carroll L, Eisenberg RJ, Cohen GH, Kwok WW, Sette A, Koelle DM: Dominance and diversity in the primary human CD4 T cell response to replication-competent vaccinia virus. *J Immunol* 178:6374-6386, 2007
1163. Johansson A, Johansson I, Eriksson M, Ahren AM, Hallmans G, Stegmayr B: Systemic antibodies to the leukotoxin of the oral pathogen *Actinobacillus actinomycetemcomitans* correlate negatively with stroke in women. *Cerebrovasc Dis* 20:226-232, 2005
1164. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G: Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. *Stroke* 31:26-32, 2000
1165. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G: Prospective study on soluble thrombomodulin and von Willebrand factor and the risk of ischemic and hemorrhagic stroke. *Thromb Haemost* 87:211-217, 2002
1166. Johansson L, Jansson JH, Stegmayr B, Nilsson TK, Hallmans G, Boman K: Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study. *Stroke* 35:826-830, 2004
1167. Joki N, Nikolov IG, Druke TB: Optimal dialysate calcium and vascular calcification. *Nephrol Dial Transplant* 22:3354-3355, 2007
1168. Jono T, Nagai R, Lin X, Ahmed N, Thornalley PJ, Takeya M, Horiuchi S: Nepsilon-(Carboxymethyl)lysine and 3-DG-imidazolone are major AGE structures in protein modification by 3-deoxyglucosone. *J Biochem (Tokyo)* 136:351-358, 2004
1169. Jonsdottir SS, Stenvinkel P, Barany P: [Selection of dialysis type--a crucial decision. Peritoneal dialysis is better for the patient and cheaper for the society]. *Lakartidningen* 102:281-282, 2005
1170. Jonsson P, Stegmayr BG: Current leakage in hemodialysis machines may be a safety risk for patients. *Artif Organs* 24:977-981, 2000
1171. Jonsson P, Forsberg U, Niklasson J, Stegmayr BG: Electrical current leakage during hemodialysis may increase blood-membrane interaction. *Int J Artif Organs* 24:136-139, 2001
1172. Jonsson P, Eliasson G, Stegmayr BG: Blood lines conduct leakage current during haemodialysis: a potential safety risk during first failure, especially for patients with central dialysis catheter as access. *Med Biol Eng Comput* 43:731-738, 2005
1173. Jonsson P, Karlsson L, Forsberg U, Gref M, Stegmayr C, Stegmayr B: Air bubbles pass the security system of the dialysis device without alarming. *Artif Organs* 31:132-139, 2007
1174. Jorgetti V, Druke TB: Value of the new bone classification system for pediatric patients with chronic kidney disease. *Clin J Am Soc Nephrol* 5:1730-1731, 2010
1175. Jorgetti V, Druke TB: Value of the new bone classification system for pediatric patients with chronic kidney disease. *Clin J Am Soc Nephrol* 2010;5:1730-1731.
1176. Jorres A, Gahl GM, Frei U: In vitro studies on the effect of dialysis solutions on peritoneal leukocytes. *Perit Dial Int* 15:S41-S45, 1995
1177. Jorres A, Ludat K, Sander K, Dunkel K, Lorenz F, Keck H, Frei U, Gahl GM: The peritoneal fibroblast and the control of peritoneal inflammation. *Kidney Int Suppl* 56:S22-S27, 1996
1178. Jorres A: Is introduction of the bicarbonate buffer in PD solution unavoidable? *Perit Dial Int* 16:444-445, 1996
1179. Jorres A, Ludat K, Lang J, Sander K, Gahl GM, Frei U, DeJonge K, Williams JD, Topley N: Establishment and functional characterization of human peritoneal fibroblasts in culture: regulation of interleukin-6 production by proinflammatory cytokines. *J Am Soc Nephrol* 7:2192-2201, 1996
1180. Jorres A, Gahl GM, Ludat K, Frei U, Passlick-Deetjen J: In vitro biocompatibility evaluation of a novel bicarbonate-buffered amino-acid solution for peritoneal dialysis. *Nephrol Dial Transplant* 12:543-549, 1997
1181. Jorres A, Dinter H, Topley N, Gahl GM, Frei U, Scholz P: Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. *Cytokine* 9:119-125, 1997
1182. Jorres A, Williams JD, Topley N: Peritoneal dialysis solution biocompatibility: inhibitory mechanisms and recent studies with bicarbonate-buffered solutions. *Perit Dial Int* 17 Suppl 2:S42-S46, 1997
1183. Jorres A, Bender TO, Finn A, Witowski J, Frohlich S, Gahl GM, Frei U, Keck H, Passlick-Deetjen J: Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. *Kidney Int* 54:2184-2193, 1998
1184. Jorres A: Effect of peritoneal dialysis on peritoneal cell biology: peritoneal fibroblasts. *Perit Dial Int* 19 Suppl 2:S348-S352, 1999
1185. Jorres A, Gahl GM, Dobis C, Polenakovic MH, Cakalaroski K, Rutkowski B, Kisielnicka E, Krieter DH, Rumpf KW, Guenther C, Gaus W, Hoegel J: Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomised multicentre trial. *International Multicentre Study Group. Lancet* 354:1337-1341, 1999
1186. Jorres A, Bender TO, Witowski J: Glucose degradation products and the peritoneal mesothelium. *Perit Dial Int* 20 Suppl 5:S19-S22, 2000
1187. Jorres A, Frei U: [Acute kidney failure]. *Internist (Berl)* 42:379-402,
1188. Jorres A: Innovative approaches to the preservation of the peritoneal membrane: from bench to bedside. *Adv Ren Replace Ther* 8:164-172, 2001
1189. Jorres A: Acute renal failure. Extracorporeal treatment strategies. *Minerva Med* 93:329-4, 2002

1190. Jorres A: Glucose degradation products in peritoneal dialysis: from bench to bedside. *Kidney Blood Press Res* 26:113-117, 2003
1191. Jorres A: PD: a biological membrane and a non-biological fluid. *Contrib Nephrol* 1-9, 2003
1192. Jorres A, Witowski J: Lessons from basic research for PD treatment. *Perit Dial Int* 25 Suppl 3:S35-S38, 2005
1193. Jorres A, Witowski J: PD membrane: biological responses to different PD fluids. *Contrib Nephrol* 150:48-53, 2006
1194. Jorres AJ: Acute renal failure: pathogenesis, diagnosis and conservative treatment. *Minerva Med* 93:85-93, 2002
1195. Jouhanneau P, Raisbeck GM, Yiou F, Lacour B, Banide H, Druke TB: Gastrointestinal absorption, tissue retention, and urinary excretion of dietary aluminum in rats determined by using <sup>26</sup>Al. *Clin Chem* 43:1023-1028, 1997
1196. Jourde-Chiche N, Dou L, Sabatier F, Calaf R, Cerini C, Robert S, Camoin-Jau L, Charpiot P, Argiles A, Dignat-George F, Brunet P: Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. *J Thromb Haemost* 7:1576-1584, 2009
1197. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P: Protein-bound toxins--update 2009. *Semin Dial* 22:334-339, 2009
1198. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P: Vascular incompetence in dialysis patients--protein-bound uremic toxins and endothelial dysfunction. *Semin Dial* 24:327-337, 2011
1199. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P: Vascular incompetence in dialysis patients--protein-bound uremic toxins and endothelial dysfunction. *Semin Dial* 2011;24:327-337.
1200. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P: Protein-bound toxins--update 2009. *Semin Dial* 2009;22:334-339.
1201. Jourde-Chiche N, Dou L, Sabatier F, Calaf R, Cerini C, Robert S, Camoin-Jau L, Charpiot P, Argiles A, Dignat-George F, Brunet P: Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. *J Thromb Haemost* 2009;7:1576-1584.
1202. Jungers P, Massy ZA, Nguyen KT, Fumeron C, Labrunie M, Lacour B, scamps-Latscha B, Man NK: Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. *Nephrol Dial Transplant* 12:2597-2602, 1997
1203. Jungers P, Nguyen KT, Massy ZA, Man NK: [Incidence of atherosclerotic cardiovascular events in patients with chronic uremia: epidemiologic studies in Ile-de-France]. *Nephrologie* 19:489-494, 1998
1204. Jungers P, Nguyen KT, Massy ZA, Zingraff J, Labrunie M, scamps-Latscha B, Man NK: Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: a multicentric study in the Ile de France district. *Nephrol Dial Transplant* 14:898-902, 1999
1205. Jungers P, Joly D, Massy Z, Chauveau P, Nguyen AT, Aupetit J, Chadeaux B: Sustained reduction of hyperhomocysteinemia with folic acid supplementation in predialysis patients. *Nephrol Dial Transplant* 14:2903-2906, 1999
1206. Jungers P, Nguyen KT, Joly D, Choukroun G, Witko-Sarsat V, Massy ZA: Atherosclerotic complications in chronic renal failure: epidemiology and predictive factors. *Adv Nephrol Neckar Hosp* 30:177-199, 2000
1207. Jungers P, Massy Z, Man NK, Labrunie M, Taupin P, Guin E, Landais P: [Incidence of end-stage renal disease in Ile de France: a prospective epidemiological survey]. *Presse Med* 29:589-592, 2000
1208. Jungers P, Choukroun G, Robino C, Massy ZA, Taupin P, Labrunie M, Man NK, Landais P: Epidemiology of end-stage renal disease in the Ile-de-France area: a prospective study in 1998. *Nephrol Dial Transplant* 15:2000-2006, 2000
1209. Jungers P, Massy ZA, Nguyen-Khoa T, Choukroun G, Robino C, Fakhouri F, Touam M, Nguyen AT, Grunfeld JP: Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. *Nephrol Dial Transplant* 16:2357-2364, 2001
1210. Jungers P, Qualim Z, Nguyen-Khoa T, Massy Z, London G: [Cardioprotection: an essential component for predialysis chronic renal failure treatment]. *Nephrologie* 24:79-88, 2003
1211. Jungers PY, Robino C, Choukroun G, Nguyen-Khoa T, Massy ZA, Jungers P: Incidence of anaemia, and use of epoetin therapy in predialysis patients: a prospective study in 403 patients. *Nephrol Dial Transplant* 17:1621-1627, 2002
1212. Jungers PY, Nguyen-Khoa T, Joly D, Choukroun G, Massy ZA, Jungers P: [Frequency of anaemia and indications for treatment with epoetin in chronic renal failure at the pre-dialysis stage]. *Presse Med* 32:212-216, 2003
1213. Jurgensen JS, Seltsam A, Jorres A: Fatal acute diclofenac-induced immune hemolytic anemia. *Ann Hematol* 80:440-442, 2001
1214. Kaiser JP, Oppermann M, Gotze O, Deppisch R, Gohl H, Asmus G, Rohrich B, von HD, Schaefer K: Significant reduction of factor D and immunosuppressive complement fragment Ba by hemofiltration. *Blood Purif* 13:314-321, 1995
1215. Kaiser T, Hermann A, Kielstein JT, Wittke S, Bartel S, Krebs R, Hausadel F, Hillmann M, Golovko I, Koester P, Haller H, Weissinger EM, Fliser D, Mischak H: Capillary electrophoresis coupled to mass spectrometry to establish polypeptide patterns in dialysis fluids. *J Chromatogr A* 1013:157-171, 2003
1216. Kaiser T, Wittke S, Just I, Krebs R, Bartel S, Fliser D, Mischak H, Weissinger EM: Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. *Electrophoresis* 25:2044-2055, 2004
1217. Kaiser T, Kamal H, Rank A, Kolb HJ, Holler E, Ganser A, Hertenstein B, Mischak H, Weissinger EM: Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. *Blood* 104:340-349, 2004
1218. Kalantar-Zadeh K, Stenvinkel P, Pillon L, Kopple JD: Inflammation and nutrition in renal insufficiency. *Adv Ren Replace Ther* 10:155-169, 2003
1219. Kalantar-Zadeh K, Stenvinkel P, Bross R, Khawar OS, Rammohan M, Colman S, Benner D: Kidney insufficiency and nutrient-based modulation of inflammation. *Curr Opin Clin Nutr Metab Care* 8:388-396, 2005
1220. Kalousova M, Sulkova S, Zima T, Deppisch R, Beck W, Bednarova V, Fortova M, Tesar V: Advanced glycation end products in hemodialyzed patients with diabetes mellitus correlate with leptin and leptin/body fat ratio. *Ren Fail* 25:277-286, 2003
1221. Kang Y, Edwards LG, Thornalley PJ: Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA G1 growth arrest and induction of apoptosis. *Leuk Res* 20:397-405, 1996
1222. Kantarci G, Vanholder R, Tuglular S, Akin H, Koc M, Ozener C, Akoglu E: Acute renal failure due to crush syndrome during Marmara earthquake. *Am J Kidney Dis* 40:682-689, 2002

1223. Kanwar M, Rosman HS, Fozo PK, Fahmy S, Vikraman N, Gardin JM, Bess RL, Cohen GI: Usefulness of carotid ultrasound to improve the ability of stress testing to predict coronary artery disease. *Am J Cardiol* 99:1196-1200, 2007
1224. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ: Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. *Biochem Soc Trans* 31:1423-1425, 2003
1225. Karachalias N, Babaei-Jadidi R, Kupich C, Ahmed N, Thornalley PJ: High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. *Ann N Y Acad Sci* 1043:777-783, 2005
1226. Karkoszka H, Chudek J, Strzelczyk P, Wiecek A, Schmidt-Gayk H, Ritz E, Kokot F: Does the vitamin D receptor genotype predict bone mineral loss in haemodialysed patients? *Nephrol Dial Transplant* 13:2077-2080, 1998
1227. Karkoszka H, Chudek J, Strzelczyk P, Wiecek A, Schmidt-Gayk H, Ritz E, Kokot F: [Vitamin D receptor gene polymorphism and the rate of bone loss of the femur neck and lumbar spine in hemodialyzed patients with chronic renal failure]. *Pol Merkur Lekarski* 5:199-202, 1998
1228. Karkoszka H, Kalita B, Wiecek A, Slimok M, Sikora A, Kokot F, Szczepanski Z: [Influence of gluten free diet on bone mineral density (BMD) in children with celiac disease]. *Przegl Lek* 57:330-333, 2000
1229. Kasiske BL, Massy ZA, Guijarro C, Ma JZ: Chronic renal allograft rejection and clinical trial design. *Kidney Int Suppl* 52:S116-S119, 1995
1230. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular disease after renal transplantation. *J Am Soc Nephrol* 7:158-165, 1996
1231. Kato S, Lindholm B, Axelsson J, Qureshi RA, Barany P, Heimbürger O, Gustafsson JA, Stenvinkel P, Nordfors L: Association between oestrogen receptor alpha gene polymorphism and mortality in female end-stage renal disease patients. *Nephrol Dial Transplant* 22:2571-2577, 2007
1232. Katz I, De Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H: The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. *Int J Geriatr Psychiatry* 22:475-484, 2007
1233. Keller CK, Bergis KH, Fliser D, Ritz E: Renal findings in patients with short-term type 2 diabetes. *J Am Soc Nephrol* 7:2627-2635, 1996
1234. Kellerer M, Mushack J, Mischak H, Haring HU: Protein kinase C (PKC) epsilon enhances the inhibitory effect of TNF alpha on insulin signaling in HEK293 cells. *FEBS Lett* 418:119-122, 1997
1235. Kellerer M, Mushack J, Seffer E, Mischak H, Ullrich A, Haring HU: Protein kinase C isoforms alpha, delta and theta require insulin receptor substrate-1 to inhibit the tyrosine kinase activity of the insulin receptor in human kidney embryonic cells (HEK 293 cells). *Diabetologia* 41:833-838, 1998
1236. Khalifeh N, Vychytil A, Horl WH: The role of peritoneal dialysis in the management of treatment-resistant congestive heart failure: A European perspective. *Kidney Int Suppl* S72-S75, 2006
1237. Kiefer T, Schenk U, Hubel E, Weber J, Mettang T, Passlick-Deetjen J, Kuhlmann U: In vitro effects of low-calcium peritoneal dialysis solutions on peritoneal macrophage functions. *Am J Kidney Dis* 25:751-760, 1995
1238. Kielstein JT, Frolich JC, Haller H, Fliser D: ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? *Nephrol Dial Transplant* 16:1742-1745, 2001
1239. Kielstein JT, bou-Rebyeh F, Hafer C, Haller H, Fliser D: Right-sided chest pain at the onset of haemodialysis. *Nephrol Dial Transplant* 16:1493-1495, 2001
1240. Kielstein JT, Schwarz A, Arnavaz A, Sehberg O, Emrich HM, Fliser D: High-flux hemodialysis--an effective alternative to hemoperfusion in the treatment of carbamazepine intoxication. *Clin Nephrol* 57:484-486, 2002
1241. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. *J Am Soc Nephrol* 13:170-176, 2002
1242. Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D: Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. *Circulation* 107:1891-1895, 2003
1243. Kielstein JT, Bode-Boger SM, Klein G, Graf S, Haller H, Fliser D: Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. *Eur J Clin Invest* 33:370-375, 2003
1244. Kielstein JT, Woywodt A, Schumann G, Haller H, Fliser D: Efficiency of high-flux hemodialysis in the treatment of valproic acid intoxication. *J Toxicol Clin Toxicol* 41:873-876, 2003
1245. Kielstein JT, Becker B, Graf S, Brabant G, Haller H, Fliser D: Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. *Am J Kidney Dis* 42:62-66, 2003
1246. Kielstein JT, Bode-Boger SM, Haller H, Fliser D: Functional changes in the ageing kidney: is there a role for asymmetric dimethylarginine? *Nephrol Dial Transplant* 18:1245-1248, 2003
1247. Kielstein JT, Simmel S, Bode-Boger SM, Roth HJ, Schmidt-Gayk H, Haller H, Fliser D: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. *Kidney Blood Press Res* 27:143-147, 2004
1248. Kielstein JT, Impraïm B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoepfer MM, Haller H, Fliser D: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. *Circulation* 109:172-177, 2004
1249. Kielstein JT, Linnenweber S, Schoepke T, Fliser D: One for all--a multi-use dialysis system for effective treatment of severe thallium intoxication. *Kidney Blood Press Res* 27:197-199, 2004
1250. Kielstein JT, Boger RH, Bode-Boger SM, Martens-Lobenhoffer J, Lonnemann G, Frolich JC, Haller H, Fliser D: Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding. *Clin Nephrol* 62:295-300, 2004
1251. Kielstein JT, Kretschmer U, Ernst T, Hafer C, Bahr MJ, Haller H, Fliser D: Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. *Am J Kidney Dis* 43:342-349, 2004
1252. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, Hoepfer MM: Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. *Arterioscler Thromb Vasc Biol* 25:1414-1418, 2005
1253. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D: Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. *Nephrol Dial Transplant* 21:2446-2451, 2006
1254. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, Cooke JP, Fliser D, Bode-Boger SM: ADMA increases arterial stiffness and decreases cerebral blood flow in humans. *Stroke* 37:2024-2029, 2006

1255. Kielstein JT, Donnerstag F, Gasper S, Menne J, Fliser D, Kielstein A, Martens-Lobenhoffer J, Scalera F, Bode-Boger SM, Cooke J: Response to Letter by Tsuda. *Stroke* 2006
1256. Kielstein JT, Czock D, Schopke T, Hafer C, Bode-Boger SM, Kuse E, Keller F, Fliser D: Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. *Crit Care Med* 34:51-56, 2006
1257. Kielstein JT, Tsikas D, Fliser D: Effects of asymmetric dimethylarginine (ADMA) infusion in humans. *Eur J Clin Pharmacol* 62 Suppl 1:39-44, 2006
1258. Kielstein JT, Fliser D: [Acute renal failure. Extracorporeal therapy]. *Internist (Berl)* 48:786-794, 2007
1259. Kielstein JT, Fliser D: Lowering asymmetric dimethylarginine--a new mechanism mediating the renoprotective effects of renin-angiotensin system inhibitors in proteinuric patients? *Blood Purif* 25:324-326, 2007
1260. Kielstein JT, Fliser D: The past, presence and future of ADMA in nephrology. *Nephrol Ther* 3:47-54, 2007
1261. Kielstein JT, Fliser D: Do sea stars have low adma levels? High adma and low epc count--duo infernal for the kidney. *Nephrol Dial Transplant* 2010;25:3138-3141.
1262. Kiersztejn M, Wiecek A, Kokot F, Kuczera M: [Level of vasopressin in renal venous blood of patients with renovascular hypertension due to unilateral stenosis of renal arteries]. *Pol Arch Med Wewn* 97:211-215, 1997
1263. Kiersztejn M, Wiecek A, Kokot F, Schmidt-Gayk H, Wystrychowski A, Kuczera M: [Levels of 1,25-dihydroxyvitamin D3 concentration in renal venous blood serum of patients with renovascular hypertension caused by unilateral renal artery stenosis]. *Pol Arch Med Wewn* 99:281-286, 1998
1264. Kieser A, Goodnight J, Kolch W, Mischak H, Mushinski JF: Identification of the primary growth response gene, ST2/T1, as a gene whose expression is differentially regulated by different protein kinase C isozymes. *FEBS Lett* 372:189-193, 1995
1265. Kieser A, Seitz T, Adler HS, Coffey P, Kremmer E, Crespo P, Gutkind JS, Henderson DW, Mushinski JF, Kolch W, Mischak H: Protein kinase C-zeta reverts v-raf transformation of NIH-3T3 cells. *Genes Dev* 10:1455-1466, 1996
1266. Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M, Hanssen KF: Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. *Metabolism* 52:163-167, 2003
1267. Kimpe JD, Cornelis R, Mees L, Vanholder R: Basal metabolism of intraperitoneally injected carrier-free <sup>74</sup>As-labeled arsenate in rabbits. *Fundam Appl Toxicol* 34:240-248, 1996
1268. Kirchner GI, Krug N, Bleck JS, Fliser D, Manns MP, Wagner S: [Fulminant course of leptospirosis complicated by multiple organ failure]. *Z Gastroenterol* 39:587-592, 2001
1269. Kirsch BM, Zeyda M, Stuhlmeier K, Grisar J, Smolen JS, Watschinger B, Stulnig TM, Horl WH, Zlabinger GJ, Saemann MD: The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. *Arthritis Res Ther* 7:R694-R703, 2005
1270. Kirsch BM, Haidinger M, Zeyda M, Bohmig GA, Tombinsky J, Muhlbacher F, Watschinger B, Horl WH, Saemann MD: Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. *Transpl Immunol* 16:254-257, 2006
1271. Kitiyakara C, Gonin J, Massy Z, Wilcox CS: Non-traditional cardiovascular disease risk factors in end-stage renal disease: oxidate stress and hyperhomocysteinemia. *Curr Opin Nephrol Hypertens* 9:477-487, 2000
1272. Kittner B, De Deyn PP, Erkinjuntti T: Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. Parallel study populations in two randomized, placebo-controlled trials. *Ann N Y Acad Sci* 903:535-541, 2000
1273. Klemm A, Franke C, Busch M, Muller A, Franke S, Lang D, Passlick-Deetjen J, Stein G: Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites. *Clin Nephrol* 61:191-197, 2004
1274. Kleophas W, Bieber B, Robinson BM, Duttlinger J, Fliser D, Lonnemann G, Rump LC, Pisoni RL, Port FK, Reichel H: Implementation and first results of a german chronic kidney disease registry. *Clin Nephrol* 2012;79:184-191.
1275. Kletzmayer J, Mayer G, Legenstein E, Heinz-Peer G, Leitha T, Horl WH, Kovarik J: Anemia and carnitine supplementation in hemodialyzed patients. *Kidney Int Suppl* 69:S93-106, 1999
1276. Kletzmayer J, Horl WH: Iron overload and cardiovascular complications in dialysis patients. *Nephrol Dial Transplant* 17 Suppl 2:25-29, 2002
1277. Kletzmayer J, Sunder-Plassmann G, Horl WH: High dose intravenous iron: a note of caution. *Nephrol Dial Transplant* 17:962-965, 2002
1278. Klimek D, Kokot F, Wiecek A, Kuczera M: [Secretion of atrial natriuretic peptide in patients with active renal stone disease]. *Pol Arch Med Wewn* 95:3-10, 1996
1279. Kmonickova E, Melkusova P, Farghali H, Holy A, Zidek Z: Nitric oxide production in mouse and rat macrophages: a rapid and efficient assay for screening of drugs immunostimulatory effects in human cells. *Nitric Oxide* 17:160-169, 2007
1280. Koc M, Toprak A, Arkan H, Odabasi Z, Elbir Y, Tulunay A, Asicioglu E, Eksioglu-Demiralp E, Glorieux G, Vanholder R, Akoglu E: Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: Relation with inflammation. *Nephrol Dial Transplant* 26:955-963, 2011
1281. Koc M, Toprak A, Arkan H, Odabasi Z, Elbir Y, Tulunay A, Asicioglu E, Eksioglu-Demiralp E, Glorieux G, Vanholder R, Akoglu E: Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: Relation with inflammation. *Nephrol Dial Transplant* 2011;26:955-963.
1282. Kohlhaas SL, Craxton A, Sun XM, Pinkoski MJ, Cohen GM: Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. *J Biol Chem* 282:12831-12841, 2007
1283. Kokot F, Nieszporek T, Wiecek A, Skrzypek J, Ziemienczyk S, Jarzab B: [Levels of erythropoietin in serum of patients with primary hyperparathyroidism]. *Pol Arch Med Wewn* 93:209-215, 1995
1284. Kokot F, Wiecek A: Arterial hypertension in uraemic patients treated with erythropoietin. *Nephron* 71:127-132, 1995
1285. Kokot F, Wiecek A, Schmidt-Gayk H, Marcinkowski W, Gilge U, Heidland A, Rudka R, Trembecki J: Function of endocrine organs in hemodialyzed patients of long-term erythropoietin therapy. *Artif Organs* 19:428-435, 1995
1286. Kokot F, Wiecek A, Grzeszczak W, Lao M, Kusmiński S, Cierpka L, Gradowska L, Jagiello R: Serum erythropoietin and parathyroid hormone concentrations in kidney transplant patients during acute graft rejection. *Transplant Proc* 28:3477-3479, 1996
1287. Kokot F, Wiecek A: Function of endocrine organs in kidney transplant patients. *Ann Transplant* 1:23-28, 1996

1288. Kokot F, Wiecek A: Evidence that the anemia of renal failure participates in overall uremic toxicity. *Kidney Int Suppl* 62:S83-S86, 1997
1289. Kokot F, Chudek J, Karkoszka H, Wiecek A: [Distal tubular acidosis in a patient with insulin dependent diabetes mellitus--selected pathophysiologic, diagnostic and therapeutic aspects]. *Pol Arch Med Wewn* 98:235-240, 1997
1290. Kokot F, Adamczak M, Wiecek A: Plasma leptin concentration in kidney transplant patients during the early post-transplant period. *Nephrol Dial Transplant* 13:2276-2280, 1998
1291. Kokot F, Wiecek A, Mesjasz J, Adamczak M, Spiechowicz U: Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients. *Nephrol Dial Transplant* 13:1200-1205, 1998
1292. Kokot F, Klimek D, Wiecek A, Kuczera M: Atrial natriuretic peptide and arginine-vasopressin secretion in patients with active renal stone disease. *Int Urol Nephrol* 30:357-365, 1998
1293. Kokot F, Ulman I, Wiecek A, Irzyniec T, Ulman J: Concentrations of leptin and neuropeptide Y in maternal plasma, umbilical cord blood and in amniotic fluid in pregnant women with EPH-gestosis. *Arch Immunol Ther Exp (Warsz)* 46:311-316, 1998
1294. Kokot F, Adamczak M, Wiecek A, Cieplik J: Does leptin play a role in the pathogenesis of essential hypertension? *Kidney Blood Press Res* 22:154-160, 1999
1295. Kokot F, Wiecek A, Adamczak M, Ulman I, Spiechowicz U, Cieplik J, Mesjasz J: Pathophysiological role of leptin in patients with chronic renal failure, in kidney transplant patients, in patients with essential hypertension, and in pregnant women with preeclampsia. *Artif Organs* 23:70-74, 1999
1296. Kokot F, Samardzija G, Klimek D, Wiecek A: Intravenous single dose of erythropoietin (rHuEPO) does not influence plasma leptin concentration in hemodialyzed patients with chronic renal failure (CRF). *Clin Nephrol* 51:389-391, 1999
1297. Kokot F, Ulman I, Wiecek A, Irzyniec T, Ulman J: [Do leptin and neuropeptide Y influence blood pressure regulation in healthy pregnant women and women with preeclampsia?]. *Pol Arch Med Wewn* 101:385-390, 1999
1298. Kokot F, Chudek J, Karkoszka H, Adamczak M, Wiecek A, Klimek D: Does PTH influence leptin concentration in haemodialysed uraemic patients? *Nephron* 82:372-373, 1999
1299. Kokot F, Chudek J, Adamczak M, Wiecek A: Interrelationship between plasma leptin concentration and severity of metabolic acidosis in haemodialysed patients with chronic renal failure. *Exp Clin Endocrinol Diabetes* 109:370-373, 2001
1300. Kokot F, Lysiak-Szydłowska W, Adamczak M, Chudek J, Ignacy W, Rutkowski B, Ficek R, Wiecek A: Are plasma concentrations of leptin and carnitine interrelated in haemodialysis patients? *Nephrol Dial Transplant* 16:434-435, 2001
1301. Kokot F, Chudek J, Lysiak-Szydłowska W, Domagala B, Adamczak M, Ignacy W, Kania M, Rutkowski B, Szczeklik A, Wiecek A: [Levels of carnitine and homocysteine in plasma of long-term hemodialysis patients with chronic renal failure]. *Pol Arch Med Wewn* 106:1131-1136, 2001
1302. Kokot F, Schinzel R, Chudek J, Heidland A, Adamczak M, Ficek R, Wiecek A: Relationship between plasma level of parathyroid hormone and carboxymethyllysine in hemodialyzed patients--does it exist? *Clin Nephrol* 59:31-34, 2003
1303. Kolch W, Philipp A, Mischak H, Dutil EM, Mullen TM, Feramisco JR, Meinkoth JL, Rose DW: Inhibition of Raf-1 signaling by a monoclonal antibody, which interferes with Raf-1 activation and with Mek substrate binding. *Oncogene* 13:1305-1314, 1996
1304. Kolch W, Mischak H, Chalmers MJ, Pitt A, Marshall AG: Clinical proteomics: a question of technology. *Rapid Commun Mass Spectrom* 18:2365-2366, 2004
1305. Kolch W, Mischak H, Pitt AR: The molecular make-up of a tumour: proteomics in cancer research. *Clin Sci (Lond)* 108:369-383, 2005
1306. Kolch W, Neuss C, Pelzing M, Mischak H: Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. *Mass Spectrom Rev* 24:959-977, 2005
1307. Kollerits B, Fliser D, Heid IM, Ritz E, Kronenberg F: Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. *Kidney Int* 71:1279-1286, 2007
1308. Kolonko A, Wiecek A, Wystrychowski A, Kokot FS: [Life threatening hypercalcemia in a patient with chronic renal failure. Case report]. *Pol Arch Med Wewn* 95:459-463, 1996
1309. Kolonko A, Wiecek A, Kokot F: [Nephrotoxicity of contrast media--etiopathogenesis and methods of prevention]. *Postepy Hig Med Dosw* 50:245-263, 1996
1310. Kolonko A, Kokot F, Wiecek A: Contrast-associated nephropathy--old clinical problem and new therapeutic perspectives. *Nephrol Dial Transplant* 13:803-806, 1998
1311. Kolonko A, Wiecek A, Kokot F: The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. *J Nephrol* 11:151-156, 1998
1312. Konner P, Watschinger B, Apfalter P, Horl WH, Vychytil A: A case of continuous ambulatory peritoneal dialysis peritonitis with an uncommon organism and an atypical clinical course. *Am J Kidney Dis* 37:E10, 2001
1313. Kontrova K, Zidkova J, Bartos B, Skop V, Sajdok J, Kazdova L, Mikulik K, Mlejnek P, Zidek V, Pravenec M: CD36 regulates fatty acid composition and sensitivity to insulin in 3T3-L1 adipocytes. *Physiol Res* 56:493-496, 2007
1314. Kooman J, Basci A, Pizzarelli F, Canaud B, Haage P, Fouque D, Konner K, Martin-Malo A, Pedrini L, Tattersall J, Tordoir J, Vennegoor M, Wanner C, ter WP, Vanholder R: EBPG guideline on haemodynamic instability. *Nephrol Dial Transplant* 22 Suppl 2:ii22-ii44, 2007
1315. Kooy RF, D'Hooge R, Reyniers E, Bakker CE, Nagels G, De BK, Storm K, Clincke G, De Deyn PP, Oostra BA, Willems PJ: Transgenic mouse model for the fragile X syndrome. *Am J Med Genet* 64:241-245, 1996
1316. Kordonouri O, Kahl A, Jorres A, Hopfenmuller W, Muller C, Danne T: The prevalence of incipient tubular dysfunction, but not of glomerular dysfunction, is increased in patients with diabetes onset in childhood. *J Diabetes Complications* 13:320-324, 1999
1317. Kork F, Holthues J, Hellweg R, Jankowski V, Tepel M, Ohring R, Heuser I, Bierbrauer J, Peters O, Schlattmann P, Zidek W, Jankowski J: A possible new diagnostic biomarker in early diagnosis of alzheimer's disease. *Curr Alzheimer Res* 6:519-524, 2009
1318. Kork F, Gentsch A, Holthues J, Hellweg R, Jankowski V, Tepel M, Zidek W, Jankowski J: A biomarker for severity of alzheimer's disease: 1h-nmr resonances in cerebrospinal fluid correlate with performance in mini-mental-state-exam. *Biomarkers* 17:36-42, 2012
1319. Kork F, Gentsch A, Holthues J, Hellweg R, Jankowski V, Tepel M, Zidek W, Jankowski J: A biomarker for severity of alzheimer's disease: 1h-nmr resonances in cerebrospinal fluid correlate with performance in mini-mental-state-exam. *Biomarkers* 2012;17:36-42.



1320. Kork F, Holthues J, Hellweg R, Jankowski V, Tepel M, Ohring R, Heuser I, Bierbrauer J, Peters O, Schlattmann P, Zidek W, Jankowski J: A possible new diagnostic biomarker in early diagnosis of alzheimer's disease. *Curr Alzheimer Res* 2009;6:519-524.
1321. Kormoczi GF, Wolfel UM, Rosenkranz AR, Horl WH, Oberbauer R, Zlabinger GJ: Serum proteins modified by neutrophil-derived oxidants as mediators of neutrophil stimulation. *J Immunol* 167:451-460, 2001
1322. Korybalska K, Wisniewska-Elnur J, Trominska J, Jorres A, Breborowicz A, Witowski J: The role of the glyoxalase pathway in reducing mesothelial toxicity of glucose degradation products. *Perit Dial Int* 26:259-265, 2006
1323. Kostner K, Banyai S, Jansen M, Khoschsorur G, Horl WH, Maurer G, Winklhofer-Roob B, Derfler K: Low density lipoprotein immunoadsorption does not increase plasma lipid peroxidation products in vivo. *Clin Chim Acta* 288:21-30, 1999
1324. Kostner K, Clodi M, Bodlaj G, Hoffmann U, Hermann K, Maurer G, Pacher R, Horl WH: Urinary apo(a) excretion is not altered by changes in glomerular filtration rate and renal plasma flow in healthy males. *Wien Klin Wochenschr* 112:121-125, 2000
1325. Kostner KM, Banyai S, Banyai M, Bodlaj G, Maurer G, Derfler K, Horl WH, Oberbauer R: Urinary apolipoprotein (a) excretion in patients with proteinuria. *Ann Med* 30:497-502, 1998
1326. Kotzmann H, Yilmaz N, Lercher P, Riedl M, Schmidt A, Schuster E, Kreuzer S, Geyer G, Frisch H, Horl WH, Mayer G, Luger A: Differential effects of growth hormone therapy in malnourished hemodialysis patients. *Kidney Int* 60:1578-1585, 2001
1327. Kotzmann H, Schmidt A, Lercher P, Schuster E, Geyer G, Frisch H, Horl WH, Mayer G, Luger A: One-year growth hormone therapy improves granulocyte function without major effects on nutritional and anthropometric parameters in malnourished hemodialysis patients. *Nephron Clin Pract* 93:C75-C82, 2003 1
1328. Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S, Kainberger F, Frisch H, Geyer G, Horl WH, Mayer G, Luger A: Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis. *J Nephrol* 17:87-94, 2004
1329. Kovacic H, Gallice P, Brunet P, Berland Y, Crevat A: Sodium pump and Na<sup>+</sup>/H<sup>+</sup> activities in uremic erythrocytes. A microcalorimetric and pH-metric study. *Clin Chim Acta* 259:31-40, 1997
1330. Kovatcheva RD, Vlahov JD, Stoinov JI, Kirilov GG, Krivoshiev SG, Arnaud F, Ortuno C, Druke TB: High-intensity focussed ultrasound (hifu) treatment in uraemic secondary hyperparathyroidism. *Nephrol Dial Transplant* 27:76-80, 2012
1331. Kovatcheva RD, Vlahov JD, Stoinov JI, Kirilov GG, Krivoshiev SG, Arnaud F, Ortuno C, Druke TB: High-intensity focussed ultrasound (hifu) treatment in uraemic secondary hyperparathyroidism. *Nephrol Dial Transplant* 2012;27:76-80.
1332. Kowalczyk A, Wiecek A, Franek E, Kokot F: [Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio-and chemotherapy]. *Pol Arch Med Wewn* 106:657-668, 2001
1333. Kramer BK, Wiecek A, Ritz E: [In what way and how intensively should blood pressure be lowered in diabetic nephropathy?]. *Dtsch Med Wochenschr* 122:829-832, 1997
1334. Kramer L, Gendo A, Madl C, Ferrara I, Funk G, Schenk P, Sunder-Plassmann G, Horl WH: Biocompatibility of a cuprophane charcoal-based detoxification device in cirrhotic patients with hepatic encephalopathy. *Am J Kidney Dis* 36:1193-1200, 2000
1335. Kramer L, Horl WH: Hepatorenal syndrome. *Semin Nephrol* 22:290-301, 2002
1336. Krasel C, Dammeier S, Winstel R, Brockmann J, Mischak H, Lohse MJ: Phosphorylation of GRK2 by protein kinase C abolishes its inhibition by calmodulin. *J Biol Chem* 276:19111-19115, 2001
1337. Krasniak A, Drozd M, Pasowicz M, Chmiel G, Michalek M, Szumilak D, Podolec P, Klimeczek P, Konieczynska M, Wicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC, Druke TB, Sulowicz W: Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. *Nephrol Dial Transplant* 22:515-521, 2007
1338. Krasniak A, Drozd M, Pasowicz M, Chmiel G, Kowalczyk-Michalek M, Szumilak D, Podolec P, Klimeczek P, Konieczynska M, Wicher-Muniak E, Tracz W, Sulowicz W, Druke T: [Influence of microinflammation and oxidative stress on atherosclerosis progression and calcifications in cardiovascular system of hemodialyzed patients during two years follow-up]. *Przegl Lek* 64:140-147, 2007
1339. Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, Beige J: The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. *Pharmacogenetics* 14:665-671, 2004
1340. Kribben A, Herget-Rosenthal S, Lange B, Erdbrugger W, Philipp T, Michel MC: Alpha2-adrenoceptors in opossum kidney cells couple to stimulation of mitogen-activated protein kinase independently of adenylyl cyclase inhibition. *Naunyn Schmiedebergs Arch Pharmacol* 356:225-232, 1997
1341. Kribben A, Herget-Rosenthal S, Lange B, Michel MC, Philipp T: Stimulation of mitogen activated protein kinase and cellular proliferation in renal proximal tubular cells. *Ren Fail* 20:229-234, 1998
1342. Kribben A, Feldkamp T, Horbelt M, Lange B, Pietruck F, Herget-Rosenthal S, Heemann U, Philipp T: ATP protects, by way of receptor-mediated mechanisms, against hypoxia-induced injury in renal proximal tubules. *J Lab Clin Med* 141:67-73, 2003
1343. Kribben A, Herget-Rosenthal S, Pietruck F, Philipp T: [Acute renal failure--an review]. *Dtsch Med Wochenschr* 128:1231-1236, 2003
1344. Krieter DH, Grude M, Lemke HD, Fink E, Bonner G, Scholkens BA, Schulz E, Muller GA: Anaphylactoid reactions during hemodialysis in sheep are ACE inhibitor dose-dependent and mediated by bradykinin. *Kidney Int* 53:1026-1035, 1998
1345. Krieter DH, Falkenhain S, Chalabi L, Collins G, Lemke HD, Canaud B: Clinical cross-over comparison of mid-dilution hemodiafiltration using a novel dialyzer concept and post-dilution hemodiafiltration. *Kidney Int* 67:349-356, 2005
1346. Krieter DH, Lemke HD, Canaud B, Wanner C: Beta(2)-microglobulin removal by extracorporeal renal replacement therapies. *Biochim Biophys Acta* 1753:146-153, 2005
1347. Krieter DH, Steinke J, Kerkhoff M, Fink E, Lemke HD, Zingler C, Muller GA, Schuff-Werner P: Contact activation in low-density lipoprotein apheresis systems. *Artif Organs* 29:47-52, 2005
1348. Krieter DH, Lemke HD, Wanner C: Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. *Nephrol Dial Transplant* 21:546, 2006
1349. Krieter DH, Morgenroth A, Barasinski A, Lemke HD, Schuster O, von HB, Wanner C: Effects of a polyelectrolyte additive on the selective dialysis membrane permeability for low-molecular-weight proteins. *Nephrol Dial Transplant* 22:491-499, 2007
1350. Kristensen B, Malm J, Carlberg B, Stegmayr B, Backman C, Fagerlund M, Olsson T: Epidemiology and etiology of ischemic stroke in young

- adults aged 18 to 44 years in northern Sweden. *Stroke* 28:1702-1709, 1997
1351. Krol E, Rutkowski B, Czekalski S, Sulowicz W, Wiecek A, Lizakowski S, Czarniak P, Szubert R, Karczewska-Maksymienko L, Orlikowska M, Kraszewska E, Magdon R: [Early diagnosis of renal diseases--preliminary results from the pilot study PolNef]. *Przegl Lek* 62:690-693, 2005
1352. Krol R, Ziaja J, Chudek J, Kolonko A, Pencak P, Oczkowicz G, Wiecek A, Cierpka L: Iliac artery stenosis as a cause of posttransplant renovascular hypertension: report of two cases. *Ann Transplant* 10:66-69, 2005
1353. Krol R, Ziaja J, Chudek J, Heitzman M, Pawlicki J, Wiecek A, Cierpka L: Surgical treatment of urological complications after kidney transplantation. *Transplant Proc* 38:127-130, 2006
1354. Krol R, Ziaja J, Kolonko A, Chudek J, Wiecek A, Cierpka L: Late caliceal fistula after kidney transplantation. *Int J Urol* 13:1115-1117, 2006
1355. Krol R, Ziaja J, Cierniak T, Pawlicki J, Chudek J, Wiecek A, Cierpka L: Simultaneous transabdominal bilateral nephrectomy in potential kidney transplant recipients. *Transplant Proc* 38:28-30, 2006
1356. Krol R, Kolonko A, Chudek J, Ziaja J, Pawlicki J, Maly A, Kunsdorf-Wnuk A, Cierpka L, Wiecek A: Did volume of lymphocele after kidney transplantation determine the choice of treatment modality? *Transplant Proc* 39:2740-2743, 2007
1357. Kronman MP, Baden HP, Jeffries HE, Heath J, Cohen GA, Zerr DM: An investigation of *Aspergillus* cardiac surgical site infections in 3 pediatric patients. *Am J Infect Control* 35:332-337, 2007
1358. Krueger K, Terne C, Werner C, Freudenberg U, Jankowski V, Zidek W, Jankowski J: Characterization of polymer membranes by maldi mass-spectrometric imaging techniques. *Anal Chem* 2013;85:4998-5004.
1359. Kruse A, Beige J: [Hyperparathyroidism--new aspects]. *Ther Umsch* 64:265-269, 2007
1360. Krysiak O, Bretschneider A, Zhong E, Webb J, Hopp H, Verlohren S, Fuhr N, Lanowska M, Nonnenmacher A, Vetter R, Jankowski J, Paul M, Schonfelder G: Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF. *Circ Res* 97:1253-1261, 2005
1361. Krysiak O, Bretschneider A, Zhong E, Webb J, Hopp H, Verlohren S, Fuhr N, Lanowska M, Nonnenmacher A, Vetter R, Jankowski J, Paul M, Schonfelder G: Soluble vascular endothelial growth factor receptor-1 (sflt-1) mediates downregulation of flt-1 and prevents activated neutrophils from women with preeclampsia from additional migration by vegf. *Circ Res* 2005;97:1253-1261.
1362. Ksiazek K, Piwocka K, Brzezinska A, Sikora E, Zabel M, Breborowicz A, Jorres A, Witowski J: Early loss of proliferative potential of human peritoneal mesothelial cells in culture: the role of p16INK4a-mediated premature senescence. *J Appl Physiol* 100:988-995, 2006
1363. Ksiazek K, Breborowicz A, Jorres A, Witowski J: Oxidative stress contributes to accelerated development of the senescent phenotype in human peritoneal mesothelial cells exposed to high glucose. *Free Radic Biol Med* 42:636-641, 2007
1364. Ksiazek K, Korybalska K, Jorres A, Witowski J: Accelerated senescence of human peritoneal mesothelial cells exposed to high glucose: the role of TGF-beta1. *Lab Invest* 87:345-356, 2007
1365. Kubey W, Luneburg P, Ericson S, Brown J, Holmes CJ: A longitudinal in vitro antimicrobial evaluation of two silver polymer surface treatments for peritoneal dialysis catheters. *Adv Perit Dial* 11:193-196, 1995
1366. Kubey W, Straka P, Holmes CJ: Importance of product design on effective bacterial removal by fluid convection in Y set and twinbag systems. *Blood Purif* 16:154-161, 1998
1367. Kubey W, Straka P, Holmes CJ: An in vitro bacterial touch contamination risk assessment of two CAPD twinbag systems. *Blood Purif* 19:62-67, 2001
1368. Kuczera M, Wiecek A, Kokot F: Markers of bone turnover in patients with nephrolithiasis. *Int Urol Nephrol* 29:523-528, 1997
1369. Kumpers P, Hafer C, David S, Hecker H, Lukasz A, Fliser D, Haller H, Kielstein JT, Faulhaber-Walter R: Angiotensin-2 in patients requiring renal replacement therapy in the icu: Relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. *Intensive Care Med* 2009;36:462-470.
1370. Kumpers P, Hafer C, Lukasz A, Lichtinghagen R, Brand K, Fliser D, Faulhaber-Walter R, Kielstein JT: Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. *Crit Care* 2010;14:R9.
1371. Kunz R, Kreutz R, Beige J, Distler A, Sharma AM: Association between the angiotensinogen 235T-variant and essential hypertension in whites: a systematic review and methodological appraisal. *Hypertension* 30:1331-1337, 1997
1372. La GG, Amore A, Armato U, Coles G, Esposito C, Deppisch R, Feriani M, Mason R, Noonan D, Schleicher E, Sterzel B, Gambaro G: The unphysiology of peritoneal dialysis solution and the peritoneal membrane: from basic research to clinical nephrology. *Nephrol Dial Transplant* 16:905-912, 2001
1373. Lacour B, Ohan J, Aznag A, Druke TB: Stimulating effects of sorbitol and L-xylose on rat ileal Ca transport in vitro. *Miner Electrolyte Metab* 21:391-397, 1995
1374. Lacour B, Tardivel S, Druke T: Stimulation by citric acid of calcium and phosphorus bioavailability in rats fed a calcium-rich diet. *Miner Electrolyte Metab* 23:79-87, 1997
1375. Lacour B, Lucas A, Auchere D, Ruellan N, de Serre Patey NM, Druke TB: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. *Kidney Int* 67:1062-1069, 2005
1376. Lacour B, Nikolov IG, Joki N, Druke TB: Lanthanum carbonate, body lanthanum accumulation and potential liver toxicity. *Nephrol Dial Transplant* 2007
1377. Lacour B, Nikolov IG, Joki N, Druke TB: Lanthanum carbonate, body lanthanum accumulation and potential liver toxicity. *Nephrol Dial Transplant* 22:1788-1789, 2007
1378. Laczika K, Knapp S, Derfler K, Soleiman A, Horl WH, Druml W: Immunoabsorption in Goodpasture's syndrome. *Am J Kidney Dis* 36:392-395, 2000
1379. Laforet P, Eymard B, Lombes A, Duboc D, Jehenson P, Rocchiccioli F, Chaussain M, Chateau D, Brunet P, Fardeau M: [Exercise intolerance caused by muscular phosphorylase kinase deficiency. Contribution of in vivo metabolic studies]. *Rev Neurol (Paris)* 152:458-464, 1996
1380. Lage C, Pischetsrieder M, Aufricht C, Jorres A, Schilling H, Passlick-Deetjen J: First in vitro and in vivo experiences with Stay-Safe Balance, a pH-neutral solution in a dual-chambered bag. *Perit Dial Int* 20 Suppl 5:S28-S32, 2000
1381. Lameire N, Verbeke M, Vanholder R: Prevention of clinical acute tubular necrosis with drug therapy. *Nephrol Dial Transplant* 10:1992-2000, 1995

1382. Lameire N, Hoste E, Van LA, Dhondt A, Bernaert P, Vanholder R: Pathophysiology, causes, and prognosis of acute renal failure in the elderly. *Ren Fail* 18:333-346, 1996
1383. Lameire N, Vanholder RC, Van LA, Lambert MC, Vijt D, Van BL, Vogeleere P, Ringoir SM: Cardiovascular diseases in peritoneal dialysis patients: the size of the problem. *Kidney Int Suppl* 56:S28-S36, 1996
1384. Lameire N, Vanholder R, Clement J, Hoste E, Van Waelegheem JP, Larno L, Lambert MC: The organization of the European Renal Disaster Relief Task Force. *Ren Fail* 19:665-671, 1997
1385. Lameire N, Van BW, Vanholder R, Colardijn F: The place of intermittent hemodialysis in the treatment of acute renal failure in the ICU patient. *Kidney Int Suppl* 66:S110-S119, 1998
1386. Lameire N, Nelde A, Hoeben H, Vanholder R: Acute renal failure in the elderly. *Geriatr Nephrol Urol* 9:153-165, 1999
1387. Lameire N, Van BW, Vanholder R: Dialysing the patient with acute renal failure in the ICU: the emperor's clothes? *Nephrol Dial Transplant* 14:2570-2573, 1999
1388. Lameire N, Vanholder R, Van BW, De VA, Dhondt A, Veys N, Hoeben H, Colardyn F: Evidence-based therapy of acute renal failure. *Acta Clin Belg* 54:263-273, 1999
1389. Lameire N, Van BW, Vanholder R: The role of peritoneal dialysis as first modality in an integrative approach to patients with end-stage renal disease. *Perit Dial Int* 20 Suppl 2:S134-S141, 2000
1390. Lameire N, Vanholder R: Drug therapy of acute renal failure. *IDrugs* 3:1206-1216, 2000
1391. Lameire N, Vanholder R: New perspectives for prevention/treatment of acute renal failure. *Curr Opin Anaesthesiol* 13:105-112, 2000
1392. Lameire N, Vanholder R, De SR: Uremic toxins and peritoneal dialysis. *Kidney Int Suppl* 78:S292-S297, 2001
1393. Lameire N, Vanholder R: Pathophysiologic features and prevention of human and experimental acute tubular necrosis. *J Am Soc Nephrol* 12 Suppl 17:S20-S32, 2001
1394. Lameire N, Biesen WV, Vanholder R: Initiation of dialysis--is the problem solved by NECOSAD? *Nephrol Dial Transplant* 17:1550-1552, 2002
1395. Lameire N, Vanholder R, Van BW: Loop diuretics for patients with acute renal failure: helpful or harmful? *JAMA* 288:2599-2601, 2002
1396. Lameire N, Wauters JP, Teruel JL, Van BW, Vanholder R: An update on the referral pattern of patients with end-stage renal disease. *Kidney Int Suppl* 27-34, 2002
1397. Lameire N, Mehta R, Vanholder R, Sever M: The organization and interventions of the ISN Renal Disaster Relief Task Force. *Adv Ren Replace Ther* 10:93-99, 2003
1398. Lameire N, Van BW, Vanholder R: Impact of peritoneal dialysis on patient and graft outcome after kidney transplantation. *Contrib Nephrol* 226-241, 2003
1399. Lameire N, Van BW, Vanholder R, Hoste E: Intermittent hemodialysis for acute renal failure patients--an update. *Contrib Nephrol* 144:255-263, 2004
1400. Lameire N, Van BW, Vanholder R: Acute renal failure. *Lancet* 365:417-430, 2005
1401. Lameire N, Jager K, Van BW, De BD, Vanholder R: Chronic kidney disease: a European perspective. *Kidney Int Suppl* S30-S38, 2005
1402. Lameire N, Eknoyan G, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod A, Vanholder R, Walker R, Wang H: A new initiative in nephrology: 'Kidney disease: improving global outcomes'. *Contrib Nephrol* 149:90-99, 2005
1403. Lameire N, Van BW, Vanholder R: The rise of prevalence and the fall of mortality of patients with acute renal failure: what the analysis of two databases does and does not tell us. *J Am Soc Nephrol* 17:923-925, 2006
1404. Lameire N, Peeters P, Vanholder R, Van BW: Peritoneal dialysis in Europe: an analysis of its rise and fall. *Blood Purif* 24:107-114, 2006
1405. Lameire N, Van BW, Vanholder R: The changing epidemiology of acute renal failure. *Nat Clin Pract Nephrol* 2:364-377, 2006
1406. Lameire N, Vanbiesen W, Vanholder R: When to start dialysis in patients with acute kidney injury? When semantics and logic become entangled with expectations and beliefs. *Crit Care* 15:171, 2011
1407. Lameire N, Vanbiesen W, Vanholder R: When to start dialysis in patients with acute kidney injury? When semantics and logic become entangled with expectations and beliefs. *Crit Care* 2011;15:171.
1408. Lameire NH, De Vriese AS, Vanholder R: Prevention and nondialytic treatment of acute renal failure. *Curr Opin Crit Care* 9:481-490, 2003
1409. Lameire NH, Vanholder R: Pathophysiology of ischaemic acute renal failure. *Best Pract Res Clin Anaesthesiol* 18:21-36, 2004
1410. Lameire NH, Vanholder RC, Van Biesen WA: How to use biomarkers efficiently in acute kidney injury. *Kidney Int* 79:1047-1050, 2011
1411. Lameire NH, Vanholder RC, Van Biesen WA: How to use biomarkers efficiently in acute kidney injury. *Kidney Int* 2011;79:1047-1050.
1412. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de GK, Fliser D, Fauler G, Marz W, Drexler H: Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. *Circulation* 111:2356-2363, 2005
1413. Lapa K, Kokot F, Oklek K, Cieslicki J, Machalski M, Chudek J, Wiecek A: [Plasma erythropoietin concentration in lung cancer patients]. *Pneumonol Alergol Pol* 70:243-250, 2002
1414. Lawrence SJ, Lottenbach KR, Newman FK, Buller RM, Bellone CJ, Chen JJ, Cohen GH, Eisenberg RJ, Belshe RB, Stanley SL, Jr., Frey SE: Antibody responses to vaccinia membrane proteins after smallpox vaccination. *J Infect Dis* 196:220-229, 2007
1415. Lazear E, Carfi A, Whitbeck JC, Cairns TM, Krummenacher C, Cohen GH, Eisenberg RJ: Engineered disulfide bonds in herpes simplex virus type 1 gD separate receptor binding from fusion initiation and viral entry. *J Virol* 82:700-709, 2008
1416. Le Grand-Piteira N, Brunet P, Lebon L, Limat L: Propagating wave pattern on a falling liquid curtain. *Phys Rev E Stat Nonlin Soft Matter Phys* 74:026305, 2006
1417. Le BN, Van BM, De LE, Martin JJ, De Deyn PP, Engelborghs S: LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia. *J Gerontol A Biol Sci Med Sci* 62:923-924, 2007
1418. Lebrun G, Jaubert D, El Mekaoui F, Rodde G, Falgas C, Brunet P: [dietary therapy in patients with chronic kidney disease]. *Prog Urol* 2011;21:793-797, 2011
1419. Lebrun G, Jaubert D, El Mekaoui F, Rodde G, Falgas C, Brunet P: [dietary therapy in patients with chronic kidney disease]. *Prog Urol* 2011;21:793-797.

1420. Le ND, Rizzo C, Hu W, Brunet P: [Neurolysis of the median nerve at the wrist with 2-portal endoscopic technique. Analysis of 102 consecutive cases]. *Chir Main* 17:221-231, 1998
1421. Lechevallier E, Dussol B, Luccioni A, Thirion X, Vacher-Copomat H, Jaber K, Brunet P, Leonetti F, Lavelle O, Coulange C, Berland Y: Posttransplantation acute tubular necrosis: risk factors and implications for graft survival. *Am J Kidney Dis* 32:984-991, 1998
1422. Ledebro I, Kessler M, Van BW, Wanner C, Wiecek A, Prichard S, Argiles A, Ritz E: Initiation of dialysis-opinions from an international survey: Report on the Dialysis Opinion Symposium at the ERA-EDTA Congress, 18 September 2000, Nice. *Nephrol Dial Transplant* 16:1132-1138, 2001
1423. Ledebro I, Wieslander A, Deppisch R: GDPs and AGEs: local and systemic effects in PD patients. *Contrib Nephrol* 38-46, 2003
1424. Lee PP, Schiffmann L, Offermann G, Beige J: Effects of parathyroidectomy on renal allograft survival. *Kidney Blood Press Res* 27:191-196, 2004
1425. Lee SM, Lee AL, Winters TJ, Tam E, Jaleel M, Stenvinkel P, Johnson RJ: Low serum uric acid level is a risk factor for death in incident hemodialysis patients. *Am J Nephrol* 2009;29:79-85.
1426. Leroyer AS, Anfosso F, Lacroix R, Sabatier F, Simoncini S, Njock SM, Jourde N, Brunet P, Camoin-Jau L, Sampol J, Dignat-George F: Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. *Thromb Haemost* 104:456-463, 2010
1427. Leroyer AS, Anfosso F, Lacroix R, Sabatier F, Simoncini S, Njock SM, Jourde N, Brunet P, Camoin-Jau L, Sampol J, Dignat-George F: Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. *Thromb Haemost* 2010;104:456-463.
1428. Lesaffer G, De SR, Lameire N, Dhondt A, Duym P, Vanholder R: Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. *Nephrol Dial Transplant* 15:50-57, 2000
1429. Lesaffer G, De SR, D'Heuvaert T, Belpaire FM, Lameire N, Vanholder R: Kinetics of the protein-bound, lipophilic, uremic toxin p-cresol in healthy rats. *Life Sci* 69:2237-2248, 2001
1430. Lesaffer G, De SR, D'Heuvaert T, Belpaire FM, Lameire N, Vanholder R: Comparative kinetics of the uremic toxin p-cresol versus creatinine in rats with and without renal failure. *Kidney Int* 64:1365-1373, 2003
1431. Lesaffer G, De SR, Belpaire FM, Van VB, Van HM, Cornelis R, Lameire N, Vanholder R: Urinary excretion of the uraemic toxin p-cresol in the rat: contribution of glucuronidation to its metabolism. *Nephrol Dial Transplant* 18:1299-1306, 2003
1432. Levillain O, Marescau B, De Deyn PP: Guanidino compound metabolism in rats subjected to 20% to 90% nephrectomy. *Kidney Int* 47:464-472, 1995
1433. Levillain O, Marescau B, De Deyn PP: Renal handling of guanidino compounds in rat and rabbit. *J Physiol* 499 ( Pt 2):561-570, 1997
1434. Levillain O, Marescau B, Possemiers I, Al BM, De Deyn PP: Influence of 72% injury in one kidney on several organs involved in guanidino compound metabolism: a time course study. *Pflugers Arch* 442:558-569, 2001
1435. Levy A, Cohen G, Gilat E, Kapon J, Dachir S, Abraham S, Herskovitz M, Teitelbaum Z, Raveh L: Extrapolating from animal studies to the efficacy in humans of a pretreatment combination against organophosphate poisoning. *Arch Toxicol* 81:353-359, 2007
1436. Liabeuf S, Druke TB, Massy ZA: Protein-bound uremic toxins: New insight from clinical studies. *Toxins (Basel)* 3:911-919, 2011
1437. Liabeuf S, Barreto DV, Kretschmer A, Barreto FC, Renard C, Andrejak M, Choukroun G, Massy Z: High circulating levels of large splice variants of tenascin-c is associated with mortality and cardiovascular disease in chronic kidney disease patients. *Atherosclerosis* 215:116-124, 2011
1438. Liabeuf S, Barreto DV, Kretschmer A, Barreto FC, Renard C, Andrejak M, Choukroun G, Massy Z: High circulating levels of large splice variants of tenascin-c is associated with mortality and cardiovascular disease in chronic kidney disease patients. *Atherosclerosis* 2011;215:116-124.
1439. Liabeuf S, Druke TB, Massy ZA: Protein-bound uremic toxins: New insight from clinical studies. *Toxins (Basel)* 2011;3:911-919.
1440. Liabeuf S, Okazaki H, Desjardins L, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Suleymanlar G, Mallamaci F, Zoccali C, London G, Massy ZA: Vascular calcification in chronic kidney disease: Are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? *Nephrol Dial Transplant* 2013
1441. Li S, Janosch P, Tanji M, Rosenfeld GC, Waymire JC, Mischak H, Kolch W, Sedivy JM: Regulation of Raf-1 kinase activity by the 14-3-3 family of proteins. *EMBO J* 14:685-696, 1995
1442. Liangos O, Kreutz R, Beige J, Offermann G, Distler A, Sharma AM: Methylenetetrahydrofolate-reductase gene C677T variant and kidney-transplant survival. *Nephrol Dial Transplant* 13:2351-2354, 1998
1443. Liberek T, Lichodziejewska-Niemierko M, Knopinska-Posluszny W, Schaub TP, Kirchgessner J, Passlick-Deetjen J, Rutkowski B: Generation of TNF $\alpha$  and interleukin-6 by peritoneal macrophages after overnight dwells with bicarbonate- or lactate-buffered dialysis fluid. *Perit Dial Int* 22:663-669, 2002
1444. Libert C, Van MW, Brouckaert P, Fiers W: Platelet-activating factor is a mediator in tumor necrosis factor/galactosamine-induced lethality. *J Inflamm* 46:139-143, 1995
1445. Libert C, Van MW, Brouckaert P, Fiers W:  $\alpha$ 1-Antitrypsin inhibits the lethal response to TNF in mice. *J Immunol* 157:5126-5129, 1996
1446. Libert C, Hochepeid T, Berger FG, Baumann H, Fiers W, Brouckaert P: High-level constitutive expression of  $\alpha$  1-acid glycoprotein and lack of protection against tumor necrosis factor-induced lethal shock in transgenic mice. *Transgenic Res* 7:429-435, 1998
1447. Libert C, Wielockx B, Grijalba B, Van MW, Kremmer E, Colten HR, Fiers W, Brouckaert P: The role of complement activation in tumour necrosis factor-induced lethal hepatitis. *Cytokine* 11:617-625, 1999
1448. Libert C, Wielockx B, Hammond GL, Brouckaert P, Fiers W, Elliott RW: Identification of a locus on distal mouse chromosome 12 that controls resistance to tumor necrosis factor-induced lethal shock. *Genomics* 55:284-289, 1999
1449. Lilaj T, Vyhytil A, Schneider B, Horl WH, Haag-Weber M: Influence of the preceding exchange on peritoneal equilibration test results: a prospective study. *Am J Kidney Dis* 34:247-253, 1999
1450. Lilaj T, Dittrich E, Puttinger H, Schneider B, Haag-Weber M, Horl WH, Vyhytil A: A preceding exchange with polyglucose versus glucose solution modifies peritoneal equilibration test results. *Am J Kidney Dis* 38:118-126, 2001
1451. Lindahl B, Dinesen B, Eliasson M, Roder M, Hallmans G, Stegmayr B: High proinsulin levels precede first-ever stroke in a nondiabetic population. *Stroke* 31:2936-2941, 2000

1452. Lindahl B, Stegmayr B, Johansson I, Weinehall L, Hallmans G: Trends in lifestyle 1986-99 in a 25- to 64-year-old population of the Northern Sweden MONICA project. *Scand J Public Health Suppl* 61:31-37, 2003
1453. Linden T, Forsback G, Deppisch R, Henle T, Wieslander A: 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. *Perit Dial Int* 18:290-293, 1998
1454. Linden T, Musi B, Jarkelid L, Forsback G, Kjellstrand P, Deppisch R, Wieslander A: Glucose degradation products in peritoneal dialysis fluids may have both local and systemic effects: a study of residual fluid and mesothelial cells. *Perit Dial Int* 21:607-610, 2001
1455. Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A: 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. *Kidney Int* 62:697-703, 2002
1456. Lindholm B, Heimbürger O, Stenvinkel P: What are the causes of protein-energy malnutrition in chronic renal insufficiency? *Am J Kidney Dis* 39:422-425, 2002
1457. Lindmark U, Stegmayr B, Nilsson B, Lindahl B, Johansson I: Food selection associated with sense of coherence in adults. *Nutr J* 4:9, 2005
1458. Lindner A, Vanholder R, De SR, Hinds TR, Vogeleere P, Sandra P, Foxall P, Ringoir S: HPLC fractions of human uremic plasma inhibit the RBC membrane calcium pump. *Kidney Int* 51:1042-1052, 1997
1459. Lissimore JL, Jankowski JT, Thomas CB, Mascotti DP, deHaseth PL: Green fluorescent protein as a quantitative reporter of relative promoter activity in *E. coli*. *Biotechniques* 28:82-89, 2000
1460. Liu DY, Thilo F, Scholze A, Wittstock A, Zhao ZG, Harteneck C, Zidek W, Zhu ZM, Tepel M: Increased store-operated and 1-oleoyl-2-acetyl-sn-glycerol-induced calcium influx in monocytes is mediated by transient receptor potential canonical channels in human essential hypertension. *J Hypertens* 25:799-808, 2007
1461. Liu DY, Scholze A, Kreutz R, Wehland-von-Trebra M, Zidek W, Zhu ZM, Tepel M: Monocytes from spontaneously hypertensive rats show increased store-operated and second messenger-operated calcium influx mediated by transient receptor potential canonical Type 3 channels. *Am J Hypertens* 20:1111-1118, 2007
1462. Liu Y, Thilo F, Kreutz R, Schulz A, Wendt N, Loddenkemper C, Jankowski V, Tepel M: Tissue expression of *trpc3* and *trpc6* in hypertensive munich wistar fromter rats showing proteinuria. *Am J Nephrol* 31:36-44, 2010
1463. Liu Y, Thilo F, Kreutz R, Schulz A, Wendt N, Loddenkemper C, Jankowski V, Tepel M: Tissue expression of *trpc3* and *trpc6* in hypertensive munich wistar fromter rats showing proteinuria. *Am J Nephrol* 2010;31:36-44.
1464. Locatelli F, Hannedouche T, Jacobson S, La GG, Loureiro A, Martin-Malo A, Papadimitriou M, Vanholder R: The effect of membrane permeability on ESRD: design of a prospective randomised multicentre trial. *J Nephrol* 12:85-88, 1999
1465. Locatelli F, Rutkowski B, Andrulli S, Enia G, Gellert R, Kramar R, Marcelli D, Zoccali C, Wiecek A, Ritz E: Gdansk bio-statistic and epidemiology course. *Nephrol Dial Transplant* 16:1559-1561, 2001
1466. Locatelli F, Cannata-Andia JB, Drueke TB, Horl WH, Fouque D, Heimbürger O, Ritz E: Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. *Nephrol Dial Transplant* 17:723-731, 2002
1467. Locatelli F, Fouque D, Heimbürger O, Drueke TB, Cannata-Andia JB, Horl WH, Ritz E: Nutritional status in dialysis patients: a European consensus. *Nephrol Dial Transplant* 17:563-572, 2002
1468. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. *Nephrol Dial Transplant* 18:1272-1280, 2003
1469. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: The importance of diabetic nephropathy in current nephrological practice. *Nephrol Dial Transplant* 18:1716-1725, 2003
1470. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougall IC, MacLeod A, Wiecek A, Cameron S: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. *Nephrol Dial Transplant* 19 Suppl 2:ii1-47, 2004
1471. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Macdougall IC, MacLeod A, Horl WH, Wiecek A, Cameron S: Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? *Nephrol Dial Transplant* 19:288-293, 2004
1472. London GM, Drueke TB: Atherosclerosis and arteriosclerosis in chronic renal failure. *Kidney Int* 51:1678-1695, 1997
1473. Lonnemann G, Sereni L, Lemke HD, Tetta C: Pyrogen retention by highly permeable synthetic membranes during in vitro dialysis. *Artif Organs* 25:951-960, 2001
1474. Lonnemann G, Novick D, Rubinstein M, Passlick-Deetjen J, Lang D, Dinarello CA: A switch to high-flux helixone membranes reverses suppressed interferon-gamma production in patients on low-flux dialysis. *Blood Purif* 21:225-231, 2003
1475. Lorenz M, Regele H, Kovarik J, Horl WH, Klausner R: Rapidly progressive glomerulonephritis and carcinoma of the hypopharynx. *Am J Kidney Dis* 37:E3, 2001
1476. Lorenz M, Kletzmayer J, Perschl A, Furrer A, Horl WH, Sunder-Plassmann G: Anemia and iron deficiencies among long-term renal transplant recipients. *J Am Soc Nephrol* 13:794-797, 2002
1477. Lorenz M, Regele H, Schillinger M, Exner M, Rasoul-Rockenschaub S, Wahrmann M, Kletzmayer J, Silberhumer G, Horl WH, Bohmig GA: Risk factors for capillary C4d deposition in kidney allografts: evaluation of a large study cohort. *Transplantation* 78:447-452, 2004
1478. Lorenz M, Billensteiner E, Bodingbauer M, Oberbauer R, Horl WH, Haas M: The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. *Am J Kidney Dis* 43:1065-1070, 2004
1479. Lorenz M, Wolzt M, Weigel G, Puttering H, Horl WH, Fodinger M, Speiser W, Sunder-Plassmann G: Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. *Am J Kidney Dis* 43:1098-1103, 2004
1480. Lorenz M, Winkelmayr WC, Horl WH, Sunder-Plassmann G: Anaemia after renal transplantation. *Eur J Clin Invest* 35 Suppl 3:89-94, 2005
1481. Lorenz M, Kletzmayer J, Huber A, Horl WH, Sunder-Plassmann G, Fodinger M: Iron overload in kidney transplants: prospective analysis of biochemical and genetic markers. *Kidney Int* 67:691-697, 2005
1482. Lorenzen J, David S, Bahlmann FH, de Groot K, Bahlmann E, Kielstein JT, Haller H, Fliser D: Endothelial progenitor cells and cardiovascular events in patients with chronic kidney disease--a prospective follow-up study. *PLoS One* 2010;5:e11477.
1483. Lorenzen J, Kramer R, Kliem V, Bode-Boeger SM, Veldink H, Haller H, Fliser D, Kielstein JT: Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. *Eur J Clin Invest* 2010;40:294-300.

1484. Lorenzen JM, David S, Richter A, de Groot K, Kielstein JT, Haller H, Thum T, Fliser D: Tlr-4+ peripheral blood monocytes and cardiovascular events in patients with chronic kidney disease--a prospective follow-up study. *Nephrol Dial Transplant* 2011;26:1421-1424.
1485. Lorenzen JM, Hafer C, Faulhaber-Walter R, Kumpers P, Kielstein JT, Haller H, Fliser D: Osteopontin predicts survival in critically ill patients with acute kidney injury. *Nephrol Dial Transplant* 2010;26:531-537.
1486. Lorenzen JM, Kielstein JT, Hafer C, Gupta SK, Kumpers P, Faulhaber-Walter R, Haller H, Fliser D, Thum T: Circulating mir-210 predicts survival in critically ill patients with acute kidney injury. *Clin J Am Soc Nephrol* 2011;6:1540-1546.
1487. Lorho R, Mourad G, Couret I, Argiles A: The dialysis patient with persisting elevation of bone alkaline phosphatase after parathyroidectomy. *Nephrol Dial Transplant* 13:2394-2396, 1998
1488. Lovric J, Dammeier S, Kieser A, Mischak H, Kolch W: Activated raf induces the hyperphosphorylation of stathmin and the reorganization of the microtubule network. *J Biol Chem* 273:22848-22855, 1998
1489. Lowbeer C, Stenvinkel P, Pecoito-Filho R, Heimburger O, Lindholm B, Gustafsson SA, Seeberger A: Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. *J Intern Med* 253:153-160, 2003
1490. Lundberg V, Stegmayr B, Asplund K, Eliasson M, Huhtasaari F: Diabetes as a risk factor for myocardial infarction: population and gender perspectives. *J Intern Med* 241:485-492, 1997
1491. Lundberg V, Tolonen H, Stegmayr B, Kuulasmaa K, Asplund K: Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project. *Maturitas* 48:39-49, 2004
1492. Lundqvist S, Holmberg G, Jakobsson G, Lithner F, Skinningsrud K, Stegmayr B, Hietala SO: Assessment of possible nephrotoxicity from iohexol in patients with normal and impaired renal function. *Acta Radiol* 39:362-367, 1998
1493. Luo J, Jankowski J, Knobloch M, van der GM, Gardanis K, Russ T, Vahlensieck U, Neumann J, Schmitz W, Tepel M, Deng MC, Zidek W, Schluter H: Identification and characterization of diadenosine 5',5''-P1,P2 -diphosphate and diadenosine 5',5''-P1,P3-triphosphate in human myocardial tissue. *FASEB J* 13:695-705, 1999
1494. Luo J, Jankowski J, Tepel M, von Der GM, Zidek W, Schluter H: Identification of diadenosine hexaphosphate in human erythrocytes. *Hypertension* 34:872-875, 1999
1495. Luo J, Jankowski V, Gungar N, Neumann J, Schmitz W, Zidek W, Schluter H, Jankowski J: Endogenous diadenosine tetraphosphate, diadenosine pentaphosphate, and diadenosine hexaphosphate in human myocardial tissue. *Hypertension* 43:1055-1059, 2004
1496. Luo J, Jankowski V, Henning L, Schluter H, Zidek W, Jankowski J: Endogenous coenzyme A glutathione disulfide in human myocardial tissue. *J Endocrinol Invest* 29:688-693, 2006
1497. Luo J, Jankowski V, Gungar N, Neumann J, Schmitz W, Zidek W, Schluter H, Jankowski J: Endogenous diadenosine tetraphosphate, diadenosine pentaphosphate, and diadenosine hexaphosphate in human myocardial tissue. *Hypertension* 2004;43:1055-1059.
1498. Luttrupp K, Lindholm B, Carrero JJ, Glorieux G, Schepers E, Vanholder R, Schalling M, Stenvinkel P, Nordfors L: Genetics/genomics in chronic kidney disease--towards personalized medicine? *Semin Dial* 2009;22:417-422.
1499. Maahs DM, Siwy J, Argiles A, Cerna M, Delles C, Dominiczak AF, Gayrard N, Iphofer A, Jansch L, Jerums G, Medek K, Mischak H, Navis GJ, Roob JM, Rossing K, Rossing P, Rychlik I, Schiffer E, Schmieder RE, Wascher TC, Winkhofer-Roob BM, Zimmerli LU, Zurbig P, Snell-Bergeon JK: Urinary collagen fragments are significantly altered in diabetes: A link to pathophysiology. *PLoS One* 2010
1500. Maahs DM, Siwy J, Argiles A, Cerna M, Delles C, Dominiczak AF, Gayrard N, Iphofer A, Jansch L, Jerums G, Medek K, Mischak H, Navis GJ, Roob JM, Rossing K, Rossing P, Rychlik I, Schiffer E, Schmieder RE, Wascher TC, Winkhofer-Roob BM, Zimmerli LU, Zurbig P, Snell-Bergeon JK: Urinary collagen fragments are significantly altered in diabetes: A link to pathophysiology. *PLoS One* 2010;5
1501. Maca T, Ahmadi R, Derfler K, Horl WH, Koppensteiner R, Minar E, Schneider B, Stumpflen A, Ehringer H: Elevated lipoprotein(a) and increased incidence of restenosis after femoropopliteal PTA. Rationale for the higher risk of recurrence in females? *Atherosclerosis* 127:27-34, 1996
1502. Macdougall IC, Horl WH, Jacobs C, Valderrabano F, Parrondo I, Thompson K, Cremers S: European best practice guidelines 6-8: assessing and optimizing iron stores. *Nephrol Dial Transplant* 15 Suppl 4:20-32, 2000
1503. Macek P, Novak P, Zidek L, Sklenar V: Backbone motions of free and pheromone-bound major urinary protein I studied by molecular dynamics simulation. *J Phys Chem B* 111:5731-5739, 2007
1504. Madsen KM, Hasholt L, Sorensen SA, Van LA, Vanholder R: The utility of single-strand conformation polymorphism (SSCP) analysis: results obtained in families with Fabry's disease. *Scand J Clin Lab Invest* 56:177-182, 1996
1505. Magez S, Truyens C, Merimi M, Radwanska M, Stijlemans B, Brouckaert P, Brombacher F, Pays E, De BP: P75 tumor necrosis factor-receptor shedding occurs as a protective host response during African trypanosomiasis. *J Infect Dis* 189:527-539, 2004
1506. Mahjoub Y, Lorne E, Maizel J, Plantevefe G, Massy ZA, Dupont H, Slama M: Effect of intra-abdominal hypertension on left ventricular relaxation: A preliminary animal study. *Br J Anaesth* 108:211-215, 2012
1507. Mahjoub Y, Lorne E, Maizel J, Plantevefe G, Massy ZA, Dupont H, Slama M: Effect of intra-abdominal hypertension on left ventricular relaxation: A preliminary animal study. *Br J Anaesth* 2012;108:211-215.
1508. Mai S, Hanley-Hyde J, Rainey GJ, Kuschak TI, Paul JT, Littlewood TD, Mischak H, Stevens LM, Henderson DW, Mushinski JF: Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression. *Neoplasia* 1:241-252, 1999
1509. Maillard A, Domanski M, Brunet P, Chaffotte A, Guittet E, Gaudin Y: Spectroscopic characterization of two peptides derived from the stem of rabies virus glycoprotein. *Virus Res* 93:151-158, 2003
1510. Maizel J, Airapetian N, Lorne E, Tribouilloy C, Massy Z, Slama M: Diagnosis of central hypovolemia by using passive leg raising. *Intensive Care Med* 33:1133-1138, 2007
1511. Makhlin J, Kofman T, Borovok I, Kohler C, Engelmann S, Cohen G, Aharonowitz Y: Staphylococcus aureus ArcR controls expression of the arginine deiminase operon. *J Bacteriol* 189:5976-5986, 2007
1512. Malm J, Kristensen B, Stegmayr B, Fagerlund M, Koskinen LO: Three-year survival and functional outcome of patients with idiopathic adult hydrocephalus syndrome. *Neurology* 55:576-578, 2000
1513. Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, Horl WH, Mattin C, Praml C, Wilkie M: Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. *Clin Nephrol* 67:140-148, 2007
1514. Mannstadt M, Touam M, Fink E, Urena P, Hruby M, Zingraff J, Uhlenbusch-Korwer I, Grassmann A, Lemke HD, Druke TB: No generation of bradykinin with a new polyacrylonitrile membrane (SPAN) in haemodialysis patients treated with ACE inhibitors. *Nephrol Dial Transplant* 10:1696-1700, 1995

1515. Mannstadt M, Druke TB: [Parathyroid hormone receptors: from cloning to physiological, physiopathological and clinical implications]. *Nephrologie* 18:5-10, 1997
1516. Marchlewska A, Stenvinkel P, Lindholm B, Danielsson A, Pecoits-Filho R, Lonnqvist F, Schalling M, Heimbürger O, Nordfors L: Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. *Kidney Int* 66:46-50, 2004
1517. Marescau B, De Deyn PP, Holvoet J, Possemiers I, Nagels G, Saxena V, Mahler C: Guanidino compounds in serum and urine of cirrhotic patients. *Metabolism* 44:584-588, 1995
1518. Marescau B, Nagels G, Possemiers I, De Broe ME, Becaus I, Billioux JM, Lornoy W, De Deyn PP: Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. *Metabolism* 46:1024-1031, 1997
1519. Margetts PJ, Gyorffy S, Kolb M, Yu L, Hoff CM, Holmes CJ, Gauldie J: Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. *J Am Soc Nephrol* 13:721-728, 2002
1520. Mariano F, Fonsato V, Lanfranco G, Pohlmeier R, Ronco C, Triolo G, Camussi G, Tetta C, Passlick-Deetjen J: Tailoring high-cut-off membranes and feasible application in sepsis-associated acute renal failure: in vitro studies. *Nephrol Dial Transplant* 20:1116-1126, 2005
1521. Marien P, Saerens J, Nanhoe R, Moens E, Nagels G, Pickut BA, Dierckx RA, De Deyn PP: Cerebellar induced aphasia: case report of cerebellar induced prefrontal aphasic language phenomena supported by SPECT findings. *J Neurol Sci* 144:34-43, 1996
1522. Marien P, Mampaey E, Vervaeke A, Saerens J, De Deyn PP: Normative data for the Boston naming test in native Dutch-speaking Belgian elderly. *Brain Lang* 65:447-467, 1998
1523. Marien P, Engelborghs S, De Deyn PP: Cerebellar neurocognition: a new avenue. *Acta Neurol Belg* 101:96-109, 2001
1524. Marien P, Engelborghs S, Fabbro F, De Deyn PP: The lateralized linguistic cerebellum: a review and a new hypothesis. *Brain Lang* 79:580-600, 2001
1525. Marien P, Pickut BA, Engelborghs S, Martin JJ, De Deyn PP: Phonological agraphia following a focal anterior insulo-opercular infarction. *Neuropsychologia* 39:845-855, 2001
1526. Marien P, Engelborghs S, Vignolo LA, De Deyn PP: The many faces of crossed aphasia in dextrals: report of nine cases and review of the literature. *Eur J Neurol* 8:643-658, 2001
1527. Marien P, Engelborghs S, Paquier P, De Deyn PP: Anomalous cerebral language organization: acquired crossed aphasia in a dextral child. *Brain Lang* 76:145-157, 2001
1528. Marien P, Paquier P, Engelborghs S, De Deyn PP: Acquired crossed aphasia in dextral children revisited. *Brain Lang* 79:426-443, 2001
1529. Marien P, Paghera B, De Deyn PP, Vignolo LA: Adult crossed aphasia in dextrals revisited. *Cortex* 40:41-74, 2004
1530. Marien P, Abutalebi J, Engelborghs S, De Deyn PP: Pathophysiology of language switching and mixing in an early bilingual child with subcortical aphasia. *Neurocase* 11:385-398, 2005
1531. Marien P, Verhoeven J, Engelborghs S, Rooker S, Pickut BA, De Deyn PP: A role for the cerebellum in motor speech planning: evidence from foreign accent syndrome. *Clin Neurol Neurosurg* 108:518-522, 2006
1532. Marien P, Verhoeven J, Brouns R, De WL, Dobbeleir A, De Deyn PP: Apraxic agraphia following a right cerebellar hemorrhage. *Neurology* 69:926-929, 2007
1533. Markowski J, Gierek T, Wiecek A, Klimek D, Chudek J: [Assessment of hearing organ ability in high-frequency auditory in patients suffering from chronic renal failure treated by haemodialysis and human recombinant erythropoietin (rhPEO)]. *Otolaryngol Pol* 56:589-596, 2002
1534. Martinka P, Lai EY, Fahling M, Jankowski V, Jankowski J, Schubert R, Gaestel M, Persson AE, Persson PB, Patzak A: Adenosine increases calcium sensitivity via receptor-independent activation of the p38/mk2 pathway in mesenteric arteries. *Acta Physiol (Oxf)* 193:37-46, 2008
1535. Martinka P, Lai EY, Fahling M, Jankowski V, Jankowski J, Schubert R, Gaestel M, Persson AE, Persson PB, Patzak A: Adenosine increases calcium sensitivity via receptor-independent activation of the p38/mk2 pathway in mesenteric arteries. *Acta Physiol (Oxf)* 2008:193:37-46.
1536. Martins C, Mazza do NM, Pecoits-Filho R, Leinig C, Goncalves LF, Fuerbringer R, Stenvinkel P, Lindholm B, Riella MC: Insulin resistance is associated with circulating fibrinogen levels in nondiabetic patients receiving peritoneal dialysis. *J Ren Nutr* 17:132-137, 2007
1537. Martola L, Elinder CG, Stenvinkel P: [Why do patients with kidney balance and chronic inflammation important causes]. *Lakartidningen* 100:4180-4183, 2003
1538. Martola L, Barany P, Stenvinkel P: Why do dialysis patients develop a heart of stone and bone of china? *Blood Purif* 23:203-210, 2005
1539. Maruyama Y, Lindholm B, Stenvinkel P: Inflammation and oxidative stress in ESRD--the role of myeloperoxidase. *J Nephrol* 17 Suppl 8:S72-S76, 2004
1540. Maruyama Y, Nordfors L, Stenvinkel P, Heimbürger O, Barany P, Pecoits-Filho R, Axelsson J, Hoff CM, Holmes CJ, Schalling M, Lindholm B: Interleukin-1 gene cluster polymorphisms are associated with nutritional status and inflammation in patients with end-stage renal disease. *Blood Purif* 23:384-393, 2005
1541. Maruyama Y, Stenvinkel P, Lindholm B: Role of interleukin-1beta in the development of malnutrition in chronic renal failure patients. *Blood Purif* 23:275-281, 2005
1542. Masin-Spasovska J, Spasovski G, Polenakovic M, Dzizkova S, Petrusevska G, Dimova B, Lekovski L, Popov Z, Ivanovski N: Chronic allograft nephropathy (CAN) in early renal protocol biopsies: does treatment of borderline and subclinical acute rejections prevent development and progression of CAN? *Prilozi* 26:91-103, 2005
1543. Masin-Spasovska J, Spasovski G, Dzizkova S, Petrusevska G, Dimova B, Lekovski L, Popov Z, Ivanovski N, Polenakovic M: The evolution of untreated borderline and subclinical rejections at first month kidney allograft biopsy in comparison with histological changes at 6 months protocol biopsies. *Prilozi* 26:25-33, 2005
1544. Masin-Spasovska J, Spasovski G, Dzizkova S, Grcevska L, Petrusevska G, Lekovski L, Popov Z, Ivanovski N: Protocol biopsies in kidney transplant recipients: histologic findings as prognostic markers for graft function and outcome. *Transplant Proc* 37:705-708, 2005
1545. Masin-Spasovska J, Spasovski G, Dzizkova S, Petrusevska G, Lekovski L, Ivanovski N, Popov Z: Do we have to treat subclinical rejections in early protocol renal allograft biopsies? *Transplant Proc* 39:2550-2553, 2007
1546. Massy ZA, Guijarro C, Kasiske BL: Clinical predictors of chronic renal allograft rejection. *Kidney Int Suppl* 52:S85-S88, 1995
1547. Massy ZA, Guijarro C, Kasiske BL: Effect of fenofibrates in heart transplant patients. *Transplantation* 59:451-452, 1995
1548. Massy ZA, Ma JZ, Louis TA, Kasiske BL: Lipid-lowering therapy in patients with renal disease. *Kidney Int* 48:188-198, 1995
1549. Massy ZA, Kasiske BL: Hyperlipidemia and its management in renal disease. *Curr Opin Nephrol Hypertens* 5:141-146, 1996

1550. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL: Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. *Kidney Int* 49:518-524, 1996
1551. Massy ZA: Hyperhomocyst(e)inaemia in renal failure--what are the implications? *Nephrol Dial Transplant* 11:2392-2393, 1996
1552. Massy ZA, Kasiske BL: Post-transplant hyperlipidemia: mechanisms and management. *J Am Soc Nephrol* 7:971-977, 1996
1553. Massy ZA, Keane WF: Pathogenesis of atherosclerosis. *Semin Nephrol* 16:12-20, 1996
1554. Massy ZA, Drueke T, Kreis H, Lacour B: Serum lipoprotein (a) levels in renal transplantation: role of renal function. *Nephron* 73:718-719, 1996
1555. Massy ZA, Keane WF, Kasiske BL: Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? *Lancet* 347:102-103, 1996
1556. Massy ZA, Guijarro C, O'Donnell MP, Kasiske BL, Keane WF: Lipids, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, and progression of renal failure. *Adv Nephrol Necker Hosp* 27:39-56, 1997
1557. Massy ZA, Guijarro C, O'Donnell MP, Kasiske BL, Keane WF: Regulation of mesangial cell proliferation by the mevalonate pathway. *Contrib Nephrol* 120:191-196, 1997
1558. Massy ZA, Guijarro C, Oda H, Kasiske BL, Keane WF, O'Donnell MP: Importance of geranylgeranyl pyrophosphate for mesangial cell DNA synthesis. *Kidney Int Suppl* 71:S80-S83, 1999
1559. Massy ZA, Nguyen KT, Lacour B, scamps-Latscha B, Man NK, Jungers P: Dyslipidaemia and the progression of renal disease in chronic renal failure patients. *Nephrol Dial Transplant* 14:2392-2397, 1999
1560. Massy ZA, Nguyen KT, Lacour B, scamps-Latscha B, Man NK, Jungers P: Dyslipidaemia and the progression of renal disease in chronic renal failure patients. *Nephrol Dial Transplant* 14:2392-2397, 1999
1561. Massy ZA: Reversal of hyperhomocyst(e)inaemia in chronic renal failure-is folic or folinic acid the answer? *Nephrol Dial Transplant* 14:2810-2812, 1999
1562. Massy ZA, Guijarro C, O'Donnell MP, Kim Y, Kashtan CE, Egido J, Kasiske BL, Keane WF: The central role of nuclear factor-kappa B in mesangial cell activation. *Kidney Int Suppl* 71:S76-S79, 1999
1563. Massy ZA, De Bandt JP, Morelon E, Thevenin M, Lacour B, Kreis H: Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A. *Nephrol Dial Transplant* 15:928, 2000
1564. Massy ZA, Drueke TB, Kreis H: Carotid atherosclerosis in renal transplant recipients. *Transplantation* 69:457, 2000
1565. Massy ZA, Kim Y, Guijarro C, Kasiske BL, Keane WF, O'Donnell MP: Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. *Biochem Biophys Res Commun* 267:536-540, 2000
1566. Massy ZA: Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients. *Nephrol Dial Transplant* 15 Suppl 5:81-91, 2000
1567. Massy ZA: Hyperlipidemia and cardiovascular disease after organ transplantation. *Transplantation* 72:S13-S15, 2001
1568. Massy ZA, Kandoussi AM, Mamzer-Bruneel MF, Kreis H, Drueke T, Lacour B: High serum apolipoprotein AIV levels in renal transplant recipients. *Clin Nephrol* 55:156-158, 2001
1569. Massy ZA, Swan SK: Cyclooxygenase-2 and atherosclerosis: friend or foe? *Nephrol Dial Transplant* 16:2286-2289, 2001
1570. Massy ZA, Guijarro C: Statins: effects beyond cholesterol lowering. *Nephrol Dial Transplant* 16:1738-1741, 2001
1571. Massy ZA: Cardiovascular risk factors in kidney transplantation. *Curr Opin Urol* 11:139-142, 2001
1572. Massy ZA, Ceballos I, Chadefaux-Vekemens B, Nguyen-Khoa T, scamps-Latscha B, Drueke TB, Jungers P: Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients. *Kidney Int Suppl* 78:S243-S245, 2001
1573. Massy ZA, Nguyen-Khoa T: Oxidative stress and chronic renal failure: markers and management. *J Nephrol* 15:336-341, 2002
1574. Massy ZA: Potential strategies to normalize the levels of homocysteine in chronic renal failure patients. *Kidney Int Suppl* S134-S136, 2003
1575. Massy ZA, Choukroun G: [Management of micro-inflammation in uremia]. *Nephrologie* 24:415-417, 2003
1576. Massy ZA, Borderie D, Nguyen-Khoa T, Drueke TB, Ekindjian OG, Lacour B: Increased plasma S-nitrosothiol levels in chronic haemodialysis patients. *Nephrol Dial Transplant* 18:153-157, 2003
1577. Massy ZA, Andrejak M: [The interest of statins in nephrology]. *Presse Med* 33:1207-1212, 2004
1578. Massy ZA, Fumeron C, Borderie D, Tuppin P, Nguyen-Khoa T, Benoit MO, Jacquot C, Buisson C, Drueke TB, Ekindjian OG, Lacour B, Iliou MC: Increased plasma S-nitrosothiol concentrations predict cardiovascular outcomes among patients with end-stage renal disease: a prospective study. *J Am Soc Nephrol* 15:470-476, 2004
1579. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, Phan O, Daudon M, Lacour B, Drueke TB, Muntzel MS: Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. *J Am Soc Nephrol* 16:109-116, 2005
1580. Massy ZA, Taupin P, Jungers P, Landais P: Prediction model of coronary heart disease in patients with chronic kidney disease: role of plasma fibrinogen as a new prognostic variable. *Prilozi* 26:63-77, 2005
1581. Massy ZA, Maziere C, Kamel S, Brazier M, Choukroun G, Tribouilloy C, Slama M, Andrejak M, Maziere JC: Impact of inflammation and oxidative stress on vascular calcifications in chronic kidney disease. *Pediatr Nephrol* 20:380-382, 2005
1582. Massy ZA: Therapy of hyperhomocysteinemia in chronic kidney disease. *Semin Nephrol* 26:24-27, 2006
1583. Massy ZA, Andrejak M: [Management of dyslipidemia in diabetic CKD patients]. *Nephrol Ther* 2 Suppl 1:S49-S52, 2006
1584. Massy ZA: [Nephrologie & Therapeutique in 2007: innovations but in continuity.]. *Nephrol Ther* 3:1-2, 2007
1585. Massy ZA, Slama M, Tribouilloy C, Drueke TB: Animal models-what they can tell us about vascular calcification in CKD. *Semin Dial* 20:110-112, 2007
1586. Massy ZA, Drueke TB, Romet M: [parathyroid hormone, a simple hormone or uremic toxin?]. *Nephrol Ther* 7:H1-4, 2011
1587. Massy ZA, Drueke TB, Romet M: [parathyroid hormone, a simple hormone or uremic toxin?]. *Nephrol Ther* 2011;7:H1-4.



1588. Massy ZA, Stenvinkel P, Druke TB: The role of oxidative stress in chronic kidney disease. *Semin Dial* 2009;22:405-408.
1589. Mathivanan S, Ahmed M, Ahn NG, Alexandre H, Amanchy R, Andrews PC, Bader JS, Balgley BM, Bantscheff M, Bennett KL, Bjorling E, Blagoev B, Bose R, Brahmachari SK, Burlingame AS, Bustelo XR, Cagnay G, Cantin GT, Cardasis HL, Celis JE, Chaerkady R, Chu F, Cole PA, Costello CE, Cotter RJ, Crockett D, DeLany JP, De Marzo AM, DeSouza LV, Deutsch EW, Dransfield E, Drewes G, Droit A, Dunn MJ, Elenitoba-Johnson K, Ewing RM, Van EJ, Faca V, Falkner J, Fang X, Fenselau C, Figeys D, Gagne P, Gelfi C, Gevaert K, Gimble JM, Gnad F, Goel R, Gromov P, Hanash SM, Hancock WS, Harsha HC, Hart G, Hays F, He F, Hebbar P, Helsens K, Hermeking H, Hide W, Hjerno K, Hochstrasser DF, Hofmann O, Horn DM, Hruban RH, Ibarrola N, James P, Jensen ON, Jensen PH, Jung P, Kandasamy K, Kheterpal I, Kikuno RF, Korf U, Korner R, Kuster B, Kwon MS, Lee HJ, Lee YJ, Lefevre M, Lehvastaiho M, Lescuyer P, Levander F, Lim MS, Lobke C, Loo JA, Mann M, Martens L, Martinez-Heredia J, McComb M, McRedmond J, Mehrle A, Menon R, Miller CA, Mischak H, Mohan SS, Mohmood R, Molina H, Moran MF, Morgan JD, Moritz R, Morzel M, Muddiman DC, Nalli A, Navarro JD, Neubert TA, Ohara O, Oliva R, Omenn GS, Oyama M, Paik YK, Pennington K, Pepperkok R, Periaswamy B, Petricoin EF, Poirier GG, Prasad TS, Purvine SO, Rahiman BA, Ramachandran P, Ramachandra YL, Rice RH, Rick J, Ronnholm RH, Salonen J, Sanchez JC, Sayd T, Seshi B, Shankari K, Sheng SJ, Shetty V, Shivakumar K, Simpson RJ, Sirdeshmukh R, Siu KW, Smith JC, Smith RD, States DJ, Sugano S, Sullivan M, Superti-Furga G, Takatalo M, Thongboonkerd V, Trinidad JC, Uhlen M, Vandekerckhove J, Vasilescu J, Veenstra TD, Vidal-Taboada JM, Vihinen M, Wait R, Wang X, Wiemann S, Wu B, Xu T, Yates JR, Zhong J, Zhou M, Zhu Y, Zurbig P, Pandey A: Human Proteinpedia enables sharing of human protein data. *Nat Biotechnol* 26:164-167, 2008
1590. Matsubara K, Stenvinkel P, Qureshi AR, Carrero JJ, Axelsson J, Heimbürger O, Barany P, Alvestrand A, Lindholm B, Suliman ME: Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. *J Nephrol* 2009;22:774-782.
1591. Matzner U, Schestag F, Hartmann D, Lullmann-Rauch R, D'Hooge R, De Deyn PP, Gieselmann V: Bone marrow stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type cells. *Hum Gene Ther* 12:1021-1033, 2001
1592. Matzner U, Hartmann D, Lullmann-Rauch R, Coenen R, Rothert F, Mansson JE, Fredman P, D'Hooge R, De Deyn PP, Gieselmann V: Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations. *Gene Ther* 9:53-63, 2002
1593. Maucher C, Weissinger EM, Kremmer E, Baccharini M, Procyk K, Henderson DW, Wolf L, Kolch W, Kaspers B, Mushinski JF, Mischak H: Activation of bcl-2 suppressible 40 and 44 kDa p38-like kinases during apoptosis of early and late B lymphocytic cell lines. *FEBS Lett* 427:29-35, 1998
1594. Mayer G, Horl WH: Cardiovascular effects of increasing hemoglobin in chronic renal failure. *Am J Nephrol* 16:263-267, 1996
1595. Maziere C, Morliere P, Massy Z, Kamel S, Louandre C, Conte MA, Maziere JC: Oxidized low-density lipoprotein elicits an intracellular calcium rise and increases the binding activity of the transcription factor NFAT. *Free Radic Biol Med* 38:472-480, 2005
1596. McCarron DA, Druke TB: Calcium and hypertension. Introduction. *Semin Nephrol* 15:489, 1995
1597. McGregor SJ, Topley N, Jorres A, Speekenbrink AB, Gordon A, Gahl GM, Junor BJ, Briggs JD, Brock JH: Longitudinal evaluation of peritoneal macrophage function and activation during CAPD: maturity, cytokine synthesis and arachidonic acid metabolism. *Kidney Int* 49:525-533, 1996
1598. McWalter GK, Higgins LG, McLellan LI, Henderson CJ, Song L, Thornalley PJ, Itoh K, Yamamoto M, Hayes JD: Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. *J Nutr* 134:3499S-3506S, 2004
1599. Medetognon-Benissan J, Tardivel S, Hennequin C, Daudon M, Druke T, Lacour B: Inhibitory effect of bikunin on calcium oxalate crystallization in vitro and urinary bikunin decrease in renal stone formers. *Urol Res* 27:69-75, 1999
1600. Meert N, Schepers E, De SR, Argiles A, Cohen G, Deppisch R, Druke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R: Inconsistency of reported uremic toxin concentrations. *Artif Organs* 31:600-611, 2007
1601. Meert N, Schepers E, Glorieux G, Van Landschoot M, Goeman JL, Waterloos MA, Dhondt A, Van der Eycken J, Vanholder R: Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: Clinical data and pathophysiological implications. *Nephrol Dial Transplant* 2011
1602. Meert N, Eloot S, Schepers E, Lemke HD, Dhondt A, Glorieux G, Van Landschoot M, Waterloos MA, Vanholder R: Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. *Nephrol Dial Transplant* 26:2624-2630 2011
1603. Meert N, Eloot S, Schepers E, Lemke HD, Dhondt A, Glorieux G, Van Landschoot M, Waterloos MA, Vanholder R: Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. *Nephrol Dial Transplant* 2011;26:2624-2630.
1604. Meert N, Schepers E, Glorieux G, Van Landschoot M, Goeman JL, Waterloos MA, Dhondt A, Van der Eycken J, Vanholder R: Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: Clinical data and pathophysiological implications. *Nephrol Dial Transplant* 2011
1605. Meier M, Kaiser T, Herrmann A, Knueppel S, Hillmann M, Koester P, Danne T, Haller H, Fliser D, Mischak H: Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. *J Diabetes Complications* 19:223-232, 2005
1606. Meier P, von F, V, Markert M, van MG, Deppisch R, Wauters JP: One-year immunological evaluation of chronic hemodialysis in end-stage renal disease patients. *Blood Purif* 18:128-137, 2000
1607. Meissner C, Deppisch R, Hug F, Schulze M, Ritz E, Ludwig H, Hansch G: L-fucose residues on cellulose-based dialysis membranes: quantification of membrane-associated L-fucose and analysis of specific lectin binding. *Glycoconj J* 12:632-638, 1995
1608. Menne J, Fliser D, Haller H: [Kidney and hypertension]. *Herz* 31:317-321, 2006
1609. Menne J, Park JK, Agrawal R, Lindschau C, Kielstein JT, Kirsch T, Marx A, Müller D, Bahlmann FH, Meier M, Bode-Boger SM, Haller H, Fliser D: Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. *FASEB J* 20:994-996, 2006
1610. Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D: The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. *J Am Soc Nephrol* 18:2046-2053, 2007
1611. Mercer AE, Maggs JL, Sun XM, Cohen GM, Chadwick J, O'Neill PM, Park BK: Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. *J Biol Chem* 282:9372-9382, 2007
1612. Merhige ME, Breen WJ, Shelton V, Houston T, D'Arcy BJ, Perna AF: Impact of myocardial perfusion imaging with PET and (82)Rb on downstream invasive procedure utilization, costs, and outcomes in coronary disease management. *J Nucl Med* 48:1069-1076, 2007

1613. Mesjasz J, Wiecek A, Gonciarz Z, Mazur W, Kokot F: [Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?]. *Pol Merkur Lekarski* 16:362-367, 2004
1614. Messner T, Lundberg V, Stegmayr B: Cardiovascular risk factor levels differ between communities of different sizes in the Northern Sweden MONICA Project. *Scand J Public Health* 31:359-366, 2003
1615. Mingrone G, De SR, Greco AV, Bertuzzi A, Gandolfi A, Ringoir S, Vanholder R: Serum uremic toxins from patients with chronic renal failure displace the binding of L-tryptophan to human serum albumin. *Clin Chim Acta* 260:27-34, 1997
1616. Minhas HS, Thornalley PJ: Reduced glutathione esters--antidotes to toxicity. Cytotoxicity induced by hydrogen peroxide, 1-chloro-2,4-dinitrobenzene, and menadione in murine P388D1 macrophages in vitro. *J Biochem Toxicol* 10:245-250, 1995
1617. Minhas HS, Thornalley PJ: Comparison of the delivery of reduced glutathione into P388D1 cells by reduced glutathione and its mono-and diethyl ester derivatives. *Biochem Pharmacol* 49:1475-1482, 1995
1618. Mischak H, Seitz T, Janosch P, Eulitz M, Steen H, Schellerer M, Philipp A, Kolch W: Negative regulation of Raf-1 by phosphorylation of serine 621. *Mol Cell Biol* 16:5409-5418, 1996
1619. Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, Knueppel S, Haller H, Fliser D: Proteomic analysis for the assessment of diabetic renal damage in humans. *Clin Sci (Lond)* 107:485-495, 2004
1620. Mischak H, Julian BA, Novak J: High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine. *Proteomics Clin Appl* 1:792-804, 2007
1621. Mischak H, Apweiler R, Banks RE, Conaway M, Coon JJ, Dominzak A, Ehrlich JH, Fliser D, Girolami M, Hermjakob H, Hochstrasser DF, Jankowski V, Julian BA, Kolch W, Massy Z, Neususs C, Novak J, Peter K, Rossing K, Schanstra JP, Semmes OJ, Theodorescu D, Thongboonkerd V, Weissinger EM, Van Eyk JE, Yamamoto T: Clinical Proteomics: a need to define the field and to begin to set adequate standards. *PROTEOMICS -Clinical Applications* 1:148-156, 2007
1622. Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A, Dylag T, Ehrlich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung HY, Maahs D, Magni F, Manns MP, Manolis E, Mayer G, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP, Vlahou A: Implementation of proteomic biomarkers: Making it work. *Eur J Clin Invest* 2012
1623. Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A, Dylag T, Ehrlich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung HY, Maahs D, Magni F, Manns MP, Manolis E, Mayer G, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP, Vlahou A: Implementation of proteomic biomarkers: Making it work. *Eur J Clin Invest* 2012
1624. Mittermayer F, Schaller G, Pleiner J, Vychytil A, Sunder-Plassmann G, Horl WH, Wolzt M: Asymmetrical dimethylarginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilation of resistance arteries in peritoneal dialysis patients. *J Am Soc Nephrol* 16:1832-1838, 2005
1625. Moal V, Brunet P, Dou L, Morange S, Sampol J, Berland Y: Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. *Nephrol Dial Transplant* 18:1834-1841, 2003
1626. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 69:1945-1953, 2006
1627. Moe SM, Drueke TB: Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. *Am J Nephrol* 23:369-379, 2003
1628. Moe SM, Drueke TB: A bridge to improving healthcare outcomes and quality of life. *Am J Kidney Dis* 43:552-557, 2004
1629. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCarty LC, Olson KA, Turner SA, Martin KJ: Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. *Kidney Int* 67:760-771, 2005
1630. Moe SM, Drueke T, Lameire N, Eknoyan G: Chronic kidney disease-mineral-bone disorder: a new paradigm. *Adv Chronic Kidney Dis* 14:3-12, 2007
1631. Mogren I, Hogberg U, Stegmayr B, Lindahl B, Stenlund H: Fetal exposure, heredity and risk indicators for cardiovascular disease in a Swedish welfare cohort. *Int J Epidemiol* 30:853-862, 2001
1632. Mohr E, Mendis T, Hildebrand K, De Deyn PP: Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. *Mov Disord* 15:1230-1237, 2000
1633. Mohr E, Hildebrand K, Mendis T, De Deyn PP: Worsening of motor function in Parkinson's disease: a "typical" response to "atypical" antipsychotic medications. *Neurology* 56:1249-1250, 2001
1634. Mohrbach J, Janssen MW, Heine GH, Gartner BC, Fliser D, Sester M, Sester U: Successful outcome of kidney transplantation from a hbv-DNA positive donor into recipients with cleared hbv-infection using a pre-emptive therapy approach. *J Clin Virol* 2010;49:53-57.
1635. Molanaei H, Carrero JJ, Heimbürger O, Nordfors L, Lindholm B, Stenvinkel P, Odar-Cederlöf I, Bertilsson L: Influence of the cyp2d6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. *Eur J Clin Pharmacol* 2009;66:269-273.
1636. Molino D, De LD, Perna AF, Cirillo M, De Santo NG: Thrombosis of vascular access associated with factor V Leiden, antiphospholipid antibodies and antiheparin antibodies in a young woman on dialysis receiving warfarin following mitral valve replacement. *Nephrol Dial Transplant* 21:1719-1720, 2006
1637. Monge M, Shahapuni I, Harbouche L, Moriniere P, Esper NE, Massy Z, Choukroun G, Fournier A: Cinacalcet and vascular calcifications induced by calcitriol. *Nephrol Dial Transplant* 21:551-552, 2006
1638. Monge M, Shahapuni I, Oprisiu R, El EN, Moriniere P, Massy Z, Choukroun G, Fournier A: Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients. *Nat Clin Pract Nephrol* 2:326-336, 2006
1639. Monge M, Massy ZA, van Zonneveld AJ, Rabelink TJ: [endothelial progenitor cells: What are we talking about?]. *Nephrol Ther* 7:521-525 2011
1640. Monge M, Massy ZA, van Zonneveld AJ, Rabelink TJ: [endothelial progenitor cells: What are we talking about?]. *Nephrol Ther* 2011;7:521-525.
1641. Monti JP, Brunet PJ, Berland YF, Vanuxem DC, Vanuxem PA, Crevat AD: Opposite effects of urea on hemoglobin-oxygen affinity in anemia of chronic renal failure. *Kidney Int* 48:827-831, 1995
1642. Moote T, Eriksson P, Stegmayr B: Ischemic stroke after acute myocardial infarction. A population-based study. *Stroke* 28:762-767, 1997

1643. Mooe T, Olofsson BO, Stegmayr B, Eriksson P: Ischemic stroke. Impact of a recent myocardial infarction. *Stroke* 30:997-1001, 1999
1644. Morawetz R, Lendenfeld T, Mischak H, Muhlbauer M, Gruber F, Goodnight J, de Graaff LH, Visser J, Mushinski JF, Kubicek CP: Cloning and characterisation of genes (*pkc1* and *pkcA*) encoding protein kinase C homologues from *Trichoderma reesei* and *Aspergillus niger*. *Mol Gen Genet* 250:17-28, 1996
1645. Morgera S, Heering P, Szentandrasei T, Manassa E, Heintzen M, Willers R, Passlick-Deetjen J, Grabensee B: Comparison of a lactate-versus acetate-based hemofiltration replacement fluid in patients with acute renal failure. *Ren Fail* 19:155-164, 1997
1646. Mortelmans AK, Duym P, Vandenbroucke J, De SR, Dhondt A, Lesaffer G, Verwimp H, Vanholder R: Intradialytic parenteral nutrition in malnourished hemodialysis patients: a prospective long-term study. *JPEN J Parenter Enteral Nutr* 23:90-95, 1999
1647. Mortelmans AK, Vanholder R: Intradialytic parenteral nutrition in malnourished hemodialysis patients. Review of the literature. *Miner Electrolyte Metab* 25:324-332, 1999
1648. Mortier S, De Vriese AS, Van d, V, Schaub TP, Passlick-Deetjen J, Lameire NH: Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. *J Am Soc Nephrol* 13:480-489, 2002
1649. Mortier S, De Vriese AS, McLoughlin RM, Topley N, Schaub TP, Passlick-Deetjen J, Lameire NH: Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. *J Am Soc Nephrol* 14:1296-1306, 2003
1650. Mourad G, Argiles A, Vela C, Lorho R, Flavir JL, Canaud B, Mion CM: Control of severe hyperparathyroidism and regression of a brown tumour after treatment with i.v. alfacalcidol in a uraemic patient. *Nephrol Dial Transplant* 10:552-554, 1995
1651. Mourad G, Argiles A: Renal transplantation relieves the symptoms but does not reverse beta 2-microglobulin amyloidosis. *J Am Soc Nephrol* 7:798-804, 1996
1652. Mourad G, Deschodt G, Turc-Baron C, Kharrat M, Segnarbieux F, Blin D, Argiles A: The dialysis patient with cystic bone defects and spinal cord symptoms. *Nephrol Dial Transplant* 11:1870-1873, 1996
1653. Mozar A, Louvet L, Godin C, Mentaverri R, Brazier M, Kamel S, Massy ZA: Indoxyl sulphate inhibits osteoclast differentiation and function. *Nephrol Dial Transplant* 2011
1654. Mozar A, Louvet L, Morliere P, Godin C, Boudot C, Kamel S, Druke TB, Massy ZA: Uremic toxin indoxyl sulfate inhibits human vascular smooth muscle cell proliferation. *Ther Apher Dial* 15:135-139, 2011
1655. Mozar A, Louvet L, Godin C, Mentaverri R, Brazier M, Kamel S, Massy ZA: Indoxyl sulphate inhibits osteoclast differentiation and function. *Nephrol Dial Transplant* 2011
1656. Mozar A, Louvet L, Morliere P, Godin C, Boudot C, Kamel S, Druke TB, Massy ZA: Uremic toxin indoxyl sulfate inhibits human vascular smooth muscle cell proliferation. *Ther Apher Dial* 2011;15:135-139.
1657. Moreno JA, Izquierdo MC, Sanchez-Nino MD, Suarez-Alvarez B, Lopez-Larrea C, Jakubowski A, Blanco J, Ramirez R, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB: The inflammatory cytokines *tweak* and *tnfalpa* reduce renal *klotho* expression through *nfkappab*. *J Am Soc Nephrol* 2011;22:1315-1325.
1658. Moreno JA, Martin-Cleary C, Gutierrez E, Toldos O, Blanco-Colio LM, Praga M, Ortiz A, Egido J: Aki associated with macroscopic glomerular hematuria: Clinical and pathophysiologic consequences. *Clin J Am Soc Nephrol* 2011;7:175-184.
1659. Mujais S, Holmes C: Modern peritoneal dialysis: concepts and approaches. *Kidney Int Suppl*S1-S2, 2006
1660. Muller E, Baurmeister U: Preparation of and optimal module housings for hollow fibre membrane ion exchangers. *J Mol Recognit* 11:273-278, 1998
1661. Muller G, Storz P, Bourteele S, Doppler H, Pfizenmaier K, Mischak H, Philipp A, Kaiser C, Kolch W: Regulation of Raf-1 kinase by TNF via its second messenger ceramide and cross-talk with mitogenic signalling. *EMBO J* 17:732-742, 1998
1662. Munch G, Keis R, Wessels A, Riederer P, Bahner U, Heidland A, Niwa T, Lemke HD, Schinzel R: Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. *Eur J Clin Chem Clin Biochem* 35:669-677, 1997
1663. Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, Biour M, Massy Z: Zoledronic Acid and renal toxicity: data from French adverse effect reporting database. *Ann Pharmacother* 39:1194-1197, 2005
1664. Muntinghe FL, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, Qureshi AR, Luttropp K, Nordfors L, Lindholm B, Brandenburg V, Schalling M, Stenvinkel P, Boeschoten EW, Krediet RT, Navis G, Dekker FW: *Ccr5* deletion protects against inflammation-associated mortality in dialysis patients. *J Am Soc Nephrol* 2009;20:1641-1649.
1665. Muntzel MS, Malena H, Druke T: Inhibition of nitric oxide synthesis attenuates insulin-mediated sympathetic activation in rats. *J Hypertens* 19:1625-1631, 2001
1666. Nagels G, Marion P, Pickut BA, Timmermans L, De Deyn PP: Actigraphic evaluation of handedness. *Electroencephalogr Clin Neurophysiol* 101:226-232, 1996
1667. Nagels G, Okkerse W, Braem M, Van Bogaert PP, De DB, Poirrier R, De Deyn PP: Decreased amount of slow wave sleep in nocturnal bruxism is not improved by dental splint therapy. *Acta Neurol Belg* 101:152-159, 2001
1668. Nagels G, Geentjens L, Kos D, Vleugels L, D'hooghe MB, Van AP, Vuylsteke K, De Deyn PP: Paced visual serial addition test in multiple sclerosis. *Clin Neurol Neurosurg* 107:218-222, 2005
1669. Nagels G, Engelborghs S, Vloeberghs E, Van DD, Pickut BA, De Deyn PP: Actigraphic measurement of agitated behaviour in dementia. *Int J Geriatr Psychiatry* 21:388-393, 2006
1670. Nagels G, D'hooghe MB, Vleugels L, Kos D, Despontin M, De Deyn PP: P300 and treatment effect of modafinil on fatigue in multiple sclerosis. *J Clin Neurosci* 14:33-40, 2007
1671. Nagels G, Engelborghs S, Vloeberghs E, Lemmens W, Pickut BA, De Deyn PP: Correlation between actigraphy and nurses' observation of activity in dementia. *Int J Geriatr Psychiatry* 22:84-86, 2007
1672. Nagels G, D'hooghe MB, Kos D, Engelborghs S, De Deyn PP: Within-session practice effect on paced auditory serial addition test in multiple sclerosis. *Mult Scler* 14:106-111, 2008
1673. Nanci A, Wuest JD, Peru L, Brunet P, Sharma V, Zalzal S, McKee MD: Chemical modification of titanium surfaces for covalent attachment of biological molecules. *J Biomed Mater Res* 40:324-335, 1998
1674. Nangaku M, Fliser D: Erythropoiesis-stimulating agents: past and future. *Kidney Int Suppl*S1-S3, 2007
1675. Nappo F, De RN, Marfella R, De LD, Ingrosso D, Perna AF, Farzati B, Giugliano D: Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. *JAMA* 281:2113-2118, 1999

1676. Narayana A, Cohen GN, Zaider M, Chan K, Lee N, Wong RJ, Boyle J, Shaha A, Kraus D, Shah J, Zelefsky MJ: High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results. *Brachytherapy* 6:157-163, 2007
1677. Nascimento MM, Pecoits-Filho R, Lindholm B, Riella MC, Stenvinkel P: Inflammation, malnutrition and atherosclerosis in end-stage renal disease: a global perspective. *Blood Purif* 20:454-458, 2002
1678. Nascimento MM, Pecoits-Filho R, Qureshi AR, Hayashi SY, Manfro RC, Pachaly MA, Renner L, Stenvinkel P, Lindholm B, Riella MC: The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. *Nephrol Dial Transplant* 19:2803-2809, 2004
1679. Nascimento MM, Qureshi AR, Stenvinkel P, Pecoits-Filho R, Heimbürger O, Cederholm T, Lindholm B, Barany P: Malnutrition and inflammation are associated with impaired pulmonary function in patients with chronic kidney disease. *Nephrol Dial Transplant* 19:1823-1828, 2004
1680. Nascimento MM, Suliman ME, Bruchfeld A, Hayashi SY, Manfro RC, Qureshi AR, Pecoits-Filho R, Pachaly MA, Renner L, Stenvinkel P, Riella MC, Lindholm B: The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. *Nephrol Dial Transplant* 19:3112-3116, 2004
1681. Nascimento MM, Bruchfeld A, Suliman ME, Hayashi SY, Pecoits-Filho R, Manfro RC, Pachaly MA, Renner L, Stenvinkel P, Riella MC, Lindholm B: Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. *Braz J Med Biol Res* 38:783-788, 2005
1682. Nascimento MM, Suliman ME, Murayama Y, Nihi M, Hayashi SY, Stenvinkel P, Riella MC, Lindholm B: Effect of high-dose thiamine and pyridoxine on advanced glycation end products and other oxidative stress markers in hemodialysis patients: a randomized placebo-controlled study. *J Ren Nutr* 16:119-124, 2006
1683. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG: Lipoprotein lipase during continuous heparin infusion: tissue stores become partially depleted. *J Lab Clin Med* 138:206-213, 2001
1684. Nasstrom B, Olivecrona G, Olivecrona T, Stegmayr BG: Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. *Scand J Clin Lab Invest* 63:45-53, 2003
1685. Nasstrom B, Stegmayr BG, Olivecrona G, Olivecrona T: Lower plasma levels of lipoprotein lipase after infusion of low molecular weight heparin than after administration of conventional heparin indicate more rapid catabolism of the enzyme. *J Lab Clin Med* 142:90-99, 2003
1686. Nasstrom B, Stegmayr B, Olivecrona G, Olivecrona T: Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. *BMC Nephrol* 5:17, 2004
1687. Nasstrom B, Stegmayr B, Gupta J, Olivecrona G, Olivecrona T: A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. *Nephrol Dial Transplant* 20:1172-1179, 2005
1688. Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D, Stover DR, Dyer MJ, Cohen GM: TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. *Br J Haematol* 139:568-577, 2007
1689. Neiryck N, Eloot S, Glorieux G, Barreto DV, Barreto FC, Liabeuf S, Lenglet A, Lemke HD, Massy ZA, Vanholder R: Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease. *PLoS One* 2012;7:e44201.
1690. Neiryck N, Glorieux G, Boelaert J, Schepers E, Liabeuf S, Dhondt A, Massy Z, Vanholder R: Uremia-related oxidative stress in leukocytes is not triggered by beta2-microglobulin. *J Ren Nutr* 2013;23:456-463.
1691. Neiryck N, Glorieux G, Schepers E, Pletinck A, Dhondt A, Vanholder R: Review of protein-bound toxins, possibility for blood purification therapy. *Blood Purif* 2013;35 Suppl 1:45-50.
1692. Neuhoff N, Kaiser T, Wittke S, Krebs R, Pitt A, Burchard A, Sundmacher A, Schlegelberger B, Kolch W, Mischak H: Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. *Rapid Commun Mass Spectrom* 18:149-156, 2004
1693. Neumann UP, Kaisers U, Langrehr JM, Glanemann M, Müller AR, Lang M, Jorres A, Settmacher U, Bechstein WO, Neuhaus P: Administration of prostacyclin after liver transplantation: a placebo controlled randomized trial. *Clin Transplant* 14:70-74, 2000
1694. Newby LK, Bhapkar MV, White HD, Topol EJ, Dougherty FC, Harrington RA, Smith MC, Asarch LF, Califf RM: Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. *Eur Heart J* 24:172-181, 2003
1695. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, Canteloup S, Kebede M, Lacour B, Druke T, scamps-Latscha B: Oxidized low-density lipoprotein induces macrophage respiratory burst via its protein moiety: A novel pathway in atherogenesis? *Biochem Biophys Res Commun* 263:804-809, 1999
1696. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V, Thevenin M, Touam M, Lambrey G, Lacour B, Druke TB, scamps-Latscha B: Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients. *Kidney Int* 56:747-753, 1999
1697. Nguyen-Khoa T, scamps-Latscha B, Lacour B, Druke TB, Massy ZA: [Lipids, monocytes and progression of renal insufficiency]. *Nephrologie* 21:337-338, 2000
1698. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Druke TB, Lacour B, Thevenin M: Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. *Nephrol Dial Transplant* 16:335-340, 2001
1699. Nguyen TC, Stegmayr B, Busund R, Bunchman TE, Carcillo JA: Plasma therapies in thrombotic syndromes. *Int J Artif Organs* 28:459-465, 2005
1700. Niccoli P, Brunet P, Roubicek C, Roux F, Baudin E, Lejeune PJ, Berland Y, Conte-Devolx B: Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis. *Eur J Endocrinol* 132:75-81, 1995
1701. Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G, Jr., Thornalley PJ, Schleicher E, Wiedner T, Lang F: Stimulation of suicidal erythrocyte death by methylglyoxal. *Cell Physiol Biochem* 18:223-232, 2006
1702. Nieszporek T, Kokot F, Wiecek A, Marcinkowski W, Rudka R, erythropoietin on secretion of hormones regulating carbohydrate metabolism in hemodialyzed patients with chronic uremia]. *Pol Arch Med Wewn* 94:488-494, 1995
1703. Nieszporek T, Kokot F, Wiecek A, Marcinkowski W, Rudka R, Trembecki J: [Influence of long-term human recombinant erythropoietin treatment on secretion of pancreatic polypeptide and gastrin in hemodialysed patients with chronic renal failure]. *Przegl Lek* 52:590-593, 1995
1704. Nieszporek T, Witkovicz J, Nowak L, Chudek J, Wiecek A: Low plasma dehydroepiandrosterone sulfate level and its relationship to adiponectin in hemodialysis patients. *Ren Fail* 29:417-421, 2007

1705. Nikolov I, Joki N, Druke T, Massy Z: Beyond phosphate--role of uraemic toxins in cardiovascular calcification. *Nephrol Dial Transplant* 21:3354-3357, 2006
1706. Nikolov IG, Joki N, Maizel J, Lacour B, Druke TB, Massy ZA: Pleiotropic effects of the non-calcium phosphate binder sevelamer. *Kidney Int Suppl* 16-S23, 2006
1707. Nikolov IG, Joki N, Nguyen-Khoa T, Guerrero IC, Maizel J, Benchrir J, Machado dos Reis L, Edelman A, Lacour B, Jorgetti V, Druke TB, Massy ZA: Lanthanum carbonate, like sevelamer-hcl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein e-deficient mice. *Nephrol Dial Transplant* 27:505-513, 2012
1708. Nikolov IG, Joki N, Nguyen-Khoa T, Guerrero IC, Maizel J, Benchrir J, Machado dos Reis L, Edelman A, Lacour B, Jorgetti V, Druke TB, Massy ZA: Lanthanum carbonate, like sevelamer-hcl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein e-deficient mice. *Nephrol Dial Transplant* 2012;27:505-513.
1709. Nilsson-Ardnor S, Wiklund PG, Lindgren P, Nilsson AK, Janunger T, Escher SA, Hallbeck B, Stegmayr B, Asplund K, Holmberg D: Linkage of ischemic stroke to the PDE4D region on 5q in a Swedish population. *Stroke* 36:1666-1671, 2005
1710. Nilsson-Ardnor S, Janunger T, Wiklund PG, Lackovic K, Nilsson AK, Lindgren P, Escher SA, Stegmayr B, Asplund K, Holmberg D: Genome-wide linkage scan of common stroke in families from northern Sweden. *Stroke* 38:34-40, 2007
1711. Nilsson B, Holmgren L, Stegmayr B, Westman G: Sense of coherence--stability over time and relation to health, disease, and psychosocial changes in a general population: a longitudinal study. *Scand J Public Health* 31:297-304, 2003
1712. Nimmegeers S, Sips P, Buys E, Decaluwe K, Brouckaert P, Van d, V: Role of the soluble guanylyl cyclase alpha(1)-subunit in mice corpus cavernosum smooth muscle relaxation. *Int J Impot Res* 2007
1713. Nimmegeers S, Sips P, Buys E, Brouckaert P, Van d, V: Functional role of the soluble guanylyl cyclase alpha(1) subunit in vascular smooth muscle relaxation. *Cardiovasc Res* 76:149-159, 2007
1714. Nistri S, Cinci L, Perna AM, Masini E, Mastroianni R, Bani D: Relaxin induces mast cell inhibition and reduces ventricular arrhythmias in a swine model of acute myocardial infarction. *Pharmacol Res* 57:43-48, 2008
1715. Norda R, Stegmayr BG: Apheresis registry in Sweden: scope, techniques and indications for treatment. A report from the Swedish apheresis study group. *Transfus Apher Sci* 24:49-55, 2001
1716. Norda R, Berseus O, Stegmayr B: Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. *Transfus Apher Sci* 25:33-41, 2001
1717. Norda R, Stegmayr BG: Therapeutic apheresis in Sweden: update of epidemiology and adverse events. *Transfus Apher Sci* 29:159-166, 2003
1718. Norda R, Knutson F, Berseus O, Akerblom O, Nilsson-Ekdahl K, Stegmayr B, Nilsson B: Unexpected effects of donor gender on the storage of liquid plasma. *Vox Sang* 93:223-228, 2007
1719. Nordfors L, Lonnqvist F, Heimbürger O, Danielsson A, Schalling M, Stenvinkel P: Low leptin gene expression and hyperleptinemia in chronic renal failure. *Kidney Int* 54:1267-1275, 1998
1720. Nordfors L, Heimbürger O, Lonnqvist F, Lindholm B, Helmrich J, Schalling M, Stenvinkel P: Fat tissue accumulation during peritoneal dialysis is associated with a polymorphism in uncoupling protein 2. *Kidney Int* 57:1713-1719, 2000
1721. Nordfors L, Stenvinkel P, Marchlewska A, Weiss R, Heimbürger O, Bergstrom J, Lindholm B, Schalling M: Molecular genetics in renal medicine: what can we hope to achieve? *Nephrol Dial Transplant* 17 Suppl 3:5-11, 2002
1722. Nordfors L, Lindholm B, Stenvinkel P: End-stage renal disease--not an equal opportunity disease: the role of genetic polymorphisms. *J Intern Med* 258:1-12, 2005
1723. Nordin M, Knutsson A, Sundbom E, Stegmayr B: Psychosocial factors, gender, and sleep. *J Occup Health Psychol* 10:54-63, 2005
1724. Norrman S, Stegmayr B, Eriksson M, Hedback B, Burell G, Brulin C: Depressive mood after a cardiac event: gender inequality and participation in rehabilitation programme. *Eur J Cardiovasc Nurs* 3:295-302, 2004
1725. Novotny JR, Muller-Beissenhirtz H, Herget-Rosenthal S, Kribben A, Duhrsen U: Grading of symptoms in hyperleukocytic leukaemia: a clinical model for the role of different blast types and promyelocytes in the development of leukostasis syndrome. *Eur J Haematol* 74:501-510, 2005
1726. Nowak L, Adamczak M, Wiecek A: Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. *Am J Hypertens* 18:1470-1475, 2005
1727. Nowicki M, Wiecek A, Chudek J: [Imidazol receptor agonists--new possibilities for treating hypertension]. *Postepy Hig Med Dosw* 49:631-643, 1995
1728. Nowicki M, Fliser D, Fode P, Ritz E: Changes in plasma phosphate levels influence insulin sensitivity under euglycemic conditions. *J Clin Endocrinol Metab* 81:156-159, 1996
1729. Nowicki M, Kokot F, Wiecek A: Partial regression of advanced cyclosporin-induced gingival hyperplasia after treatment with azithromycin. A case report. *Ann Transplant* 3:25-27, 1998
1730. Obermaier C, Jankowski V, Schmutzler C, Bauer J, Wildgruber R, Infanger M, Kohrle J, Krause E, Weber G, Grimm D: Free-flow isoelectric focusing of proteins remaining in cell fragments following sonication of thyroid carcinoma cells. *Electrophoresis* 2005;26:2109-2116.
1731. O'Donnell MP, Kasiske BL, Massy ZA, Gujjarro C, Swan SK, Keane WF: Isoprenoids and Ras: potential role in chronic rejection. *Kidney Int Suppl* 52:S29-S33, 1995
1732. O'Donnell MP, Massy ZA, Gujjarro C, Kasiske BL, Kim Y, Keane WF: Isoprenoids, Ras and proliferative glomerular disease. *Contrib Nephrol* 120:219-227, 1997
1733. Oczko-Grzesik B, Wiecek A, Kokot F: Influence of IFN-alpha on plasma erythropoietin levels in patients with hepatitis B virus-associated chronic active hepatitis. *J Interferon Cytokine Res* 21:669-676, 2001
1734. Ohgren B, Weinehall L, Stegmayr B, Boman K, Hallmans G, Wall S: What else adds to hypertension in predicting stroke? An incident case-referent study. *J Intern Med* 248:475-482, 2000
1735. Okkerse W, Brebels A, De Deyn PP, Nagels G, De DB, Van Bogaert PP, Braem M: Influence of a bite-plane according to Jeanmonod, on bruxism activity during sleep. *J Oral Rehabil* 29:980-985, 2002
1736. Okkerse W, Brebels A, Spaepen AJ, Nagels G, Van Bogaert PP, De Deyn PP, Braem M: A new method for semiautomatic analysis of surface EMG in patients with oral parafunctions. *Cranio* 22:241-249, 2004
1737. Olaizola I, Zingraff J, Heuguerot C, Fajardo L, Leger A, Lopez J, Acuna G, Petraglia A, Alvarez A, Caorsi H, Druke T, Ambrosioni P: [(99m)Tc]-sestamibi parathyroid scintigraphy in chronic haemodialysis

- patients: static and dynamic explorations. *Nephrol Dial Transplant* 15:1201-1206, 2000
1738. Oppert M, Jorres A, Barckow D, Eckardt KU, Frei U, Kaisers U: Inhaled nitric oxide for ARDS due to sickle cell disease. *Swiss Med Wkly* 134:165-167, 2004
1739. Oppert M, Jorres A: Transfuse or not transfuse in acute renal failure? This is the question. *Intensive Care Med* 31:1469-1470, 2005
1740. Ortiz A, Massy ZA, Fliser D, Lindholm B, Wiecek A, Martinez-Castelao A, Covic A, Goldsmith D, Suleymanlar G, London GM, Zoccali C: Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. *Nat Rev Nephrol* 8:141-150, 2011
1741. Ortiz A, Massy ZA, Fliser D, Lindholm B, Wiecek A, Martinez-Castelao A, Covic A, Goldsmith D, Suleymanlar G, London GM, Zoccali C: Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. *Nat Rev Nephrol* 2011;8:141-150.
1742. Ortiz A, Sanchez-Nino MD, Izquierdo MC, Blanco-Colio LM, Selgas R, Ruiz-Ortega M, Egido J, Sanz AB: Tweak and the kidney: The dual role of a multifunctional cytokine. *Adv Exp Med Biol* 2010;691:323-335.
1743. Ortiz A, Sanchez-Nino MD, Sanz AB: The meaning of urinary creatinine concentration. *Kidney Int* 2011;79:791.
1744. Ostman PO, Anneroth G, Johansson I, Stegmayr B, Skoglund A: Life-style survey of patients with oral lichenoid reactions. *Acta Odontol Scand* 54:96-101, 1996
1745. Pajda M, Matug A, Widlak M, Antoniak K, Ficek R, Chudek J, Wiecek A: Influence of parathyroidectomy on blood pressure and function of the transplanted kidney in patients with tertiary hyperparathyroidism. *Ann Transplant* 11:11-15, 2006
1746. Pan JC, Pei YQ, An L, Lai L, D'Hooge R, De Deyn PP: Epileptiform activity and hippocampal damage produced by intrahippocampal injection of guanidinosuccinic acid in rat. *Neurosci Lett* 209:121-124, 1996
1747. Park SH, Carrero JJ, Lindholm B, Stenvinkel P: Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: Two sides of the same coin. *Clin Nephrol* 2009;72:87-96.
1748. Park YS, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, O'Donnell MP: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. *Am J Kidney Dis* 31:190-194, 1998
1749. Passlick-Deetjen J, Kirchgessner J: Bicarbonate: the alternative buffer for peritoneal dialysis. *Perit Dial Int* 16 Suppl 1:S109-S113, 1996
1750. Passlick-Deetjen J, Jaeckle-Meyer I: Bicarbonate buffers in peritoneal dialysis. *Artif Organs* 22:17-19, 1998
1751. Passlick-Deetjen J, Lage C: Lactate-buffered and bicarbonate-buffered solutions with less glucose degradation products in a two-chamber system. *Perit Dial Int* 20 Suppl 2:S42-S47, 2000
1752. Passlick-Deetjen J, Pischetsrieder M, Witowski J, Bender TO, Jorres A, Lage C: In vitro superiority of dual-chambered peritoneal dialysis solution with possible clinical benefits. *Perit Dial Int* 21 Suppl 3:S96-101, 2001
1753. Passlick-Deetjen J, Lage C, Jorres A: Continuous flow peritoneal dialysis: solution formulation and biocompatibility. *Semin Dial* 14:384-387, 2001
1754. Passlick-Deetjen J, Quellhorst E: Continuous flow peritoneal dialysis (CFPD): a glimpse into the future. *Nephrol Dial Transplant* 16:2296-2299, 2001
1755. Passlick-Deetjen J, Pohlmeier R: On-line hemodiafiltration. Gold standard or top therapy? *Contrib Nephrol* 201-211, 2002
1756. Passlick-Deetjen J, Schaub TP, Schilling H: Solutions for APD: special considerations. *Semin Dial* 15:407-413, 2002
1757. Passlick-Deetjen J, Bedenbender-Stoll E: Why thermosensing? A primer on thermoregulation. *Nephrol Dial Transplant* 20:1784-1789, 2005
1758. Patel SR, Ke HQ, Vanholder R, Koenig RJ, Hsu CH: Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. *J Clin Invest* 96:50-59, 1995
1759. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. *J Am Soc Nephrol* 9:655-663, 1998
1760. Patruta SI, Horl WH: Iron and infection. *Kidney Int Suppl* 69:S125-S130, 1999
1761. Patschan D, Witzke O, Duhrsen U, Erbel R, Philipp T, Herget-Rosenthal S: Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome. *Nephrol Dial Transplant* 21:1549-1554, 2006
1762. Pecoits-Filho R, Lindholm B, Stenvinkel P: The malnutrition, inflammation, and atherosclerosis (MIA) syndrome --the heart of the matter. *Nephrol Dial Transplant* 17 Suppl 11:28-31, 2002
1763. Pecoits-Filho R, Barany P, Lindholm B, Heimbürger O, Stenvinkel P: Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. *Nephrol Dial Transplant* 17:1684-1688, 2002
1764. Pecoits-Filho R, Nordfors L, Heimbürger O, Lindholm B, Anderstam B, Marchlewska A, Stenvinkel P: Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. *Eur J Clin Invest* 32:811-817, 2002
1765. Pecoits-Filho R, Araujo MR, Lindholm B, Stenvinkel P, Abensur H, Romao JE, Jr., Marcondes M, De Oliveira AH, Noronha IL: Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. *Nephrol Dial Transplant* 17:1480-1486, 2002
1766. Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimbürger O, Barany P, Hoff CM, Holmes CJ, Suliman M, Lindholm B, Schalling M, Nordfors L: A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. *Kidney Int Suppl* 172-S176, 2003
1767. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P: Update on interleukin-6 and its role in chronic renal failure. *Nephrol Dial Transplant* 18:1042-1045, 2003
1768. Pecoits-Filho R, Nordfors L, Lindholm B, Hoff CM, Schalling M, Stenvinkel P: Genetic approaches in the clinical investigation of complex disorders: malnutrition, inflammation, and atherosclerosis (MIA) as a prototype. *Kidney Int Suppl* 162-S167, 2003
1769. Pecoits-Filho R, Stenvinkel P, Heimbürger O, Lindholm B: Beyond the membrane--the role of new PD solutions in enhancing global biocompatibility. *Kidney Int Suppl* 124-S132, 2003
1770. Pecoits-Filho R, Lindholm B, Stenvinkel P: End-stage renal disease: a state of chronic inflammation and hyperleptinemia. *Eur J Clin Invest* 33:527-528,
1771. Pecoits-Filho R, Heimbürger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Associations between circulating inflammatory markers and residual renal function in CRF patients. *Am J Kidney Dis* 41:1212-1218, 2003

1772. Pecoits-Filho R, Goncalves S, Barberato SH, Bignelli A, Lindholm B, Riella MC, Stenvinkel P: Impact of residual renal function on volume status in chronic renal failure. *Blood Purif* 22:285-292, 2004
1773. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimbürger O, Lindholm B: Chronic inflammation in peritoneal dialysis: the search for the holy grail? *Perit Dial Int* 24:327-339, 2004
1774. Pecoits-Filho R, Sylvestre LC, Stenvinkel P: Chronic kidney disease and inflammation in pediatric patients: from bench to playground. *Pediatr Nephrol* 20:714-720, 2005
1775. Pecoits-Filho R, Carvalho MJ, Stenvinkel P, Lindholm B, Heimbürger O: Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. *Perit Dial Int* 26:53-63, 2006
1776. Peeters P, Terryn W, Vanholder R, Lameire N: Delayed graft function in renal transplantation. *Curr Opin Crit Care* 10:489-498, 2004
1777. Peeters P, Vanholder R: Transplantation as a therapeutic option for diabetic nephropathy. *Acta Clin Belg* 59:125-133, 2004
1778. Peeters P, Van LS, Vanholder R: Acute kidney injury in solid organ transplant recipients. *Acta Clin Belg Suppl* 389-392, 2007
1779. Peeters P, Praet M, Van VB, Naeyaert JM, Vanholder R: End-stage disease of native kidneys in a patient with biopsy-proven Arndt-Gottron scleromyxoedema and recurrence in the transplanted kidney. *Nephrol Dial Transplant* 22:3065-3069, 2007
1780. Peiffert D, Brunet P, Salmon R, Hannoun JM, Giovannini M: Cancer of the anal canal (cancer of the anus). *Gastroenterol Clin Biol* 30 Spec No 2:2S52-2S56, 2006
1781. Peltonen M, Stegmayr B, Asplund K: Time trends in long-term survival after stroke: the Northern Sweden Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) study, 1985-1994. *Stroke* 29:1358-1365, 1998
1782. Peltonen M, Huhtasaari F, Stegmayr B, Lundberg V, Asplund K: Secular trends in social patterning of cardiovascular risk factor levels in Sweden. The Northern Sweden MONICA Study 1986-1994. Multinational Monitoring of Trends and Determinants in Cardiovascular Disease. *J Intern Med* 244:1-9, 1998
1783. Perletti GP, Folini M, Lin HC, Mischak H, Piccinini F, Tashjian AH, Jr.: Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells. *Oncogene* 12:847-854, 1996
1784. Perna A, Morrone MC: The lowest spatial frequency channel determines brightness perception. *Vision Res* 47:1282-1291, 2007
1785. Perna A: [Cardiovascular risk factors, homocysteine and folates]. *G Ital Nefrol* 24:109, 2007
1786. Perna AF, Ingrosso D, De Santo NG, Galletti P, Zappia V: Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. *Kidney Int* 47:247-253, 1995
1787. Perna AF, Ingrosso D, Galletti P, Zappia V, De Santo NG: Membrane protein damage and methylation reactions in chronic renal failure. *Kidney Int* 50:358-366, 1996
1788. Perna AF, De Santo NG, Ingrosso D: Adverse effects of hyperhomocysteinemia and their management by folic acid. *Miner Electrolyte Metab* 23:174-178, 1997
1789. Perna AF, Ingrosso D, De Santo NG, Galletti P, Brunone M, Zappia V: Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. *J Am Soc Nephrol* 8:1899-1905, 1997
1790. Perna AF, D'Aniello A, Lowenson JD, Clarke S, De Santo NG, Ingrosso D: D-aspartate content of erythrocyte membrane proteins is decreased in uremia: implications for the repair of damaged proteins. *J Am Soc Nephrol* 8:95-104, 1997
1791. Perna AF, Castaldo P, Ingrosso D, De Santo NG: Homocysteine, a new cardiovascular risk factor, is also a powerful uremic toxin. *J Nephrol* 12:230-240, 1999
1792. Perna AF, Ingrosso D, Castaldo P, De Santo NG, Galletti P, Zappia V: Homocysteine, a new crucial element in the pathogenesis of uremic cardiovascular complications. *Miner Electrolyte Metab* 25:95-99, 1999
1793. Perna AF, Castaldo P, De Santo NG, Galletti P, Ingrosso D: Homocysteine and chronic renal failure. *Miner Electrolyte Metab* 25:279-285, 1999
1794. Perna AF, Ingrosso D, Castaldo P, Galletti P, De Santo NG: Homocysteine and transmethylation in uremia. *Kidney Int Suppl* 78:S230-S233, 2001
1795. Perna AF, Castaldo P, De Santo NG, di CE, Cimmino A, Galletti P, Zappia V, Ingrosso D: Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: implications for mechanism. *Kidney Int* 59:2299-2308, 2001
1796. Perna AF, Ingrosso D, Satta E, Romano M, Cimmino A, Galletti P, Zappia V, De Santo NG: Metabolic consequences of hyperhomocysteinemia in uremia. *Am J Kidney Dis* 38:S85-S90, 2001
1797. Perna AF, Ingrosso D, Lombardi C, Acanfora F, Satta E, Cesare CM, Violetti E, Romano MM, De Santo NG: Possible mechanisms of homocysteine toxicity. *Kidney Int Suppl* S137-S140, 2003
1798. Perna AF, Ingrosso D, De Santo NG: Homocysteine and oxidative stress. *Amino Acids* 25:409-417, 2003
1799. Perna AF, Ingrosso D, Molino D, Galletti P, Montini G, Zacchello G, Bellantuono R, Caringella A, Fede C, Chimenz R, De Santo NG: Hyperhomocysteinemia and protein damage in chronic renal failure and kidney transplant pediatric patients--Italian initiative on uremic hyperhomocysteinemia (IIUH). *J Nephrol* 16:516-521, 2003
1800. Perna AF, Ingrosso D, Lombardi C, Cesare CM, Acanfora F, Satta E, De Santo NG: Homocysteine in uremia. *Am J Kidney Dis* 41:S123-S126, 2003
1801. Perna AF, Ingrosso D, Satta E, Lombardi C, Galletti P, D'Aniello A, De Santo NG: Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences. *J Am Soc Nephrol* 15:2747-2754, 2004
1802. Perna AF, Ingrosso D, Satta E, Lombardi C, Acanfora F, De Santo NG: Homocysteine metabolism in renal failure. *Curr Opin Clin Nutr Metab Care* 7:53-57, 2004
1803. Perna AF, Acanfora F, Satta E, Lombardi C, Ingrosso D, De Santo NG: Hyperhomocysteinemia and cardiovascular disease in uremia: the newest evidence in epidemiology and mechanisms of action. *Semin Nephrol* 24:426-430, 2004
1804. Perna AF, Ingrosso D, De Santo NG: MTHFR C677T polymorphism and skin color: the white man's blackness. *Kidney Int* 65:2444, 2004
1805. Perna AF, Capasso R, Lombardi C, Acanfora F, Satta E, Ingrosso D: Hyperhomocysteinemia and macromolecule modifications in uremic patients. *Clin Chem Lab Med* 43:1032-1038, 2005
1806. Perna AF, Capasso R, Acanfora F, Satta E, Lombardi C, Ingrosso D, Violetti E, Romano MM, De Santo NG: Toxic effects of hyperhomocysteinemia in chronic renal failure and in uremia: cardiovascular and metabolic consequences. *Semin Nephrol* 26:20-23, 2006

1807. Perna AF, Satta E, Acanfora F, Lombardi C, Ingrosso D, De Santo NG: Increased plasma protein homocysteinylation in hemodialysis patients. *Kidney Int* 69:869-876, 2006
1808. Perna AF, Acanfora F, Satta E, Lombardi C, Capasso R, Ingrosso D, De Santo NG: L-Propionyl carnitine, homocysteine and S-adenosylhomocysteine in hemodialysis. *J Nephrol* 20:63-65, 2007
1809. Perna AF, Acanfora F, Luciano MG, Pulzella P, Capasso R, Satta E, Cinzia L, Pollastro RM, Iannelli S, Ingrosso D, De Santo NG: Plasma protein homocysteinylation in uremia. *Clin Chem Lab Med* 45:1678-1682, 2007
1810. Perna AF, Ingrosso D, Violetti E, Luciano MG, Sepe I, Lanza D, Capasso R, Ascione E, Raiola I, Lombardi C, Stenvinkel P, Massy Z, De Santo NG: Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit. *Semin Dial* 2009;22:351-356.
1811. Perna AG, Ostler DA, Ivan D, Lazar AJ, Diwan AH, Prieto VG, Reed JA: Renal cell carcinoma marker (RCC-Ma) is specific for cutaneous metastasis of renal cell carcinoma. *J Cutan Pathol* 34:381-385, 2007
1812. Persson M, Carlberg B, Weinehall L, Nilsson L, Stegmayr B, Lindholm LH: Risk stratification by guidelines compared with risk assessment by risk equations applied to a MONICA sample. *J Hypertens* 21:1089-1095, 2003
1813. Peters B, Andersson Y, Stegmayr B, Molne J, Jensen G, Dahlberg P, Holm-Gunnarsson I, Ekberg J, Bjurstrom K, Haux SB, Hadimeri H: A study of clinical complications and risk factors in 1001 native and transplant kidney biopsies in Sweden. *Acta Radiol* 2013
1814. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, Ketteler M, Meert N, Maizel J, Nikolov IG, Vanholder R, Lacour B, Druke TB, Massy ZA: Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. *Circulation* 112:2875-2882, 2005
1815. Phan O, Ivanovski O, Nikolov IG, Joki N, Maizel J, Louvet L, Chasseraud M, Nguyen-Khoa T, Lacour B, Druke TB, Massy ZA: Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE<sup>-/-</sup>) mice with chronic renal failure. *Nephrol Dial Transplant* 23:82-90, 2008
1816. Pickut BA, Saerens J, Marien P, Borggreve F, Goeman J, Vandevivere J, Vervaeke A, Dierckx R, De Deyn PP: Discriminative use of SPECT in frontal lobe-type dementia versus (senile) dementia of the Alzheimer's type. *J Nucl Med* 38:929-934, 1997
1817. Pickut BA, Dierckx RA, Dobbelaier A, Audenaert K, Van LK, Vervaeke A, quantification in patients suffering from dementia of the Alzheimer type. *Psychiatry Res* 90:103-112, 1999
1818. Piecha G, Chudek J, Wiecek A: [Calcimimetics--a new treatment for hyperparathyroidism?]. *Pol Merkur Lekarski* 18:581-584, 2005
1819. Piecha G, Adamczak M, Chudek J, Wiecek A: Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. *Kidney Blood Press Res* 30:187-194, 2007
1820. Piecha G, Chudek J, Wiecek A: Multiple endocrine neoplasia type 1. *Eur J Intern Med* 19:99-103, 2008
1821. Pieters B, Johnston TA, Jones TK, Cohen G, Jonmarker C: Resistant hypoxemia in an infant with a right ventricle-to-pulmonary artery (Sano) shunt. *J Cardiothorac Vasc Anesth* 21:880-882, 2007
1822. Pietruck F, Kuhlmann MK, Lange B, Feldkamp T, Herget-Rosenthal S, Rauen U, Burkhardt G, Kohler H, Philipp T, Kribben A: Effect of quercetin on hypoxic injury in freshly isolated rat proximal tubules. *J Lab Clin Med* 142:106-112, 2003
1823. Pietruck F, Kribben A, Van TN, Patschan D, Herget-Rosenthal S, Janssen O, Mann K, Philipp T, Witzke O: Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. *Transpl Int* 18:483-486, 2005
1824. Pietruck F, Horbelt M, Feldkamp T, Engeln K, Herget-Rosenthal S, Philipp T, Kribben A: Digital fluorescence imaging of organic cation transport in freshly isolated rat proximal tubules. *Drug Metab Dispos* 34:339-342, 2006
1825. Pletinck A, Van Landschoot M, Steppan S, Laukens D, Passlick-Deetjen J, Vanholder R, Van Biesen W: Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. *Nephrol Dial Transplant* 27:548-556, 2012
1826. Pletinck A, Van Landschoot M, Steppan S, Laukens D, Passlick-Deetjen J, Vanholder R, Van Biesen W: Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. *Nephrol Dial Transplant* 2012;27:548-556.
1827. Pliquet RU, Klein C, Grunewald T, Ruf BR, Beige J: Lack of evidence for systemic cytomegalovirus reactivation in maintenance hemodialysis patients. *Eur J Clin Microbiol Infect Dis* 2011;30:1557-1560.
1828. Plum J, Fuscholler A, Schoenicke G, Busch T, Erren C, Fieseler C, Kirchgessner J, Passlick-Deetjen J, Grabensee B: In vivo and in vitro effects of amino-acid-based and bicarbonate-buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations. *Nephrol Dial Transplant* 12:1652-1660, 1997
1829. Plum J, Erren C, Fieseler C, Kirchgessner J, Passlick-Deetjen J, Grabensee B: An amino acid-based peritoneal dialysis fluid buffered with bicarbonate versus glucose/bicarbonate and glucose/lactate solutions: an intraindividual randomized study. *Perit Dial Int* 19:418-428, 1999
1830. Polenakovic M, Sikole A, Stojcev N, Spasovski G, Amitov V, Nikolov V, Masin G, Klinkmann H: Survival of patients on chronic hemodialysis: single center experience. *Artif Organs* 23:61-64, 1999
1831. Polenakovic M, Spasovski G: Eutox cme course: Progression in ckd and management of the risk factors in dialysis patients (meeting report). *Prilozi* 32:359-360, 2011
1832. Polenakovic M, Spasovski G: Eutox cme course: Progression in ckd and management of the risk factors in dialysis patients (meeting report). *Prilozi* 2011;32:359-360.
1833. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A: Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. *Am J Hypertens* 20:11-20, 2007
1834. Potmesil P, Holy A, Kmonickova E, Krizkova J, Zidek Z: Acyclic nucleoside phosphonate antivirals activate gene expression of monocyte chemotactic protein 1 and 3. *J Biomed Sci* 14:59-66, 2007
1835. Praet M, Quatacker J, Van LA, Vanholder R, Lameire N, Ringoir S: Non-invasive diagnosis of Fabry's disease by electronmicroscopic evaluation of urinary sediment. *Nephrol Dial Transplant* 10:902-903, 1995
1836. Pravenec M, Hyakukoku M, Houstek J, Zidek V, Landa V, Mlejnek P, Miksik I, Dudova-Mothejzickova K, Pecina P, Vrbacky M, Drahota Z, Vojtiskova A, Mracek T, Kazdova L, Oliyarnyk O, Wang J, Ho C, Qi N, Sugimoto K, Kurtz T: Direct linkage of mitochondrial genome variation to risk factors for type 2 diabetes in conplastic strains. *Genome Res* 17:1319-1326, 2007
1837. Pravenec M, Kazdova L, Landa V, Zidek V, Mlejnek P, Simakova M, Jansa P, Forejt J, Kren V, Krenova D, Qi N, Wang JM, Chan D, Aitman TJ, Kurtz TW: Identification of mutated Srebf1 as a QTL influencing risk for hepatic steatosis in the spontaneously hypertensive rat. *Hypertension* 51:148-153, 2008



1838. Prejbisz A, Kabat M, Januszewicz A, Szelenberger W, Piotrowska AJ, Piotrowski W, Piwonski J, Makowiecka-Ciesla M, Widecka K, Patera B, Bieniaszewski L, Narkiewicz K, Tykarski A, Piejko A, Grodzicki T, Czerwińska B, Wiecek A: Characterization of insomnia in patients with essential hypertension. *Blood Press* 15:213-219, 2006
1839. Prinsen BH, Kaysen GA, Klomp LW, de BJ, Barrett PH, Thornalley PJ, Battah S, Berger R, Rabelink TJ, de Sain-van der Velden MG: Idiopathic hypoalbuminemia explained by reduced synthesis rate and an increased catabolic rate. *Clin Biochem* 35:545-553, 2002
1840. Prouty SM, Maroo A, Maucher C, Mischak H, Kolch W, Sedivy JM: Studies of perinuclear and nuclear translocation of the Raf-1 protein in rodent fibroblasts. *Biochim Biophys Acta* 1402:6-16, 1998
1841. Pupim LB, Heimbürger O, Qureshi AR, Ikizler TA, Stenvinkel P: Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. *Kidney Int* 68:2368-2374, 2005
1842. Pupim LB, Flakoll PJ, Majchrzak KM, ftab Guy DL, Stenvinkel P, Ikizler TA: Increased muscle protein breakdown in chronic hemodialysis patients with type 2 diabetes mellitus. *Kidney Int* 68:1857-1865, 2005
1843. Rabbani N, Sebekova K, Sebekova K, Jr., Heidland A, Thornalley PJ: Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. *Kidney Int* 72:1113-1121, 2007
1844. Rabinowitz J, Katz IR, De Deyn PP, Brodaty H, Greenspan A, Davidson M: Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. *J Clin Psychiatry* 65:1329-1334, 2004
1845. Rabinowitz J, Davidson M, De Deyn PP, Katz I, Brodaty H, Cohen-Mansfield J: Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance. *Am J Geriatr Psychiatry* 13:991-998, 2005
1846. Rabinowitz J, Katz I, De Deyn PP, Greenspan A, Brodaty H: Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone. *Int Psychogeriatr* 19:227-240, 2007
1847. Rabitsch W, Knobl P, Greinix H, Prinz E, Kalhs P, Horl WH, Derfler K: Removal of persisting isoagglutinins with Ig-Therasorb immunoadsorption after major ABO-incompatible non-myeloablative allogeneic haematopoietic stem cell transplantation. *Nephrol Dial Transplant* 18:2405-2408, 2003
1848. Rabitsch W, Knobl P, Prinz E, Keil F, Greinix H, Kalhs P, Worel N, Jansen M, Horl WH, Derfler K: Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isoagglutinins with Ig-Therasorb immunoadsorption. *Bone Marrow Transplant* 32:1015-1019, 2003
1849. Rademakers R, Melquist S, Cruys M, Theuns J, Del-Favero J, Poorkaj P, Baker M, Sleegers K, Crook R, De PT, Bel KS, Adamson J, Van den BD, Van den BM, Gass J, Corsmit E, De RP, Thomas N, Engelborghs S, Heckman M, Litvan I, Crook J, De Deyn PP, Dickson D, Schellenberg GD, Van BC, Hutton ML: High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. *Hum Mol Genet* 14:3281-3292, 2005
1850. Raedler TJ, Wittke S, Jahn H, Koessler A, Mischak H, Wiedemann K: Capillary electrophoresis mass spectrometry as a potential tool to detect lithium-induced nephropathy: Preliminary results. *Prog Neuropsychopharmacol Biol Psychiatry* 32:673-678, 2008
1851. Rahman MM, Barrett JW, Brouckaert P, McFadden G: Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding protein. *J Biol Chem* 281:22517-22526, 2006
1852. Raiola P, Manzo M, Saggese A, Tomasino G, Cicchella T, Rambaldi M, Pisano M, Lizza B, Perna AF: Treatment of anaemia resistant to conventional erythropoietin therapy with thymopentin in haemodialysis patients. *Nephrol Dial Transplant* 10 Suppl 6:48-50, 1995
1853. Raj DS, Carrero JJ, Shah VO, Qureshi AR, Barany P, Heimbürger O, Lindholm B, Ferguson J, Moseley PL, Stenvinkel P: Soluble cd14 levels, interleukin 6, and mortality among prevalent hemodialysis patients. *Am J Kidney Dis* 2009;54:1072-1080.
1854. Ralevic V, Jankowski J, Schluter H: Structure-activity relationships of diadenosine polyphosphates (Ap(n)As), adenosine polyphospho guanosines (Ap(n)Gs) and guanosine polyphospho guanosines (Gp(n)Gs) at P2 receptors in the rat mesenteric arterial bed. *Br J Pharmacol* 134:1073-1083, 2001
1855. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L: Mir-143 and mir-145: Molecular keys to switch the phenotype of vascular smooth muscle cells. *Circ Cardiovasc Genet* 4:197-205, 2011
1856. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L: Mir-143 and mir-145: Molecular keys to switch the phenotype of vascular smooth muscle cells. *Circ Cardiovasc Genet* 2011;4:197-205.
1857. Rantapaa-Dahlqvist S, Neumann-Andersen G, Backman C, Dahlen G, Stegmayr B: Echocardiographic findings, lipids and lipoprotein(a) in patients with systemic lupus erythematosus. *Clin Rheumatol* 16:140-148, 1997
1858. Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, Raj DS: Cytokine gene polymorphism and progression of renal and cardiovascular diseases. *Kidney Int* 72:549-556, 2007
1859. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. *N Engl J Med* 342:1484-1491, 2000
1860. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, Abdalla M: Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. *Mov Disord* 21:1844-1850, 2006
1861. Ratnakumari L, Qureshi IA, Butterworth RF, Marescau B, De Deyn PP: Arginine-related guanidino compounds and nitric oxide synthase in the brain of ornithine transcarbamylase deficient spf mutant mouse: effect of metabolic arginine deficiency. *Neurosci Lett* 215:153-156, 1996
1862. Rautio A, Lundberg V, Messner T, Nasic S, Stegmayr B, Eliasson M: Favourable trends in the incidence and outcome of myocardial infarction in nondiabetic, but not in diabetic, subjects: findings from the MONICA myocardial infarction registry in northern Sweden in 1989-2000. *J Intern Med* 258:369-377, 2005
1863. Regele H, Exner M, Watschinger B, Wenter C, Wahrmann M, Osterreicher C, Saemann MD, Mersich N, Horl WH, Zlabinger GJ, Bohmig GA: Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. *Nephrol Dial Transplant* 16:2058-2066, 2001
1864. Reviron D, Mercier P, Jaber K, Dussol B, Brunet P, Berland Y: Kidney transplantation: generic HLA DR compatibility reduces acute rejection episodes. *Transplant Proc* 28:2812-2813, 1996
1865. Reviron D, Dussol B, Andre M, Brunet P, Mercier P, Berland Y: TNF-alpha and IL-6 gene polymorphism and rejection in kidney transplantation recipients. *Transplant Proc* 33:350-351, 2001
1866. Rezg R, Barreto FC, Barreto DV, Liabeuf S, Druke TB, Massy ZA: Inhibitors of vascular calcification as potential therapeutic targets. *J Nephrol* 24:416-427, 2011
1867. Rezg R, Barreto FC, Barreto DV, Liabeuf S, Druke TB, Massy ZA: Inhibitors of vascular calcification as potential therapeutic targets. *J Nephrol* 2011;24:416-427.
1868. Ricard-Sutra E, Garrigue V, Bismuth J, Chong G, Argiles A, Mourad G: [Sequential protocols with thymoglobuline and delayed introduction of calcineurin: effects on renal function in renal transplant recipients with

- non immunological risk and low risk of delayed graft function]. *Nephrologie* 25:127-132, 2004
1869. Richard MA, Grob JJ, Laurans R, Hesse S, Brunet P, Stoppa AM, Bonerandi JJ, Berland Y, Maraninchi D: Sweet's syndrome induced by granulocyte colony-stimulating factor in a woman with congenital neutropenia. *J Am Acad Dermatol* 35:629-631, 1996
1870. Richter J, Focke D, Ebert T, Kovacs P, Bachmann A, Lossner U, Kralisch S, Kratzsch J, Beige J, Anders M, Bast I, Bluher M, Stumvoll M, Fasshauer M: Serum levels of the adipokine progranulin depend on renal function. *Diabetes Care* 2013;36:410-414.
1871. Riegel W, Ulrich C, Friedrichsohn C, Passlick-Deetjen J, Kohler H: Liver cell reactive components in peritoneal dialysis fluids. *Miner Electrolyte Metab* 25:373-379, 1999
1872. Riegel W, Ulrich C, Sauernheimer S, Deppisch RM, Kohler H: Hepatotoxic substance(s) removed by high-flux membranes enhances the positive acute phase response. *Kidney Int Suppl* 78:S308-S314, 2001
1873. Riegersperger M, van HM, Fodinger M, Wojcik J, Horl WH, Winkelmayr WC, Sunder-Plassmann G: No associations between prolactin concentrations and response to erythropoiesis-stimulating agents in hemodialysis patients. *Am J Nephrol* 27:390-396, 2007
1874. Rifai K, Ernst T, Kretschmer U, Bahr MJ, Schneider A, Hafer C, Haller H, Manns MP, Fliser D: Prometheus--a new extracorporeal system for the treatment of liver failure. *J Hepatol* 39:984-990, 2003
1875. Rifai K, Ernst T, Kretschmer U, Hafer C, Haller H, Manns MP, Fliser D: The Prometheus device for extracorporeal support of combined liver and renal failure. *Blood Purif* 23:298-302, 2005
1876. Rifai K, Ernst T, Kretschmer U, Haller H, Manns MP, Fliser D: Removal selectivity of Prometheus: a new extracorporeal liver support device. *World J Gastroenterol* 12:940-944, 2006
1877. Rifai K, Hafer C, Rosenau J, Athmann C, Haller H, Peter MM, Fliser D: Treatment of severe refractory pruritus with fractionated plasma separation and adsorption (Prometheus). *Scand J Gastroenterol* 41:1212-1217, 2006
1878. Ringel J, Beige J, Kunz R, Distler A, Sharma AM: Genetic variants of the renin-angiotensin system, diabetic nephropathy and hypertension. *Diabetologia* 40:193-199, 1997
1879. Riser BL, Barreto FC, Rezg R, Valaitis PW, Cook CS, White JA, Gass JH, Maizel J, Louvet L, Drueke TB, Holmes CJ, Massy ZA: Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. *Nephrol Dial Transplant* 26:3349-3357, 2011
1880. Riser BL, Barreto FC, Rezg R, Valaitis PW, Cook CS, White JA, Gass JH, Maizel J, Louvet L, Drueke TB, Holmes CJ, Massy ZA: Daily peritoneal administration of sodium pyrophosphate in a dialysis solution prevents the development of vascular calcification in a mouse model of uraemia. *Nephrol Dial Transplant* 2011;26:3349-3357.
1881. Ritz E, Bergis K, Fliser D: [The metabolic syndrome]. *Dtsch Med Wochenschr* 120:489-490, 1995
1882. Ritz E, Passlick-Deetjen J, Lippert J: What is the appropriate dialysate calcium concentration for the dialysis patient? *Nephrol Dial Transplant* 11 Suppl 3:91-95, 1996
1883. Ritz E, Passlick-Deetjen J, Zeier M, Stefanski A: Prescription of calcium concentration and PTH control. *Perit Dial Int* 16 Suppl 1:S300-S304, 1996
1884. Ritz E, Amann K, Fliser D: The sympathetic nervous system and the kidney: its importance in renal diseases. *Blood Press Suppl* 3:14-19, 1998
1885. Ritz E, Koch M, Fliser D, Schwenger V: How can we improve prognosis in diabetic patients with end-stage renal disease? *Diabetes Care* 22 Suppl 2:B80-B83, 1999
1886. Ritz E, Wiecek A: [The kidney in the Bible]. *Dtsch Med Wochenschr* 131:2916-2919, 2006
1887. Rivas MA, Carnevale RP, Proietti CJ, Rosembli C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV, Schillaci R: TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. *Exp Cell Res* 314:509-529, 2008
1888. Robert PH, Verhey FR, Byrne EJ, Hurt C, De Deyn PP, Nobili F, Riello R, Rodriguez G, Frisoni GB, Tsolaki M, Kyriazopoulou N, Bullock R, Burns A, Vellas B: Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. *Eur Psychiatry* 20:490-496, 2005
1889. Rodriguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heimbürger O, Lindholm B, Stenvinkel P: Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. *Atherosclerosis* 180:333-340, 2005
1890. Rodriguez-Ayala E, Yao Q, Holmen C, Lindholm B, Sumitran-Holgersson S, Stenvinkel P: Imbalance between detached circulating endothelial cells and endothelial progenitor cells in chronic kidney disease. *Blood Purif* 24:196-202, 2006
1891. Rodríguez AE, Pecoits-Filho R, Heimbürger O, Lindholm B, Nordfors L, Stenvinkel P: Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. *Nephrol Dial Transplant* 19:421-426, 2004
1892. Rodu B, Stegmayr B, Nasic S, Asplund K: Impact of smokeless tobacco use on smoking in northern Sweden. *J Intern Med* 252:398-404, 2002
1893. Rodu B, Stegmayr B, Nasic S, Cole P, Asplund K: Evolving patterns of tobacco use in northern Sweden. *J Intern Med* 253:660-665, 2003
1894. Rodu B, Stegmayr B, Nasic S, Cole P, Asplund K: The influence of smoking and smokeless tobacco use on weight amongst men. *J Intern Med* 255:102-107, 2004
1895. Rogacev KS, Bittenbring JT, Fliser D: Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. *N Engl J Med* 2011;365:1745-1746; author reply 1746-1747.
1896. Rogachev B, Hausmann MJ, Yulzari R, Weiler M, Holmes C, Faict D, Chaimovitz C, Douvdevani A: Effect of bicarbonate-based dialysis solutions on intracellular pH (pHi) and TNFalpha production by peritoneal macrophages. *Perit Dial Int* 17:546-553, 1997
1897. Rogacev KS, Pickering JW, Seiler S, Zawada AM, Emrich I, Fliser D, Heine GH: The chronic kidney disease epidemiology collaboration (ckd-epi) equation incorporating both cystatin c and creatinine best predicts individual risk: A cohort study in 444 patients with chronic kidney disease. *Nephrol Dial Transplant* 2013;29:348-355.
1898. Rogacev KS, Seiler S, Zawada AM, Reichart B, Herath E, Roth D, Ulrich C, Fliser D, Heine GH: Cd14++cd16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. *Eur Heart J* 2010;32:84-92.
1899. Roland J, Pickut BA, Abib A, Vandevivere J, De Deyn PP: Primary cerebral lymphoma visualised by means of In-111-pentetreotide scintigraphy. *Acta Neurol Belg* 98:356-359, 1998
1900. Rolfes A, Beige J, Finckh U, Kohler B, Schaberg T, Lokies J, Lode H: Amplification of *Mycobacterium tuberculosis* from peripheral blood. *J Clin Microbiol* 33:3312-3314, 1995

1901. Ronco C, Crepaldi C, Brendolan A, Bragantini L, d'Intini V, Inguaggiato P, Bonello M, Krause B, Deppisch R, Goehl H, Scabardi A: Evolution of synthetic membranes for blood purification: the case of the Polyflux family. *Nephrol Dial Transplant* 18 Suppl 7:vii10-vii20, 2003
1902. Rose M, Scholler G, Jorres A, Danzer G, Klapp BF: Patients' expressions of complaints as a predictor of the course of acute hepatitis A. *J Psychosom Res* 48:107-113, 2000
1903. Rosengren A, Stegmayr B, Johansson I, Huhtasaari F, Wilhelmson L: Coronary risk factors, diet and vitamins as possible explanatory factors of the Swedish north-south gradient in coronary disease: a comparison between two MONICA centres. *J Intern Med* 246:577-586, 1999
1904. Rosenkranz AR, Kormoczi GF, Thalhammer F, Menzel EJ, Horl WH, Mayer G, Zlabinger GJ: Novel C5-dependent mechanism of neutrophil stimulation by bioincompatible dialyzer membranes. *J Am Soc Nephrol* 10:128-135, 1999
1905. Rosenkranz AR, Peherstorfer E, Kormoczi GF, Zlabinger GJ, Mayer G, Horl WH, Oberbauer R: Complement-dependent acceleration of apoptosis in neutrophils by dialyzer membranes. *Kidney Int Suppl* 78:S216-S220, 2001
1906. Roskiewicz F, Andriamanana I, Gras-Champel V, Andrejak M, Massy ZA: [Iatrogenic angioedema: the role of angiotensin converting enzyme inhibitor and angiotensin II receptor blockers]. *Nephrol Ther* 3:89-95, 2007
1907. Rossert J, Levin A, Roger SD, Horl WH, Fouqueray B, Gassmann-Mayer C, Frei D, McClellan WM: Effect of early correction of anemia on the progression of CKD. *Am J Kidney Dis* 47:738-750, 2006
1908. Rossert JA, McClellan WM, Roger SD, Verbeelen DL, Horl WH: Contribution of anaemia to progression of renal disease: a debate. *Nephrol Dial Transplant* 17 Suppl 1:60-66, 2002
1909. Rossing K, Mischak H, Parving HH, Christensen PK, Walden M, Hillmann M, Kaiser T: Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. *Kidney Int* 68:193-205, 2005
1910. Rostand SG, Druke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. *Kidney Int* 56:383-392, 1999
1911. Rotkegel S, Wiecek A, Nieszporek T, Ziaj J, Kokot F, Cierpka L: [Clinical, biochemical and hormonal characteristics of 84 patients with incidentally found adrenal tumor (incidentaloma)]. *Pol Arch Med Wewn* 112:1451-1457, 2004
1912. Rottey S, Vanholder R, De SG, Lameire N: Progression of renal failure in patients with compromised renal function is not always present: evaluation of underlying disease. *Clin Nephrol* 54:1-10, 2000
1913. Roubicek C, Brunet P, Mallet MN, Dussol B, Gonzales A, Andrieu D, Merzouk T, Jaber K, Berland Y: [Nasal carriage of *Staphylococcus aureus*: prevalence in a hemodialysis center and effect on bacteremia]. *Nephrologie* 16:229-232, 1995
1914. Roubicek C, Brunet P, Huiart L, Thirion X, Leonetti F, Dussol B, Jaber K, Andrieu D, Ramanarivo P, Berland Y: Timing of nephrology referral: influence on mortality and morbidity. *Am J Kidney Dis* 36:35-41, 2000
1915. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Heraut P, Mahjoubi M: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. *J Clin Oncol* 15:251-260, 1997
1916. Roussanne MC, Gogusev J, Hory B, Duchambon P, Souberbielle JC, Nabarra B, Pierrat D, Sarfati E, Druke T, Bourdeau A: Persistence of Ca<sup>2+</sup>-sensing receptor expression in functionally active, long-term human parathyroid cell cultures. *J Bone Miner Res* 13:354-362, 1998
1917. Roussanne MC, Duchambon P, Gogusev J, Sarfati E, Bourdeau A, Druke TB: Parathyroid hyperplasia in chronic renal failure: role of calcium, phosphate, and calcitriol. *Nephrol Dial Transplant* 14 Suppl 1:68-69, 1999
1918. Roussanne MC, Lieberherr M, Souberbielle JC, Sarfati E, Druke T, Bourdeau A: Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate. *Eur J Clin Invest* 31:610-616, 2001
1919. Rubinstein SM, Cohen G, Fineberg J: Dynamics of precursors to frictional sliding. *Phys Rev Lett* 98:226103, 2007
1920. Rutkowski B, Czekalski S, Sulowicz W, Wiecek A, Krol E, Szubert R, Kraszewska E: [Epidemiology of kidney diseases in Poland--pilot study (PolNef)]. *Przegl Lek* 61:22-24, 2004
1921. Rydval A, Brandstrom AK, Banga R, Asplund K, Backlund U, Stegmayr BG: Plasma cortisol is often decreased in patients treated in an intensive care unit. *Intensive Care Med* 26:545-551, 2000
1922. Rzepka E, Adamczak M, Kokot F, Wiecek A: [Influence of aging on plasma leptin concentration]. *Pol Arch Med Wewn* 107:125-133, 2002
1923. Saemann MD, Bohmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C, Stockl J, Horl WH, Zlabinger GJ: Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. *FASEB J* 14:2380-2382, 2000
1924. Saemann MD, Bohmig GA, Osterreicher CH, Staffler G, Diakos C, Krieger PM, Horl WH, Stockinger H, Zlabinger GJ: Suppression of primary T-cell responses and induction of alloantigen-specific hyporesponsiveness in vitro by the Janus kinase inhibitor tyrphostin AG490. *Transplantation* 70:1215-1225, 2000
1925. Saemann MD, Parolini O, Bohmig GA, Kelemen P, Krieger PM, Neumuller J, Knarr K, Kammlander W, Horl WH, Diakos C, Stuhlmeier K, Zlabinger GJ: Bacterial metabolite interference with maturation of human monocyte-derived dendritic cells. *J Leukoc Biol* 71:238-246, 2002
1926. Saemann MD, Diakos C, Kelemen P, Kriehuber E, Zeyda M, Bohmig GA, Horl WH, Baumruker T, Zlabinger GJ: Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3. *Am J Transplant* 3:1341-1349, 2003
1927. Saemann MD, Zeyda M, Stulnig TM, Bohmig GA, Wekerle T, Horl WH, Zlabinger GJ: Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation. *Transpl Int* 17:481-489, 2004
1928. Saemann MD, Kelemen P, Bohmig GA, Horl WH, Zlabinger GJ: Hyporesponsiveness in alloreactive T-cells by NF-kappaB inhibitor-treated dendritic cells: resistance to calcineurin inhibition. *Am J Transplant* 4:1448-1458, 2004
1929. Saemann MD, Weichhart T, Horl WH, Zlabinger GJ: Tamm-Horsfall protein: a multilayered defence molecule against urinary tract infection. *Eur J Clin Invest* 35:227-235, 2005
1930. Saemann MD, Weichhart T, Zeyda M, Staffler G, Schunn M, Stuhlmeier KM, Sobanov Y, Stulnig TM, Akira S, von GA, von AU, Horl WH, Zlabinger GJ: Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. *J Clin Invest* 115:468-475, 2005
1931. Saemann MD, Horl WH, Weichhart T: Uncovering host defences in the urinary tract: cathelicidin and beyond. *Nephrol Dial Transplant* 22:347-349, 2007

1932. Saldanha JF, Leal Vde O, Stenvinkel P, Carraro-Eduardo JC, Mafra D: Resveratrol: Why is it a promising therapy for chronic kidney disease patients? *Oxid Med Cell Longev* 2014;2013:963217.
1933. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, Kretschmer A, Steppan S, Valsek M, Kribben A, Nierhaus M, Jankowski V, Zidek W, Jankowski J: Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. *Am J Nephrol* 35:31-39, 2012
1934. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, Kretschmer A, Steppan S, Valsek M, Kribben A, Nierhaus M, Jankowski V, Zidek W, Jankowski J: Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. *Am J Nephrol* 2012;35:31-39.
1935. Sampol J, Dussol B, Fenouillet E, Capo C, Mege JL, Halimi G, Bechis G, Brunet P, Rochat H, Berland Y, Guieu R: High adenosine and deoxyadenosine concentrations in mononuclear cells of hemodialyzed patients. *J Am Soc Nephrol* 12:1721-1728, 2001
1936. Samtleben W, Dengler C, Reinhardt B, Nothdurft A, Lemke HD: Comparison of the new polyethersulfone high-flux membrane DIAPES HF800 with conventional high-flux membranes during on-line haemodiafiltration. *Nephrol Dial Transplant* 18:2382-2386, 2003
1937. Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, Valcheva P, Gracia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, Valdivielso JM: Beyond proteinuria: Vdr activation reduces renal inflammation in experimental diabetic nephropathy. *Am J Physiol Renal Physiol* 2011;302:F647-657.
1938. Sanchez-Nino MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J, Ortiz A: Globotriaosylsphingosine actions on human glomerular podocytes: Implications for fabry nephropathy. *Nephrol Dial Transplant* 2010;26:1797-1802.
1939. Saner F, Sotiropoulos GC, Radtke A, Malago M, Broelsch CE, Herget-Rosenthal S: Small-for-size syndrome after living-donor liver transplantation treated by "portal vein wrapping" and single plasmapheresis. *Transplantation* 79:625, 2005
1940. Saner FH, Koeppen S, Meyer M, Kohnle M, Herget-Rosenthal S, Sotiropoulos GC, Paul A, Radtke A, Malago M, Broelsch CE: Treatment of central pontine myelinolysis with plasmapheresis and immunoglobulins in liver transplant patient. *Transpl Int* 21:390-391, 2008
1941. Santangelo F, Witko-Sarsat V, Drueke T, scamps-Latscha B: Restoring glutathione as a therapeutic strategy in chronic kidney disease. *Nephrol Dial Transplant* 19:1951-1955, 2004
1942. Santoro A, Canova C, Mancini E, Deppisch R, Beck W: Protein loss in on-line hemofiltration. *Blood Purif* 22:261-268, 2004
1943. Sanz AB, Sanchez-Nino MD, Ortiz A: Tweak, a multifunctional cytokine in kidney injury. *Kidney Int* 2011;80:708-718.
1944. Sarti C, Stegmayr B, Tolonen H, Mahonen M, Tuomilehto J, Asplund K: Are changes in mortality from stroke caused by changes in stroke event rates or case fatality? Results from the WHO MONICA Project. *Stroke* 34:1833-1840, 2003
1945. Sartor C, Brunet P, Simon S, Tamalet C, Berland Y, Drancourt M: Transmission of hepatitis C virus between hemodialysis patients sharing the same machine. *Infect Control Hosp Epidemiol* 25:609-611, 2004
1946. Satta E, Perna AF, Lombardi C, Acanfora F, Violetti E, Romano MM, Capasso R, Pisano M, Paduano F, De Santo NG: [Hyperhomocysteinemia in chronic renal failure.]. *G Ital Nefrol* 23:480-489, 2006
1947. Sauer IM, Baurmeister U: Cell-free artificial liver support. *Ther Apher Dial* 10:105-107, 2006
1948. Sayan BS, Sayan AE, Yang AL, Aqeilan RI, Candi E, Cohen GM, Knight RA, Croce CM, Melino G: Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. *Proc Natl Acad Sci U S A* 104:10871-10876, 2007
1949. scamps-Latscha B, Drueke T, Witko-Sarsat V: Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. *Semin Dial* 14:193-199, 2001
1950. Schaefer M, Mischak H, Schnell S, Griese A, Iakubov R, Riepenhausen G, Schoff C: Mechanisms of arginine-vasopressin-induced Ca<sup>2+</sup> oscillations in beta-cells (HIT-T15): a role for oscillating protein kinase C. *Endocrinology* 145:4635-4644, 2004
1951. Schaeffner ES, Fodinger M, Kramar R, Frei U, Horl WH, Sunder-Plassmann G, Winkelmayer WC: Prognostic associations between lipid markers and outcomes in kidney transplant recipients. *Am J Kidney Dis* 47:509-517, 2006
1952. Schaller G, Scheiber-Mojdehkar B, Wolz M, Puttinger H, Mittermayer F, Horl WH, Fodinger M, Sunder-Plassmann G, Vychytil A: Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. *Kidney Int* 68:2814-2822, 2005
1953. Schenk P, Rosenkranz AR, Wolff G, Horl WH, Traindl O: Recombinant tissue plasminogen activator is a useful alternative to heparin in priming quinton permcat. *Am J Kidney Dis* 35:130-136, 2000
1954. Schepers E, Meert N, Glorieux G, Goeman J, Van der EJ, Vanholder R: P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. *Nephrol Dial Transplant* 22:592-596, 2007
1955. Schepers E, Glorieux G, Dou L, Cerini C, Gayrard N, Louvet L, Maugard C, Preus P, Rodriguez-Ortiz M, Argiles A, Brunet P, Cohen G, Jankowski J, Jankowski V, Massy Z, Rodriguez M, Vanholder R: Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: An in vitro evaluation. *Blood Purif* 30:277-287.
1956. Schepers E, Barreto DV, Liabeuf S, Glorieux G, Eloit S, Barreto FC, Massy Z, Vanholder R: Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. *Clin J Am Soc Nephrol* 6:2374-2383, 2011
1957. Schepers E, Barreto DV, Liabeuf S, Glorieux G, Eloit S, Barreto FC, Massy Z, Vanholder R: Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease. *Clin J Am Soc Nephrol* 2011;6:2374-2383.
1958. Schepers E, Glorieux G, Dhondt A, Leybaert L, Vanholder R: Flow cytometric calcium flux assay: Evaluation of cytoplasmic calcium kinetics in whole blood leukocytes. *J Immunol Methods* 2009;348:74-82.
1959. Schepers E, Glorieux G, Dou L, Cerini C, Gayrard N, Louvet L, Maugard C, Preus P, Rodriguez-Ortiz M, Argiles A, Brunet P, Cohen G, Jankowski J, Jankowski V, Massy Z, Rodriguez M, Vanholder R: Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: An in vitro evaluation. *Blood Purif* 2010;30:277-287.
1960. Schepkens H, Vanholder R, Billiow JM, Lameire N: Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. *Am J Med* 110:438-441, 2001
1961. Schepkens H, Stubbe J, Hoeben H, Vanholder R, Lameire N: Severe hyponatraemia and hypouricaemia in Gitelman's syndrome. *Nephrol Dial Transplant* 16:2250-2252, 2001

1962. Schepkens H, Hoeben H, Vanholder R, Lameire N: Mimicry of surreptitious diuretic ingestion and the ability to make a genetic diagnosis. *Clin Nephrol* 55:233-237, 2001
1963. Schiffer E, Mischak H, Novak J: High resolution proteome/peptidome analysis of body fluids by capillary electrophoresis coupled with MS. *Proteomics* 6:5615-5627, 2006
1964. Schiffer E, Mischak H, Theodorescu D, Vlahou A: Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform. *World J Urol* 26:67-74, 2008
1965. Schiffer E, Liabeuf S, Lacroix C, Temmar M, Renard C, Monsarrat B, Choukroun G, Lemke HD, Vanholder R, Mischak H, Massy ZA: Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. *J Hypertens* 29:783-790, 2011
1966. Schiffer E, Liabeuf S, Lacroix C, Temmar M, Renard C, Monsarrat B, Choukroun G, Lemke HD, Vanholder R, Mischak H, Massy ZA: Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. *J Hypertens* 2011;29:783-790.
1967. Schindler K, Zauner C, Buchmayer H, Fodinger M, Wolf G, Bieglmayer C, Heinz G, Wilfing A, Horl WH, Sunder-Plassmann G: High prevalence of hyperhomocysteinemia in critically ill patients. *Crit Care Med* 28:991-995, 2000
1968. Schindler R, Beck W, Deppisch R, Aussieker M, Wilde A, Gohl H, Frei U: Short bacterial DNA fragments: detection in dialysate and induction of cytokines. *J Am Soc Nephrol* 15:3207-3214, 2004
1969. Schluter H, Grobeta I, Bachmann J, Kaufmann R, van der GM, Tepel M, Nofer JR, Assmann G, Karas M, Jankowski J, Zidek W: Adenosine(5') oligophospho-(5') guanosines and guanosine(5') oligophospho-(5') guanosines in human platelets. *J Clin Invest* 101:682-688, 1998
1970. Schluter H, Jankowski J, Rykl J, Thiemann J, Belgardt S, Zidek W, Wittmann B, Pohl T: Detection of protease activities with the mass-spectrometry-assisted enzyme-screening (MES) system. *Anal Bioanal Chem* 377:1102-1107, 2003
1971. Schluter H, Rykl J, Thiemann J, Kurzwaski S, Gobom J, Tepel M, Zidek W, Linscheid M: Mass spectrometry-assisted protease substrate screening. *Anal Chem* 79:1251-1255, 2007
1972. Schluter H, Jankowski J, Rykl J, Thiemann J, Belgardt S, Zidek W, Wittmann B, Pohl T: Detection of protease activities with the mass-spectrometry-assisted enzyme-screening (mes) system. *Anal Bioanal Chem* 2003;377:1102-1107.
1973. Schmaldienst S, Horl WH: Bacterial infections during immunosuppression -immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. *Nephrol Dial Transplant* 11:1243-1245, 1996
1974. Schmaldienst S, Winkler S, Breiteneder S, Horl WH: Severe nephrotic syndrome in a patient with Schonlein-Henoch purpura: complete remission after cyclosporin A. *Nephrol Dial Transplant* 12:790-792, 1997
1975. Schmaldienst S, Horl WH: Bacterial infections after renal transplantation. *Contrib Nephrol* 124:18-33, 1998
1976. Schmaldienst S, Banyai S, Stulnig TM, Heinz G, Jansen M, Horl WH, Derfler K: Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. *Atherosclerosis* 151:493-499, 2000
1977. Schmaldienst S, Traunmuller F, Burgmann H, Rosenkranz AR, Thalhammer-Scherrer R, Horl WH, Thalhammer F: Multiple-dose pharmacokinetics of cefepime in long-term hemodialysis with high-flux membranes. *Eur J Clin Pharmacol* 56:61-64, 2000
1978. Schmaldienst S, Goldammer A, Spitzauer S, Derfler K, Horl WH, Knobl P: Local anticoagulation of the extracorporeal circuit with heparin and subsequent neutralization with protamine during immunoadsorption. *Am J Kidney Dis* 36:490-497, 2000
1979. Schmaldienst S, Horl WH: Degranulation of polymorphonuclear leukocytes by dialysis membranes--the mystery clears up? *Nephrol Dial Transplant* 15:1909-1910, 2000
1980. Schmaldienst S, Bekesi G, Deicher R, Franz M, Horl WH, Pohanka E: Recombinant human granulocyte colony-stimulating factor after kidney transplantation: a retrospective analysis to evaluate the benefit or risk of immunostimulation. *Transplantation* 69:527-531, 2000
1981. Schmaldienst S, Mullner M, Goldammer A, Spitzauer S, Banyai S, Horl WH, Derfler K: Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? *Rheumatology (Oxford)* 40:513-521, 2001
1982. Schmaldienst S, Dittrich E, Horl WH: Urinary tract infections after renal transplantation. *Curr Opin Urol* 12:125-130, 2002
1983. Schmaldienst S, Jansen M, Hollenstein U, Graninger W, Regele H, Horl WH, Derfler K: Treatment of systemic lupus erythematosus by immunoadsorption in a patient suffering from tuberculosis. *Am J Kidney Dis* 39:415-418, 2002
1984. Schmaldienst S, Oberpichler A, Tschesche H, Horl WH: Angiogenin: a novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation. *Kidney Blood Press Res* 26:107-112, 2003
1985. Schmidt-Gayk H, Druke T, Ritz E: Non-invasive circulating indicators of bone metabolism in uraemic patients: can they replace bone biopsy? *Nephrol Dial Transplant* 11:415-418, 1996
1986. Schmidt A, Luger A, Horl WH: Sexual hormone abnormalities in male patients with renal failure. *Nephrol Dial Transplant* 17:368-371, 2002
1987. Schmidt A, Marescau B, Boehm EA, Renema WK, Peco R, Das A, Steinfeld R, Chan S, Wallis J, Davidoff M, Ullrich K, Waldschutz R, Heerschap A, De Deyn PP, Neubauer S, Isbrandt D: Severely altered guanidino compound levels, disturbed body weight homeostasis and impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. *Hum Mol Genet* 13:905-921, 2004
1988. Schmidt S, Sharma AM, Zilch O, Beige J, Walla-Friedel M, Ganten D, Distler A, Ritz E: Association of M235T variant of the angiotensinogen gene with familial hypertension of early onset. *Nephrol Dial Transplant* 10:1145-1148, 1995
1989. Schmidt S, Beige J, Walla-Friedel M, Michel MC, Sharma AM, Ritz E: A polymorphism in the gene for the angiotensin II type 1 receptor is not associated with hypertension. *J Hypertens* 15:1385-1388, 1997
1990. Schmidt S, Westhoff TH, Compton F, Zidek W, van der GM: Avoiding the cross-talk phenomenon when assessing cardiac output using the transpulmonary thermodilution technique via the femoral vein access. *Crit Care Med* 35:2670, 2007
1991. Schmidt S, Westhoff TH, Hofmann C, Schaefer JH, Zidek W, Compton F, van der GM: Effect of the venous catheter site on transpulmonary thermodilution measurement variables. *Crit Care Med* 35:783-786, 2007
1992. Schmidt S, Westhoff TH, Krauser P, Zidek W, van der GM: The uraemic toxin phenylacetic acid increases the formation of reactive oxygen species in vascular smooth muscle cells. *Nephrol Dial Transplant* 23:65-71, 2008

1993. Schmidt S, Westhoff TH, Krauser P, Ignatius R, Jankowski J, Jankowski V, Zidek W, van der Giet M: The uraemic toxin phenylacetic acid impairs macrophage function. *Nephrol Dial Transplant* 23:3485-3493, 2008
1994. Schmidt S, Westhoff TH, Krauser P, Ignatius R, Jankowski J, Jankowski V, Zidek W, van der Giet M: The uraemic toxin phenylacetic acid impairs macrophage function. *Nephrol Dial Transplant* 2008;23:3485-3493.
1995. Schmieder RE, Schrader J, Zidek W, Tebbe U, Paar WD, Bramlage P, Pittrow D, Bohm M: Low-grade albuminuria and cardiovascular risk : what is the evidence? *Clin Res Cardiol* 96:247-257, 2007
1996. Schmitt-Bernard CF, Guittard C, Arnaud B, Demaille J, Argiles A, Claustres M, Tuffery-Giraud S: BIGH3 exon 14 mutations lead to intermediate type I/IIIA of lattice corneal dystrophies. *Invest Ophthalmol Vis Sci* 41:1302-1308, 2000
1997. Schmitt-Bernard CF, Chavanieu A, Derancourt J, Arnaud B, Demaille JG, Calas B, Argiles A: In vitro creation of amyloid fibrils from native and Arg124Cys mutated betaIGH3((110-131)) peptides, and its relevance for lattice corneal amyloid dystrophy type I. *Biochem Biophys Res Commun* 273:649-653, 2000
1998. Schmitt-Bernard CF, Claustres M, Arnaud B, Demaille J, Argiles A: Lattice corneal dystrophy. *Ophthalmology* 107:1613-1614, 2000
1999. Schmitt-Bernard CF, Schneider C, Argiles A: Clinical, histopathologic, and ultrastructural characteristics of BIGH3(TGFB1) amyloid corneal dystrophies are supportive of the existence of a new type of LCD: the LCDi. *Cornea* 21:463-468, 2002
2000. Schmitt-Bernard CF, Chavanieu A, Herrada G, Subra G, Arnaud B, Demaille JG, Calas B, Argiles A: BIGH3 (TGFB1) Arg124 mutations influence the amyloid conversion of related peptides in vitro. *Eur J Biochem* 269:5149-5156, 2002
2001. Schmitt-Bernard CF, Pouliquen Y, Argiles A: [BIG-H3 protein: mutation of codon 124 and corneal amyloidosis]. *J Fr Ophtalmol* 27:510-522, 2004
2002. Schmitt CP, Haraldsson B, Doetschmann R, Zimmering M, Greiner C, Boswald M, Klaus G, Passlick-Deetjen J, Schaefer F: Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children. *Kidney Int* 61:1527-1536, 2002
2003. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M: Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. *Circulation* 109:369-374, 2004
2004. Scholze A, Jankowski V, Henning L, Haass W, Wittstock A, Suvd-Erdene S, Zidek W, Tepel M, Jankowski J: Phenylacetic acid and arterial vascular properties in patients with chronic kidney disease stage 5 on hemodialysis therapy. *Nephron Clin Pract* 107:c1-c6, 2007
2005. Scholze A, Rattensperger D, Zidek W, Tepel M: Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. *Obesity (Silver Spring)* 15:1617-1622, 2007
2006. Scholze A, Burkert A, Mardanzai K, Suvd-Erdene S, Hausberg M, Zidek W, Tepel M: Increased arterial vascular tone during the night in patients with essential hypertension. *J Hum Hypertens* 21:60-67, 2007
2007. Scholze A, Krueger K, Diedrich M, Rath C, Torges A, Jankowski V, Maier A, Thilo F, Zidek W, Tepel M: Superoxide dismutase type 1 in monocytes of chronic kidney disease patients. *Amino Acids* 41:427-438, 2011
2008. Scholze A, Jankowski V, Henning L, Haass W, Wittstock A, Suvd-Erdene S, Zidek W, Tepel M, Jankowski J: Phenylacetic acid and arterial vascular properties in patients with chronic kidney disease stage 5 on hemodialysis therapy. *Nephron Clin Pract* 2007;107:c1-6.
2009. Scholze A, Krueger K, Diedrich M, Rath C, Torges A, Jankowski V, Maier A, Thilo F, Zidek W, Tepel M: Superoxide dismutase type 1 in monocytes of chronic kidney disease patients. *Amino Acids* 2011;41:427-438.
2010. Schoonjans R, Van VB, Van HN, Vandamme W, Vanholder R, Lameire N, Lefebvre R, De VM: The 13C-octanoic acid breath test: validation of a new noninvasive method of measuring gastric emptying in rats. *Neurogastroenterol Motil* 14:287-293, 2002
2011. Schoonjans R, Van VB, Vandamme W, Van VH, Van HN, Van BW, Mast A, Sas S, Vanholder R, Lameire N, De VM: Gastric emptying of solids in cirrhotic and peritoneal dialysis patients: influence of peritoneal volume load. *Eur J Gastroenterol Hepatol* 14:395-398, 2002
2012. Schoonjans R, Van VB, Vandamme W, Van HN, Verdiveel H, Vanholder R, Lameire N, De VM: Dyspepsia and gastroparesis in chronic renal failure: the role of *Helicobacter pylori*. *Clin Nephrol* 57:201-207, 2002
2013. Schorr U, Beige J, Ringel J, Turan S, Kreutz R, Distler A, Sharma AM: Hpa II polymorphism of the atrial natriuretic peptide gene and the blood pressure response to salt intake in normotensive men. *J Hypertens* 15:715-718, 1997
2014. Schorr U, Blaschke K, Beige J, Distler A, Sharma AM: Angiotensinogen M235T variant and salt sensitivity in young normotensive Caucasians. *J Hypertens* 17:475-479, 1999
2015. Schorr U, Blaschke K, Beige J, Distler A, Sharma AM: G-protein beta3 subunit 825T allele and response to dietary salt in normotensive men. *J Hypertens* 18:855-859, 2000
2016. Schroder M, Riedel E, Beck W, Deppisch RM, Pommer W: Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes. *Kidney Int Suppl* 78:S19-S24, 2001
2017. Schuchardt M, Prufer J, Prufer N, Wiedon A, Huang T, Chebli M, Jankowski V, Jankowski J, Schafer-Korting M, Zidek W, van der Giet M, Tolle M: The endothelium-derived contracting factor uridine adenosine tetraphosphate induces p2y(2)-mediated pro-inflammatory signaling by monocyte chemoattractant protein-1 formation. *J Mol Med (Berl)* 89:799-810, 2011
2018. Schuchardt M, Tolle M, Prufer J, Prufer N, Huang T, Jankowski V, Jankowski J, Zidek W, van der Giet M: Uridine adenosine tetraphosphate activation of the purinergic receptor p2y enhances in vitro vascular calcification. *Kidney Int* 81:256-265, 2012
2019. Schuchardt M, Prufer J, Prufer N, Wiedon A, Huang T, Chebli M, Jankowski V, Jankowski J, Schafer-Korting M, Zidek W, van der Giet M, Tolle M: The endothelium-derived contracting factor uridine adenosine tetraphosphate induces p2y(2)-mediated pro-inflammatory signaling by monocyte chemoattractant protein-1 formation. *J Mol Med (Berl)* 2011;89:799-810.
2020. Schuchardt M, Tolle M, Prufer J, Prufer N, Huang T, Jankowski V, Jankowski J, Zidek W, van der Giet M: Uridine adenosine tetraphosphate activation of the purinergic receptor p2y enhances in vitro vascular calcification. *Kidney Int* 2012;81:256-265.
2021. Schulze A, Hess T, Wevers R, Mayatepek E, Bachert P, Marescau B, Knopp MV, De Deyn PP, Bremer HJ, Rating D: Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: diagnostic tools for a new inborn error of metabolism. *J Pediatr* 131:626-631, 1997
2022. Schulze A, Mayatepek E, Bachert P, Marescau B, De Deyn PP, Rating D: Therapeutic trial of arginine restriction in creatine deficiency syndrome. *Eur J Pediatr* 157:606-607, 1998
2023. Schulze A, Mayatepek E, Frank S, Marescau B, De Deyn PP, Bachert P: Disturbed metabolism of guanidino compounds characterized by elevated excretion of beta-guanidinopropionic acid and gamma-

- guanidinobutyric acid--an effect of vigabatrin treatment? *J Inher Metab Dis* 21:268-271, 1998
2024. Schwartz M, De Deyn PP, van den KM, Pickut BA: Cervical dystonia as a probable consequence of focal cerebral lesion. *Mov Disord* 10:797-798, 1995
2025. Schwarz C, Regele H, Huttary N, Wahrmann M, Exner M, Nagy-Bojarsky K, Kletzmayer J, Horl WH, Bohmig GA: Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy. *Wien Klin Wochenschr* 118:397-404,
2026. Schwenger V, Hofmann A, Khalifeh N, Meyer T, Zeier M, Horl WH, Ritz E: [Uremic patients--late referral, early death]. *Dtsch Med Wochenschr* 128:1216-1220, 2003
2027. Schwenger V, Morath C, Schonfelder K, Klein W, Weigel K, Deppisch R, Henle T, Ritz E, Zeier M: An oral load of the early glycation compound lactuloselysine fails to accumulate in the serum of uraemic patients. *Nephrol Dial Transplant* 21:383-388, 2006
2028. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, Ritz E, Bierhaus A, Nawroth PP, Zeier M: Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. *J Am Soc Nephrol* 17:199-207, 2006
2029. Seck SM, Dussol B, Brunet P, Burtey S: Clinical features and outcomes of anca-associated renal vasculitis. *Saudi J Kidney Dis Transpl* 23:301-305, 2012
2030. Seck SM, Dussol B, Brunet P, Burtey S: Clinical features and outcomes of anca-associated renal vasculitis. *Saudi J Kidney Dis Transpl* 2012;23:301-305.
2031. Sengoelge G, Fodinger M, Skoupy S, Ferrara I, Zangerle C, Rogy M, Horl WH, Sunder-Plassmann G, Menzel J: Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. *Kidney Int* 54:1637-1651, 1998
2032. Sengoelge G, Perschl A, Ferrara I, Horl WH, Sunder-Plassmann G: Surface antigens of human mesangial cells: impact of growth surface or IL-1alpha. *Tissue Antigens* 60:383-395, 2002
2033. Sengoelge G, Kletzmayer J, Papagiannopoulos M, Bohle B, Horl WH, Fodinger M, Sunder-Plassmann G: TGF-beta1 impairs homocysteine metabolism in human renal cells: possible implications for transplantation. *Transpl Int* 16:843-848, 2003
2034. Sengoelge G, Kletzmayer J, Ferrara I, Perschl A, Horl WH, Sunder-Plassmann G: Impairment of transendothelial leukocyte migration by iron complexes. *J Am Soc Nephrol* 14:2639-2644, 2003
2035. Sengoelge G, Rainer V, Kletzmayer J, Jansen M, Derfler K, Fodinger M, Horl WH, Sunder-Plassmann G: Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients. *Kidney Int* 66:295-302, 2004
2036. Sengoelge G, Sunder-Plassmann G, Horl WH: Potential risk for infection and atherosclerosis due to iron therapy. *J Ren Nutr* 15:105-110, 2005
2037. Sengolge G, Horl WH, Sunder-Plassmann G: Intravenous iron therapy: well-tolerated, yet not harmless. *Eur J Clin Invest* 35 Suppl 3:46-51, 2005
2038. Seo MJ, Oh SJ, Kim SI, Cho KW, Jo I, Schaub T, Schilling H, Passlick-Deetjen J, Han DC: High glucose dialysis solutions increase synthesis of vascular endothelial growth factors by peritoneal vascular endothelial cells. *Perit Dial Int* 21 Suppl 3:S35-S40, 2001
2039. Settergren B, Ahlm C, Alexeyev O, Billheden J, Stegmayr B: Pathogenetic and clinical aspects of the renal involvement in hemorrhagic fever with renal syndrome. *Ren Fail* 19:1-14, 1997
2040. Settergren B, Stegmayr BG, Elgh F: Lack of serologic evidence for an association between Hantavirus infection and end-stage renal disease. *Nephron* 80:93, 1998
2041. Sever MS, Ereğ E, Vanholder R, Akoglu E, Yavuz M, Ergin H, Tekce M, Korular D, Tulbek MY, Keven K, Van VB, Lameire N: The Marmara earthquake: epidemiological analysis of the victims with nephrological problems. *Kidney Int* 60:1114-1123, 2001
2042. Sever MS, Ereğ E, Vanholder R, Koc M, Yavuz M, Ergin H, Kazancıoğlu R, Serdengeçti K, Okumus G, Özdemir N, Schindler R, Lameire N: Treatment modalities and outcome of the renal victims of the Marmara earthquake. *Nephron* 92:64-71, 2002
2043. Sever MS, Ereğ E, Vanholder R, Akoglu E, Yavuz M, Ergin H, Turkmen F, Korular D, Yenicesu M, Erbilgin D, Hoeben H, Lameire N: Clinical findings in the renal victims of a catastrophic disaster: the Marmara earthquake. *Nephrol Dial Transplant* 17:1942-1949, 2002
2044. Sever MS, Ereğ E, Vanholder R, Ozener C, Yavuz M, Kayacan SM, Ergin H, Apaydin S, Cobanoğlu M, Donmez O, Erdem Y, Lameire N: Lessons learned from the Marmara disaster: Time period under the rubble. *Crit Care Med* 30:2443-2449, 2002
2045. Sever MS, Ereğ E, Vanholder R, Ozener C, Yavuz M, Ergin H, Kiper H, Korular D, Canbakan B, Arinsoy T, VanBiesen W, Lameire N: The Marmara earthquake: admission laboratory features of patients with nephrological problems. *Nephrol Dial Transplant* 17:1025-1031, 2002
2046. Sever MS, Ereğ E, Vanholder R, Yurugen B, Kantarci G, Yavuz M, Ergin H, Bozfakioglu S, Dalmak S, Tulbek MY, Kiper H, Lameire N: Renal replacement therapies in the aftermath of the catastrophic Marmara earthquake. *Kidney Int* 62:2264-2271, 2002
2047. Sever MS, Ereğ E, Vanholder R, Kantarci G, Yavuz M, Turkmen A, Ergin H, Tulbek MY, Duranay M, Manga G, Sevinir S, Lameire N: Serum potassium in the crush syndrome victims of the Marmara disaster. *Clin Nephrol* 59:326-333, 2003
2048. Sever MS, Ereğ E, Vanholder R, Lameire N: Effect of gender on various parameters of crush syndrome victims of the Marmara earthquake. *J Nephrol* 17:399-404, 2004
2049. Sever MS, Ereğ E, Vanholder R, Kalkan A, Guney N, Usta N, Yilmaz C, Kutanis C, Turgut R, Lameire N: Features of chronic hemodialysis practice after the Marmara earthquake. *J Am Soc Nephrol* 15:1071-1076, 2004
2050. Sever MS, Ereğ E, Vanholder R, Koc M, Yavuz M, Aysuna N, Ergin H, Ataman R, Yenicesu M, Canbakan B, Demircan C, Lameire N: Lessons learned from the catastrophic Marmara earthquake: factors influencing the final outcome of renal victims. *Clin Nephrol* 61:413-421, 2004
2051. Sever MS, Vanholder R, Lameire N: Management of crush-related injuries after disasters. *N Engl J Med* 354:1052-1063, 2006
2052. Sever MS, Kellum J, Hoste E, Vanholder R: Application of the rifle criteria in patients with crush-related acute kidney injury after mass disasters. *Nephrol Dial Transplant* 26:515-524, 2011
2053. Sever MS, Kellum J, Hoste E, Vanholder R: Application of the rifle criteria in patients with crush-related acute kidney injury after mass disasters. *Nephrol Dial Transplant* 2011;26:515-524.
2054. Sevin C, Benraiss A, Van DD, Bonnin D, Nagels G, Verot L, Laurendeau I, Vidaud M, Gieselmann V, Vanier M, De Deyn PP, Aubourg P, Cartier N: Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. *Hum Mol Genet* 15:53-64, 2006

2055. Sevin C, Verot L, Benraiss A, Van DD, Bonnin D, Nagels G, Fouquet F, Gieselmann V, Vanier MT, De Deyn PP, Aubourg P, Cartier N: Partial cure of established disease in an animal model of metachromatic leukodystrophy after intracerebral adeno-associated virus-mediated gene transfer. *Gene Ther* 14:405-414, 2007
2056. Shahapuni I, Monge M, Oprisiu R, Mazouz H, Westeel PF, Moriniere P, Massy Z, Choukroun G, Fournier A: Drug Insight: renal indications of calcimimetics. *Nat Clin Pract Nephrol* 2:316-325, 2006
2057. Shahapuni I, Bonne JF, Mailliez S, Aghai R, Massy Z, Fournier A: Parathyroid hormone synthesis suppression by 25(OH)<sub>2</sub> vit D<sub>3</sub>. *Kidney Int* 71:1325-1326, 2007
2058. Sharma AM, Beige J, Distler A: Role of genetic variants of the renin-angiotensin system in chronic renal allograft injury. *Kidney Int* 53:1461-1465, 1998
2059. Sheorajpanday R, Slabbynck H, Van De SW, Galdermans D, Neetens I, De Deyn PP: Small cell lung carcinoma presenting as collapsin response-mediating protein (CRMP) -5 paraneoplastic optic neuropathy. *J Neuroophthalmol* 26:168-172, 2006
2060. Sheorajpanday RV, De Deyn PP: Epileptic fits and epilepsy in the elderly: general reflections, specific issues and therapeutic implications. *Clin Neurol Neurosurg* 109:727-743, 2007
2061. Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M: Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. *J Clin Invest* 101:1142-1147, 1998
2062. Sikole A, Spasovski G, Zafirov D, Polenakovic M: Epoetin omega for treatment of anemia in maintenance hemodialysis patients. *Clin Nephrol* 57:237-245, 2002
2063. Silver J, Drueke TB: Master genes for bone growth, 1,25-dihydroxyvitamin D<sub>3</sub> synthesis, and renal conservation of phosphate and calcium. *Curr Opin Nephrol Hypertens* 7:359-361, 1998
2064. Simon N, Brunet P, Roumenov D, Dussol B, Barre J, Duche JC, Albengres E, D'Athis PD, Chauvet-Monges AM, Berland Y, Tillement JP: Trimetazidine does not modify blood levels and immunosuppressant effects of cyclosporine A in renal allograft recipients. *Br J Clin Pharmacol* 44:591-594, 1997
2065. Simon N, Dussol B, Sampol E, Purgus R, Brunet P, Lacarelle B, Berland Y, Bruguerolle B, Urien S: Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. *Clin Pharmacokinet* 45:493-501, 2006
2066. Sindic CJ, Seelldrayers P, Vande GL, De SE, Nagels G, De Deyn PP, Medaer R, Guillaume D, D'hooghe MB, Deville MC, Decoo D, Sadzot B, Van LW, Strauven T, Pepin J, Merckx H, Caekebeke J, van der Toel MA: Long-term follow up of glatiramer acetate compassionate use in Belgium. *Acta Neurol Belg* 105:81-85, 2005
2067. Skoczylas A, Wiecek A: [Ghrelin, a new hormone involved not only in the regulation of appetite]. *Wiad Lek* 59:697-701, 2006
2068. Skoufos L, Topley N, Cooker L, Dawnay A, Millar DJ, Holmes CJ, Faict D: The in vitro biocompatibility performance of a 25 mmol/L bicarbonate/10 mmol/L lactate-buffered peritoneal dialysis fluid. *Kidney Int Suppl*S94-S99, 2003
2069. Skoupy S, Fodinger M, Veitl M, Perschl A, Puttinger H, Rohrer C, Schindler K, Vychytil A, Horl WH, Sunder-Plassmann G: Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients. *J Am Soc Nephrol* 13:1331-1337, 2002
2070. Slabbynck H, Bedert L, De Deyn PP, Galdermans D, Coolen D: Unilateral segmental hyperhidrosis associated with pulmonary adenocarcinoma. *Chest* 114:1215-1217, 1998
2071. Sladkova E, Hes O, Mischak H, McGuire BM: Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. *Electrophoresis* 28:4469-4483, 2007
2072. Sniehotta M, Schiffer E, Zurbig P, Novak J, Mischak H: CE -a multifunctional application for clinical diagnosis. *Electrophoresis* 28:1407-1417, 2007
2073. Soderberg S, Ahren B, Stegmayr B, Johnson O, Wiklund PG, Weinehall L, Hallmans G, Olsson T: Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort. *Stroke* 30:328-337, 1999
2074. Soderberg S, Stegmayr B, hlbeck-Glader C, Slunga-Birgander L, Ahren B, Olsson T: High leptin levels are associated with stroke. *Cerebrovasc Dis* 15:63-69, 2003
2075. Soderberg S, Stegmayr B, Stenlund H, Sjoström LG, Agren A, Johansson L, Weinehall L, Olsson T: Leptin, but not adiponectin, predicts stroke in males. *J Intern Med* 256:128-136, 2004
2076. Sodergren A, Stegmayr B, Lundberg V, Ohman ML, Wallberg-Jonsson S: Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. *Ann Rheum Dis* 66:263-266, 2007
2077. Solez K, Benediktsson H, Cavallo T, Croker B, Demetris AJ, Drachenberg C, Emancipator S, Furness PN, Gaber LW, Gibson IW, Gough J, Gupta R, Halloran P, Hayry P, Kashgarian M, Marcussen N, Massy ZA, Mihatsch MJ, Morozumi K, Noronha I, Olsen S, Papadimitriou J, Paul LC, Picken M, Racusen LC. : Report of the Third Banff Conference on Allograft Pathology (July 20-24, 1995) on classification and lesion scoring in renal allograft pathology. *Transplant Proc* 28:441-444, 1996
2078. Song L, Morrison JJ, Botting NP, Thornalley PJ: Analysis of glucosinolates, isothiocyanates, and amine degradation products in vegetable extracts and blood plasma by LC-MS/MS. *Anal Biochem* 347:234-243, 2005
2079. Song L, Thornalley PJ: Effect of storage, processing and cooking on glucosinolate content of Brassica vegetables. *Food Chem Toxicol* 45:216-224,
2080. Sonikian M, Gogusev J, Zingraff J, Loric S, Quednau B, Bessou G, Siffert W, Drueke TB, Reusch HP, Luft FC: Potential effect of metabolic acidosis on beta 2-microglobulin generation: in vivo and in vitro studies. *J Am Soc Nephrol* 7:350-356, 1996
2081. Sorrentino SA, Bahlmann FH, Besler C, Muller M, Schulz S, Kirchhoff N, Doerries C, Horvath T, Limbourg A, Limbourg F, Fliser D, Haller H, Drexler H, Landmesser U: Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. *Circulation* 116:163-173, 2007
2082. Sotiropoulos GC, Lang H, Herget-Rosenthal S, Molmenti EP, Baba HA, Karaliotas C, Broelsch CE, Saner FH: Salvage plasmapheresis for small-for-size syndrome following hepatic resection for colorectal liver metastases. *Int J Colorectal Dis* 2007
2083. S, Gayrard N, Mejean C, Swarcz I, Mourad G, Argiles A: [Molecular mechanisms involved in kidney ischemia-reperfusion]. *Nephrol Ther* 1:315-321, 2005
2084. Spanaus KS, Kronenberg F, Ritz E, Schlapbach R, Fliser D, Hersberger M, Kollerits B, König P, von EA: B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. *Clin Chem* 53:1264-1272, 2007
2085. Spasovski G, Ivanovski N, Masin-Spasovska J, Dzikova S, Grcavska L, Petrusavska G, Lekovski L, Popov Z, Polenakovic M: Recurrent



- glomerulonephritis in living kidney transplantation. *Prilozi* 26:79-90, 2005
2086. Spasovski G, Vanholder R: Effect of lowering dialysate calcium on bone and mineral parameters related to adynamic bone disease. *Ther Apher Dial* 11:455-456, 2007
2087. Spasovski G, Gelev S, Masin-Spasovska J, Selim G, Sikole A, Vanholder R: Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. *Bone* 41:698-703, 2007
2088. Spasovski G: New aspects of treatment of renal bone disease in dialysis patients. *Prilozi* 28:205-213, 2007
2089. Spasovski G, Masin-Spasovska J, Ivanovski N: Do we have the same clinical results with Neoral((R)) and Equoral((R)) treatment in kidney transplant recipients? A pilot study. *Transpl Int* 21:392-394, 2008
2090. Spasovski G, Vanholder R: Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride? *Nephrol Dial Transplant* 26:1442-1443, 2011
2091. Spasovski G, Ortiz A, Vanholder R, El Nahas M: Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. *Proteomics Clin Appl* 5:233-240, 2011
2092. Spasovski G, Ortiz A, Vanholder R, El Nahas M: Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. *Proteomics Clin Appl* 2011;5:233-240.
2093. Spasovski G, Vanholder R: Is combined calcium/magnesium phosphate binder really noninferior to sevelamer hydrochloride? *Nephrol Dial Transplant* 2011;26:1442-1443; author reply 1443-1444.
2094. Spasovski GB, Bervoets AR, Behets GJ, Ivanovski N, Sikole A, Dams G, Couettenye MM, De Broe ME, D'Haese PC: Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. *Nephrol Dial Transplant* 18:1159-1166, 2003
2095. Spasovski GB: Bone biopsy in the diagnosis of renal osteodystrophy. *Prilozi* 25:83-93, 2004
2096. Spasovski GB: Bone biopsy as a diagnostic tool in the assessment of renal osteodystrophy. *Int J Artif Organs* 27:918-923, 2004
2097. Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, Gill M, Jones C, De Broe ME, D'Haese PC: Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. *Nephrol Dial Transplant* 21:2217-2224, 2006
2098. Spasovski GB: First two AB-incompatible living kidney transplantations in the Balkans -should it be a procedure of choice in a developing country? *Int J Artif Organs* 30:173-175, 2007
2099. Spasovski GB: Bone health and vascular calcification relationships in chronic kidney disease. *Int Urol Nephrol* 39:1209-1216, 2007
2100. Sperschneider H, Deppisch R, Beck W, Wolf H, Stein G: Impact of membrane choice and blood flow pattern on coagulation and heparin requirement--potential consequences on lipid concentrations. *Nephrol Dial Transplant* 12:2638-2646, 1997
2101. Spiechowicz U, Kokot F, Wiecek A: [Markers of calcium--phosphate metabolism and bones alterations in long term kidney transplant patients]. *Przegł Lek* 60:690-694, 2003
2102. Spiechowicz U, Kokot F, Wiecek A: Function of parathyroid glands in kidney transplant patients--diagnostic value of CAP and CIP. *Ann Transplant* 9:33-36, 2004
2103. Spigset O, Hagg S, Stegmayr B, Dahlqvist R: Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. *Eur J Clin Pharmacol* 56:699-703, 2000
2104. Sprigg N, Gray LJ, Bath PM, Boysen G, De Deyn PP, Friis P, Leys D, Marttila R, Olsson JE, O'Neill D, Ringelstein B, van der Sande JJ, Lindstrom E: Relationship between outcome and baseline blood pressure and other haemodynamic measures in acute ischaemic stroke: data from the TAIST trial. *J Hypertens* 24:1413-1417, 2006
2105. Sprigg N, Gray LJ, Bath PM, Lindstrom E, Boysen G, De Deyn PP, Friis P, Leys D, Marttila R, Olsson JE, O'Neill D, Ringelstein EB, van der Sande JJ, Turpie AG: Early recovery and functional outcome are related with causal stroke subtype: data from the tinzaparin in acute ischemic stroke trial. *J Stroke Cerebrovasc Dis* 16:180-184, 2007
2106. Sprigg N, Gray LJ, Bath PM, Lindstrom E, Boysen G, De Deyn PP, Friis P, Leys D, Marttila R, Olsson JE, O'Neill D, Ringelstein EB, van der Sande JJ, Turpie AG: Stroke severity, early recovery and outcome are each related with clinical classification of stroke: data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST). *J Neurol Sci* 254:54-59, 2007
2107. Staniszevska MA, Jankowski J: An update of the frequency and type of diagnostic x-ray examinations in Poland. *Int J Occup Med Environ Health* 12:127-134, 1999
2108. Stegmayr B, Asplund K: Diabetes as a risk factor for stroke. A population perspective. *Diabetologia* 38:1061-1068, 1995
2109. Stegmayr B, Asplund K: Exploring the declining case fatality in acute stroke. Population-based observations in the northern Sweden MONICA Project. *J Intern Med* 240:143-149, 1996
2110. Stegmayr B, Asplund K, Kuulasmaa K, Rajakangas AM, Thorvaldsen P, Tuomilehto J: Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA Project. An ecological study of 18 populations. *Stroke* 28:1367-1374, 1997
2111. Stegmayr B: Apheresis of plasma compounds as a therapeutic principle in severe sepsis and multiorgan dysfunction syndrome. *Clin Chem Lab Med* 37:327-332, 1999
2112. Stegmayr B, Asplund K, Danielsson BP, Hulter-Asberg K, Norrving B, Peltonen M, Terent A, Thorngren M, Wester PO: [Stroke unit care saves lives. The Swedish national quality assessment registry of stroke care is the first of its kind in the world]. *Lakartidningen* 96:2719-24, 2726, 1999
2113. Stegmayr B, Asplund K, Hulter-Asberg K, Norrving B, Peltonen M, Terent A, Wester PO: Stroke units in their natural habitat: can results of randomized trials be reproduced in routine clinical practice? *Riks-Stroke Collaboration*. *Stroke* 30:709-714, 1999
2114. Stegmayr B: Is there a place for LDL-apheresis in non-homozygous patients? *Int J Artif Organs* 22:723-725, 1999
2115. Stegmayr B, Vinogradova T, Malyutina S, Peltonen M, Nikitin Y, Asplund K: Widening gap of stroke between east and west. Eight-year trends in occurrence and risk factors in Russia and Sweden. *Stroke* 31:2-8, 2000
2116. Stegmayr B: Various clinical approaches to minimise complications in peritoneal dialysis. *Int J Artif Organs* 25:365-372, 2002
2117. Stegmayr B, Asplund K: Informed consent for genetic research on blood stored for more than a decade: a population based study. *BMJ* 325:634-635,
2118. Stegmayr B, Asplund K: [Improved survival after stroke but unchanged risk of incidence]. *Lakartidningen* 100:3492-3498, 2003

2119. Stegmayr B, Korach JM, Norda R, Rock G, Fadel F: Is there a need for a national or a global apheresis registry? *Transfus Apher Sci* 29:179-185, 2003
2120. Stegmayr B, Asplund K: Stroke in Northern Sweden. *Scand J Public Health Suppl* 61:60-69, 2003
2121. Stegmayr B, Lundberg V, Asplund K: The events registration and survey procedures in the Northern Sweden MONICA Project. *Scand J Public Health Suppl* 61:9-17, 2003
2122. Stegmayr B, Asplund K: [Genetic research on blood samples stored for years in biobanks. Most people are willing to provide informed consent]. *Lakartidningen* 100:618-620, 2003
2123. Stegmayr B, Wikdahl AM: Access in therapeutic apheresis. *Ther Apher Dial* 7:209-214, 2003
2124. Stegmayr B, Eriksson M, Asplund K: Declining mortality from subarachnoid hemorrhage: changes in incidence and case fatality from 1985 through 2000. *Stroke* 35:2059-2063, 2004
2125. Stegmayr B, Lalau JD, Johnson O: In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis? *Transfus Apher Sci* 30:213-220, 2004
2126. Stegmayr B: Peritoneal dialysis as a plausible option in morbus Osler: case report. *Adv Perit Dial* 21:128-130, 2005
2127. Stegmayr B, Eliasson M, Rodu B: The decline of smoking in northern Sweden. *Scand J Public Health* 33:321-324, 2005
2128. Stegmayr B, Klingstedt J, Grahn BE, Vinnervik P: The new WAA apheresis registry. *Transfus Apher Sci* 34:259-262, 2006
2129. Stegmayr B: Advantages and disadvantages of surgical placement of PD catheters with regard to other methods. *Int J Artif Organs* 29:95-100, 2006
2130. Stegmayr B, Forsberg U, Jonsson P, Stegmayr C: The sensor in the venous chamber does not prevent passage of air bubbles during hemodialysis. *Artif Organs* 31:162-166, 2007
2131. Stegmayr B, Ptak J, Wikstrom B: World apheresis registry report. *Transfus Apher Sci* 36:13-16, 2007
2132. Stegmayr B: Editorial for ESFH 2006 Umea Congress. *Transfus Apher Sci* 37:175-176, 2007
2133. Stegmayr BG, Jakobson S, Rydvall A, Bjorsell-Ostling E: Plasma exchange in patients with acute renal failure in the course of multiorgan failure. *Int J Artif Organs* 18:45-52, 1995
2134. Stegmayr BG: Plasmapheresis in severe sepsis or septic shock. *Blood Purif* 14:94-101, 1996
2135. Stegmayr BG: Plasma exchange in patients with septic shock including acute renal failure. *Blood Purif* 14:102-108, 1996
2136. Stegmayr BG, Banga R, Lundberg L, Wikdahl AM, Plum-Wirell M: PD treatment for severe congestive heart failure. *Perit Dial Int* 16 Suppl 1:S231-S235, 1996
2137. Stegmayr BG, Norberg AK, Granbom L, Wikdahl AM: No risk for peritonitis by sampling with a modified PET. *Perit Dial Int* 17:613-614, 1997
2138. Stegmayr BG: Beta-blockers may cause ultrafiltration failure in peritoneal dialysis patients. *Perit Dial Int* 17:541-545, 1997
2139. Stegmayr BG, Wikdahl AM, Granbom L, Engman U: Peritoneal dialysis by twin bags is a good alternative to hemodialysis for sparsely populated areas. *Perit Dial Int* 17:95-96, 1997
2140. Stegmayr BG: Authors' response: no increased risk for peritonitis by insulin injected into the peritoneal dialysis solution bag through Coloplast. *ANNA J* 24:591, 1997
2141. Stegmayr BG: Better response to s.c. erythropoietin in CAPD than HD patients. *Scand J Urol Nephrol* 31:183-187, 1997
2142. Stegmayr BG, Wikdahl AM, Arnerlov C, Petersen E: A modified lateral technique for the insertion of peritoneal dialysis catheters enabling immediate start of dialysis. *Perit Dial Int* 18:329-331, 1998
2143. Stegmayr BG: Modification of the technique for intraperitoneal instillation of x-ray media in PD patients. *Perit Dial Int* 18:342, 1998
2144. Stegmayr BG, Almroth G, Berlin G, Fehrman I, Kurkus J, Norda R, Olander R, Sterner G, Thysell H, Wikstrom B, Wiren JE: Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. *Int J Artif Organs* 22:81-87, 1999
2145. Stegmayr BG, Gothefors L, Malmer B, Muller Wiefel DE, Nilsson K, Sundelin B: Wegener granulomatosis in children and young adults. A case study of ten patients. *Pediatr Nephrol* 14:208-213, 2000
2146. Stegmayr BG: Is there a future for adsorption techniques in sepsis? *Blood Purif* 18:149-155, 2000
2147. Stegmayr BG: Beta-blocker use in peritoneal dialysis patients. *Semin Dial* 14:73, 2001
2148. Stegmayr BG: The presence of superantigens and complex host responses in severe sepsis may need a broad therapeutic approach. *Ther Apher* 5:111-114, 2001
2149. Stegmayr BG, Plum WM: Intravenously administered erythropoietin may cause a direct increase in blood pressure in CAPD patients. *Perit Dial Int* 21:316-317, 2001
2150. Stegmayr BG: Apheresis as therapy for patients with severe sepsis and multiorgan dysfunction syndrome. *Ther Apher* 5:123-127, 2001
2151. Stegmayr BG: Three purse-string sutures allow immediate start of peritoneal dialysis with a low incidence of leakage. *Semin Dial* 16:346-348, 2003
2152. Stegmayr BG, Banga R, Berggren L, Norda R, Rydvall A, Vikerfors T: Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. *Crit Care Med* 31:1730-1736, 2003
2153. Stegmayr BG: Ultrafiltration and dry weight-what are the cardiovascular effects? *Artif Organs* 27:227-229, 2003
2154. Stegmayr BG, Ivanovich P, Korach JM, Rock G, Norda R, Ramlow W: World apheresis registry. *J Clin Apher* 20:126-127, 2005
2155. Stegmayr BG, Wikdahl AM, Bergstrom M, Nilsson C, Engman U, Arnerlov C, Petersen E: A randomized clinical trial comparing the function of straight and coiled Tenckhoff catheters for peritoneal dialysis. *Perit Dial Int* 25:85-88, 2005
2156. Stegmayr BG: A survey of blood purification techniques. *Transfus Apher Sci* 32:209-220, 2005
2157. Stegmayr BG, Ivanovich P, Korach JM, Rock G, Norda R, Ramlow W: World apheresis association--world apheresis registry. *Transfus Apher Sci* 32:205-207, 2005
2158. Stegmayr BG, Brannstrom M, Bucht S, Dimeny E, Ekspong A, Granroth B, Grontoft KC, Hadimeri H, Holmberg B, Ingman B, Isaksson B, Johansson G, Lindberger K, Lundberg L, Lundstrom O, Mikaelsson L, Mortzell M, Olausson E, Persson B, Svensson L, Wikdahl AM: Minimized weight gain between hemodialysis contributes to a reduced risk of death. *Int J Artif Organs* 29:675-680, 2006

2159. Stegmayr CJ, Jonsson P, Forsberg U, Stegmayr BG: Development of air micro bubbles in the venous outlet line: an in vitro analysis of various air traps used for hemodialysis. *Artif Organs* 31:483-488, 2007
2160. Steiner S, Schaller G, Puttinger H, Fodinger M, Kopp CW, Seidinger D, Grisar J, Horl WH, Minar E, Vychytil A, Wolzt M, Sunder-Plassmann G: History of cardiovascular disease is associated with endothelial progenitor cells in peritoneal dialysis patients. *Am J Kidney Dis* 46:520-528, 2005
2161. Steiner S, Winkelmayr WC, Kleinert J, Grisar J, Seidinger D, Kopp CW, Watschinger B, Minar E, Horl WH, Fodinger M, Sunder-Plassmann G: Endothelial progenitor cells in kidney transplant recipients. *Transplantation* 81:599-606, 2006
2162. Stengel B, Antignac C, Baverel G, Choukroun G, Cussenot O, Dussaule JC, Friedlander G, Lang P, Lelievre-Pegorier M, Massy Z, Monteiro R, Parini A, Souillou JP, Baud L, Ronco P: [Renal and urinary tract disease national research program]. *Nephrol Ther* 3:157-162, 2007
2163. Stenlund T, Ahlgren C, Lindahl B, Burell G, Knutsson A, Stegmayr B, Birgander LS: Patients with burnout in relation to gender and a general population. *Scand J Public Health* 35:516-523, 2007
2164. Stenvinkel P, Ottosson-Seeberger A, Alvestrand A, Bolinder J: Effect of insulin on renal sodium handling and renal haemodynamics in insulin-dependent (type 1) diabetes mellitus patients. *Acta Diabetol* 32:230-234, 1995
2165. Stenvinkel P: Sodium and insulin--is there a relationship? *Nephrol Dial Transplant* 10:1286-1287, 1995
2166. Stenvinkel P: [Acute renal failure can be prevented. New discoveries on the significance of hypoxia in the renal medulla]. *Lakartidningen* 92:3667-3669, 1995
2167. Stenvinkel P, Ottosson-Seeberger A, Alvestrand A: Renal hemodynamics and sodium handling in moderate renal insufficiency: the role of insulin resistance and dyslipidemia. *J Am Soc Nephrol* 5:1751-1760, 1995
2168. Stenvinkel P: Low molecular weight heparin--does it favourably affect lipid levels? *Nephrol Dial Transplant* 10:16-18, 1995
2169. Stenvinkel P, Berglund L: Lipoprotein(a) in chronic renal disease. *Miner Electrolyte Metab* 22:16-21, 1996
2170. Stenvinkel P, Heimbürger O, Lonnqvist F: Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. *Nephrol Dial Transplant* 12:1321-1325, 1997
2171. Stenvinkel P, Ottosson-Seeberger A, de PK, Alvestrand A: A calcium-channel blocker, amlodipine, attenuates insulin antinatriuresis but does not modulate insulin-mediated attenuation of cardiovascular reactivity in healthy man. *Nephrol Dial Transplant* 12:1600-1607, 1997
2172. Stenvinkel P, Berglund L, Ericsson S, Alvestrand A, Angelin B, Eriksson M: Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. *Eur J Clin Invest* 27:169-177, 1997
2173. Stenvinkel P, Bolinder J, Alvestrand A: Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy. *Acta Diabetol* 34:10-17, 1997
2174. Stenvinkel P, Heimbürger O, Lonnqvist F, Barany P: Does the ob gene product leptin stimulate erythropoiesis in patients with chronic renal failure? *Kidney Int* 53:1430-1431, 1998
2175. Stenvinkel P, Holmberg I, Heimbürger O, Diczfalusy U: A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. *Nephrol Dial Transplant* 13:2594-2600, 1998
2176. Stenvinkel P: Leptin--a new hormone of definite interest for the nephrologist. *Nephrol Dial Transplant* 13:1099-1101, 1998
2177. Stenvinkel P, Heimbürger O, Tuck CH, Berglund L: Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. *Kidney Int* 53:1336-1342, 1998
2178. Stenvinkel P, Heimbürger O, Jogestrand T, Karnell A, Samuelsson A: Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure? *Kidney Int* 55:2531-2532, 1999
2179. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. *Kidney Int* 55:1899-1911, 1999
2180. Stenvinkel P, Heimbürger O, Wang T, Lindholm B, Bergstrom J, Elinder CG: High serum hyaluronan indicates poor survival in renal replacement therapy. *Am J Kidney Dis* 34:1083-1088, 1999
2181. Stenvinkel P: Leptin and its clinical implications in chronic renal failure. *Miner Electrolyte Metab* 25:298-302, 1999
2182. Stenvinkel P, Andersson P, Wang T, Lindholm B, Bergstrom J, Palmblad J, Heimbürger O, Cederholm T: Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? *J Intern Med* 246:503-507, 1999
2183. Stenvinkel P, Heimbürger O: The enigma of increasing serum leptin levels during peritoneal dialysis. *Am J Kidney Dis* 34:947-950, 1999
2184. Stenvinkel P, Lonnqvist F, Schalling M: Molecular studies of leptin: implications for renal disease. *Nephrol Dial Transplant* 14:1103-1112, 1999
2185. Stenvinkel P, Lindholm B, Lonnqvist F, Katzarski K, Heimbürger O: Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. *J Am Soc Nephrol* 11:1303-1309, 2000
2186. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen GA, Bergstrom J: Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). *Nephrol Dial Transplant* 15:953-960, 2000
2187. Stenvinkel P: Leptin and blood pressure--is there a link? *Nephrol Dial Transplant* 15:1115-1117, 2000
2188. Stenvinkel P, Lindholm B, Heimbürger O: New strategies for management of malnutrition in peritoneal dialysis patients. *Perit Dial Int* 20:271-275, 2000
2189. Stenvinkel P, Alvestrand A, Angelin B, Eriksson M: LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. *Eur J Clin Invest* 30:866-870, 2000
2190. Stenvinkel P, Elinder CG, Barany P: Physical activity promotes health also among dialysis patients. *Int J Cardiol* 72:299-300, 2000
2191. Stenvinkel P, Lindholm B, Heimbürger M, Heimbürger O: Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. *Nephrol Dial Transplant* 15:1624-1630, 2000
2192. Stenvinkel P: Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. *Blood Purif* 19:143-151, 2001
2193. Stenvinkel P: The role of inflammation in the anaemia of end-stage renal disease. *Nephrol Dial Transplant* 16 Suppl 7:36-40, 2001

2194. Stenvinkel P, Chung SH, Heimbürger O, Lindholm B: Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients. *Perit Dial Int* 21 Suppl 3:S157-S162, 2001
2195. Stenvinkel P: Endothelial dysfunction and inflammation-is there a link? *Nephrol Dial Transplant* 16:1968-1971, 2001
2196. Stenvinkel P: Inflammatory and atherosclerotic interactions in the depleted uremic patient. *Blood Purif* 19:53-61, 2001
2197. Stenvinkel P, Barany P: [Unusual but serious adverse effect. Epoetin treatment of patients with kidney diseases caused erythroblastopenia]. *Lakartidningen* 99:4162-4163, 2002
2198. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: sources, consequences, and therapy. *Semin Dial* 15:329-337, 2002
2199. Stenvinkel P, Heimbürger O, Jogestrand T: Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. *Am J Kidney Dis* 39:274-282, 2002
2200. Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? *Kidney Int* 62:1791-1798, 2002
2201. Stenvinkel P: Inflammation in end-stage renal failure: could it be treated? *Nephrol Dial Transplant* 17 Suppl 8:33-38, 2002
2202. Stenvinkel P, Barany P, Chung SH, Lindholm B, Heimbürger O: A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. *Nephrol Dial Transplant* 17:1266-1274, 2002
2203. Stenvinkel P, Barany P: Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. *Nephrol Dial Transplant* 17 Suppl 5:32-37, 2002
2204. Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? *Kidney Int Suppl* 103-108, 2002
2205. Stenvinkel P, Pecoits-Filho R, Lindholm B: Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. *J Am Soc Nephrol* 14:1927-1939, 2003
2206. Stenvinkel P: Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. *J Ren Nutr* 13:144-148, 2003
2207. Stenvinkel P, Pecoits-Filho R, Lindholm B: Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease? *Adv Ren Replace Ther* 10:332-345, 2003
2208. Stenvinkel P: Anaemia and inflammation: what are the implications for the nephrologist? *Nephrol Dial Transplant* 18 Suppl 8:viii17-viii22, 2003
2209. Stenvinkel P, Marchlewska A, Pecoits-Filho R, Heimbürger O, Zhang Z, Hoff C, Holmes C, Axelsson J, Arvidsson S, Schalling M, Barany P, Lindholm B, Nordfors L: Adiponectin in renal disease: relationship to phenotype and genetic variation in the gene encoding adiponectin. *Kidney Int* 65:274-281, 2004
2210. Stenvinkel P, Lindholm B, Heimbürger O: Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease. *Semin Dial* 17:505-515, 2004
2211. Stenvinkel P, Diczfalussy U, Lindholm B, Heimbürger O: Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. *Nephrol Dial Transplant* 19:972-976, 2004
2212. Stenvinkel P, Heimbürger O, Lindholm B: Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. *Nephrol Dial Transplant* 19:2181-2183, 2004
2213. Stenvinkel P: Inflammation in end-stage renal disease--a fire that burns within. *Contrib Nephrol* 149:185-199, 2005
2214. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, Jogestrand T, Heimbürger O, Holmes C, Schalling M, Nordfors L: Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. *Kidney Int* 67:2383-2392, 2005
2215. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Gimdt M: IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. *Kidney Int* 67:1216-1233, 2005
2216. Stenvinkel P, Pecoits-Filho R, Lindholm B: Gene polymorphism association studies in dialysis: the nutrition-inflammation axis. *Semin Dial* 18:322-330, 2005
2217. Stenvinkel P, Lindholm B: C-reactive protein in end-stage renal disease: are there reasons to measure it? *Blood Purif* 23:72-78, 2005
2218. Stenvinkel P: C-reactive protein--does it promote vascular disease? *Nephrol Dial Transplant* 21:2718-2720, 2006
2219. Stenvinkel P: Inflammation in end-stage renal disease: the hidden enemy. *Nephrology (Carlton)* 11:36-41, 2006
2220. Stenvinkel P: New insights on inflammation in chronic kidney disease-genetic and non-genetic factors. *Nephrol Ther* 2:111-119, 2006
2221. Stenvinkel P, Karimi M, Johansson S, Axelsson J, Suliman M, Lindholm B, Heimbürger O, Barany P, Alvestrand A, Nordfors L, Qureshi AR, Ekstrom TJ, Schalling M: Impact of inflammation on epigenetic DNA methylation -a novel risk factor for cardiovascular disease? *J Intern Med* 261:488-499, 2007
2222. Stenvinkel P, Ekstrom TJ: Does the uremic milieu affect the epigenotype? *J Ren Nutr* 2009;19:82-85.
2223. Stenvinkel P, Johnson RJ: Kidney biomimicry--a rediscovered scientific field that could provide hope to patients with kidney disease. *Arch Med Res* 2013;44:584-590.
2224. Stenvinkel P, Larsson TE: Chronic kidney disease: A clinical model of premature aging. *Am J Kidney Dis* 2013;62:339-351.
2225. Stenvinkel P: [Cardiovascular disease increases the risk of renal failure]. *Lakartidningen* 104:2495, 2007
2226. Stepien O, Gogusev J, Zhu DL, Iouzalén L, Herembert T, Druke TB, Marche P: Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. *J Cardiovasc Pharmacol* 31:786-793, 1998
2227. Sterky E, Stegmayr BG: Elderly patients on haemodialysis have 50% less functional capacity than gender- and age-matched healthy subjects. *Scand J Urol Nephrol* 39:423-430, 2005
2228. Stevens PE, Druml W, Horl WH: Prophylaxis and conservative management of acute renal failure in the ICU. *Int J Artif Organs* 19:90-94, 1996
2229. Stockler S, Marescau B, De Deyn PP, Trijbels JM, Hanefeld F: Guanidino compounds in guanidinoacetate methyltransferase deficiency, a new inborn error of creatine synthesis. *Metabolism* 46:1189-1193, 1997
2230. Storms G, Dirix T, Saerens J, Verstraeten S, De Deyn PP: On the use of scaling and clustering in the study of semantic deficits. *Neuropsychology* 17:289-301, 2003

2231. Storms G, Saerens J, De Deyn PP: Normative data for the Boston Naming Test in native Dutch-speaking Belgian children and the relation with intelligence. *Brain Lang* 91:274-281, 2004
2232. Stratton RJ, Bircher G, Fouque D, Stenvinkel P, de MR, Engfer M, Elia M: Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. *Am J Kidney Dis* 46:387-405, 2005
2233. Streicher J, Valent P, Schmidt H, Sengolge G, Wagner O, Strobl W, Horl WH, Derfler K: Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia. *J Investig Med* 47:378-387, 1999
2234. Stummvoll GH, Aringer M, Smolen JS, Schmaldienst S, Jimenez-Boj E, Horl WH, Graninger WB, Derfler K: IgG immunoabsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. *Ann Rheum Dis* 64:1015-1021, 2005
2235. Sturm I, Watschinger B, Geissler K, Guber SE, Popow-Kraupp T, Horl WH, Pohanka E: Chronic parvovirus B19 infection-associated pure red cell anaemia in a kidney transplant recipient. *Nephrol Dial Transplant* 11:1367-1370, 1996
2236. Suliman M, Stenvinkel P, Qureshi AR, Kalantar-Zadeh K, Barany P, Heimbürger O, Vonesh EF, Lindholm B: The reverse epidemiology of plasma total homocysteine as a mortality risk factor is related to the impact of wasting and inflammation. *Nephrol Dial Transplant* 22:209-217, 2007
2237. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, Heimbürger O, Lindholm B, Bergstrom J: Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. *Kidney Int* 57:1727-1735, 2000
2238. Suliman ME, Stenvinkel P, Heimbürger O, Barany P, Lindholm B, Bergstrom J: Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. *Am J Kidney Dis* 40:480-488, 2002
2239. Suliman ME, Barany P, vino Filho JC, Qureshi AR, Stenvinkel P, Heimbürger O, Anderstam B, Lindholm B, Bergstrom J: Influence of nutritional status on plasma and erythrocyte sulphur amino acids, sulph-hydryls, and inorganic sulphate in end-stage renal disease. *Nephrol Dial Transplant* 17:1050-1056, 2002
2240. Suliman ME, Stenvinkel P, Barany P, Heimbürger O, Anderstam B, Lindholm B: Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus. *Am J Kidney Dis* 41:S89-S95, 2003
2241. Suliman ME, Heimbürger O, Barany P, Anderstam B, Pecoits-Filho R, Rodriguez AE, Qureshi AR, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. *J Am Soc Nephrol* 14:1614-1622, 2003
2242. Suliman ME, Stenvinkel P, Qureshi AR, Barany P, Heimbürger O, Anderstam B, Alvestrand A, Lindholm B: Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. *Am J Kidney Dis* 44:455-465, 2004
2243. Suliman ME, Stenvinkel P, Lindholm B: Is hyperhomocysteinemia a contributor to atherosclerosis in chronic kidney disease patients? *Nephron Clin Pract* 101:c187-c189, 2005
2244. Suliman ME, Qureshi AR, Stenvinkel P, Pecoits-Filho R, Barany P, Heimbürger O, Anderstam B, Rodriguez AE, vino Filho JC, Alvestrand A, Lindholm B: Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. *Am J Clin Nutr* 82:342-349, 2005
2245. Suliman ME, Barany P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P: Homocysteine in uraemia--a puzzling and conflicting story. *Nephrol Dial Transplant* 20:16-21, 2005
2246. Suliman ME, Johnson RJ, Garcia-Lopez E, Qureshi AR, Molinaei H, Carrero JJ, Heimbürger O, Barany P, Axelsson J, Lindholm B, Stenvinkel P: J-shaped mortality relationship for uric acid in CKD. *Am J Kidney Dis* 48:761-771, 2006
2247. Suliman ME, Stenvinkel P, Jogestrand T, Maruyama Y, Qureshi AR, Barany P, Heimbürger O, Lindholm B: Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. *Clin Nephrol* 66:418-425, 2006
2248. Suliman ME, Stenvinkel P, Barany P, Rashid QA, Lindholm B: Hyperhomocysteinemia, malnutrition, and inflammation in ESRD patients. *Semin Nephrol* 26:14-19, 2006
2249. Suliman ME, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P: Soluble adhesion molecules in end-stage renal disease: a predictor of outcome. *Nephrol Dial Transplant* 21:1603-1610, 2006
2250. Suliman ME, Lindholm B, Barany P, Qureshi AR, Stenvinkel P: Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. *Semin Dial* 20:523-529, 2007
2251. Sunder-Plassmann G, Horl WH: Mediators in continuous extracorporeal treatment of multiple organ dysfunction syndrome. *Contrib Nephrol* 116:10-15, 1995
2252. Sunder-Plassmann G, Horl WH: Importance of iron supply for erythropoietin therapy. *Nephrol Dial Transplant* 10:2070-2076, 1995
2253. Sunder-Plassmann G, Hofbauer R, Sengoelge G, Horl WH: Quantification of leukocyte migration: improvement of a method. *Immunol Invest* 25:49-63, 1996
2254. Sunder-Plassmann G, Horl WH: Can hemodialysis technique modify the hypercatabolic state? *Ren Fail* 18:395-404, 1996
2255. Sunder-Plassmann G, Horl WH: Safety of intravenous injection of iron saccharate in haemodialysis patients. *Nephrol Dial Transplant* 11:1797-1802, 1996
2256. Sunder-Plassmann G, Spitzauer S, Horl WH: The dilemma of evaluating iron status in dialysis patients--limitations of available diagnostic procedures. *Nephrol Dial Transplant* 12:1575-1580, 1997
2257. Sunder-Plassmann G, Horl WH: Erythropoietin and iron. *Clin Nephrol* 47:141-157, 1997
2258. Sunder-Plassmann G, Horl WH: Safety aspects of parenteral iron in patients with end-stage renal disease. *Drug Saf* 17:241-250, 1997
2259. -Plassmann G, Horl WH: Laboratory diagnosis of anaemia in dialysis patients: use of common laboratory tests. *Curr Opin Nephrol Hypertens* 6:566-569, 1997
2260. Sunder-Plassmann G, Patruta SI, Horl WH: Pathobiology of the role of iron in infection. *Am J Kidney Dis* 34:S25-S29, 1999
2261. Sunder-Plassmann G, Fodinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayer J, Enzenberger B, Janata O, Winkelmayer WC, Paul G, Auinger M, Barnas U, Horl WH: Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. *J Am Soc Nephrol* 11:1106-1116, 2000
2262. Sunder-Plassmann G, Horl WH: Novel aspects of erythropoietin response in renal failure patients. *Nephrol Dial Transplant* 16 Suppl 5:40-44, 2001

2263. Sunder-Plassmann G, Horl WH: Effect of erythropoietin on cardiovascular diseases. *Am J Kidney Dis* 38:S20-S25, 2001
2264. Sunder-Plassmann G, Horl WH: The clinical potential of novel erythropoiesis stimulating protein. *Expert Opin Biol Ther* 1:733-739, 2001
2265. Sunder-Plassmann G, Kittler H, Eberle C, Hirschl MM, Woisetschlager C, Derhaschnig U, Laggner AN, Horl WH, Fodinger M: Angiotensin converting enzyme DD genotype is associated with hypertensive crisis. *Crit Care Med* 30:2236-2241, 2002
2266. Sunder-Plassmann G, Horl WH: A critical appraisal for definition of hyperfiltration. *Am J Kidney Dis* 43:396-397, 2004
2267. Svensson M, Friberger P, Lundstrom O, Stegmayr B: Activation of FXII during haemodialysis. *Scand J Clin Lab Invest* 56:649-652, 1996
2268. Sydor A, Drozd M, Krasniak A, Milkowski A, Chmiel G, Malczak J, Zabawa-Holys S, Moskal K, Podwysocki A, Szmigielski M, Czarnecka D, Gozdecka H, Kowalczyk-Michalek M, Szczeklik A, Wiecek A, Sulowicz W: [Hyperhomocysteinemia and advancement of atherosclerosis in patients with chronic renal failure on maintenance hemodialysis]. *Przegł Lek* 59:962-967, 2002
2269. Szwarc I, Argiles A, Garrigue V, Delmas S, Chong G, Deleuze S, Mourad G: Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. *Transplantation* 82:675-680, 2006
2270. Szwarc I, Soullier S, Gayraud N, Mejean C, Mourad G, Argiles A: Ischemic postconditioning prevents ischemic acute renal failure. *Transplant Proc* 39:2554-2556, 2007
2271. Szwarc I, Mourad G, Argiles A: Post-conditioning to reduce renal ischaemia/reperfusion injury. *Nephrol Dial Transplant* 24:2288-2289, 2009
2272. Szwarc I, Mourad G, Argiles A: Post-conditioning to reduce renal ischaemia/reperfusion injury. *Nephrol Dial Transplant* 2009;24:2288-2289; author reply 2289-2290.
2273. Tablante NL, Brunet PY, Odor EM, Salem M, Harter-Dennis JM, Hueston WD: Risk factors associated with early respiratory disease complex in broiler chickens. *Avian Dis* 43:424-428, 1999
2274. Tabouy LJ, Chauvet-Monges AM, Brunet PJ, Braguer DL, Garcia PA, Berland YF, Crevat AD: In vitro mitochondrial test to assess haemodialyser biocompatibility. *Nephrol Dial Transplant* 12:1635-1639, 1997
2275. Tabouy LJ, Chauvet-Monges AM, Carles GP, Brunet PJ, Braguer DL, Rebouillon PA, Berland YF, Crevat AD: Calcium channel blockers correct in vitro mitochondrial toxicity of cellulose acetate. *Kidney Int* 52:1381-1389, 1997
2276. Taes YE, Marescau B, De VA, De Deyn PP, Schepers E, Vanholder R, Delanghe JR: Guanidino Compounds After Creatine Supplementation in Renal Failure Patients and their Relation to Inflammatory Status. *Nephrol Dial Transplant* 2007
2277. Takahashi N, Fiers W, Brouckaert P: Anti-tumor activity of tumor necrosis factor in combination with interferon-gamma is not affected by prior tolerization. *Int J Cancer* 63:846-854, 1995
2278. Takahashi N, Brouckaert P, Fiers W: Mechanism of tolerance to tumor necrosis factor: receptor-specific pathway and selectivity. *Am J Physiol* 269:R398-R405, 1995
2279. Tardivel S, Razanamaniraka L, Drueke T, Lacour B: Mechanism of the enhancing effect of sorbitol on ileal Ca uptake in rat enterocytes. *Pflugers Arch* 429:470-476, 1995
2280. Tardivel S, Medetognon J, Randoux C, Kebede M, Drueke T, Daudon M, Hennequin C, Lacour B: Alpha-1-microglobulin: inhibitory effect on calcium oxalate crystallization in vitro and decreased urinary concentration in calcium oxalate stone formers. *Urol Res* 27:243-249, 1999
2281. Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter WP, Vanholder R: EBPG guideline on dialysis strategies. *Nephrol Dial Transplant* 22 Suppl 2:ii5-21, 2007
2282. Tattersall J, Dekker F, Heimbürger O, Jager KJ, Lameire N, Lindley E, Van Biesen W, Vanholder R, Zoccali C: When to start dialysis: Updated guidance following publication of the initiating dialysis early and late (ideal) study. *Nephrol Dial Transplant* 26:2082-2086, 2011
2283. Tattersall J, Dekker F, Heimbürger O, Jager KJ, Lameire N, Lindley E, Van Biesen W, Vanholder R, Zoccali C: When to start dialysis: Updated guidance following publication of the initiating dialysis early and late (ideal) study. *Nephrol Dial Transplant* 2011;26:2082-2086.
2284. Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen J, Pischetsrieder M: In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazolones under conditions similar to continuous ambulatory peritoneal dialysis. *Biochem Biophys Res Commun* 280:1408-1414, 2001
2285. Tauer A, Zhang X, Schaub TP, Zimmeck T, Niwa T, Passlick-Deetjen J, Pischetsrieder M: Formation of advanced glycation end products during CAPD. *Am J Kidney Dis* 41:S57-S60, 2003
2286. Tauer A, Bender TO, Fleischmann EH, Niwa T, Jorres A, Pischetsrieder M: Fate of the glucose degradation products 3-deoxyglucosone and glyoxal during peritoneal dialysis. *Mol Nutr Food Res* 49:710-715, 2005
2287. Taulan M, Paquet F, Argiles A, Demaille J, Romey MC: Comprehensive analysis of the renal transcriptional response to acute uranyl nitrate exposure. *BMC Genomics* 7:2, 2006
2288. Tepel M, Jankowski J, Schluter H, Bachmann J, van der GM, Ruess C, Terliesner J, Zidek W: Diadenosine polyphosphates' action on calcium and vessel contraction. *Am J Hypertens* 10:1404-1410, 1997
2289. Tepel M, Jankowski J, Ruess C, Steinmetz M, van der GM, Zidek W: Activation of Na<sup>+</sup>, H<sup>+</sup> exchanger produces vasoconstriction of renal resistance vessels. *Am J Hypertens* 11:1214-1221, 1998
2290. Tepel M, Pytlík M, van der GM, Schluter H, Jankowski J, Zidek W: Effect of dexamethasone on the lymphocytic Na<sup>+</sup>/H<sup>+</sup> antiporter activity. *J Hypertens* 17:1553-1556, 1999
2291. Tepel M, van der GM, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. *Circulation* 107:992-995, 2003
2292. Tepel M, Zidek W: [Role of transient receptor potential channels in the cardiovascular system]. *Dtsch Med Wochenschr* 132:2442-2444, 2007
2293. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. *Circulation* 2003;107:992-995.
2294. ter Steege JC, Van d, V, Forget PP, Brouckaert P, Buurman WA: The role of endogenous IFN-gamma, TNF-alpha and IL-10 in LPS-induced nitric oxide release in a mouse model. *Cytokine* 10:115-123, 1998
2295. Terrier-Lenglet A, Nollet A, Liabeuf S, Barreto DV, Brazier M, Lemke HD, Vanholder R, Choukroun G, Massy ZA: [plasma malondialdehyde may not predict mortality in patient with chronic kidney disease]. *Nephrol Ther* 7:219-224, 2011

2296. Terrier-Lenglet A, Nollet A, Liabeuf S, Barreto DV, Brazier M, Lemke HD, Vanholder R, Choukroun G, Massy ZA: [plasma malondialdehyde may not predict mortality in patient with chronic kidney disease]. *Nephrol Ther* 2011;7:219-224.
2297. Terryn W, Benoit D, Van LA, Peeters P, Schepkens H, Cokelaere K, Vanholder R: Goodpasture's syndrome associated with autoimmune thrombotic thrombocytopenic purpura an unusual case. *Nephrol Dial Transplant* 22:3672-3673, 2007
2298. Terryn W, Poppe B, Wuyts B, Claes K, Maes B, Verbeelen D, Vanholder R, De BK, Lameire N, De PA, De SG: Two-tier approach for the detection of alpha-galactosidase A deficiency in a predominantly female haemodialysis population. *Nephrol Dial Transplant* 23:294-300, 2008
2299. Teta D, Maillard M, Tedjani A, Passlick-Deetjen J, Burnier M: The effect of pH-neutral peritoneal dialysis fluids on adipokine secretion from cultured adipocytes. *Nephrol Dial Transplant* 22:862-869, 2007
2300. Tetta C, Lemke HD: Pyrogen permeability in aqueous conditions. *Artif Organs* 26:1063, 2002
2301. Tetta C, Bellomo R, Kellum J, Ricci Z, Pohlmeiere R, Passlick-Deetjen J, Ronco C: High volume hemofiltration in critically ill patients: why, when and how? *Contrib Nephrol* 144:362-375, 2004
2302. Tetzner F, Scholze A, Wittstock A, Zidek W, Tepel M: Impaired vascular reactivity in patients with chronic kidney disease. *Am J Nephrol* 28:218-223, 2008
2303. Thalhammer F, Rosenkranz AR, Burgmann H, Graninger W, Hollenstein U, Schenk P, Thalhammer-Scherrer R, Traindl O, Horl WH, Breyer S: Single-dose pharmacokinetics of teicoplanin during hemodialysis therapy using high-flux polysulfone membranes. *Wien Klin Wochenschr* 109:362-365, 1997
2304. Thalhammer F, Kletzmayer J, El M, I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H: Ofloxacin clearance during hemodialysis: a comparison of polysulfone and cellulose acetate hemodialyzers. *Am J Kidney Dis* 32:642-645, 1998
2305. Thalhammer F, Horl WH: Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. *Clin Pharmacokinet* 39:271-279, 2000
2306. Theodorescu D, Fliser D, Wittke S, Mischak H, Krebs R, Walden M, Ross M, Eltze E, Bettendorf O, Wulfing C, Semjonow A: Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. *Electrophoresis* 26:2797-2808, 2005
2307. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF: Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. *Lancet Oncol* 7:230-240, 2006
2308. Theodorescu D, Mischak H: Mass spectrometry based proteomics in urine biomarker discovery. *World J Urol* 25:435-443, 2007
2309. Theodorescu D, Schiffer E, Bauer HW, Douwes F, Eichhorn F, Polley R, Schmidt T, Schofer W, Zuerbig P, Good DM, Coon JJ, Mischak H: Discovery and validation of urinary biomarkers for prostate cancer. *Proteomics Clin Appl* 2:in press, 2008
2310. Theuns J, Brouwers N, Engelborghs S, Slegers K, Bogaerts V, Corsmit E, De PT, van Duijn CM, De Deyn PP, Van BC: Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. *Am J Hum Genet* 78:936-946, 2006
2311. Thiemann J, Jankowski J, Rykl J, Kurzawski S, Pohl T, Wittmann-Liebold B, Schluter H: Principle and applications of the protein-purification-parameter screening system. *J Chromatogr A* 1043:73-80, 2004
2312. Thiemann J, Jankowski J, Rykl J, Kurzawski S, Pohl T, Wittmann-Liebold B, Schluter H: Principle and applications of the protein-purification-parameter screening system. *J Chromatogr A* 2004;1043:73-80.
2313. Thilo F, Scholze A, Liu DY, Zidek W, Tepel M: Association of transient receptor potential canonical type 3 (TRPC3) channel transcripts with proinflammatory cytokines. *Arch Biochem Biophys* 471:57-62, 2008
2314. Thomas S, Schenk U, Fischer FP, Mettang T, Passlick-Deetjen J, Kuhlmann U: In vitro effects of glucose polymer-containing peritoneal dialysis fluids on phagocytic activity. *Am J Kidney Dis* 29:246-253, 1997
2315. Thornalley PJ: Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor. *Crit Rev Oncol Hematol* 20:99-128, 1995
2316. Thornalley PJ, Westwood M, Lo TW, McLellan AC: Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. *Contrib Nephrol* 112:24-31, 1995
2317. Thornalley PJ, Ladan MJ, Ridgway SJ, Kang Y: Antitumor activity of S-(p-bromobenzyl)glutathione diesters in vitro: a structure-activity study. *J Med Chem* 39:3409-3411, 1996
2318. Thornalley PJ, McLellan AC, Lo TW, Benn J, Sonksen PH: Negative association between erythrocyte reduced glutathione concentration and diabetic complications. *Clin Sci (Lond)* 91:575-582, 1996
2319. Thornalley PJ: Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification--a role in pathogenesis and antiproliferative chemotherapy. *Gen Pharmacol* 27:565-573, 1996
2320. Thornalley PJ, Edwards LG, Kang Y, Wyatt C, Davies N, Ladan MJ, Double J: Antitumor activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis. *Biochem Pharmacol* 51:1365-1372, 1996
2321. Thornalley PJ: Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. *Cell Mol Biol (Noisy -le-grand)* 44:1013-1023, 1998
2322. Thornalley PJ: Glutathione-dependent detoxification of alpha- and antiproliferative activity of glyoxalase I inhibitors. *Chem Biol Interact* 111-112:137-151, 1998
2323. Thornalley PJ, Langborg A, Minhas HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. *Biochem J* 344 Pt 1:109-116, 1999
2324. Thornalley PJ, Minhas HS: Rapid hydrolysis and slow alpha,beta-dicarbonyl cleavage of an agent proposed to cleave glucose-derived protein cross-links. *Biochem Pharmacol* 57:303-307, 1999
2325. Thornalley PJ, Yurek-George A, Argirov OK: Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions. *Biochem Pharmacol* 60:55-65, 2000
2326. Thornalley PJ, Argirova M, Ahmed N, Mann VM, Argirov O, Dawnay A: Mass spectrometric monitoring of albumin in uremia. *Kidney Int* 58:2228-2234, 2000
2327. Thornalley PJ, Jahan I, Ng R: Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human

- red blood cells during hyperglycaemia by thiamine in vitro. *J Biochem (Tokyo)* 129:543-549, 2001
2328. Thornalley PJ: Methods for studying the binding of advanced glycated proteins to receptors for advanced glycation endproducts (AGE receptors). *Methods Mol Biol* 196:49-62, 2002
2329. Thornalley PJ: Isothiocyanates: mechanism of cancer hemopreventive action. *Anticancer Drugs* 13:331-338, 2002
2330. Thornalley PJ: Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. *Int Rev Neurobiol* 50:37-57, 2002
2331. Thornalley PJ: Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. *Arch Biochem Biophys* 419:31-40, 2003
2332. Thornalley PJ: The enzymatic defence against glycation in health, disease and therapeutics: a symposium to examine the concept. *Biochem Soc Trans* 31:1341-1342, 2003
2333. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawney A: Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. *Biochem J* 375:581-592, 2003
2334. Thornalley PJ: Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation. *Biochem Soc Trans* 31:1343-1348, 2003
2335. Thornalley PJ: Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. *Biochem Soc Trans* 31:1372-1377, 2003
2336. Thornalley PJ: Glycation, receptor-mediated cell activation and vascular complications of diabetes. *Diab Vasc Dis Res* 1:21-22, 2004
2337. Thornalley PJ: Glycation free adduct accumulation in renal disease: the new AGE. *Pediatr Nephrol* 20:1515-1522, 2005
2338. Thornalley PJ: Measurement of protein glycation, glycated peptides, and glycation free adducts. *Perit Dial Int* 25:522-533, 2005
2339. Thornalley PJ: Dicarbonyl intermediates in the maillard reaction. *Ann N Y Acad Sci* 1043:111-117, 2005
2340. Thornalley PJ: Advanced glycation end products in renal failure. *J Ren Nutr* 16:178-184, 2006
2341. Thornalley PJ: Unease on the role of glyoxalase 1 in high-anxiety-related behaviour. *Trends Mol Med* 12:195-199, 2006
2342. Thornalley PJ: Endogenous alpha-oxoaldehydes and formation of protein and nucleotide advanced glycation endproducts in tissue damage. *Novartis Found Symp* 285:229-243, 2007
2343. Thornalley PJ: Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE)--an introduction. *Mol Nutr Food Res* 51:1107-1110, 2007
2344. Thornalley PJ, Babaei-Jadidi R, Al AH, Rabbani N, Antonysunil A, Larkin J, Ahmed A, Rayman G, Bodmer CW: High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. *Diabetologia* 50:2164-2170, 2007
2345. Tolle M, Levkau B, Keul P, Brinkmann V, Giebing G, Schonfelder G, Schafers M, von Wnuck LK, Jankowski J, Jankowski V, Chun J, Zidek W, van der GM: Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. *Circ Res* 96:913-920, 2005
2346. Tolle M, Giebing G, Tietge UJ, Jankowski J, Jankowski V, Henning L, Hori MP, Weiss W, Zidek W, van der GM: Diguanosine pentaphosphate: an endogenous activator of Rho-kinase possibly involved in blood pressure regulation. *J Hypertens* 24:1991-2000, 2006
2347. Tolle M, Jankowski V, Schuchardt M, Wiedon A, Huang T, Hub F, Kowalska J, Jemielity J, Guranowski A, Loddenkemper C, Zidek W, Jankowski J, van der Giet M: Adenosine 5'-tetraphosphate is a highly potent purinergic endothelium-derived vasoconstrictor. *Circ Res* 2008;103:1100-1108.
2348. Tolle M, Schuchardt M, Wiedon A, Huang T, Klockel L, Jankowski J, Jankowski V, Zidek W, van der Giet M: Differential effects of uridine adenosine tetraphosphate on purinoceptors in the rat isolated perfused kidney. *Br J Pharmacol* 2010;161:530-540.
2349. Tolle M, Huang T, Schuchardt M, Jankowski V, Prufer N, Jankowski J, Tietge UJ, Zidek W, van der Giet M: High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid a. *Cardiovasc Res* 2012;94:154-162.
2350. Tolle M, Giebing G, Tietge UJ, Jankowski J, Jankowski V, Henning L, Hori MP, Weiss W, Zidek W, van der Giet M: Diguanosine pentaphosphate: An endogenous activator of rho-kinase possibly involved in blood pressure regulation. *J Hypertens* 2006;24:1991-2000.
2351. Tolle M, Huang T, Schuchardt M, Jankowski V, Prufer N, Jankowski J, Tietge UJ, Zidek W, van der Giet M: High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid a. *Cardiovasc Res* 2012;94:154-162.
2352. Tolle M, Jankowski V, Schuchardt M, Wiedon A, Huang T, Hub F, Kowalska J, Jemielity J, Guranowski A, Loddenkemper C, Zidek W, Jankowski J, van der Giet M: Adenosine 5'-tetraphosphate is a highly potent purinergic endothelium-derived vasoconstrictor. *Circ Res* 2008;103:1100-1108.
2353. Tolle M, Levkau B, Keul P, Brinkmann V, Giebing G, Schonfelder G, Schafers M, von Wnuck Lipinski K, Jankowski J, Jankowski V, Chun J, Zidek W, Van der Giet M: Immunomodulator fty720 induces enos-dependent arterial vasodilatation via the lysophospholipid receptor s1p3. *Circ Res* 2005;96:913-920.
2354. Tolle M, Schuchardt M, Wiedon A, Huang T, Klockel L, Jankowski J, Jankowski V, Zidek W, van der Giet M: Differential effects of uridine adenosine tetraphosphate on purinoceptors in the rat isolated perfused kidney. *Br J Pharmacol* 2010;161:530-540.
2355. Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimbürger O, Barany P, Axelsson J, Alvestrand A, Stenvinkel P, Lindholm B, Suliman ME: Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. *Clin J Am Soc Nephrol* 2:889-897, 2007
2356. Topley N, Kaur D, Petersen MM, Jorres A, Williams JD, Faict D, Holmes CJ: In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. *J Am Soc Nephrol* 7:218-224, 1996
2357. Topley N, Kaur D, Petersen MM, Jorres A, Passlick-Deetjen J, Coles GA, Williams JD: Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. *Kidney Int* 49:1447-1456, 1996
2358. Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, Koorman J, Martin-Malo A, Pedrini L, Pizzarelli F, Tattersall J, Vennegeer M, Wanner C, ter WP, Vanholder R: EBPG on Vascular Access. *Nephrol Dial Transplant* 22 Suppl 2:ii88-117, 2007
2359. Torremans A, Marescau B, Vanholder R, De SR, Billiouw JM, De Deyn PP: The low nanomolar levels of N G-monomethylarginine in serum and urine of patients with chronic renal insufficiency are not significantly different from control levels. *Amino Acids* 24:375-381, 2003



2360. Torremans A, D'Hooge R, Van d, V, Marescau B, Vanholder R, Lameire N, De Deyn PP, Van Bogaert PP: Effect of NaCl on currents evoked by uremic retention solutes in dissociated mouse neurons. *Brain Res* 1008:107-112, 2004
2361. Torremans A, Marescau B, Possemiers I, Van DD, D'Hooge R, Isbrandt D, De Deyn PP: Biochemical and behavioural phenotyping of a mouse model for GAMT deficiency. *J Neurol Sci* 231:49-55, 2005
2362. Torremans A, Marescau B, Van DD, Van GC, Van MF, Van Bogaert PP, D'Hooge R, de VJ, De Deyn PP: GSA: behavioral, histological, electrophysiological and neurochemical effects. *Physiol Behav* 84:251-264, 2005
2363. Torremans A, Marescau B, Kranzlin B, Gretz N, Billiow JM, Vanholder R, De SR, Bouwman K, Brouns R, De Deyn PP: Biochemical validation of a rat model for polycystic kidney disease: comparison of guanidino compound profile with the human condition. *Kidney Int* 69:2003-2012, 2006
2364. Torrents E, Grinberg I, Gorovitz-Harris B, Lundstrom H, Borovok I, Aharonowitz Y, Sjoberg BM, Cohen G: NrdR controls differential expression of the *Escherichia coli* ribonucleotide reductase genes. *J Bacteriol* 189:5012-5021, 2007
2365. Touam M, Zingraff J, Jungers P, Chadefaux-Vekemans B, Druke T, Massy ZA: Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. *Kidney Int* 56:2292-2296, 1999
2366. Touam M, Orozco R, Fumeron C, Ganea A, Druke T, Grunfeld JP: [Refractory ascites in hemodialysis: treatment by paracentesis-reinjection during dialysis]. *Nephrologie* 22:25-28, 2001
2367. Touam M, Guery B, Goupy C, Menoyo V, Druke T: Hypothyroidism and resistance to human recombinant erythropoietin. *Nephrol Dial Transplant* 19:1020-1021, 2004
2368. Touam M, Menoyo V, Attaf D, Thebaud HE, Druke TB: High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism. *Kidney Int* 67:2065-2066, 2005
2369. Toussaint O, Baret PV, Brion JP, Cras P, Collette F, De Deyn PP, Geenen V, Kienlen-Campard P, Labeur C, Legros JJ, Neve J, Octave JN, Pierard GE, Salmon E, van den Bosch de Aguilar, Van der LM, Leuven FV, Vanfleteren J: Experimental gerontology in Belgium: from model organisms to age-related pathologies. *Exp Gerontol* 35:901-916, 2000
2370. Tozija L, Antova Z, Cakalaroski K, Polenakovic M, Spasovski G: Infection as a risk factor in the outcome of patients with acute renal failure assessed by SOFA score. *Prilozi* 27:17-27, 2006
2371. Tramuto F, Bonura F, Perna AM, Mancuso S, Firenze A, Romano N, Vitale F: Genetic diversity of HIV-1 non-B strains in Sicily: evidence of intersubtype recombinants by sequence analysis of gag, pol, and env genes. *AIDS Res Hum Retroviruses* 23:1131-1138, 2007
2372. Traut M, Haufe CC, Eismann U, Deppisch RM, Stein G, Wolf G: Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated beta-2-microglobulin concentrations. Results of a cross-over study. *Blood Purif* 25:432-440, 2007
2373. Trecherel E, Godin C, Louandre C, Benchitrit J, Poirot S, Maziere JC, Massy ZA, Galmiche A: Upregulation of bad, a pro-apoptotic protein of the bcl2 family, in vascular smooth muscle cells exposed to uremic conditions. *Biochem Biophys Res Commun* 2012;417:479-483.
2374. Trecherel E, Godin C, Louandre C, Benchitrit J, Poirot S, Maziere JC, Massy ZA, Galmiche A: Upregulation of bad, a pro-apoptotic protein of the bcl2 family, in vascular smooth muscle cells exposed to uremic conditions. *Biochem Biophys Res Commun* 2012;417:479-483.
2375. Trembecki J, Kokot F, Wiecek A, Marcinkowski W, Rudka R: [Influence of long-term erythropoietin (rHuEPO) therapy on the function of the pituitary-gonadal axis in hemodialyzed male patients with end stage renal failure]. *Pol Arch Med Wewn* 94:144-152, 1995
2376. Trembecki J, Kokot F, Wiecek A, Marcinkowski W, Rudka R: [Improvement of sexual function in hemodialyzed male patients with chronic renal failure treated with erythropoietin (rHuEPO)]. *Przegl Lek* 52:462-466, 1995
2377. Treutler T, Ruf B, Beige J: [Polyuria]. *Ther Umsch* 63:615-618, 2006
2378. Tribl B, Vogelsang H, Pohanka E, Grampp S, Gangl A, Horl WH: Broadband ultrasound attenuation of the calcaneus. A tool for assessing bone status in patients with chronic renal failure. *Acta Radiol* 39:637-641, 1998
2379. Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M, Slama M, Massy Z: Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. *Eur Heart J* 29:339-347, 2008
2380. Trondle U, Sunder-Plassmann G, Burgmann H, Buchmayer H, Kramer L, Bieglmayer C, Horl WH, Fodinger M: Molecular and clinical characterisation of homocystinuria in two Austrian families with cystathionine beta-synthase deficiency. *Acta Med Austriaca* 28:145-151, 2001
2381. Tsimaratos M, Brunet P, Dussol B, Michel G, Mege JL, Casanova P, Jaber K, Burtey S, Picon G, Berland Y: Kostmann's syndrome and IgA nephropathy: an unknown association. *Nephron* 74:478, 1996
2382. Tylicki L, Rutkowski B, Horl WH: Multifactorial determination of hypertensive nephroangiosclerosis. *Kidney Blood Press Res* 25:341-353, 2002
2383. Tylicki L, Rutkowski B, Horl WH: Antioxidants: a possible role in kidney protection. *Kidney Blood Press Res* 26:303-314, 2003
2384. Tylicki L, Habicht A, Watschinger B, Horl WH: Treatment of hypertension in renal transplant recipients. *Curr Opin Urol* 13:91-98, 2003
2385. Tylicki L, Fodinger M, Puttinger H, Rutkowski P, Strozecki P, Tyszko S, Rutkowski B, Horl WH: Methylenetetrahydrofolate reductase gene polymorphisms in essential hypertension relation: with the development of hypertensive end-stage renal disease. *Am J Hypertens* 18:1442-1448, 2005
2386. Tylicki L, Puttinger H, Rutkowski P, Nieweglowski T, Rutkowski B, Horl WH: Multifactorial analysis of determinators for renal injury in essential hypertension. *J Hum Hypertens* 20:93-95, 2006
2387. Tylicki L, Puttinger H, Rutkowski P, Rutkowski B, Horl WH: Smoking as a risk factor for renal injury in essential hypertension. *Nephron Clin Pract* 103:c121-c128, 2006
2388. Ueffing M, Lovric J, Philipp A, Mischak H, Kolch W: Protein kinase C-epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity. *Oncogene* 15:2921-2927, 1997
2389. ull-Watschinger S, Konstantin H, Demetriou D, Schillinger M, Habicht A, Horl WH, Watschinger B: Pre-Transplant Predictors of Cerebrovascular Events After Kidney Transplantation. *Nephrol Dial Transplant* 2007
2390. Unver B, Sunder-Plassmann G, Horl WH, Apsner R: Long-term citrate anticoagulation for high-flux haemodialysis in a patient with heparin-induced thrombocytopenia type II. *Acta Med Austriaca* 29:146-148, 2002
2391. Urena P, Bererhi L, Houhou S, Bournerias F, Eckardt KU, Kurtz A, Druke TB: No acute change of serum erythropoietin in response to

- hypocalcemia or antihypertensive agents in uremic patients. *Nephron* 70:197-201, 1995
2392. Urena P, Ferreira A, Kung VT, Morieux C, Simon P, Ang KS, Souberbielle JC, Segre GV, Druke TB, de Vernejoul MC: Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. *J Bone Miner Res* 10:932-939, 1995
2393. Urena P, Ferreira A, Morieux C, Druke T, de Vernejoul MC: PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. *Nephrol Dial Transplant* 11:2008-2016, 1996
2394. Vaccaro O, Perna AF, Mancini FP, Iovine C, Cuomo V, Sacco M, Tufano A, Rivellesse AA, Ingrosso D, Riccardi G: Plasma homocysteine and microvascular complications in type 1 diabetes. *Nutr Metab Cardiovasc Dis* 10:297-304, 2000
2395. AA, Ingrosso D, Riccardi G: Plasma homocysteine and its determinants in diabetic retinopathy. *Diabetes Care* 23:1026-1027, 2000
2396. Vacher-Coponat H, Brunet C, Lyonnet L, Bonnet E, Loundou A, Sampol J, Moal V, Dussol B, Brunet P, Berland Y, gnat-George F, Paul P: Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients. *Nephrol Dial Transplant* 2007
2397. Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtsey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y: A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (catm2) in renal transplantation. *Transplantation* 2012;93:437-443.
2398. Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtsey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y: A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (catm2) in renal transplantation. *Transplantation* 2012;93:437-443.
2399. Vahlensieck U, Boknik P, Gombosova I, Huke S, Knapp J, Linck B, Luss H, Muller HL, Neumann J, Deng MC, Scheld HH, Jankowski H, Schluter H, Zidek W, Zimmermann N, Schmitz W: Inotropic effects of diadenosine tetraphosphate (AP4A) in human and animal cardiac preparations. *J Pharmacol Exp Ther* 288:805-813, 1999
2400. Valderrabano F, Horl WH, Jacobs C, Macdougall IC, Parrondo I, Manhaeve D, Milisen K: Patients and methods. *Nephrol Dial Transplant* 15 Suppl 4:2-7, 2000
2401. Valderrabano F, Horl WH, Jacobs C, Macdougall IC, Parrondo I, Cremers S, Abraham IL: European best practice guidelines 1-4: evaluating anaemia and initiating treatment. *Nephrol Dial Transplant* 15 Suppl 4:8-14, 2000
2402. Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP: PRE-dialysis survey on anaemia management. *Nephrol Dial Transplant* 18:89-100, 2003
2403. Valli A, Suliman ME, Meert N, Vanholder R, Lindholm B, Stenvinkel P, Watanabe M, Barany P, Alvestrand A, Anderstam B: Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. *Clin Chim Acta* 379:87-94, 2007
2404. Van de NN, Verbeke F, Dhondt A, Colardijn F, Van BW, Vanholder R, Lameire N: The dialytic management of acute renal failure in the elderly. *Semin Dial* 15:127-132, 2002
2405. Van de WC, Brans B, Vanholder R, Hoeben H, Van LK, Dierckx RA: Predictive value of <sup>99</sup>Tcm-DTPA captopril scintigraphy in patients with a solitary kidney and reduced kidney function. *Nucl Med Commun* 20:263-266, 1999
2406. Van den NK, Vanderstraeten G, Vanholder R: Peripheral motor and sensory nerve conduction studies in haemodialysis patients. A study of 54 patients. *Electromyogr Clin Neurophysiol* 38:467-474, 1998
2407. Van den NN, Mouton V, Lamot C, Van NG, Dhondt A, Vanholder R, Afschrift M, Lameire N: Outcome in a post-cardiac surgery population with acute renal failure requiring dialysis: does age make a difference? *Nephrol Dial Transplant* 18:732-736, 2003
2408. van der GM, Jankowski J, Schluter H, Zidek W, Tepel M: Mediation of the vasoactive properties of diadenosine tetraphosphate via various purinoceptors. *J Hypertens* 16:1939-1943, 1998
2409. van der GM, Cinkilic O, Jankowski J, Tepel M, Zidek W, Schluter H: Evidence for two different P2X-receptors mediating vasoconstriction of Ap5A and Ap6A in the isolated perfused rat kidney. *Br J Pharmacol* 127:1463-1469, 1999
2410. van der GM, Schmid A, Jankowski J, Schluter H, Zidek W, Tepel M: CoenzymeA glutathione disulfide is a potent modulator of angiotensin II-induced vasoconstriction. *Am J Hypertens* 14:164-168, 2001
2411. van der GM, Westhoff T, Cinkilic O, Jankowski J, Schluter H, Zidek W, Tepel M: The critical role of adenosine and guanosine in the affinity of dinucleoside polyphosphates to P(2X)-receptors in the isolated perfused rat kidney. *Br J Pharmacol* 132:467-474, 2001
2412. van der GM, Schmidt S, Tolle M, Jankowski J, Schluter H, Zidek W, Tepel M: Effects of dinucleoside polyphosphates on regulation of coronary vascular tone. *Eur J Pharmacol* 448:207-213, 2002 van der Giet M, Schmidt S, Tolle M, Jankowski J, Schluter H, Zidek W, Tepel M: Effects of dinucleoside polyphosphates on regulation of coronary vascular tone. *Eur J Pharmacol* 2002;448:207-213.
2413. van der Giet M, Westhoff T, Cinkilic O, Jankowski J, Schluter H, Zidek W, Tepel M: The critical role of adenosine and guanosine in the affinity of dinucleoside polyphosphates to p(2x)-receptors in the isolated perfused rat kidney. *Br J Pharmacol* 2001;132:467-474.
2414. van der Giet M, Schmidt S, Tolle M, Jankowski J, Schluter H, Zidek W, Tepel M: Effects of dinucleoside polyphosphates on regulation of coronary vascular tone. *Eur J Pharmacol* 2002;448:207-213.
2415. van der Giet M, Westhoff T, Cinkilic O, Jankowski J, Schluter H, Zidek W, Tepel M: The critical role of adenosine and guanosine in the affinity of dinucleoside polyphosphates to p(2x)-receptors in the isolated perfused rat kidney. *Br J Pharmacol* 2001;132:467-474.
2416. van der ZJ, Rademakers R, Engelborghs S, Gijssels I, Bogaerts V, Vandenberghe R, Santens P, Caekebeke J, De PT, Peeters K, Lubke U, Van den BM, Martin JJ, Cruts M, De Deyn PP, Van BC, Dermaut B: A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. *Brain* 129:841-852, 2006
2417. van der ZJ, Le B, I, Maurer-Stroh S, Engelborghs S, Gijssels I, Camuzat A, Brouwers N, Vandenberghe R, Slegers K, Hannequin D, Dermaut B, Schymkowitz J, Campion D, Santens P, Martin JJ, Lacomblez L, De PT, Peeters K, Mattheijssens M, Verclletto M, Van den BM, Cruts M, De Deyn PP, Rousseau F, Brice A, Van BC: Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. *Hum Mutat* 28:416, 2007
2418. van der ZJ, Urwin H, Engelborghs S, Bruyland M, Vandenberghe R, Dermaut B, De PT, Peeters K, Santens P, De Deyn PP, Fisher EM, Collinge J, Isaacs AM, Van BC: CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. *Hum Mol Genet* 17:313-322, 2008
2419. Van Loo AA, Vanholder RC, Bernaert PR, Vermassen FE, Van d, V, Lameire NH: Pretransplantation hemodialysis strategy influences early renal graft function. *J Am Soc Nephrol* 9:473-481, 1998
2420. Van B, Vanholder R, Lameire N: Impact of pretransplantation dialysis modality on patient outcome after renal transplantation: the role of peritoneal dialysis revisited. *Perit Dial Int* 19:103-106, 1999

2421. Van BW, Vanholder R, Vogelaers D, Peleman R, Verschraegen G, Vijt D, Lameire N: The need for a center-tailored treatment protocol for peritonitis. *Perit Dial Int* 18:274-281, 1998
2422. Van BW, Sieben G, Lameire N, Vanholder R: Application of Kohonen neural networks for the non-morphological distinction between glomerular and tubular renal disease. *Nephrol Dial Transplant* 13:59-66, 1998
2423. Van BW, Vanholder R, Lameire N: Recent developments in osmotic agents for peritoneal dialysis. *Adv Ren Replace Ther* 5:218-231, 1998
2424. Van BW, Dequidt C, Vijt D, Vanholder R, Lameire N: Analysis of the reasons for transfers between hemodialysis and peritoneal dialysis and their effect on survivals. *Adv Perit Dial* 14:90-94, 1998
2425. Van BW, Vanholder R, Debacquer D, De BG, Lameire N: Comparison of survival on CAPD and haemodialysis: statistical pitfalls. *Nephrol Dial Transplant* 15:307-311, 2000
2426. Van BW, Vanholder RC, Veys N, Dhondt A, Lameire NH: An evaluation of an integrative care approach for end-stage renal disease patients. *J Am Soc Nephrol* 11:116-125, 2000
2427. Van BW, Vanholder R, Lameire N: The role of peritoneal dialysis as the first-line renal replacement modality. *Perit Dial Int* 20:375-383, 2000
2428. Van BW, Vanholder R, Van LA, Van d, V, Lameire N: Peritoneal dialysis favorably influences early graft function after renal transplantation compared to hemodialysis. *Transplantation* 69:508-514, 2000
2429. Van BW, Veys N, Vanholder R, Lameire N: Peritoneal-dialysis-related peritonitis: the art of rope-dancing. *Nephrol Dial Transplant* 17:1878-1882, 2002
2430. Van BW, Dequidt C, Vanholder R, Lameire N: The impact of healthy start peritoneal dialysis on the evolution of residual renal function and nutrition parameters. *Adv Perit Dial* 18:44-48, 2002
2431. Van BW, Veys N, Vanholder R, Lameire N: The role of APD in the improvement of outcomes in an ESRD program. *Semin Dial* 15:422-426, 2002
2432. Van BW, Vanholder R, Veys N, Lameire N: Peritoneal dialysis in anuric patients: concerns and cautions. *Semin Dial* 15:305-310, 2002
2433. Van BW, Veys N, Vanholder R, Lameire N: New concepts in peritoneal dialysis: new wine in old barrels? *Artif Organs* 27:398-405, 2003
2434. Van BW, Vanholder R, Lameire N: Dialysis strategies in critically ill acute renal failure patients. *Curr Opin Crit Care* 9:491-495, 2003
2435. 2174. Van BW, Vanholder R, Lameire N: In search of the holy grail and the golden fleece. *Perit Dial Int* 24:501-503, 2004
2436. Van BW, Yegenaga I, Vanholder R, Verbeke F, Hoste E, Colardyn F, Lameire N: Relationship between fluid status and its management on acute renal failure (ARF) in intensive care unit (ICU) patients with sepsis: a prospective analysis. *J Nephrol* 18:54-60, 2005
2437. Van BW, Vanholder R, Veys N, Verbeke F, Lameire N: Efficacy of erythropoietin administration in the treatment of anemia immediately after renal transplantation. *Transplantation* 79:367-368, 2005
2438. Van BW, Vanholder R, Veys N, Lameire N: Improving salt balance in peritoneal dialysis patients. *Perit Dial Int* 25 Suppl 3:S73-S75, 2005
2439. Van BW, Vanholder R, Lameire N: Animal models in peritoneal dialysis: a story of kangaroos and ostriches. *Perit Dial Int* 26:571-573, 2006
2440. Van BW, Veys N, Verbeke F, Vanholder R: Chronic kidney disease: the cinderella of general medicine. Epidemiology of and screening for CKD in Belgium. *Acta Clin Belg* 61:319-325, 2006
2441. Van BW, Veys N, Vanholder R, Lameire N: The impact of the pre-transplant renal replacement modality on outcome after cadaveric kidney transplantation: the ghent experience. *Contrib Nephrol* 150:254-258, 2006
2442. Van BW, van der TA, Veys N, Lameire N, Vanholder R: Evaluation of the peritoneal membrane function by three letter word acronyms: PET, PDC, SPA, PD-Adequest, POL: what to do? *Contrib Nephrol* 150:37-41, 2006
2443. Van BW, Eloot S, Verleysen A, Glorieux G, Veys N, Vanholder R, Lameire N: Clamping of the dialysate outlet line in the Genius dialysis system does not alter dialysate flow or clearances. *Nephrol Dial Transplant* 21:1069-1072, 2006
2444. Van BW, Vanholder R, Veys N, Verbeke F, Delanghe J, De BD, Lameire N: The importance of standardization of creatinine in the implementation of guidelines and recommendations for CKD: implications for CKD management programmes. *Nephrol Dial Transplant* 21:77-83, 2006
2445. Van BW, Vanholder R, Verbeke F, Lameire N: Is peritoneal dialysis associated with increased cardiovascular morbidity and mortality? *Perit Dial Int* 26:429-434, 2006
2446. Van BW, Verbeke F, Vanholder R: Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro peritoneal dialysis. *Nephrol Dial Transplant* 22:53-58, 2007
2447. Van BW, Lameire N, Vanholder R, Mehta R: Relation between acute kidney injury and multiple-organ failure: the chicken and the egg question. *Crit Care Med* 35:316-317, 2007
2448. Van BW, Veys N, Vanholder R: Intermittent hemodialysis for renal replacement therapy in intensive care: new evidence for old truths. *Contrib Nephrol* 156:304-308, 2007
2449. Van BW, De BD, Verbeke F, Delanghe J, Lameire N, Vanholder R: The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. *Eur Heart J* 28:478-483, 2007
2450. Van BW, Lameire N, Peeters P, Vanholder R: Belgium's mixed private/public health care system and its impact on the cost of end-stage renal disease. *Int J Health Care Finance Econ* 7:133-148, 2007
2451. Van Biesen W, Van Massenhove J, Hoste E, Vanholder R: Defining acute kidney injury: Playing hide-and-seek with the unknown man? *Nephrol Dial Transplant* 2011;26:399-401.
2452. Van Biesen W, Vanmassenhove J, Van Canneyt K, Vanholder R, Eloot S: Influence of switching connection ports of double-lumen permanent tunnelled catheters on total solute removal during dialysis. *J Nephrol* 2011;24:338-344
2453. Van Biesen W, Van Massenhove J, Hoste E, Vanholder R: Defining acute kidney injury: Playing hide-and-seek with the unknown man? *Nephrol Dial Transplant* 2011;26:399-401.
2454. Van Biesen W, Vanmassenhove J, Van Canneyt K, Vanholder R, Eloot S: Influence of switching connection ports of double-lumen permanent tunnelled catheters on total solute removal during dialysis. *J Nephrol* 2011;24:338-344.
2455. Van BB, Vanhoutte G, Pirici D, Van DD, Wils H, Cuijt I, Vennekens K, Zabielski M, Michalik A, Theuns J, De Deyn PP, Van der LA, Van BC, Kumar-Singh S: Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease. *Neurobiol Aging* 2006

2456. Van CN, D'Hooge R, Verhoye M, Peeters RR, De Deyn PP, Van der LA: Simultaneous electroencephalographic recording and functional magnetic resonance imaging during pentylentetrazol-induced seizures in rat. *Neuroimage* 19:627-636, 2003
2457. Van DD, D'Hooge R, Hauben E, Reyniers E, Gantois I, Bakker CE, Oostra BA, Kooy RF, De Deyn PP: Spatial learning, contextual fear conditioning and conditioned emotional response in *Fmr1* knockout mice. *Behav Brain Res* 117:127-136, 2000
2458. Van DD, D'Hooge R, Staufenbiel M, Van GC, Van MF, De Deyn PP: Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. *Eur J Neurosci* 17:388-396, 2003
2459. Van DD, Marescau B, Cremers T, Mulder J, Engelborghs S, De Deyn PP: Regional distribution of biogenic amines, amino acids and cholinergic markers in the CNS of the C57BL/6 strain. *Amino Acids* 28:377-387, 2005
2460. Van DD, Errigiers V, Kooy RF, Willemsen R, Mientjes E, Oostra BA, De Deyn PP: Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). *Behav Brain Res* 162:233-239, 2005
2461. Van DD, Marescau B, Engelborghs S, Cremers T, Mulder J, Staufenbiel M, De Deyn PP: Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. *Neurochem Int* 46:409-422, 2005
2462. Van DD, Vloeberghs E, Abramowski D, Staufenbiel M, De Deyn PP: APP23 mice as a model of Alzheimer's disease: an example of a transgenic approach to modeling a CNS disorder. *CNS Spectr* 10:207-222, 2005
2463. Van DD, Abramowski D, Staufenbiel M, De Deyn PP: Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. *Psychopharmacology (Berl)* 180:177-190, 2005
2464. Van DD, Lenders G, De Deyn PP: Effect of Morris water maze diameter on visual-spatial learning in different mouse strains. *Neurobiol Learn Mem* 85:164-172, 2006
2465. Van DD, De Deyn PP: Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. *Eur Neuropsychopharmacol* 16:59-69, 2006
2466. Van DD, De Deyn PP: Drug discovery in dementia: the role of rodent models. *Nat Rev Drug Discov* 5:956-970, 2006
2467. Van DD, Coen K, De Deyn PP: Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. *Psychopharmacology (Berl)* 2007
2468. Van GB, Hultdin J, Johansson I, Stegmayr B, Hallmans G, Nilsson TK, Weinehall L, Witthoft C, Palmqvist R, Winkvist A: Folate, vitamin B12, and risk of ischemic and hemorrhagic stroke: a prospective, nested case-referent study of plasma concentrations and dietary intake. *Stroke* 36:1426-1431, 2005
2469. Van HM, De CK, Vanholder R, Cornelis R: In vivo distribution and fractionation of indium in rats after subcutaneous and oral administration of [(114m)In]InAs. *J Environ Monit* 7:365-370, 2005
2470. Van LS, Dhondt A, de SJ, Vanholder R: Right atrial thrombus in an asymptomatic hemodialysis patient with malfunctioning catheter and patent foramen ovale. *Hemodial Int* 9:236-240, 2005
2471. Van LS, De WK, Vanholder R: Online hemodiafiltration. *Artif Organs* 30:579-585, 2006
2472. Van LS, Veys N, Verbeke F, Vanholder R, Van BW: The fate of older diabetic patients on peritoneal dialysis: myths and mysteries and suggestions for further research. *Perit Dial Int* 27:611-618, 2007
2473. Van Laecke S, Marechal C, Verbeke F, Peeters P, Van Biesen W, Devuyt O, Jadoul M, Vanholder R: The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. *Nephrol Dial Transplant* 2011;26:2362-2369.
2474. Van Laecke S, Vanholder R: Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. *N Engl J Med* 2011;365:1745; author reply 1746-1747.
2475. Van Laecke S, Vanholder R: Magnesium and vascular dysfunction in malignant hypertension. *Hypertension* 2011;58:e7; author reply e8.
2476. Van Laecke S, Marechal C, Verbeke F, Peeters P, Van Biesen W, Devuyt O, Jadoul M, Vanholder R: The relation between hypomagnesaemia and vascular stiffness in renal transplant recipients. *Nephrol Dial Transplant* 2011;26:2362-2369.
2477. Van Laecke S, Vanholder R: Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. *N Engl J Med* ;365:1745; 2011
2478. Van Laecke S, Vanholder R: Magnesium and vascular dysfunction in malignant hypertension. *Hypertension* 2011
2479. Van LA, Vanholder R, Madsen K, Praet M, Kint J, De PA, Messiaen L, Lameire N, Hasholt L, Sorensen SA, Ringoir S: Novel frameshift mutation in a heterozygous woman with Fabry disease and end-stage renal failure. *Am J Nephrol* 16:352-357, 1996
2480. Van LA, Vanholder R, Bernaert P, De RJ, Lameire N: Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomized prospective study. *Nephrol Dial Transplant* 11:1815-1821, 1996
2481. Van LA, Vanholder R, Buytaert I, De PA, Praet M, Elewaut A, Lameire N: Alport syndrome and diffuse leiomyomatosis with major morbid events presenting at adult age. *Nephrol Dial Transplant* 12:776-780, 1997
2482. Van MW, Libert C, Fiers W, Brouckaert P: Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice. *J Immunol* 159:3555-3564, 1997
2483. Van MW, Denecker G, Rodriguez I, Brouckaert P, Vandenabeele P, Libert C: Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins. *J Immunol* 163:5235-5241, 1999
2484. Van MW, Brouckaert P, Libert C: Caspase-1 is not involved in experimental hepatitis in mouse. *FEBS Lett* 445:115-118, 1999
2485. Van MW, Vanden BJ, Brouckaert P, Libert C: Tumor necrosis factor-induced lethal hepatitis: pharmacological intervention with verapamil, tannic acid, picotamide and K76COOH. *FEBS Lett* 467:201-205, 2000
2486. Van MW, Hochepeid T, Brouckaert P, Libert C: The major acute-phase protein, serum amyloid P component, in mice is not involved in endogenous resistance against tumor necrosis factor alpha-induced lethal hepatitis, shock, and skin necrosis. *Infect Immun* 68:5026-5029, 2000
2487. Van V, Schoonjans RS, Struijk DG, Verbanck JJ, Vanholder RC, Van B, Lefebvre RA, De V, Lameire NH: Influence of dialysate on gastric emptying time in peritoneal dialysis patients. *Perit Dial Int* 22:32-38, 2002
2488. Van VB, Vanholder R, De PP, Vogelaers D, Ringoir S: Immunomodulating effects of antibiotics: literature review. *Infection* 24:275-291, 1996
2489. Van VB, Schoonjans R, Vanholder R, De VM, Vandamme W, Van LS, Lameire N: Delayed gastric emptying in dyspeptic chronic hemodialysis patients. *Am J Kidney Dis* 36:962-968, 2000

2490. Van VB, Schoonjans R, Vanholder R, Vandamme W, De VM, Lameire N: Dyspepsia and gastric emptying in chronic renal failure patients. *Clin Nephrol* 56:302-307, 2001
2491. Van VB, Vermassen F, Hesse U, Van d, V, Vanholder R: [Aspects of kidney donation by living donors]. *Acta Clin Belg* 56:17-20, 2001
2492. Van VB, Schoonjans R, Vanholder R, De VM, Depoortere I, Peeters TL, Lefebvre R: In vitro evaluation of motilin agonism by macrolide immunosuppressive drugs. *Nephrol Dial Transplant* 17:973-977, 2002
2493. Vanbelleghem H, Vanholder R, Levin NW, Becker G, Craig JC, Ito S, Lau J, Locatelli F, Zoccali C, Solez K, Hales M, Lameire N, Eknoyan G: The Kidney Disease: improving Global Outcomes website: comparison of guidelines as a tool for harmonization. *Kidney Int* 71:1054-1061, 2007
2494. Vanbelleghem H, Vanholder R, Levin NW, Becker G, Craig JC, Ito S, Lau J, Locatelli F, Zoccali C, Solez K, Hales M, Lameire N, Eknoyan G: The Kidney Disease: Improving Global Outcomes website: Comparison of guidelines as a tool for harmonization. *Kidney Int* 2007
2495. Vanholder R, De SR, Waterloos MA, Van LN, Vogeleere P, Hoste E, Ringoir S: Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. *Kidney Int* 47:510-517, 1995
2496. Vanholder R: Phagocytic function in dialysis. *Contrib Nephrol* 113:72-79, 1995
2497. Vanholder R, Van LA, Dhondt AM, Glorieux G, De SR, Ringoir S: Second symposium on uraemic toxicity. Summary of a symposium held in Gent, Belgium, 22-24 September 1994. *Nephrol Dial Transplant* 10:414-418, 1995
2498. Vanholder R, De SR, Vogeleere P, Ringoir S: Middle molecules: toxicity and removal by hemodialysis and related strategies. *Artif Organs* 19:1120-1125, 1995
2499. Vanholder R, Burgelman M, De SR, Voogeleere P, Ringoir S: Two-pool versus single-pool models in the determination of urea kinetic parameters. *Blood Purif* 14:437-450, 1996
2500. Vanholder R, Van LA, Dhondt AM, Ringoir S: The role of dialysis membranes in infection. *Nephrol Dial Transplant* 11 Suppl 2:101-103, 1996
2501. Vanholder R, Lameire N, Hoste E, Van LA, Dhondt AM, Ringoir S: Different types of dialyzer membranes: does the bio(in)compatibility matter in the treatment of ARF? *Ren Fail* 18:471-479, 1996
2502. Vanholder R, Lameire N: Second European peritoneal dialysis meeting, Gent, 11-12 March 1996. *Nephrol Dial Transplant* 11:2103-2106, 1996
2503. Vanholder R: Relationship between biocompatibility and neutrophil function in hemodialysis patients. *Adv Ren Replace Ther* 3:312-314, 1996
2504. Vanholder R, Van LA, Dhondt AM, De SR, Ringoir S: Influence of uraemia and haemodialysis on host defence and infection. *Nephrol Dial Transplant* 11:593-598, 1996
2505. Vanholder R, Lameire N, Waterloos MA, Van LN, De SR, Vogeleere P, Lambert MC, Vijt D, Ringoir S: Disturbed host defense in peritoneal cavity during CAPD: characterization of responsible factors in dwell fluid. *Kidney Int* 50:643-652, 1996
2506. Vanholder R: Uremic toxins. *Adv Nephrol Necker Hosp* 26:143-163,
2507. Vanholder R, Camez A, Veys N, Van LA, Dhondt AM, Ringoir S: Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. *Thromb Haemost* 77:650-655, 1997
2508. Vanholder R, De KF, Kips J, Praet M, Naeyaert JM: The pathophysiology of lupus erythematosus. *Eur J Dermatol* 8:4-7, 1998
2509. Vanholder R: Phenacetin or anything: what makes or made analgesics nephrotoxic? *Acta Clin Belg* 53:299-302, 1998
2510. Vanholder R, De SR, Lesaffer G: p-cresol: a toxin revealing many neglected but relevant aspects of uraemic toxicity. *Nephrol Dial Transplant* 14:2813-2815, 1999
2511. Vanholder R, De SR: Pathophysiologic effects of uremic retention solutes. *J Am Soc Nephrol* 10:1815-1823, 1999
2512. Vanholder R, Heering P, Loo AV, Biesen WV, Lambert MC, Hesse U, Vennet MV, Grabensee B, Lameire N: Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared with hemodialysis. *Am J Kidney Dis* 33:934-940, 1999
2513. Vanholder R, Lameire N: Does biocompatibility of dialysis membranes affect recovery of renal function and survival? *Lancet* 354:1316-1318, 1999
2514. Vanholder R, Glorieux G: Molecular mechanisms of vitamin D hyporesponsiveness in renal failure. *Nephrol Dial Transplant* 14:16-19, 1999
2515. Vanholder R, De VA, Lameire N: The role of dialyzer biocompatibility in acute renal failure. *Blood Purif* 18:1-12, 2000
2516. Vanholder R, Sever MS, Ereik E, Lameire N: Acute renal failure related to the crush syndrome: towards an era of seismo-nephrology? *Nephrol Dial Transplant* 15:1517-1521, 2000
2517. Vanholder R, Sever MS, Ereik E, Lameire N: Rhabdomyolysis. *J Am Soc Nephrol* 11:1553-1561, 2000
2518. Vanholder R: Problems and solutions for artificial kidney. *Technol Health Care* 8:373-379, 2000
2519. Vanholder R, Dhondt AM, Van BW: Is Kt/V Urea a Satisfactory Measure for Dosing the Newer Dialysis Regimens? *Semin Dial* 14:12-14, 2001
2520. Vanholder R, Lameire N: Reply. *Blood Purif* 19:71-72, 2001
2521. Vanholder R, Van BW, Lameire N: What is the renal replacement method of first choice for intensive care patients? *J Am Soc Nephrol* 12 Suppl 17:S40-S43, 2001
2522. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, scamps-Latscha B, Henle T, Jorres A, Massy ZA, Rodriguez M, Stegmayr B, Stenvinkel P, Wratten ML: Uremic toxicity: present state of the art. *Int J Artif Organs* 24:695-725, 2001
2523. Vanholder R, De SR, Lameire N: Protein-bound uremic solutes: the forgotten toxins. *Kidney Int Suppl* 78:S266-S270, 2001
2524. Vanholder R, De SR, Lameire NH: Redesigning the map of uremic toxins. *Contrib Nephrol* 42-70, 2001
2525. Vanholder R: Vascular access: care and monitoring of function. *Nephrol Dial Transplant* 16:1542-1545, 2001
2526. Vanholder R, Sever MS, De SM, Ereik E, Lameire N: Intervention of the Renal Disaster Relief Task Force in the 1999 Marmara, Turkey earthquake. *Kidney Int* 59:783-791, 2001
2527. Vanholder R, Van BW: Incidence of infectious morbidity and mortality in dialysis patients. *Blood Purif* 20:477-480, 2002
2528. Vanholder R, DeSmet R, Lesaffer G: Dissociation between dialysis adequacy and Kt/V. *Semin Dial* 15:3-7, 2002

2529. Vanholder R, Veys N, Van BW, Lameire N: Alternative timeframes for hemodialysis. *Artif Organs* 26:160-162, 2002
2530. Vanholder R, Cornelis R, Dhondt A, Lameire N: The role of trace elements in uraemic toxicity. *Nephrol Dial Transplant* 17 Suppl 2:2-8, 2002
2531. Vanholder R, Glorieux G, Lameire N: The other side of the coin: impact of toxin generation and nutrition on the uremic syndrome. *Semin Dial* 15:311-314, 2002
2532. Vanholder R, Peleman R: Increased incidence of tuberculosis in immigrant dialysis populations. *Artif Organs* 26:661-663, 2002
2533. Vanholder R: Vascular access. *Int J Artif Organs* 25:347-353, 2002
2534. Vanholder R, Glorieux G, Lameire N: Uraemic toxins and cardiovascular disease. *Nephrol Dial Transplant* 18:463-466, 2003
2535. Vanholder R, Smet RD, Glorieux G, Dhondt A: Survival of hemodialysis patients and uremic toxin removal. *Artif Organs* 27:218-223, 2003
2536. Vanholder R, Glorieux G, De SR, Lameire N: New insights in uremic toxins. *Kidney Int Suppl* S6-10, 2003
2537. Vanholder R: Central vein hemodialysis catheters and infection: a plea for timely referral and appropriate hygienic measures. *Acta Clin Belg* 58:342-344, 2003
2538. Vanholder R: [Uremic toxins]. *Nephrologie* 24:373-376, 2003
2539. Vanholder R, De SR, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, scamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. *Kidney Int* 63:1934-1943, 2003
2540. Vanholder R, Glorieux G, Lameire N: New insights in uremic toxicity. *Contrib Nephrol* 149:315-324, 2005
2541. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. *Nephrol Dial Transplant* 20:1048-1056, 2005
2542. Vanholder R, Van BW, Lameire N: To pee or not to pee: no more the question in ARF? *Nephron Clin Pract* 99:c61-c62, 2005
2543. Vanholder R, del Canizo JF, Sauer IM, Stegmayr B: The European artificial organ scene: present status. *Artif Organs* 29:498-506, 2005
2544. Vanholder R: Intervention of the renal disaster relief task force (RDRTF) in the Kashmir earthquake. *Nephrol Dial Transplant* 21:40, 2006
2545. Vanholder R: Chronic kidney disease in adults--UK guidelines for identification, management and referral. *Nephrol Dial Transplant* 21:1776-1777, 2006
2546. Vanholder R, Van BW, Verbeke F, Lameire N: The epidemic of cardio-vascular disease in renal failure: where does it come from, where do we go? *Acta Clin Belg* 61:205-211, 2006
2547. Vanholder R, Schepers E, Meert N, Lameire N: What is uremia? Retention versus oxidation. *Blood Purif* 24:33-38, 2006
2548. Vanholder R, van der TA, De SM, Hoste E, Koc M, Hussain A, Khan S, Sever MS: Earthquakes and crush syndrome casualties: lessons learned from the Kashmir disaster. *Kidney Int* 71:17-23, 2007
2549. Vanholder R, Meert N, Schepers E, Glorieux G, Argiles A, Brunet P, Cohen G, Druke T, Mischak H, Spasovski G, Massy Z, Jankowski J: Review on uraemic solutes II--variability in reported concentrations: causes and consequences. *Nephrol Dial Transplant* 22:3115-3121, 2007
2550. Vanholder R, Van BW, Hoste E, van der TA, Sever MS: The role of the Renal Disaster Relief Task Force in the prevention and treatment of Crush syndrome in mass disasters. *Acta Clin Belg Suppl* 405-407, 2007
2551. Vanholder R: Approach for guideline development. *Nephrol Dial Transplant* 22 Suppl 2:ii1-ii4, 2007
2552. Vanholder R, Van BW, Lameire N, Sever MS: The role of the International Society of Nephrology/Renal Disaster Relief Task Force in the rescue of renal disaster victims. *Contrib Nephrol* 156:325-332, 2007
2553. Vanholder R, Glorieux G, Devolder I, Van LS: Pigmentation markers: more color in the picture of uremic toxicity? *Blood Purif* 25:480-482, 2007 Vanholder R, Bammens B, de Loor H, Glorieux G, Meijers B, Schepers E, Massy Z, Evenepoel P: Warning: The unfortunate end of p-cresol as a uraemic toxin. *Nephrol Dial Transplant* 2011;26:1464-1467.
2554. Vanholder R, Borniche D, Claus S, Correa-Rotter R, Crestani R, Ferir MC, Gibney N, Hurtado A, Luyckx VA, Portilla D, Rodriguez S, Sever MS, Vanmassenhove J, Wainstein R: When the earth trembles in the americas: The experience of haiti and chile 2010. *Nephron Clin Pract* 2011;117:c184-197.
2555. Vanholder R, Eloot S, Schepers E, Neiryck N, Glorieux G, Massy Z: An obituary for gfr as the main marker for kidney function? *Semin Dial* 2012;25:9-14.
2556. Vanholder R, Van Biesen W, Hoste E, Lameire N: Pro/con debate: Continuous versus intermittent dialysis for acute kidney injury: A never-ending story yet approaching the finish? *Crit Care* 2011;15:204.
2557. Vanholder R, Veys N, Van Biesen W: Hemodialysis: Long weekend hemodialysis intervals--killing fields? *Nat Rev Nephrol* 2011;8:5-6.
2558. Vanholder R, Abou-Deif O, Argiles A, Baurmeister U, Beige J, Brouckaert P, Brunet P, Cohen G, De Deyn PP, Druke TB, Fliser D, Glorieux G, Herget-Rosenthal S, Horl WH, Jankowski J, Jorres A, Massy ZA, Mischak H, Perna AF, Rodriguez-Portillo JM, Spasovski G, Stegmayr BG, Stenvinkel P, Thornalley PJ, Wanner C, Wiecek A: The role of eutox in uremic toxin research. *Semin Dial* ;22:323-328. 2009
2559. Vanholder R, Argiles A, Beige J, Brunet P, Druke TB, Fliser D, Herget-Rosenthal S, Horl WH, Jorres A, Perna A, Rodriguez-Portillo M, Spasovski G, Stegmayr B, Stenvinkel P, Wanner C, Wiecek A, Massy ZA: Conservative treatment of the uremic syndrome. *Semin Dial* ;22:449-453. 2009
2560. Vanholder R, Bammens B, de Loor H, Glorieux G, Meijers B, Schepers E, Massy Z, Evenepoel P: Warning: The unfortunate end of p-cresol as a uraemic toxin. *Nephrol Dial Transplant* ;26:1464-1467. 2011
2561. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J: A bench to bedside view of uremic toxins. *J Am Soc Nephrol* ;19:863-870. 2008
2562. Vanholder R, Borniche D, Claus S, Correa-Rotter R, Crestani R, Ferir MC, Gibney N, Hurtado A, Luyckx VA, Portilla D, Rodriguez S, Sever MS, Vanmassenhove J, Wainstein R: When the earth trembles in the americas: The experience of haiti and chile 2010. *Nephron Clin Pract* ;117:c184-197. 2011
2563. Vanholder R, Eloot S, Schepers E, Neiryck N, Glorieux G, Massy Z: An obituary for gfr as the main marker for kidney function? *Semin Dial* ;25:9-14. 2012
2564. Vanholder R, Glorieux G, Van Biesen W: Advantages of new hemodialysis membranes and equipment. *Nephron Clin Pract* ;114:c165-172. 2009

2565. Vanholder R, Meert N, Schepers E, Glorieux G: From uremic toxin retention to removal by convection: Do we know enough? *Contrib Nephrol* ;161:125-131, 2008
2566. Vanholder R, Meert N, Schepers E, Glorieux G: Uremic toxins: Do we know enough to explain uremia? *Blood Purif* 26:77-81, 2011
2567. Vanholder R, Van Biesen W, Hoste E, Lameire N: Pro/con debate: Continuous versus intermittent dialysis for acute kidney injury: A never-ending story yet approaching the finish? *Crit Care* 15:204, 2011
2568. Vanholder R, Van Laecke S, Glorieux G: What is new in uremic toxicity? *Pediatr Nephrol* ;23:1211-1221, 2008
2569. Vanholder R, Veys N, Van Biesen W: Hemodialysis: Long weekend hemodialysis intervals--killing fields? *Nat Rev Nephrol* ;8:5-6, 2011
2570. Vanholder RC, Lameire NH: Osmotic agents in peritoneal dialysis. *Kidney Int Suppl* 56:S86-S91, 1996
2571. Vanholder RC, Glorieux G, De SR, De Deyn PP: Low water-soluble uremic toxins. *Adv Ren Replace Ther* 10:257-269, 2003
2572. Vanneste G, Dhaese I, Sips P, Buys E, Brouckaert P, Lefebvre RA: Gastric motility in soluble guanylate cyclase alpha 1 knock-out mice. *J Physiol* 584:907-920, 2007
2573. Vanpoucke H, Van VB, Vanholder R, Van RL: Significance of qualitative polymerase chain reaction combined with quantitation of viral load in the diagnosis and follow-up of cytomegalovirus infection after solid-organ transplantation. *Intervirology* 42:398-404, 1999
2574. Vaslaki L, Major L, Berta K, Karatson A, Misz M, Pethoe F, Ladanyi E, Fodor B, Stein G, Pischetsrieder M, Zima T, Wojke R, Gauly A, Passlick-Deetjen J: On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. *Blood Purif* 24:163-173, 2006
2575. Vaslaki LR, Berta K, Major L, Weber V, Weber C, Wojke R, Passlick-Deetjen J, Falkenhagen D: On-line hemodiafiltration does not induce inflammatory response in end-stage renal disease patients: results from a multicenter cross-over study. *Artif Organs* 29:406-412, 2005
2576. Velden J, Paust HJ, Hoxha E, Turner JE, Steinmetz OM, Wolf G, Jabs WJ, Ozcan F, Beige J, Heering PJ, Schroder S, Kneissler U, Disteldorf E, Mittrucker HW, Stahl RA, Helmchen U, Panzer U: Renal il-17 expression in human anca-associated glomerulonephritis. *Am J Physiol Renal Physiol* 2012
2577. Velden J, Paust HJ, Hoxha E, Turner JE, Steinmetz OM, Wolf G, Jabs WJ, Ozcan F, Beige J, Heering PJ, Schroder S, Kneissler U, Disteldorf E, Mittrucker HW, Stahl RA, Helmchen U, Panzer U: Renal il-17 expression in human anca-associated glomerulonephritis. *Am J Physiol Renal Physiol* 2012
2578. Vellas B, Cunha L, Gertz HJ, De Deyn PP, Wesnes K, Hammond G, Schwalen S: Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. *Curr Med Res Opin* 21:1423-1429, 2005
2579. Verbeke F, Segers P, Heireman S, Vanholder R, Verdonck P, Van Bortel LM: Noninvasive assessment of local pulse pressure: importance of brachial-to-radial pressure amplification. *Hypertension* 46:244-248, 2005
2580. Verbeke F, Vogelaers D, Vanholder R, Lameire N: Disseminated *Mycobacterium avium* complex infection in a renal transplant patient. *Eur J Intern Med* 16:53-55, 2005
2581. Verbeke F, Van BW, Peeters P, Van Bortel LM, Vanholder RC: Arterial stiffness and wave reflections in renal transplant recipients. *Nephrol Dial Transplant* 22:3021-3027, 2007
2582. Verbeke F, Marechal C, Van Laecke S, Van Biesen W, Devuyst O, Van Bortel LM, Jadoul M, Vanholder R: Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. *Hypertension* 2011;58:833-838
2583. Verbeke F, Van Biesen W, Honkanen E, Wikstrom B, Jensen PB, Krzesinski JM, Rasmussen M, Vanholder R, Rensma PL: Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: Outcome of the calcification outcome in renal disease (cord) study. *Clin J Am Soc Nephrol* 2011;6:153-159.
2584. Verbeke F, Van Biesen W, Vanholder R: The role of collagen metabolism in ckd-associated arterial senescence: Underestimated and underappreciated. *Nephrol Dial Transplant* 2011;26:2726-2728.
2585. Verbeke F, Marechal C, Van Laecke S, Van Biesen W, Devuyst O, Van Bortel LM, Jadoul M, Vanholder R: Aortic stiffness and central wave reflections predict outcome in renal transplant recipients. *Hypertension* 2011;58:833-838, 2011
2586. Verbeke F, Van Biesen W, Honkanen E, Wikstrom B, Jensen PB, Krzesinski JM, Rasmussen M, Vanholder R, Rensma PL: Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: Outcome of the calcification outcome in renal disease (cord) study. *Clin J Am Soc Nephrol* ;6:153-159, 2011
2587. Verbeke F, Van Biesen W, Vanholder R: The role of collagen metabolism in ckd-associated arterial senescence: Underestimated and underappreciated. *Nephrol Dial Transplant* ;26:2726-2728, 2011
2588. Verhelst J, Berwaerts J, Marescau B, Abs R, Neels H, Mahler C, De Deyn PP: Serum creatine, creatinine, and other guanidino compounds in patients with thyroid dysfunction. *Metabolism* 46:1063-1067, 1997
2589. Vermeersch P, Buys E, Pokreisz P, Marsboom G, Ichinose F, Sips P, Pellens M, Gillijns H, Swinnen M, Graveline A, Collen D, Dewerchin M, Brouckaert P, Bloch KD, Janssens S: Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia. *Circulation* 116:936-943, 2007
2590. Versijpt J, Van LK, Dierckx RA, Dumont F, De Deyn PP, Slegers G, Korf J: Scintigraphic visualization of inflammation in neurodegenerative disorders. *Nucl Med Commun* 24:209-221, 2003
2591. Verslegers W, De Deyn PP: [Visual impairment due to optic neuropathy in 2 patients on amiodarone, and ethambutol and isoniazide therapy, respectively]. *Ned Tijdschr Geneesk* 145:1872, 2001
2592. Verslegers WR, De Deyn PP: [Brain abscess: a difficult diagnosis]. *Ned Tijdschr Geneesk* 147:1478, 2003
2593. Verslegers WR, van den KM, De Deyn PP: [Manipulation of mental competence: an ethical problem in case of electrical stimulation of the subthalamic nucleus for severe Parkinson's disease]. *Ned Tijdschr Geneesk* 148:1997-1998, 2004
2594. Verslegers WR, De Deyn PP, Cras P: [The practice guideline 'Dementia' (second revision) from the Dutch College of General Practitioners]. *Ned Tijdschr Geneesk* 148:1843-1844, 2004
2595. Verslegers WR, De Deyn PP, De SD: [Not every TIA is primarily vascular]. *Ned Tijdschr Geneesk* 148:294-295, 2004
2596. Verslegers WR, Pickut BA, De Deyn PP: Paroxysmal neuralgic upper cervical pain attacks: the lower syndrome of cluster headache. *Clin Neurol Neurosurg* 108:737-743, 2006
2597. Verslegers WR, De Deyn PP: [Serious intoxication after inhaling methanol]. *Ned Tijdschr Geneesk* 150:2057, 2006
2598. Veys N, Biesen WV, Vanholder R, Lameire N: Peritoneal dialysis catheters: the beauty of simplicity or the glamour of technicality?

- Percutaneous vs surgical placement. *Nephrol Dial Transplant* 17:210-212, 2002
2599. Vicca S, Hennequin C, Nguyen-Khoa T, Massy ZA, scamps-Latscha B, Druke TB, Lacour B: Caspase-dependent apoptosis in THP-1 cells exposed to oxidized low-density lipoproteins. *Biochem Biophys Res Commun* 273:948-954, 2000
2600. Vicca S, Massy ZA, Hennequin C, Rihane D, Nguyen-Khoa T, Druke TB, Lacour B: New insights into the effects of the protein moiety of oxidized LDL (oxLDL). *Kidney Int Suppl* 125-S127, 2003
2601. Vicca S, Massy ZA, Hennequin C, Rihane D, Druke TB, Lacour B: Apoptotic pathways involved in U937 cells exposed to LDL oxidized by hypochlorous acid. *Free Radic Biol Med* 35:603-615, 2003
2602. Vincenti F, Tuncer M, Castagneto M, Klinger M, Friman S, Scheuermann EH, Wiecek A, Russ GR, Martinek A, Nonnast-Daniel B: Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation. *Transplant Proc* 37:1001-1004, 2005
2603. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N: Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. *Am J Transplant* 7:1506-1514, 2007
2604. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El-Shahawy M, Budde K, Goto N: Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus. *Am J Transplant* 2007
2605. Vloeberghs E, Van DD, Engelborghs S, Nagels G, Staufenbiel M, De Deyn PP: Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. *Eur J Neurosci* 20:2757-2766, 2004
2606. Vloeberghs E, Van DD, Coen K, Staufenbiel M, De Deyn PP: Aggressive male APP23 mice modeling behavioral alterations in dementia. *Behav Neurosci* 120:1380-1383, 2006
2607. Vloeberghs E, Van DD, D'Hooge R, Staufenbiel M, De Deyn PP: APP23 mice display working memory impairment in the plus-shaped water maze. *Neurosci Lett* 407:6-10, 2006
2608. Vloeberghs E, Van DD, Franck F, Staufenbiel M, De Deyn PP: Mood and male sexual behaviour in the APP23 model of Alzheimer's disease. *Behav Brain Res* 180:146-151, 2007
2609. Volkman X, Fischer U, Bahr MJ, Ott M, Lehner F, MacFarlane M, Cohen GM, Manns MP, Schulze-Osthoff K, Bantel H: Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. *Hepatology* 46:1498-1508, 2007
2610. Vorbeck-Meister I, Sommer R, Vorbeck F, Horl WH: Quality of water used for haemodialysis: bacteriological and chemical parameters. *Nephrol Dial Transplant* 14:666-675, 1999
2611. Vychytil A, Lorenz M, Schneider B, Horl WH, Haag-Weber M: New criteria for management of catheter infections in peritoneal dialysis patients using ultrasonography. *J Am Soc Nephrol* 9:290-296, 1998
2612. Vychytil A, Lorenz M, Schneider B, Horl WH, Haag-Weber M: New strategies to prevent *Staphylococcus aureus* infections in peritoneal dialysis patients. *J Am Soc Nephrol* 9:669-676, 1998
2613. Vychytil A, Fodinger M, Wolf G, Enzenberger B, Auinger M, Prischl F, Buxbaum M, Wiesholzer M, Mannhalter C, Horl WH, Sunder-Plassmann G: Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. *Kidney Int* 53:1775-1782, 1998
2614. Vychytil A, Fodinger M, Papagiannopoulos M, Wolf G, Horl WH, Sunder-Plassmann G: Peritoneal elimination of homocysteine moieties in continuous ambulatory peritoneal dialysis patients. *Kidney Int* 55:2054-2061, 1999
2615. Vychytil A, Lilaj T, Schneider B, Horl WH, Haag-Weber M: Tidal peritoneal dialysis for home-treated patients: should it be preferred? *Am J Kidney Dis* 33:334-343, 1999
2616. Vychytil A, Lilaj T, Lorenz M, Horl WH, Haag-Weber M: Ultrasonography of the catheter tunnel in peritoneal dialysis patients: what are the indications? *Am J Kidney Dis* 33:722-727, 1999
2617. Vychytil A, Horl WH: The role of tidal peritoneal dialysis in modern practice: A European perspective. *Kidney Int Suppl* 96-S103, 2006
2618. Waelput W, Broekaert D, Vandekerckhove J, Brouckaert P, Tavernier J, Libert C: A mediator role for metallothionein in tumor necrosis factor-induced lethal shock. *J Exp Med* 194:1617-1624, 2001
2619. Waelput W, Brouckaert P, Broekaert D, Tavernier J: A role for leptin in the systemic inflammatory response syndrome (SIRS) and in immune response, an update. *Curr Med Chem* 13:465-475, 2006
2620. Wagner C, Deppisch R, Deneffeh B, Hug F, Andrassy K, Hansch GM: Expression patterns of the lipopolysaccharide receptor CD14, and the FCgamma receptors CD16 and CD64 on polymorphonuclear neutrophils: data from patients with severe bacterial infections and lipopolysaccharide-exposed cells. *Shock* 19:5-12, 2003
2621. Wahrman M, Exner M, Schillinger M, Haidbauer B, Regele H, Kormoczi GF, Horl WH, Bohmig GA: Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. *Am J Transplant* 6:1033-1041, 2006
2622. Walter R, Mischak H, Haller H: Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESRD patients. *Nephrol Dial Transplant* 17 Suppl 3:24-29, 2002
2623. Walton GM, Cohen GL: A question of belonging: race, social fit, and achievement. *J Pers Soc Psychol* 92:82-96, 2007
2624. Wang QJ, Acs P, Goodnight J, Giese T, Blumberg PM, Mischak H, Mushinski JF: The catalytic domain of protein kinase C-delta in reciprocal delta and epsilon chimeras mediates phorbol ester-induced macrophage differentiation of mouse promyelocytes. *J Biol Chem* 272:76-82, 1997
2625. Wang QJ, Acs P, Goodnight J, Blumberg PM, Mischak H, Mushinski JF: The catalytic domain of PKC-epsilon, in reciprocal PKC-delta and -epsilon chimeras, is responsible for conferring tumorigenicity to NIH3T3 cells, whereas both regulatory and catalytic domains of PKC-epsilon contribute to in vitro transformation. *Oncogene* 16:53-60, 1998
2626. Wang QJ, Lu G, Schlapkohl WA, Goerke A, Larsson C, Mischak H, Blumberg PM, Mushinski JF: The V5 domain of protein kinase C plays a critical role in determining the isoform-specific localization, translocation, and biological function of protein kinase C-delta and -epsilon. *Mol Cancer Res* 2:129-140, 2004
2627. Wang X, Axelsson J, Nordfors L, Qureshi AR, Avesani C, Barany P, Schalling M, Heimburger O, Lindholm B, Stenvinkel P: Changes in fat mass after initiation of maintenance dialysis is influenced by the uncoupling protein 2 exon 8 insertion/deletion polymorphism. *Nephrol Dial Transplant* 22:196-202, 2007
2628. Wang Y, Beck W, Deppisch R, Marshall SM, Hoenich NA, Thompson MG: Advanced glycation end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A/2C receptors. *Am J Physiol Cell Physiol* 293:C328-C336, 2007
2629. Wang Y, Beck W, Deppisch R, Marshall SM, Hoenich NA, Thompson MG: Differential effects of dialysis and ultrafiltrate from individuals with



- CKD, with or without diabetes, on platelet phosphatidylserine externalization. *Am J Physiol Renal Physiol* 294:F220-F228, 2008
2630. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J: Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. *Nephrol Dial Transplant* 19:2570-2575, 2004
2631. Watelle M, Demedts P, Franck F, De Deyn PP, Wauters A, Neels H: Analysis of the antiepileptic phenyltriazine compound lamotrigine using gas chromatography with nitrogen phosphorus detection. *Ther Drug Monit* 19:460-464, 1997
2632. Webster L, Abordo EA, Thornalley PJ, Limb GA: Induction of TNF alpha and IL-1 beta mRNA in monocytes by methylglyoxal-and advanced glycated endproduct-modified human serum albumin. *Biochem Soc Trans* 25:250S, 1997
2633. Weinehall L, Ohgren B, Persson M, Stegmayr B, Boman K, Hallmans G, Lindholm LH: High remaining risk in poorly treated hypertension: the 'rule of halves' still exists. *J Hypertens* 20:2081-2088, 2002
2634. Weinreich T, Passlick-Deetjen J, Ritz E: Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group. *Am J Kidney Dis* 25:452-460, 1995
2635. Weinreich T, Ritz E, Passlick-Deetjen J: Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group. *Perit Dial Int* 16:260-268, 1996
2636. Weinreich T, De los RT, Gaulty A, Passlick-Deetjen J: Effects of an increase in time vs. frequency on cardiovascular parameters in chronic hemodialysis patients. *Clin Nephrol* 66:433-439, 2006
2637. Weissinger EM, Eissner G, Grammer C, Fackler S, Haefner B, Yoon LS, Lu KS, Bazarov A, Sedivy JM, Mischak H, Kolch W: Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells. *Mol Cell Biol* 17:3229-3241, 1997
2638. Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S, Krebs R, Golovko I, Rupprecht HD, Haubitz M, Hecker H, Mischak H, Fliser D: Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. *Kidney Int* 65:2426-2434, 2004
2639. Weissinger EM, Oettrich K, Evans C, Genieser HG, Schwede F, Dangers M, Dammann E, Kolb HJ, Mischak H, Ganser A, Kolch W: Activation of protein kinase A (PKA) by 8-Cl-cAMP as a novel approach for antileukaemic therapy. *Br J Cancer* 91:186-192, 2004
2640. Weissinger EM, Kaiser T, Meert N, De SR, Walden M, Mischak H, Vanholder RC: Proteomics: a novel tool to unravel the pathophysiology of uraemia. *Nephrol Dial Transplant* 19:3068-3077, 2004
2641. Weissinger EM, Hertenstein B, Mischak H, Ganser A: Online coupling of capillary electrophoresis with mass spectrometry for the identification of biomarkers for clinical diagnosis. *Expert Rev Proteomics* 2:639-647, 2005
2642. Weissinger EM, Mischak H, Ganser A, Hertenstein B: Value of proteomics applied to the follow-up in stem cell transplantation. *Ann Hematol* 85:205-211, 2006
2643. Weissinger EM, Nguyen-Khoa T, Fumeron C, Saltiel C, Walden M, Kaiser T, Mischak H, Druke TB, Lacour B, Massy ZA: Effects of oral vitamin C supplementation in hemodialysis patients: a proteomic assessment. *Proteomics* 6:993-1000, 2006
2644. Weissinger EM, Mischak H: Application of proteomics to posttransplantational follow-up. *Methods Mol Med* 134:217-228, 2007
2645. Wennberg M, Lundh T, Bergdahl IA, Hallmans G, Jansson JH, Stegmayr B, Custodio HM, Skerfving S: Time trends in burdens of cadmium, lead, and mercury in the population of northern Sweden. *Environ Res* 100:330-338, 2006
2646. Wennberg M, Bergdahl IA, Stegmayr B, Hallmans G, Lundh T, Skerfving S, Stromberg U, Vessby B, Jansson JH: Fish intake, mercury, long-chain n-3 polyunsaturated fatty acids and risk of stroke in northern Sweden. *Br J Nutr* 98:1038-1045, 2007
2647. Wernert V, Schaf O, Faure V, Brunet P, Dou L, Berland Y, Boulet P, Kuchta B, Denoyel R: Adsorption of the uremic toxin p-cresol onto hemodialysis membranes and microporous adsorbent zeolite silicalite. *J Biotechnol* 123:164-173, 2006
2648. Westhoff T, Jankowski J, Schmidt S, Luo J, Giebing G, Schluter H, Tepel M, Zidek W, van der GM: Identification and characterization of adenosine 5'-tetrphosphate in human myocardial tissue. *J Biol Chem* 278:17735-17740, 2003
2649. Westhoff T, Jankowski J, Schmidt S, Luo J, Giebing G, Schluter H, Tepel M, Zidek W, van der Giet M: Identification and characterization of adenosine 5'-tetrphosphate in human myocardial tissue. *J Biol Chem* ;278:17735-17740. 2003
2650. Westhoff TH, Schmidt S, Zidek W, Beige J, van der GM: Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. *Clin Nephrol* 65:393-400, 2006
2651. Westhoff TH, Schmidt S, Vallbracht-Israng K, Yildirim H, Franke N, Dimeo F, Zidek W, van der GM: Small artery elasticity assessed by pulse wave analysis is no measure of endothelial dysfunction. *J Hypertens* 25:571-576, 2007
2652. Westhoff TH, Franke N, Schmidt S, Vallbracht-Israng K, Meissner R, Yildirim H, Schlattmann P, Zidek W, Dimeo F, van der GM: Too old to benefit from sports? The cardiovascular effects of exercise training in elderly subjects treated for isolated systolic hypertension. *Kidney Blood Press Res* 30:240-247, 2007
2653. Westhoff TH, Schmidt S, Glander P, Liefeld L, Martini S, Offermann G, Neumayer HH, Zidek W, van der GM, Budde K: The impact of FTY720 (fingolimod) on vasodilatory function and arterial elasticity in renal transplant patients. *Nephrol Dial Transplant* 22:2354-2358, 2007
2654. Westhoff TH, Franke N, Schmidt S, Vallbracht-Israng K, Zidek W, Dimeo F, van der GM: Beta-blockers do not impair the cardiovascular benefits of endurance training in hypertensives. *J Hum Hypertens* 21:486-493, 2007
2655. Westhoff TH, Schmidt S, Zidek W, van der GM: Validation of the Stabil-O-Graph blood pressure self-measurement device. *J Hum Hypertens* 22:233-235, 2008
2656. Westwood ME, Thornalley PJ: Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. *J Protein Chem* 14:359-372, 1995
2657. Westwood ME, Thornalley PJ: Induction of synthesis and secretion of interleukin 1 beta in the human monocytic THP-1 cells by human serum albumins modified with methylglyoxal and advanced glycation endproducts. *Immunol Lett* 50:17-21, 1996
2658. Westwood ME, Argirov OK, Abordo EA, Thornalley PJ: Methylglyoxal-modified arginine residues--a signal for receptor-mediated endocytosis and degradation of proteins by monocytic THP-1 cells. *Biochim Biophys Acta* 1356:84-94, 1997
2659. Wiecek A, Fliser D, Nowicki M, Ritz E: Effect of moxonidine on urinary electrolyte excretion and renal haemodynamics in man. *Eur J Clin Pharmacol* 48:203-208, 1995
2660. Wiecek A: [Use of human recombinant erythropoietin (rHuEPO) for treatment of anemia in patients with chronic kidney failure who don't require additional dialysis therapy]. *Przegł Lek* 52:93-94, 1995

2661. Wiecek A, Kokot F, Adamczak M, Ramos P, Derylo A: [Etiology and outcome of acute renal failure in elderly patients]. *Pol Arch Med Wewn* 94:159-163, 1995
2662. Wiecek A, Kokot F, Marcinkowski W: Long-term persistence of improvement of renal anaemia in spite of discontinued erythropoietin treatment. *Nephron* 69:489-490, 1995
2663. Wiecek A, Kyrzcz-Krzemien S, Franek E, Kokot F, Holowiecki J, Klin M: [The effect of short-term erythropoietin therapy on selected parameters of cell mediated and humoral immunity in hemodialyzed uremic patients]. *Pol Arch Med Wewn* 93:41-47, 1995
2664. Wiecek A: Calcium metabolism in patients with chronic uremia. *Clin Nephrol* 46:277-279, 1996
2665. Wiecek A, Kokot F, Spiechowicz U, Cieplok J, Czerwińska B, Strzelczyk P, Dyjas R: [Requirement for blood in hemodialyzed patients with chronic renal failure in the period before and after introduction to erythropoietin (r-HuEPO) treatment]. *Przegl Lek* 53:866-869, 1996
2666. Wiecek A, Kokot F: Does industrial environment influence the prevalence of arterial hypertension, plasma cholesterol and uric acid concentration and activity of the renin-aldosterone system? *Przegl Lek* 53:356-359, 1996
2667. Wiecek A, Kokot F, Adamczak M, Spiechowicz U, Cieplok J, Czerwińska B, Ramos P: [Renin plasma profile and sodium sensitivity of blood pressure in hypertensive patients with or without a family history of hypertension]. *Pol Arch Med Wewn* 96:451-457, 1996
2668. Wiecek A, Nowicki M, Kokot F, Ritz E: Acute failure of the transplanted kidney--pathophysiology, diagnosis and prevention. *Ann Transplant* 1:5-9, 1996
2669. Wiecek A, Franek E, Kokot F, Rudka R: Influence of acetate and bicarbonate hemodialysis on the plasma erythropoietin concentration in patients with chronic renal failure. *Int J Artif Organs* 20:108-111, 1997
2670. Wiecek A: [Treatment of hypertension during the course of kidney diseases]. *Przegl Lek* 54:773-776, 1997
2671. Wiecek A: Compliance of patients with arterial hypertension to therapeutic recommendations. *Przegl Lek* 55 Suppl 1:65-66, 1998
2672. Wiecek A: [The role of hypertension in progression of chronic renal failure--therapeutic prospects]. *Pol Arch Med Wewn* 104:665-670, 2000
2673. Wiecek A, Ritz E: International one-day Nephrology Update. *Nephrol Dial Transplant* 16:1995, 2001
2674. Wiecek A: [Hypo- and hyperkalemia--practical aspects of diagnosis and therapy]. *Pol Arch Med Wewn* 105 Suppl:185-186, 2001
2675. Wiecek A, Kokot F, Chudek J, Adamczak M: The adipose tissue--a novel endocrine organ of interest to the nephrologist. *Nephrol Dial Transplant* 17:191-195, 2002
2676. Wiecek A, Chudek J, Ficek R: [Studies on the renin-angiotensin-aldosterone system as an example of scientific achievements of professor Franciszek Kokot]. *Pol Arch Med Wewn* 110:1083-1088, 2003
2677. Wiecek A, Chudek J, Kokot F: Role of angiotensin II in the progression of diabetic nephropathy--therapeutic implications. *Nephrol Dial Transplant* 18 Suppl 5:v16-v20, 2003
2678. Wiecek A, Mikhail A: European regulatory guidelines for biosimilars. *Nephrol Dial Transplant* 21 Suppl 5:v17-v20, 2006
2679. Wiecek A, Adamczak M, Chudek J: Adiponectin--an adipokine with unique metabolic properties. *Nephrol Dial Transplant* 22:981-988, 2007
2680. Wiecek A, Nieszporek T, Chudek J: Perspectives in the treatment of renal anaemia new concepts and new drugs. *Prilozi* 28:225-237, 2007
2681. Wieczorowska-Tobis K, Polubinska A, Schaub TP, Schilling H, Wisniewska J, Witowski J, Passlick-Deetjen J, Breborowicz A: Influence of neutral-pH dialysis solutions on the peritoneal membrane: a long-term investigation in rats. *Perit Dial Int* 21 Suppl 3:S108-S113, 2001
2682. Wieczorowska-Tobis K, Brelinska R, Witowski J, Passlick-Deetjen J, Schaub TP, Schilling H, Breborowicz A: Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products. *Perit Dial Int* 24:48-57, 2004
2683. Wiedon A, Tolle M, Bastine J, Schuchardt M, Huang T, Jankowski V, Jankowski J, Zidek W, van der Giet M: Uridine adenosine tetraphosphate (up4a) is a strong inducer of smooth muscle cell migration via activation of the p2y2 receptor and cross-communication to the pdgf receptor. *Biochem Biophys Res Commun* 2012:417:1035-1040.
2684. Wiedon A, Tolle M, Bastine J, Schuchardt M, Huang T, Jankowski V, Jankowski J, Zidek W, van der Giet M: Uridine adenosine tetraphosphate (up4a) is a strong inducer of smooth muscle cell migration via activation of the p2y2 receptor and cross-communication to the pdgf receptor. *Biochem Biophys Res Commun* 417:1035-1040, 2012
2685. Wielockx B, Hochepeid T, Staelens J, Van MW, Brouckaert P, Libert C: Detection, characterisation and purification of a murine liver factor capable of desensitising towards the lethal activity of tumour necrosis factor. *Cytokine* 15:59-65, 2001
2686. Wieslander A, Linden T, Musi B, Carlsson O, Deppisch R: Biological significance of reducing glucose degradation products in peritoneal dialysis fluids. *Perit Dial Int* 20 Suppl 5:S23-S27, 2000
2687. Wieslander A, Linden T, Musi B, Jarkelid L, Speidel R, Beck W, Henle T, Deppisch R: Exogenous uptake of carbonyl stress compounds promoting AGE formation from peritoneal dialysis fluids. *Contrib Nephrol* 82-89, 2001
2688. Wieslander AP, Deppisch R, Svensson E, Forsback G, Speidel R, Rippe B: In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. *Perit Dial Int* 15:158-164, 1995
2689. Wikdahl AM, Granbom L, Stegmayr BG: No increased risk for peritonitis by insulin injected into peritoneal dialysis solution bag through Coloplast. *ANNA J* 24:401-406, 1997
2690. Wikdahl AM, Engman U, Stegmayr BG, Sorensen JG: One-dose cefuroxime i.v. and i.p. reduces microbial growth in PD patients after catheter insertion. *Nephrol Dial Transplant* 12:157-160, 1997
2691. Wikdahl AM, Granbom L, Stegmayr BG: Lower catheter-related peritonitis rates with catheter insertion through the rectus muscle, and the internal cuff between the peritoneum and the inner fascia. *Perit Dial Int* 18:331-334, 1998
2692. Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, Hamsten A, Holmberg D, Asplund K: Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. *Stroke* 36:1661-1665, 2005
2693. Wiklund PG, Brown WM, Brott TG, Stegmayr B, Brown RD, Jr., Nilsson-Ardnor S, Hardy JA, Kissela BM, Singleton A, Holmberg D, Rich SS, Meschia JF: Lack of aggregation of ischemic stroke subtypes within affected sibling pairs. *Neurology* 68:427-431, 2007
2694. Willekens BM, Rooker S, Dua G, Appel B, Martin JJ, Crols R, De Deyn PP: Central nervous system metastases of pulmonary adenocarcinoma mimicking neurofibromatosis type 2. *Acta Neurol Belg* 106:87-89, 2006

2695. Willemsse JL, Brouns R, Heylen E, De Deyn PP, Hendriks DF: Carboxypeptidase U (TAFII) activity is induced in vivo in ischemic stroke patients receiving thrombolytic therapy. *J Thromb Haemost* 6:200-202, 2008
2696. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. *Kidney Int* 66:408-418, 2004
2697. Wimmer T, Cohen G, Saemann MD, Horl WH: Effects of Tamm-Horsfall protein on polymorphonuclear leukocyte function. *Nephrol Dial Transplant* 19:2192-2197, 2004
2698. Winkelmayr WC, Lorenz M, Kramar R, Fodinger M, Horl WH, Sunder-Plassmann G: C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. *Am J Transplant* 4:1148-1154, 2004
2699. Winkelmayr WC, Lorenz M, Kramar R, Horl WH, Sunder-Plassmann G: Percentage of hypochromic red blood cells is an independent risk factor for mortality in kidney transplant recipients. *Am J Transplant* 4:2075-2081, 2004
2700. Winkelmayr WC, Kramar R, Curhan GC, Chandraker A, Endler G, Fodinger M, Horl WH, Sunder-Plassmann G: Fasting plasma total homocysteine levels and mortality and allograft loss in kidney transplant recipients: a prospective study. *J Am Soc Nephrol* 16:255-260, 2005
2701. Winkelmayr WC, Huber A, Wagner OF, Horl WH, Sunder-Plassmann G, Fodinger M: Associations between MTHFR 1793G>A and plasma total homocysteine, folate, and vitamin B in kidney transplant recipients. *Kidney Int* 67:1980-1985, 2005
2702. Winpenninckx B, Erriegers V, Reyniers E, De Deyn PP, Abidi FE, Schwartz CE, Kooy RF: Family MRX9 revisited: further evidence for locus heterogeneity in MRX. *Am J Med Genet* 112:17-22, 2002
2703. Witasz A, Nordfors L, Lindholm B, Stenvinkel P: Use of single-nucleotide polymorphisms in the search for genetic modifiers of the uremic phenotype. *J Ren Nutr* 17:17-22, 2007
2704. Witko-Sarsat V, Nguyen KT, Jungers P, Druke T, scamps-Latscha B: Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia. *Adv Nephrol Necker Hosp* 28:321-341, 1998
2705. Witko-Sarsat V, Friedlander M, Nguyen KT, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Druke T, scamps-Latscha B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. *J Immunol* 161:2524-2532, 1998
2706. Witko-Sarsat V, Nguyen-Khoa T, Jungers P, Druke TB, scamps-Latscha B: Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. *Nephrol Dial Transplant* 14 Suppl 1:76-78, 1999
2707. Witko-Sarsat V, Gausson V, Nguyen AT, Touam M, Druke T, Santangelo F, scamps-Latscha B: AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. *Kidney Int* 64:82-91, 2003
2708. Witkowicz-Kulhawik I, Wiecek A, Kokot F: [Resistance to erythropoietin therapy--causes and methods of treatment]. *Pol Arch Med Wewn* 96:75-83, 1996
2709. Witowski J, Topley N, Jorres A, Liberek T, Coles GA, Williams JD: Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. *Kidney Int* 47:282-293, 1995
2710. Witowski J, Jorres A, Coles GA, Williams JD, Topley N: Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. *Kidney Int* 50:1212-1223, 1996
2711. Witowski J, Jorres A: Glucose degradation products: relationship with cell damage. *Perit Dial Int* 20 Suppl 2:S31-S36, 2000
2712. Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jorres A: Effect of glucose degradation products on human peritoneal mesothelial cell function. *J Am Soc Nephrol* 11:729-739, 2000
2713. Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-Pawlaczyk M, Wisniewska J, Polubinska A, Friess H, Gahl GM, Frei U, Jorres A: IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. *J Immunol* 165:5814-5821, 2000
2714. Witowski J, Thiel A, Dechend R, Dunkel K, Fouquet N, Bender TO, Langrehr JM, Gahl GM, Frei U, Jorres A: Synthesis of C-X-C and C-C chemokines by human peritoneal fibroblasts: induction by macrophage-derived cytokines. *Am J Pathol* 158:1441-1450, 2001
2715. Witowski J, Bender TO, Gahl GM, Frei U, Jorres A: Glucose degradation products and peritoneal membrane function. *Perit Dial Int* 21:201-205, 2001
2716. Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jorres A: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. *J Am Soc Nephrol* 12:2434-2441, 2001
2717. Witowski J, Bender TO, Wisniewska-Elnur J, Ksiazek K, Passlick-Deetjen J, Breborowicz A, Jorres A: Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se. *Perit Dial Int* 23:381-390, 2003
2718. Witowski J, Jorres A, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Bender TO, Passlick-Deetjen J, Breborowicz A: Glucose degradation products in peritoneal dialysis fluids: do they harm? *Kidney Int Suppl* 148-S151, 2003
2719. Witowski J, Ksiazek K, Jorres A: Interleukin-17: a mediator of inflammatory responses. *Cell Mol Life Sci* 61:567-579, 2004
2720. Witowski J, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Jorres A, Lage C, Schaub TP, Passlick-Deetjen J, Breborowicz A, Grzegorzewska A, Ksiazek A, Liberek T, Lichodziejewska-Niemierko M, Majdan M, Rutkowski B, Stompor T, Sulowicz W: Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. *Nephrol Dial Transplant* 19:917-924, 2004
2721. Witowski J, Jorres A: Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences. *Perit Dial Int* 25 Suppl 3:S31-S34, 2005
2722. Witowski J, Jorres A: Preventing peritoneal fibrosis--an ace up our sleeve? *Perit Dial Int* 25:25-29, 2005
2723. Witowski J, Jorres A: Peritoneal cell culture: fibroblasts. *Perit Dial Int* 26:292-299, 2006
2724. Witowski J, Ksiazek K, Warnecke C, Kuzlan M, Korybalska K, Tayama H, Wisniewska-Elnur J, Pawlaczyk K, Trominska J, Breborowicz A, Jorres A: Role of mesothelial cell-derived granulocyte colony-stimulating factor in interleukin-17-induced neutrophil accumulation in the peritoneum. *Kidney Int* 71:514-525, 2007
2725. Wittke S, Fliser D, Haubitz M, Bartel S, Krebs R, Hausadel F, Hillmann M, Golovko I, Koester P, Haller H, Kaiser T, Mischak H, Weissinger EM: Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the

- establishment of new diagnostic markers. *J Chromatogr A* 1013:173-181, 2003
2726. Wittke S, Kaiser T, Mischak H: Differential polypeptide display: the search for the elusive target. *J Chromatogr B Analyt Technol Biomed Life Sci* 803:17-26, 2004
2727. Wittke S, Mischak H, Walden M, Kolch W, Radler T, Wiedemann K: Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. *Electrophoresis* 26:1476-1487, 2005
2728. Wittke S, Haubitz M, Walden M, Rohde F, Schwarz A, Mengel M, Mischak H, Haller H, Gwinner W: Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. *Am J Transplant* 5:2479-2488, 2005
2729. Wnuk RS, Kokot F, Wiecek A, Irzyniec T: [Use of third generation bisphosphonates in treatment of neoplastic hypercalcemia]. *Pol Tyg Lek* 50:43-44, 1995
2730. Wojnar J, Franek E, Waclawik A, Markiewicz M, Wiecek A, Kokot F, Holowiecki J: [Level of erythropoietin during autologous transplantation of stem cells from bone marrow and peripheral blood]. *Acta Haematol Pol* 26:291-297, 1995
2731. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Katarinen M, Poulter N, Primates P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzo D, Vescio F: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. *JAMA* 289:2363-2369, 2003
2732. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primates P, Stegmayr B, Thamm M: Hypertension treatment and control in five European countries, Canada, and the United States. *Hypertension* 43:10-17, 2004
2733. Wollmer MA, Slegers K, Ingelsson M, Zekanowski C, Brouwers N, Maruszak A, Brunner F, Huynh KD, Kilander L, Brundin RM, Hedlund M, Giedraitis V, Glaser A, Engelborghs S, De Deyn PP, Kapaki E, Tsolaki M, Daniilidou M, Molyva D, Paraskevas GP, Thal DR, Barcikowska M, Kuznicki J, Lannfelt L, Van BC, Nitsch RM, Hock C, Papassotiropoulos A: Association study of cholesterol-related genes in Alzheimer's disease. *Neurogenetics* 8:179-188, 2007
2734. Wollmer MA, Slegers K, Ingelsson M, Zekanowski C, Brouwers N, Maruszak A, Brunner F, Huynh KD, Kilander L, Brundin RM, Hedlund M, Giedraitis V, Glaser A, Engelborghs S, De Deyn PP, Kapaki E, Tsolaki M, Daniilidou M, Molyva D, Paraskevas GP, Thal DR, Barcikowska M, Kuznicki J, Lannfelt L, Van BC, Nitsch RM, Hock C, Papassotiropoulos A: Association study of cholesterol-related genes in Alzheimer's disease. *Neurogenetics* 2007
2735. Wooten MW, Seibenhener ML, Heikkila JE, Mischak H: Delta-protein kinase C phosphorylation parallels inhibition of nerve growth factor-induced differentiation independent of changes in Trk A and MAP kinase signalling in PC12 cells. *Cell Signal* 10:265-276, 1998
2736. Wostyn P, Audenaert K, De Deyn PP: Alzheimer's disease-related changes in diseases characterized by elevation of intracranial or intraocular pressure. *Clin Neurol Neurosurg* 110:101-109, 2008
2737. Wratten ML, Tetta C, De SR, Neri R, Sereni L, Camussi G, Vanholder R: Uremic ultrafiltrate inhibits platelet-activating factor synthesis. *Blood Purif* 17:134-141, 1999
2738. Wu G, Brouckaert P, Olivecrona T: Rapid downregulation of adipose tissue lipoprotein lipase activity on food deprivation: evidence that TNF-alpha is involved. *Am J Physiol Endocrinol Metab* 286:E711-E717, 2004
2739. Wuyts B, Bernard D, Van den NN, Van de WJ, Van VB, De SR, De GF, Vanholder R, Delanghe JR: Reevaluation of formulas for predicting creatinine clearance in adults and children, using compensated creatinine methods. *Clin Chem* 49:1011-1014, 2003
2740. Wystrychowski A, Pidasheva S, Canaff L, Chudek J, Kokot F, Wiecek A, Hendy GN: Functional characterization of calcium-sensing receptor codon 227 mutations presenting as either familial (benign) hypocalcaemic hypercalcaemia or neonatal hyperparathyroidism. *J Clin Endocrinol Metab* 90:864-870, 2005
2741. Wyzgal J, Niemczyk M, Ziolkowski J, Durlik M, Wiecek A: Results of a 6-month, multicenter, open-label, prospective study concerning efficacy and safety of mycophenolate sodium in de novo kidney transplant recipients. *Transplant Proc* 39:2730-2732, 2007
2742. Xiao Y, daz-Carroll L, Ortiz AM, Whitbeck JC, Alexander E, Lou H, Davis HL, Braciale TJ, Eisenberg RJ, Cohen GH, Isaacs SN: A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. *Vaccine* 25:1214-1224, 2007
2743. Xiong H, Carr RA, Locke CS, Katz DA, Achari R, Doan TT, Wang P, Jankowski JR, Sleep DJ: Dual effects of rifampin on the pharmacokinetics of atrasentan. *J Clin Pharmacol* 47:423-429, 2007
2744. Xu K, Thornalley PJ: Studies on the mechanism of the inhibition of human leukaemia cell growth by dietary isothiocyanates and their cysteine adducts in vitro. *Biochem Pharmacol* 60:221-231, 2000
2745. Xu K, Thornalley PJ: Antitumour activity of sphingoid base adducts of phenethyl isothiocyanate. *Bioorg Med Chem Lett* 10:53-54, 2000
2746. Xu K, Thornalley PJ: Signal transduction activated by the cancer chemopreventive isothiocyanates: cleavage of BID protein, tyrosine phosphorylation and activation of JNK. *Br J Cancer* 84:670-673, 2001
2747. Xu K, Thornalley PJ: Involvement of glutathione metabolism in the cytotoxicity of the phenethyl isothiocyanate and its cysteine conjugate to human leukaemia cells in vitro. *Biochem Pharmacol* 61:165-177, 2001
2748. Yaghoobian J, Druke TB: Regulation of the transcription of parathyroid-hormone/parathyroid-hormone-related peptide receptor mRNA by dexamethasone in ROS 17/2.8 osteosarcoma cells. *Nephrol Dial Transplant* 13:580-586, 1998
2749. Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB, Wang LJ, Nie H, Zidek W, Tepel M, Zhu ZM: Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. *Biochem Biophys Res Commun* 354:427-433, 2007
2750. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, Suske G, Ahmed N, Thornalley PJ, Sarthy VP, Hammes HP, Brownlee M: Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription. *Cell* 124:275-286, 2006
2751. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, Suske G, Rabbani N, Thornalley PJ, Sarthy VP, Hammes HP, Brownlee M: High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A. *J Biol Chem* 282:31038-31045, 2007
2752. Yao D, Taguchi T, Matsumura T, Pestell R, Edelstein D, Giardino I, Suske G, Ahmed N, Thornalley PJ, Sarthy VP, Hammes HP, Brownlee M: Methylglyoxal modification of mSin3A links glycolysis to angiopoietin-2 transcription. *Cell* 128:625, 2007
2753. Yao Q, Axelsson J, Stenvinkel P, Lindholm B: Chronic systemic inflammation in dialysis patients: an update on causes and consequences. *ASAIO J* 50:iii-ivii, 2004
2754. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P: Traditional and non-traditional risk factors as contributors to atherosclerotic

- cardiovascular disease in end-stage renal disease. *Scand J Urol Nephrol* 38:405-416, 2004
2755. Yao Q, Axelsson J, Heimbürger O, Stenvinkel P, Lindholm B: Systemic inflammation in dialysis patients with end-stage renal disease: causes and consequences. *Minerva Urol Nefrol* 56:237-248, 2004
2756. Yao Q, Wang X, Chung SH, Pecoits-Filho R, Stenvinkel P, Wang T, Heimbürger O, Lindholm B: The role of peritoneal dialysis in renal replacement therapy: an update on medical aspects. *Panminerva Med* 47:19-30, 2005
2757. Yao Q, Nordfors L, Axelsson J, Heimbürger O, Qureshi AR, Barany P, Lindholm B, Lonnqvist F, Schalling M, Stenvinkel P: Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. *Atherosclerosis* 182:105-111, 2005
2758. Yao Q, Pawlaczyk K, Ayala ER, Kuzlan M, Styszynski A, Breborowicz A, Heimbürger O, Qian J, Stenvinkel P, Axelsson J, Lindholm B: Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution. *Blood Purif* 24:575-582, 2006
2759. Yao Q, Ayala ER, Qian JQ, Stenvinkel P, Axelsson J, Lindholm B: A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells. *Clin Nephrol* 68:295-301, 2007
2760. Yegenaga I, Hoste E, Van BW, Vanholder R, Benoit D, Kantarci G, Dhondt A, Colardyn F, Lameire N: Clinical characteristics of patients developing ARF due to sepsis/systemic inflammatory response syndrome: results of a prospective study. *Am J Kidney Dis* 43:817-824, 2004
2761. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W: Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. *Nature* 401:173-177, 1999
2762. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, Kolch W: Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. *Mol Cell Biol* 20:3079-3085, 2000
2763. Yilmaz MI, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P: Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences. *Clin Nephrol* 68:1-9, 2007
2764. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Cakir E, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J: Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. *Nephrol Dial Transplant* 23:959-965, 2008
2765. Yilmaz MI, Axelsson J, Sonmez A, Carrero JJ, Saglam M, Eyileten T, Caglar K, Kirkpantur A, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P: Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. *Clin J Am Soc Nephrol* 4:535-541, 2009
2766. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Oguz Y, Aslan I, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J: Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/nampt. A novel marker of endothelial damage? *Clin Transplant* 23:241-248, 2009
2767. Yoon MS, Jankowski V, Montag S, Zidek W, Henning L, Schluter H, Tepel M, Jankowski J: Characterisation of advanced glycation endproducts in saliva from patients with diabetes mellitus. *Biochem Biophys Res Commun* 323:377-381, 2004
2768. Zaider M, Zelefsky MJ, Cohen GN, Chui CS, Yorke ED, Hunt MA, Happersett L: The role of external beam in brachytherapy. *Future Oncol* 3:159-168, 2007
2769. Zamylnski J, Olejek A, Wiecek A, Manka G, Chudek J, Bodzek P, masiewicz-Bodzek A: [The influence of metabolic changes on intrauterine fetal growth in normal gestation and gestation complicated by diabetes]. *Postepy Hig Med Dosw (Online)* 59:490-495, 2005
2770. Zamylnski J, Chudek J, Olejek A, Kobylec-Zamylnska B, Manka G, Bodzek P, Wiecek A: Galanin concentrations in maternal circulation, amniotic fluid and umbilical cord blood during term labor: relationship with maternal body mass and neonatal birth weight. *Gynecol Endocrinol* 23:295-299, 2007
2771. Zarzecki M, Chudek J, Kulach A, Holowiecka A, Kania M, Kopec P, Kukla M, Machala L, Pyda M, Rozmus W, Szpak S, Wiecek A: [Causes of chronic renal failure and clinical status of patients during initiation of hemodialysis therapy in upper Silesian region]. *Wiad Lek* 57:145-150, 2004
2772. Zarzecki M, Chudek J, Kukla M, Kopec P, Mamcarz E, Wnuk Z, Kokot F, Wiecek A: [Prevalence of anemia, calcium-phosphorus abnormalities and metabolic acidosis in different stages of chronic renal failure]. *Pol Arch Med Wewn* 112:1211-1219, 2004
2773. Zawada AM, Rogacev KS, Muller S, Rotter B, Winter P, Fliser D, Heine GH: Massive analysis of cDNA ends (mace) and miRNA expression profiling identifies proatherogenic pathways in chronic kidney disease mace and miRNA profiling in CKD. *Epigenetics* 9, 2013
2774. Zewinger S, Speer T, Kleber ME, Scharnagl H, Woitas R, Lepper PM, Pfahler K, Seiler S, Heine GH, Marz W, Silbernagel G, Fliser D: HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. *J Am Soc Nephrol* 14
2775. Zdrojewski T, Szpakowski P, Bandosz P, Pajak A, Wiecek A, Krupa-Wojciechowska B, Wyrzykowski B: Arterial hypertension in Poland in 2002. *J Hum Hypertens* 18:557-562, 2004
2776. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E: Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? *Kidney Int* 63:298-305, 2003
2777. Zelefsky MJ, Yamada Y, Cohen GN, Sharma N, Shippy AM, Fridman D, Zaider M: Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications. *Radiother Oncol* 84:185-189, 2007
2778. Zelefsky MJ, Yamada Y, Cohen GN, Shippy A, Chan H, Fridman D, Zaider M: Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* 67:65-70, 2007
2779. Zeyda M, Poglitsch M, Geyeregger R, Smolen JS, Zlabinger GJ, Horl WH, Waldhausl W, Stulnig TM, Saemann MD: Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. *Arthritis Rheum* 52:2730-2739, 2005
2780. Zeyda M, Geyeregger R, Poglitsch M, Watschinger B, Horl WH, Stulnig TM, Saemann MD: The novel immunosuppressant FK778 inhibits formation of the immunologic synapse. *Transplant Proc* 37:1970-1971, 2005
2781. Zeyda M, Kirsch BM, Geyeregger R, Stuhlmeier KM, Zlabinger GJ, Horl WH, Saemann MD, Stulnig TM: Inhibition of human dendritic cell maturation and function by the novel immunosuppressant FK778. *Transplantation* 80:1105-1111, 2005
2782. Zeyda M, Stuhlmeier KM, Kirsch B, Watschinger B, Horl WH, Stulnig TM, Saemann MD: The malononitrilamide FK778 inhibits activation of

- NF-kappaB in human dendritic cells. *Transplant Proc* 37:1968-1969, 2005
2783. Zeyda M, Geyeregger R, Poglitsch M, Weichhart T, Zlabinger GJ, Koyasu S, Horl WH, Stulnig TM, Watschinger B, Saemann MD: Impairment of T cell interactions with antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF-kappaB in immunological synapse formation. *J Leukoc Biol* 81:319-327, 2007
2784. Zhang P, Duchambon P, Gogusev J, Nabarra B, Sarfati E, Bourdeau A, Druke TB: Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. *Kidney Int* 57:437-445, 2000
2785. Zhang Q, Zhang K, Zou Y, Perna A, Wang Y: A quantitative study on the in vitro and in vivo acetylation of high mobility group A1 proteins. *J Am Soc Mass Spectrom* 18:1569-1578, 2007
2786. Zhang X, Cornelis R, De KJ, Mees L, Vanderbiesen V, Vanholder R: Determination of total arsenic in serum and packed cells of patients with renal insufficiency. *Anal Bioanal Chem* 353:143-147, 1995
2787. Zhang X, Cornelis R, De KJ, Mees L, Vanderbiesen V, De CA, Vanholder R: Accumulation of arsenic species in serum of patients with chronic renal disease. *Clin Chem* 42:1231-1237, 1996
2788. Zhang X, Cornelis R, Mees L, Vanholder R, Lameire N: Chemical speciation of arsenic in serum of uraemic patients. *Analyst* 123:13-17, 1998
2789. Zhou Z, de Wijs-Meijler D, Lankhuizen I, Jankowski J, Jankowski V, Jan Danser AH, Duncker DJ, Merkus D: Blunted coronary vasodilator response to uridine adenosine tetraphosphate in post-infarct remodeled myocardium is due to reduced p1 receptor activation. *Pharmacol Res* 77:22-29, 2013
2790. Ziaja J, Marcinkowski W, Cierpka L, Wiecek A: [The influence of simultaneous pancreas and kidney transplantation on long-term diabetic complications in patients with insulin dependent diabetes mellitus]. *Pol Merkur Lekarski* 15:455-458, 2003
2791. Ziaja J, Krol R, Chudek J, Zakliczynska H, Sekta S, Siekiera U, Wiecek A, Cierpka L: Early donor lymph node procurement and local HLA typing reduce cold ischemia time and risk of acute tubular necrosis in cadaveric kidney transplantation. *Transplant Proc* 38:39-41, 2006
2792. Ziaja J, Chudek J, Krol R, Stanczyk A, Pawlicki J, Gasinska T, Kajor M, Wiecek A, Cierpka L: [Long-term consequences of surgical excision of cortisol producing adrenocortical adenoma]. *Endokrynol Pol* 58:207-212, 2007
2793. Ziaja J, Chudek J, Krol R, Pawlicki J, Wiecek A, Cierpka L: Rare normalization of blood pressure after unilateral adrenalectomy in 31 patients with Conn syndrome. *Langenbecks Arch Surg* 392:431-435, 2007
2794. Ziaja J, Chudek J, Krol R, Pawlicki J, Wiecek A, Cierpka L: Rare normalization of blood pressure after unilateral adrenalectomy in 31 patients with Conn syndrome. *Langenbecks Arch Surg* 2007
2795. Zidek N, Hellmann J, Kramer PJ, Hewitt PG: Acute hepatotoxicity: a predictive model based on focused illumina microarrays. *Toxicol Sci* 99:289-302, 2007
2796. Zidek W: [Treatment of arterial hypertension]. *Internist (Berl)* 48:613-622, 2007
2797. Zidek Z, Kmonickova E, Holy A: Secretion of antiretroviral chemokines by human cells cultured with acyclic nucleoside phosphonates. *Eur J Pharmacol* 574:77-84, 2007
2798. Zimmerli LU, Schiffer E, Zurbig P, Good DM, Kellmann M, Muls L, Pitt AR, Coon JJ, Schmieder RE, Peter KH, Mischak H, Kolch W, Delles C, Dominiczak AF: Urinary proteomic biomarkers in coronary artery disease. *Mol Cell Proteomics* 7:290-298, 2008
2799. Zingraff J, Caillat-Vigneron N, Urena P, Gagne ER, Bererhi L, Moretti JL, Bardin T, Druke TB: Plasma kinetics of 125I-labelled amyloid P component in beta 2M amyloidosis: a possible approach to quantitate disease activity. *Nephrol Dial Transplant* 10:223-229, 1995
2800. Zingraff J, Droz D, Touam M, Voisin MC, Druke T: Chronic arthropathy and rectal bleeding in a long-term haemodialysis patient. *Nephrol Dial Transplant* 10:2153-2155, 1995
2801. Zingraff J, Leger A, Skhiri H, Billotey C, Sarfati E, Druke T: Localization of ectopic parathyroid tissue: usefulness of 99mTc sestamibi scanning in a dialysis patient with severe secondary hyperparathyroidism. *Nephrol Dial Transplant* 11:2504-2506, 1996
2802. Zingraff J, Druke T: Severe osteoarthropathy associated with diffuse soft-tissue calcifications in a long-term haemodialysis patient. *Nephrol Dial Transplant* 13:2149-2150, 1998
2803. Zingraff J, Druke T: Beta2-microglobulin amyloidosis: past and future. *Artif Organs* 22:581-584, 1998
2804. Zoraster R, Vanholder R, Sever MS: Disaster management of chronic dialysis patients. *Am J Disaster Med* 2:96-106, 2007
2805. Zou Y, Webb K, Perna AD, Zhang Q, Clarke S, Wang Y: A mass spectrometric study on the in vitro methylation of HMGA1a and HMGA1b proteins by PRMTs: methylation specificity, the effect of binding to AT-rich duplex DNA, and the effect of C-terminal phosphorylation. *Biochemistry* 46:7896-7906, 2007
2806. Zurbig P, Renfrow MB, Schiffer E, Novak J, Walden M, Wittke S, Just I, Pelzing M, Neususs C, Theodorescu D, Root KE, Ross MM, Mischak H: Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. *Electrophoresis* 27:2111-2125, 2006